<SEC-DOCUMENT>0001144204-11-046337.txt : 20110815
<SEC-HEADER>0001144204-11-046337.hdr.sgml : 20110815
<ACCEPTANCE-DATETIME>20110815060347
ACCESSION NUMBER:		0001144204-11-046337
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110815
DATE AS OF CHANGE:		20110815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APRICUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001017491
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870449967
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22245
		FILM NUMBER:		111033021

	BUSINESS ADDRESS:	
		STREET 1:		6330 NANCY RIDGE DRIVE,
		STREET 2:		SUITE 103
		CITY:			SAN DIEGO,
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 222-8041

	MAIL ADDRESS:	
		STREET 1:		6330 NANCY RIDGE DRIVE,
		STREET 2:		SUITE 103
		CITY:			SAN DIEGO,
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEXMED INC
		DATE OF NAME CHANGE:	19970311
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v230961_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>&#160;</div>

<div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WASHINGTON, DC&#160;&#160;20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 10-Q</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt"><font style="DISPLAY: inline;" face="Wingdings">x</font></td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission file number 0-22245</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">APRICUS BIOSCIENCES, INC.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 3pt">&#160; </font></font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact Name of Issuer as Specified in Its Charter)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Nevada</font></font></div>
</td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">87-0449967</font></font></div>
</td>
</tr><tr>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or Other Jurisdiction of</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(I.R.S. Employer</font></div>
</td>
</tr><tr>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Incorporation or Organization)</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6330 Nancy Ridge Drive, Suite 103, San Diego, CA 92121 </font></font>

<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address of Principal Executive Offices)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(858) 222-8041 </font></font>

<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Issuer&#8217;s Telephone Number, Including Area Code)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Indicate by check mark whether the registrant:&#160;&#160;(1) has filed all reports required to be filed by Section 13 or 15 (d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes <font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;<a name="Check4"><!--EFPlaceholder--></a>&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Indicate by check mark whether the registrant has submitted electronically and posted on its Corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font><a name="Check5"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 14.4pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 14.4pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160;&#160;See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (check one):&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 14.4pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 14.4pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Large accelerated filer&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;Accelerated filer <font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;Non-accelerated filer&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;(do not check if a smaller reporting company)&#160;&#160;Smaller reporting company&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font> Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common equity, as of the latest practicable date: as of<font style="DISPLAY: inline; FONT-WEIGHT: bold"> August </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">, 2011, 20,022,080 </font>shares of Common Stock, par value $0.001 per share, were outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Table of Contents</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Page</font></font></div>
</td>
</tr><tr>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" colspan="2" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Part I. FINANCIAL INFORMATION</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financial Statements</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Balance Sheets at June 30, 2011 (unaudited) and December 31, 2010</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1</font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2011 and 2010</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2</font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Consolidated Statement of Changes in Stockholders&#8217; Equity for the Six Months Ended June 30, 2011</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Unaudited Consolidated Financial Statements</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></td>
</tr><tr bgcolor="white">
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</td>
<td valign="top" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">21</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quantitative and Qualitative Disclosures about Market Risk</font></div>
</td>
<td valign="top" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">27</div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Controls and Procedures</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" colspan="2" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Part II. OTHER INFORMATION</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Proceedings</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1A.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk Factors</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 6.</font></div>
</td>
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signatures</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="top">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit Index</font></div>
</td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32</font></td>
</tr></table>
</div>

<div align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I.&#160;&#160;FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1.&#160;&#160;FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apricus Biosciences, Inc. and Subsidiaries</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Balance Sheets</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">June 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Assets</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current assets</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,140,225</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,145,683</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,867</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">288,778</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Restricted cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">70,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">604,343</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">106,693</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">188,504</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,361,785</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,477,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,457,778</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,420,939</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intangible assets, net of accumulated amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,701,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued rental income and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">204,890</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">189,478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Debt issuance cost, net of accumulated amortization of $47,860 and $29,289</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">55,830</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,401</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,080,283</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,863,638</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Liabilities and Stockholders' Equity</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Short-term borrowing from banks</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">401,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,210,555</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">789,544</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Payroll related liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">730,584</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">816,520</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">343,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">209,705</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease payable - current portion</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31,263</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred compensation - current portion</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">392,477</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,596</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,676,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,316,628</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long term liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Convertible notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,150</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">72,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">102,211</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deferred compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">768,882</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">805,788</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,513,023</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,296,877</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Commitments and contingencies</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders' equity:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">

<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock, $.001 par value, 75,000,000 shares authorized,&#160;&#160;20,012,080 and 18,521,951 issued and outstanding at June 30, 2011 and December 31, 2010, respectively</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,012&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,519&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in-capital</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">217,992,554</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">212,788,450</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated deficit</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(212,445,306</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(201,240,208</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total stockholders' equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,567,260</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,566,761</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total liabilities and stockholders' equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,080,283</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,863,638</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="9" valign="top" width="62%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying notes are an integral part of these consolidated financial statements.</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apricus Biosciences, Inc. and Subsidiaries</font></div>
</td>
</tr><tr>
<td valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Operations (Unaudited)</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE THREE MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License fee revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">668,899</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,449</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contract service revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">926,253</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,438,377</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,310,768</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,881,579</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,595,152</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,470,927</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,182,217</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,916,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost of services</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,006,225</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,021,951</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,011,233</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,059,183</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gross profit</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">588,927</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">448,976</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,170,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">857,496</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Costs and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,971,832</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">477,566</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,072,378</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">903,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,687,041</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,640,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,593,294</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,879,936</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss on sale of Bio-Quant subsidiary</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,759,920</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,759,920</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total costs and expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,418,793</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,117,966</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,425,592</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,783,895</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,829,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,668,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,254,608</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,926,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income (expense)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Interest expense, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(75,708</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,609,657</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(173,452</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,589,704</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rental income</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">111,482</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">222,962</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total other income (expense)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,774</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,609,657</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">49,510</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,589,704</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,794,092</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,278,647</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,516,103</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.39</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.47</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.58</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.64</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 4px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">used for basic and diluted loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,817,009</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,140,451</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,475,598</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,264,515</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<div align="left">&#160;</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying notes are an integral part of these consolidated financial statements.</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apricus Biosciences, Inc. and Subsidiaries</font></div>
</td>
</tr><tr>
<td valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Paid-In</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders'</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Shares)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Amount)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deficit</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equity</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,521,951</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,519</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">212,788,450</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(201,240,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11,566,761</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of stock and compensation expense for employees</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">209,138</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">209</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,037,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,037,295</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of compensatory stock to the board of directors</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">108,412</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">108,438</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">674,466</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">676</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,740,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,741,403</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock upon exercise of warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">581,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">582</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,317,879</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,318,461</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at June 30, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,012,080</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,012</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">217,992,554</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(212,445,306</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,567,260</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The accompanying notes are an integral part of these consolidated financial statements.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apricus Biosciences, Inc. and Subsidiaries</font></td>
</tr><tr>
<td valign="top" width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Cash Flows (Unaudited)</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div align="left">
<div align="left">
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ffffff">
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS ENDED</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ffffff">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from operating activities</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,516,103</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reserve for related party note receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">275,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">417,477</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">471,398</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash interest, amortization of beneficial conversion feature and</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">deferred financing costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,571</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,716,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash write off of deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">133,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,145,733</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,194,927</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss on disposal of fixed assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">920</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">312</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-cash loss on sale of Bio-Quant subsidiary</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,759,920</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in operating assets and liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease (increase) in accounts receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44,675</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,182</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease (increase) in other receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(25,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">437,794</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease in due from related party</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">204,896</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in prepaid expenses and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">79,550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(117,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in accrued rental income and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(17,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,628,934</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(120,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in payroll related liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(45,013</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">138,124</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease in due to related party</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(99,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Decrease (increase) in deferred compensation</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">286,975</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,496</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Increase (decrease) in deferred revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,100</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,107</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,506,770</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,665,363</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from sale of fixed assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,142</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital expenditures</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(176,710</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(296,856</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Release (deposit) of restricted cash</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">534,343</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(603,000</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by (used in)&#160;&#160;investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">357,633</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(898,714</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash flows from financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of convertible notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,300,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from exercise of warrants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,318,461</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock, net of offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,741,403</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,306,296</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of convertible notes payable, net of debt issue costs</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,896,310</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Repayment of short-term borrowing</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(401,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">401,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Repayment of convertible notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,592,012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Repayment of capital lease obligations</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(15,204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,310</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from sale of Bio-Quant subsidiary</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">500,019</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; PADDING-BOTTOM: 2px; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net cash provided by financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,143,679</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,299,284</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net increase&#160;(decrease)&#160;in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(5,458</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,735,207</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents, beginning of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,145,683</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">479,888</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash and cash equivalents, end of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,140,225</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,215,095</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for interest</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">174,422</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">67,762</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Supplemental Information:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock in payment of convertible notes payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">397,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuance of common stock in payment of notes payable to former Bio-Quant shareholders</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,129,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Sales of investment in consolidated subsidiary:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts Receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">199,236</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,833</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Equipment and leasehold improvements, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">780,983</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intangible assets, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,642,003</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts Payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(207,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Payroll related liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(40,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Capital lease payable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(118,270</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying notes are an integral part of these consolidated financial statements.</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Apricus Biosciences, Inc. and Subsidiaries</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes to Unaudited</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Consolidated Financial Statements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BASIS OF PRESENTATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Apricus Biosciences, Inc. (formerly NexMed, Inc.) and subsidiaries (the &#8220;Company&#8221; or &#8220;our&#8221; or &#8220;we&#8221;) was incorporated in Nevada in 1987.&#160;&#160;On September 10, 2010, the Company changed its name from &#8220;NexMed, Inc.&#8221; to &#8220;Apricus Biosciences, Inc.&#8221; The Company has historically focused its efforts on drug development using its patented drug delivery technology known as NexACT&#174;.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.&#160;&#160;Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. In the opinion of the Company&#8217;s management, all adjustments that are of a normal recurring nature, considered necessary for fair presentation, have been included in the accompanying consolidated financial statements. The unaudited consolidated financial statements and statements of operations for the interim periods are not necessarily indicative of results for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K filed with the Securities Exchange Commission for the year ended December 31, 2010. The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, including those related to bad debts, intangible assets, income taxes, stock-based compensation and commitments and contingencies.&#160;&#160;The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 14, 2009, the Company acquired Bio-Quant, Inc. (&#8220;Bio-Quant&#8221;), a <font style="DISPLAY: inline; FONT-SIZE: 10pt">specialty biotech contract research organization (&#8220;CRO&#8221;) based in San Diego.&#160;&#160;The acquisition was made pursuant to an </font>Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated November 20, 2009 by and among the Company and BQ Acquisition Corp., a wholly-owned subsidiary of the Company and Bio-Quant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Since that time, the Bio-Quant CRO allowed the Company to increase its active pre-clinical and clinical product pipeline from 4 drug candidates to 13 drug candidates </font>utilizing<font style="DISPLAY: inline"> the internal </font>research <font style="DISPLAY: inline">capabilities of the CRO. </font>The Company used the Bio-Quant resources to advance its product candidates and expand the uses and routes of its NexACT&#174; delivery technology. As<font style="DISPLAY: inline"> a result of this internal </font>research <font style="DISPLAY: inline">focus</font>,<font style="DISPLAY: inline"> the cash flow generating capabilities of the CRO diminished over time </font>since the Company was using the capabilities and resources of Bio-Quant for internal development activities rather than for external customer growth. In<font style="DISPLAY: inline"> connection with the </font>valuation of the future expected cash flows and the goodwill related to Bio-Quant at December 31, 2010, an impairment charge of $9,084,476 was taken in 2010 to write off the entire value of goodwill<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline">from this acquisition</font>.<font style="DISPLAY: inline">&#160;During 2011, the Company considered the significance of its enhanced product candidate pipeline, the resources needed to further develop each of those product opportunities and the value being derived from the CRO business with diminished cash flows towards operations. </font><font style="DISPLAY: inline">Based on the change in strategic focus, on </font>June 30, 2011, the Company entered into a stock purchase agreement with Samm Solutions, Inc. doing business as BioTox Sciences (&#8220;BioTox&#8221;), a San Diego-based CRO, to sell all of the outstanding capital stock of Bio-Quant, Inc., which was one of the Company&#8217;s wholly owned subsidiaries (see Note 3).</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through June 30, 2011, the date of the sale of Bio-Quant, the Company operated in two segments &#8211; designing and developing pharmaceutical products through its wholly-owned subsidiary NexMed (USA), Inc. and providing pre-clinical CRO services through its wholly-owned subsidiary, Bio-Quant.&#160;&#160;For periods subsequent to June 30, 2011 the Company will operate in one segment designing and developing pharmaceutical products through its wholly-owned subsidiary NexMed (USA), Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is focusing its efforts on new and patented pharmaceutical products and product candidates based on our patented drug delivery technology known as NexACT&#174;.&#160;&#160;&#160;The Company continues with its efforts to expand the uses of the&#160;&#160;NexACT&#174;&#160;&#160;technology into the oral, subcutaneous, ocular and rectal delivery of multi-classes of drugs for these and other indications.&#160;&#160;The Company is also seeking commercialization partnerships for its product, Vitaros&#174;, which is approved in Canada for the treatment of erectile dysfunction (&#8220;ED&#8221;) and its additional existing clinical and pre-clinical pipeline of product candidates such as&#160;&#160;Femprox&#174; for female sexual arousal disorder, MycoVa&#8482; for onychomycosis excluding tinea pedis (nail fungal infection), RayVa&#8482; for Raynaud&#8217;s Syndrome and PrevOnco&#8482; for liver cancer and is enhancing its business development efforts by offering potential partners clearly defined regulatory paths for our products and product candidates under development.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective June&#160;21, 2010, the Company completed a reverse stock split pursuant to which each fifteen shares of Company's common stock then issued and outstanding were automatically converted into one share of the Company's common stock; no change was made to the per-share par value of the common stock. The authorized common stock was also proportionately reverse split by a factor of fifteen-for-one. All share and per share amounts in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split as if it had occurred at the beginning of the earliest period presented.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying consolidated financial statements have been prepared on a basis which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.&#160;&#160;The Company has an accumulated deficit of approximately $212.4 million at June 30, 2011 and recorded a net loss of approximately $11.2&#160;&#160;million for the six months ended June 30, 2011 and has principally been financed through private placements of equity securities,&#160;&#160;debt financing and up-front payments received from commercial partners for its products under development.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s cash reserves of approximately $9.1 million at June 30, 2011, are expected to provide us with sufficient cash to fund our operations into the second half of 2012.&#160;&#160;This projection is based on the monthly operating expenses of maintaining our public listing, continuing essential business development and research and development efforts for our current pipeline together with the receipt of multiple licensing payments from commercial partners and from possible future cash earn-out revenues resulting from the sale of Bio-Quant.&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To the extent we sign additional licensing agreements in 2011 or 2012 and receive up-front and milestone payments for </font>one or more of our product pipeline candidates and/or the NexACT<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>technology itself, we expect that our cash reserves plus those payments should provide us with sufficient cash to fund our operations well into 2013.<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> A change in any of these assumptions or any unexpected expenses, may change these projected cash reserve amounts and/or timelines.</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company currently expects that it will be cash flow positive from operations, which includes cash expected to be received from up-front and milestone payments from the licensing of its products and NexACT&#174;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>technology, during 2011 as the Company plans to enter into out-licensing agreements for its NexACT&#174; technology with pharmaceutical and biotechnology companies worldwide. The Company&#8217;s cash flow positive guidance assumes the Company does not commence any clinical trials, which would be expected to increase our expenses significantly.&#160;&#160;At the same time, the Company is actively pursuing partnering opportunities for its approved and clinical stage NexACT&#174; based candidates in the areas of sexual dysfunction, oncology, inflammation, dermatology, pain and autoimmune diseases.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>The successful licensing of one or more of these candidates and/or the NexACT&#174; technology itself would be expected to generate additional revenues for funding the Company&#8217;s long-term growth strategy.&#160;&#160;To that end, as discussed in Note 15, the Company, in December 2010, entered into a licensing agreement with Bracco SpA (&#8220;Bracco&#8221;) for its topical alprostadil-based cream treatment for erectile dysfunction (&#8220;Vitaros&#174;&#8221;) for sale in Italy and in January 2011, and the Company entered into exclusive license agreement with Elis Pharmaceuticals Ltd. (&#8220;Elis&#8221;) and Neopharm Group (&#8220;Neopharm&#8221;) for Vitaros&#174;.&#160;&#160;Under the terms of the Elis License Agreement, Elis has been granted exclusive rights in United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia, Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen and under the terms of the Neopharm License Agreement, Neopharm has been granted exclusive rights in Israel and the Palestinian Territories of the Gaza Strip and the West Bank to commercialize and market Vitaros&#174;. The Company continues to be active in discussions with other potential commercial partners for other territories. In April 2011, we filed a marketing application in Europe for approval of Vitaros&#174; as a treatment for patients with ED. In addition, the Company expects revenues from the sale of Vitaros&#174; in the approved territory(ies) which would also increase its cash position.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent accounting pronouncements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effective January 1, 2010, the Company adopted ASU No. 2009-17, <font style="DISPLAY: inline; FONT-STYLE: italic">Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities</font>. The amendments in this update replace the<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>quantitative-based risks and rewards calculation for determining which reporting entity, if any, has a controlling financial interest in a</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">variable interest entity with an approach focused on identifying which reporting entity has the power to direct the activities of a variable interest entity that most significantly impact the entity&#8217;s economic performance and (1) the obligation to absorb losses of the entity or (2) the right to receive benefits from the entity. An approach that is expected to be primarily qualitative will be more effective for identifying which reporting entity has a controlling financial interest in a variable interest entity. The amendments in this update also require additional disclosures about a reporting entity&#8217;s involvement in variable interest entities, which will enhance the information provided to users of financial statements. The Company evaluated their business relationships to identify potential variable interest entities and have concluded that consolidation of such entities is not required for the periods presented. On a quarterly basis, the Company will continue to reassess our involvement with variable interest entities.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2010, the FASB issued ASU No. 2010-17, Topic 605 - Revenue Recognition - Milestone Method (&#8220;USA 2010-17&#8221;), which provides guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for research or development transactions. The amendments in ASU 2010-17 are effective on a prospective basis for milestones achieved in fiscal years beginning on or after June 15, 2010, and interim periods within those years. The Company has adopted ASU 2010-17 effective as of the first quarter of fiscal 2011. This ASU did not have any impact on the Company&#8217;s consolidated financial statements upon adoption.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued ASU No. 2010-28, <font style="DISPLAY: inline; FONT-STYLE: italic">Intangibles &#8212; Goodwill and Other (Topic 350): &#8220;When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts</font>. ASU 2010-28 is effective for fiscal years<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>beginning after December 15, 2010 and amends the criteria for performing Step 2 of the goodwill impairment test for reporting units<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>with zero or negative carrying amounts and requires performing Step 2 if qualitative factors indicate that it is more likely than not that<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>a goodwill impairment exists. The Company has adopted ASU 2010-28 effective as of the first quarter of fiscal 2011. This ASU did not have any impact on the Company&#8217;s consolidated financial statements upon adoption.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued ASU No. 2010-27, <font style="DISPLAY: inline; FONT-STYLE: italic">Fees Paid to the Federal Government by Pharmaceutical Manufacturers </font>( &#8220;ASU 2010-27&#8221;) which provides guidance on how to recognize and classify the fees mandated by the Patient<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (together, the &#8220;Acts&#8221;). The Acts<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>impose an annual fee for each calendar year beginning on or after January 1, 2011 payable by branded prescription drug<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>manufacturers and importers on branded prescription drugs. The liability for the fee should be estimated and recorded in full upon the<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>first qualifying sale with a corresponding deferred cost that is amortized to expense using a straight-line method of allocation over the<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>calendar year that it is payable. ASU 2010-27 is effective for calendar years beginning on or after December 31, 2010, when the fee<font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>initially becomes effective. As the Company does not currently have a commercial product, the effect of this guidance will be limited to future transactions.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ACQUISITION OF BIO-QUANT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In connection with the Company&#8217;s acquisition of Bio-Quant, which was consummated on December 14, 2009 (the &#8220;Effective Time&#8221;), each outstanding share of common stock of Bio-Quant was canceled and converted into the right to receive 60.93 shares of common stock, par value $0.001 per share, of the Company (the &#8220;Apricus Shares&#8221;), as well as a promissory note (each, a &#8220;Note&#8221;) in the original principal amount of $2,771.37.&#160;&#160;&#160;In connection with the closing of the Merger, the Company issued an aggregate of 266,667 Apricus Shares and Notes in the aggregate original principal amount of $12,129,010 to the shareholders of Bio-Quant.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Notes accrued interest at a rate of 10% per annum through their repayment, with all principal and interest accrued thereunder becoming due and payable one year from the closing date of the Merger.&#160;&#160;The terms of the Notes provide that the principal amounts and all interest thereunder were payable by the Company in cash or, at the Company&#8217;s option, in Apricus Shares, which would be valued for purposes of conversion at the fixed price of $2.52 per share.&#160;&#160;The Merger Agreement provides that if the Company repaid the Notes in Apricus Shares, the total number of Apricus Shares issuable to Bio-Quant shareholders could not exceed 19.99% of outstanding Apricus Shares at the Effective Time unless the Company received stockholder approval to do so in accordance with applicable rules of the NASDAQ Capital Market.&#160;&#160;The Company received stockholder approval at its May 24, 2010 meeting for the potential issuance of shares in full repayment of the remaining amounts owed under the Notes, and, on June 21, 2010, the Company repaid the remaining outstanding principal and interest accrued under the Notes in Apricus Shares.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Intangible assets acquired from Bio-Quant of $4,160,000 consisted primarily of developed Know-How and the Bio-Quant Trade Name. Developed Know-How related to Bio-Quant&#8217;s pre-clinical service expertise including, but not limited to, its extensive inventory of internally developed cell lines. The Bio-Quant Trade Name represents future revenue attributable to the reputation and name recognition of Bio-Quant within the pharmaceutical industry where Bio-Quant is a known expert in pre-clinical services. (See Note 3 and Note 7 for the sale of Bio-Quant and the write-off of these intangibles).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At the time of acquisition, Bio-Quant was a revenue generating, cash flow positive CRO.&#160;&#160;Bio-Quant was expected to continue its revenue growth and cash generating CRO business.&#160;&#160;The $9,084,476 of goodwill generated from the acquisition of Bio-Quant consisted largely of the ability of the Bio-Quant CRO to continue to grow its revenues and generate positive cash flow to contribute to the pharmaceutical product development business segment of the Company.&#160;&#160;As discussed in Note 1, the Company shifted the focus of the Bio-Quant CRO from growing revenues and generating increased positive cash flow to largely supporting the Company&#8217;s research and development business segment which designs and develops pharmaceutical drug candidates.<font style="DISPLAY: inline"> The Bio-Quant CRO allowed the Company to increase its active pre-clinical and clinical product pipeline from 4 drug candidates to 13 drug candidates </font>utilizing<font style="DISPLAY: inline"> the internal capabilities of the CRO. However, as a result of this internal</font> research<font style="DISPLAY: inline"> focus the cash flow generating capabilities of the CRO diminished over time and in connection with the </font>valuation of the future expected cash flows and the goodwill related to Bio-Quant at December 31, 2010, an impairment charge of $9,084,476 was taken in 2010 to write off the entire value of goodwill<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline">from this acquisition</font>.<font style="DISPLAY: inline"> During 2011, the Company, considered the significance of its enhanced product</font> candidate<font style="DISPLAY: inline"> pipeline, the resources needed to further develop each of those product opportunities and the value being derived from the CRO business with diminished cash flows towards operations. Based on </font>this<font style="DISPLAY: inline"> change in strategic focus, on </font>June 30, 2011, the Company entered into a stock purchase agreement with BioTox to sell all of the outstanding capital stock of Bio-Quant. (See Note 3).</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SALE OF BIO-QUANT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company sold all of the outstanding capital stock of Bio-Quant, which was one of the Company&#8217;s wholly owned subsidiaries, to BioTox on June 30, 2011.&#160;&#160;&#160;The Company received $500,019 at closing as an initial payment and will be entitled to receive earn-out payments calculated as a percentage of the future gross revenue of BioTox&#8217;s CRO services business.&#160;&#160;Over the ten-year term of the earn-out, the Company will be entitled to receive a minimum of $4,500,000 with the right to receive amounts in excess of this, depending on the gross revenue of BioTox over this ten-year period.&#160;&#160;The earn-out obligations are secured with a first priority lien on all the assets of Bio-Quant as well as the assets of BioTox for a certain period of time. After the sale, the Company does not beneficially own any equity shares in Bio-Quant or BioTox.&#160;&#160;The Company evaluated the sale of Bio-Quant in accordance with ASC Topic 205-20, <font style="DISPLAY: inline; FONT-STYLE: italic">Discontinued Operations</font>. The Company does not expect to recognize continuing direct cash flows from Bio-Quant after the sale.&#160;&#160;However, the transaction is structured with a low down payment and a payment stream over 10 years that is contingent on the operational success of BioTox. This payment structure was negotiated as a means to improve the likely cash available for investment in the growth of the business, which was expected to have the effect of&#160;&#160;encouraging higher revenues for BioTox and potentially greater earn-out payments to the Company over the ten year earn-out period.&#160;&#160;The Company does not have any vote or influence on the execution of the operations but retains a significant amount of collection risk depending on the operational success of the disposed CRO business.&#160;&#160;This continued exposure to the operating risk of BioTox and the extended post sale earn-out period indicates future continuing involvement in the continuing operations of the CRO. As such, the Company determined that it would not be appropriate to classify the sale of Bio-Quant as a discontinued operation in the consolidated financial statements.</font></font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company also considered whether BioTox should be consolidated as a Variable Interest Entity (&#8220;VIE&#8221;) under ASU No. 2009-17, <font style="DISPLAY: inline; FONT-STYLE: italic">Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities</font>. The Company determined that BioTox is a VIE because it could potentially lack sufficient equity at risk to fund its operational activities without additional subordinated financial support. The Company determined that it does not have the power to direct the activities of BioTox, nor does it have the obligation to absorb additional losses and it will not participate in any residual revenues thus it is not the primary beneficiary of the VIE. As such, the Company will not consolidate the financial information of the Buyer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The estimated fair value of the earn-out payments expected to be received over the next ten years is approximately $2.3, million which represents the minimum payments of $4,500,000 discounted at 13.0% over the ten-year period.&#160;&#160;&#160;This receivable is carried on the Company&#8217;s balance sheet as of June 30, 2011 at $0 due to a reserve of $2.3 million established at June 30, 2011, based on the length of time over which the payments will be received and lack of measurable external inputs available to determine the fair value of the minimum earn-out amounts due. This reserve increases the loss on sale of the Bio-Quant subsidiary and is not reflected as a bad debt expense. In the event that actual future cash receipts from BioTox differ from our estimates or we adjust our estimates in future periods, our financial position and results of operations could be materially impacted.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following represents proforma results for the six months ended June 30, 2011 and 2010, respectively, as if the transaction had occurred on January 1, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma financial results</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As Reported</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bio-Quant</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjusted</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,182,217</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,094,041</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,088,176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,946,748</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,258,350</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.58</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.42</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">used for basic and diluted loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,475,598</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,475,598</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,475,598</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pro forma financial results</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="10" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">As Reported</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bio-Quant</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjusted</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,916,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,560,266</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">356,413</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,516,103</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(52,499</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,463,604</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.64</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.63</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">used for basic and diluted loss per share</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,264,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,264,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,264,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The unaudited proforma condensed financial information may not necessarily be indicative of the results of operations that would have been achieved if the sale of the subsidiary had occurred at that time. The proforma adjustments are based on certain assumptions that the Company believes are reasonable under the circumstances.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ACCOUNTING FOR STOCK-BASED COMPENSATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The value of restricted stock grants is calculated based upon the closing stock price of the Company&#8217;s Common Stock on the date of the grant.&#160;&#160;For stock options granted to employees and directors, we recognize compensation expense based on the grant-date fair value estimated in accordance with the appropriate accounting guidance, and recognized over the expected service period. We estimate the fair value of each option award on the date of grant using the Black-Scholes option pricing model. Stock options and warrants issued to consultants are accounted for in accordance with accounting guidance. Compensation expense is calculated each quarter for consultants using the Black-Scholes option pricing model until the option is fully vested and is included in research and development or general and administrative facility expenses, based upon the services performed by the recipient.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 1996, the Company adopted the Stock Option and Long-Term Incentive Compensation Plan (the &#8220;Incentive Plan&#8221;) and the Recognition and Retention Stock Incentive Plan (the &#8220;Recognition Plan&#8221;).&#160;&#160;A total of 133,333 shares were set aside for these two plans.&#160;&#160;In May 2000, the Stockholders&#8217; approved an increase in the number of shares reserved for the Incentive Plan and Recognition Plan to a total of 500,000.&#160;&#160;In June 2006, the Company adopted the NexMed, Inc. 2006 Stock Incentive Plan (&#8220;the 2006 Plan&#8221;).&#160;&#160;A total of 200,000 shares were initially reserved for the issuance under the 2006 Plan and an additional 133,333 shares were added to the 2006 Plan in June 2008.&#160;&#160;The Company received stockholder approval at its May 24, 2010 meeting to add an additional 1,000,000 shares to the 2006 Plan. The Company received stockholder approval at its May 16, 2011 meeting to increase the number of shares reserved for the 2006 Plan by 2,500,000 to 3,833,333. Options granted under the Company&#8217;s plans generally vest over a period of one to five years, with exercise prices of currently outstanding options ranging from $1.69 to $48.75.&#160;&#160;The maximum term under these plans is 10 years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes information about options outstanding at June 30, 2011:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" colspan="2" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="11" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Options Outstanding</font></font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="8" valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Options Exercisable</font></font></font></td>
<td align="right" colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="right" colspan="2" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Range of</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Exercise Prices</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Number</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Outstanding</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="11%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Weighted </font></font></font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Average<br>
Remaining</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Contractual Life</font></font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Weighted</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Average</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Aggregate</font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Intrinsic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Number</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Exercisable</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Weighted</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Average</font></font></font></font></div>

<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Exercise Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Aggregate</font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Intrinsic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">1.69 - 5.36</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">870,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">9.6 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">4.36</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">109,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">4.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">85,391</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">8.25 - 48.75</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">46,818</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">4.4 years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">14.61</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">46,818</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">14.61</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">916,818</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="11%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">9.3 years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">4.88</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">156,808</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">7.18</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: times new roman">85,391</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div align="left">&#160;</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of stock option activity is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average Remaining</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></font></font></div>

<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number of</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="38%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Price</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Life</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Value</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="38%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">107,604</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.37</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5.8</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">years</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="38%" style="PADDING-LEFT: 9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">842,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="38%" style="PADDING-LEFT: 9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="38%" style="PADDING-LEFT: 9%; PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(33,286</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11.50</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="38%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at June 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">916,818</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.88</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9.3</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="38%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested or expected to vest at</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="38%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;June 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">892,431</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.88</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9.3</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="38%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at June 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">156,808</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7.18</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7.5</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">years</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Expected Volatility.</font> The Company uses analysis of historical volatility to compute the expected volatility of its stock options.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Expected Term. </font>The expected term is based on several factors including historical observations of employee exercise patterns during the Company&#8217;s history and expectations of employee exercise behavior in the future giving consideration to the contractual terms of the stock-based awards.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Risk-Free Interest Rate</font>. The interest rate used in valuing awards is based on the yield at the time of grant of a U.S. Treasury security with an equivalent remaining term.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Dividend Yield</font>. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Pre-Vesting Forfeitures</font>. Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Total unrecognized compensation cost related to unvested stock options as of June 30, 2011 was approximately $3.1 million.&#160;&#160;That cost is expected to be recognized over 3 years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Compensatory Share Issuances</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The value of restricted stock grants is calculated based upon the closing stock price of the Company&#8217;s Common Stock on the date of the grant.&#160;&#160;The value of the grant is expensed over the vesting period of the grant in accordance with FASB ASC 718.&#160;&#160;As of June 30, 2011, there was approximately $839,000 of total unrecognized compensation cost related to non-vested restricted stock.&#160;&#160;That cost is expected to be recognized over 3 years.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2011, the Board of Directors awarded Dr. Bassam Damaj, the Company&#8217;s current Chairman, President and Chief Executive Officer an option (the &#8220;Option&#8221;)<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>to purchase up to 300,000 shares of common stock of the Company.&#160;&#160;The exercise price of the Option is equal to $3.89 per share, the fair market value of the Company&#8217;s common stock on the date of grant (January 31, 2011).&#160;&#160;The Options become exercisable over a period of three years, with one-third of the Options vesting immediately upon the date of grant and the remaining two-thirds vesting quarterly over the two-year period beginning on the first anniversary of the date of grant. The expense related to this Option grant will be recorded in 2011, 2012 and 2013 based on the vesting period.&#160;&#160;&#160;As a result of this Option grant, the Company recognized approximately $429,000 as compensation expense during the six months ended June 30, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table indicates where the total stock-based compensation expense resulting from stock options and awards appears in the Unaudited Consolidated Statements of Operations:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE THREE MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX&#160;MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">110,783</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,284</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">136,420</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,284</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">415,557</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,040,090</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,009,313</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,184,643</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">526,340</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,050,374</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,145,733</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,194,927</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The stock-based compensation expense has not been tax-effected due to the recording of a full valuation allowance against U.S. net deferred tax assets.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font>5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WARRANTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of warrant activity for the six month period ended June 30, 2011 is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div>
</td>
</tr><tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common Shares</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div>
</td>
</tr><tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issuable upon</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div>
</td>
</tr><tr>
<td valign="bottom" width="49%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Price</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Life</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,675,658</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.72</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.28 years</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="49%" style="PADDING-LEFT: 4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Issued</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="49%" style="PADDING-LEFT: 4%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(581,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.27</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="49%" style="PADDING-LEFT: 4%; PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cancelled</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(16,684</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17.25</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="49%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Outstanding at June 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,077,642</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.29</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.54 years</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="49%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercisable at June 30, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">922,043</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.63</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.46 years</font></div>
</td>
</tr></table>
</div>

<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LOSS PER SHARE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At June 30, 2011 and 2010, respectively, options to acquire 916,818 and 156,771 shares of Common Stock, warrants to acquire 1,077,642 and 250,895 shares of Common Stock and convertible securities convertible into 636,257 and 466,200 shares of Common Stock were excluded from the calculation of diluted loss per share, as their effect would be anti-dilutive.&#160;&#160;Loss per share for the three and six months ended June 30, 2011 and 2010 was calculated as follows (net loss / weighted average common shares outstanding):</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE THREE MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30,</font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(7,794,092</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,278,647</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,516,103</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;used for basic and diluted loss per share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,817,009</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,140,451</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,475,598</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,264,515</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#c0ffc0">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic and diluted loss per common share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.39</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.47</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.58</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1.64</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr></table>
</div>

<div align="left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;INTANGIBLE ASSETS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">The intangible assets of the Company at December 31, 2010 and through June 30, 2011 consisted of Know-How and Trade Name related to the Bio-Quant CRO segment. On June 30, 2011, the Bio-Quant business was sold to BioTox and the intangibles associated with the business were removed from the consolidated accounts of the Company. During 2010 and for the first half of 2011, the Company amortized Know-How over the expected useful life of 10 years and the Trade Name over the expected useful life of 20 years. </font>Amortization expense amounted to $59,509 and $179,924 for the six months ended June 30, 2011 and 2010, respectively.&#160;&#160;During 2010, the Company took an impairment charge of $1,083,646 to write down the fair value of Know-How to $1,637,000.&#160;&#160;<font style="DISPLAY: inline">Such impairment was derived mainly from the fact that Bio-Quant significantly changed its strategic focus in 2010.&#160;&#160;Rather than serve the greater CRO market, Bio-Quant was primarily performing </font>internal <font style="DISPLAY: inline">CRO services for the Company&#8217;s own pharmaceutical product development segment</font> (NexMed USA).<font style="DISPLAY: inline">&#160;&#160;As such, the ongoing revenue, profits and cash flows for Bio-Quant were significantly reduced from the initial projections for Bio-Quant when it was acquired by the Company in December 2009.</font></font></font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONVERTIBLE NOTES PAYABLE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">2010 Convertible Notes</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 15, 2010, the Company issued convertible notes (the &#8220;2010 Convertible Notes&#8221;) in an aggregate principal amount of $4 million. The 2010 Convertible Notes are secured by a first priority mortgage on the Company&#8217;s facility in East Windsor, New Jersey and are due on December 31, 2012.&#160;&#160;The proceeds were used to repay the 2008 Convertible Notes (see below) then outstanding in the aggregate sum of $2.6 million.&#160;&#160;As such, the Company received approximately $1.4 million in net proceeds from the issuance of the 2010 Convertible Notes.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The 2010 Convertible Notes are, at the holders&#8217; option,&#160;&#160;payable in cash at maturity on December 31, 2012 or convertible at any time into shares of Common Stock at a current conversion price of $6.29 per share (with an initial conversion price of $8.70 per share) (the &#8220;conversion price&#8221;), which price is subject to adjustment upon certain dilutive issuances of common stock.&#160;&#160;The 2010 Convertible Notes have a coupon rate of 7% per annum, which is payable at the Company&#8217;s option in cash or, if the Company&#8217;s net cash balance is less than $3 million at the time of payment, in shares of Common Stock.&#160;&#160;If paid in shares of Common Stock, then the price of the stock issued will be the lesser of $1.20 below or 95% of the five-day weighted average of the market price of the Common Stock prior to the time of payment.&#160;&#160;Such additional interest consideration is considered contingent and therefore would only be recognized upon occurrence.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The conversion price at June 30, 2011 was $6.29 per share which represents an adjusted price from $8.70 at issuance due to certain dilutive equity financings since the issuance of the notes. At June 30, 2011, the conversion price was above the current market price of the Common Stock.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Conversion of 2008 convertible notes during 2010</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 26, 2010, the Company agreed to convert $397,988 of the then outstanding 2008 Convertible Notes into Common Stock at a price of $7.50 per share.&#160;&#160;As such, the Company issued 53,333 shares of Common Stock to the note holders in repayment of such $397,988 principal amount plus interest.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The remaining balance outstanding on the remaining 2008 Convertible Notes of $2,592,012 was repaid in full on March 15, 2010 with the proceeds received from the 2010 Convertible Notes.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized a debt inducement charge in interest expense for the differential between the original conversion rate of $30.00 per share and the various adjusted conversion prices in 2009 and 2010.&#160;&#160;Non-cash interest expense recognized for these conversions was $1,200,000 during the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;NOTES PAYABLE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Former Bio-Quant Shareholders&#8217; Notes</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 14, 2009, the Company issued $12,129,010 in promissory notes (the &#8220;Notes&#8221;) in connection with the acquisition of Bio-Quant as discussed in Note 2 above. The Notes bore interest at a rate of 10% per annum, with all principal and interest accrued thereunder becoming due and payable one year from the closing date of the Merger, or December 14, 2010.&#160;&#160;The terms of the Notes provided that the principal amounts and all interest thereunder were payable by the Company in cash or, at the Company&#8217;s option, in shares of Company common stock, which were valued at the fixed price of $2.52 per share.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January and March 2010, the Company repaid $2,230,201 of outstanding principal of the Notes through the issuance of Common Stock at $2.52 per share, which is the fixed payment price pursuant to the terms of the Notes.&#160;&#160;As such, the Company issued 1,003,210 shares of Common Stock to the note holders in repayment of such $2,230,201 principal amount plus interest.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company recognized a beneficial conversion charge for the differential between the original conversion rate of $2.52 per share and the market price of the Company&#8217;s Common Stock at the time of the above payments.&#160;&#160;As such the beneficial conversion charge non-cash interest expense recognized with respect to the Notes for the&#160;&#160;three and six months ended June 30, 2010 was $1,627,101and $6,139,741, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">2010 Promissory Notes</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January 2010, the Company raised gross proceeds of $2.3 million in an offering of unsecured promissory notes (the &#8220;2010 Notes&#8221;).&#160;&#160;The 2010 Notes accrued interest at a rate of 10% per annum and were due and payable in full six months from the date of issuance. The principal and accrued interest due under the Notes was payable, at the election of the Company, in either cash or shares of Common Stock, par value $0.001 per share.&#160;&#160;The weighted average conversion price of the 2010 Notes was $5.55 per share, with the conversion prices ranging from $5.40 to $6.00 per share.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 17, 2010, the 2010 Notes were repaid in full with the issuance of 415,504 shares of common stock to repay such $2.3 million principal amount and interest.&#160;&#160;The Company recognized a beneficial conversion charge on the differential between the original conversion rates of $5.40 to $6.00 per share and the market price of the Company&#8217;s Common Stock at the time of repayment.&#160;&#160;The Company has recorded a beneficial conversion charge to interest expense of $0 and $660,819 during the three and six months ended June 30, 2010, respectively, as a result of the conversion.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LINES OF CREDIT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 8, 2010, Bio-Quant entered into a Loan and Security Agreement with Square 1 Bank for a revolving line of credit (&#8220;Credit Line&#8221;) in the amount of $250,000.&#160;&#160;The Credit Line was secured by a $255,000 cash deposit from the Company which was classified as restricted cash on the accompanying consolidated balance sheet at December 31, 2010.&#160;&#160;The Credit Line bore interest at the rate of 4.25% per annum or 1% above the Prime Rate and expired on March 7, 2011 and was repaid in full at that time.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 12, 2010, Bio-Quant entered into a Loan and Security Agreement with Torrey Pines Bank for a revolving line of credit (&#8220;TP Credit Line&#8221;) in the amount of $250,000.&#160;&#160;The TP Credit Line was secured by a $278,824 cash deposit from the Company which is included in restricted cash on the accompanying consolidated balance sheet at December 31, 2010.&#160;&#160;The TP Credit Line bore interest at the rate of 2.6% per annum and expired on April 12, 2011 and was repaid in full at that time.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFERRED COMPENSATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February 27, 2002, the Company entered into an employment agreement with Y. Joseph Mo, Ph.D., that had a constant term of five years, and pursuant to which Dr. Mo would serve as the Company's Chief Executive Officer and President.&#160;&#160;Under the employment agreement, Dr. Mo was entitled to deferred compensation in an annual amount equal to one sixth of the sum of his base salary and bonus for the 36 calendar months preceding the date on which the deferred compensation payments commenced subject to certain limitations, including annual vesting through January 1, 2007, as set forth in the employment agreement.&#160;&#160;The deferred compensation is payable monthly for 180 months commencing on termination of employment.&#160;&#160;Dr. Mo&#8217;s employment was terminated as of December 15, 2005.&#160;&#160;At such date, the Company accrued deferred compensation of $1,178,197 based upon the estimated present value of the obligation.&#160;&#160;The monthly deferred compensation payment through May 15, 2021 is $9,158.&#160;&#160;As of June 30, 2011, the Company has a discounted accrued balance of approximately $839,500 included in deferred compensation. The remaining amounts accrued in Deferred Compensation also relate to severance amounts due to former employees of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;COMMON STOCK TRANSACTIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 21, 2010, the Company entered into a Sales Agreement with Brinson Patrick Securities Corporation (the &#8220;Sales Manager&#8221;) to issue and sell through the Sales Manager, as agent, up to $10,000,000 of common stock from time to time pursuant to the Company&#8217;s effective shelf registration statement on Form S-3 (File No. 333-165960).&#160; During the six months ended June 30, 2011, the Company had sold an aggregate of 674,466 shares of common stock under the Sales Agreement at a weighted average sales price of approximately $4.26 per share, resulting in offering proceeds of approximately $2.7 million, net of sales commissions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2010, the Company had sold an aggregate of 518,264 shares of common stock under the Sales Agreement at a weighted average sales price of approximately $6.73 per share, resulting in offering proceeds of approximately $3.3 million, net of sales commissions.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approximately 63% of the Bio-Quant notes payable described in Note 8 were held by executives of the Company.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FasTrack Pharmaceuticals, Inc. (&#8220;FasTrack&#8221;) and Sorrento Pharmaceuticals, Inc. (&#8220;Sorrento&#8221;) were formed by Bio-Quant in 2008 and in 2009 Bio-Quant spun-off its pharmaceutical assets to the two companies to enable it to focus on its core business of pre-clinical CRO testing services.&#160;&#160;&#160;FasTrack subsequently acquired Sorrento&#8217;s assets and liabilities in March 2011.&#160;&#160;FasTrack is a privately-held, development stage company of whom two executive officers and one director of the Company are minority shareholders.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">On April 4, 2011 the Company and FasTrack entered&#160;&#160;into an Asset Purchase Agreement</font>,<font style="DISPLAY: inline"> pursuant to which</font><font style="DISPLAY: inline"> FasTrack sold </font>to the Company all <font style="DISPLAY: inline">the rights</font> it had<font style="DISPLAY: inline"> in </font>certain <font style="DISPLAY: inline">back-up compounds for PrevOnco</font>&#8482;.<font style="DISPLAY: inline">&#160;</font>PrevOnco&#8482; for the treatment of solid tumors, contains a marketed anti-ulcer compound, lansoprazole that could be <font style="DISPLAY: inline">used alone or in combination with other chemotherapeutic agents.&#160; The Company believes </font>PrevOnco&#8482; <font style="DISPLAY: inline">can be optimized further to increase its efficacy in combination with our NexAct&#174; technology.&#160;</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In exchange for the PrevOnco&#8482; back up compound portfolio, the Company loaned FasTrack $250,000 in the form of a secured convertible note and restructured the existing outstanding demand notes and interest payable due to the Company into a second secured convertible note in the amount of $224,520. The notes are due on April 4, 2013 and bear interest at the rate of prime plus 1% (currently 4.25%).&#160;&#160;The notes automatically convert to common stock of FasTrack if, prior to the maturity date,&#160;&#160;FasTrack completes a material round of financing, or closes a merger or acquisition transaction (&#8220;M&amp;A event&#8221;), or completes a public offering at an offering price equal to the financing or M&amp;A value at that time discounted by 10%.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition and separately, the Company granted FasTrack an option to enter into a license to the Company&#8217;s NexACT&#174; permeation enhancer for the combination of two to-be-determined specific drugs chosen by FasTrack and agreed to by the Company. It is understood that these to-be-determined products would be outside of the Company&#8217;s core focus and expertise and it is expected that these drugs would not be candidates that the Company would likely pursue on its own. Under the terms of the license, the Company would receive $500,000 in cash, plus milestones of more than $5,000,000 per compound, and product sales royalties following the exercise of the license option by FasTrack.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company considered whether FasTrack should be consolidated as a Variable Interest Entity (VIE) under ASU No. 2009-17, <font style="DISPLAY: inline; FONT-STYLE: italic">Consolidations (Topic 810): Improvements to Financial Reporting by Enterprises Involved with Variable Interest Entities</font>. The Company determined that FasTrack is a VIE because it lacks sufficient equity at risk to fund its operational activities without additional subordinated financial support. The Company has a variable interest in the VIE related to the convertible notes due from FasTrack even though we do not currently have a direct equity interest in FasTrack.&#160;&#160;In the accompanying consolidated financial statements the loans and Notes are valued at a zero book value at June 30, 2011 and December 31, 2010 for accounting purposes for lack of marketability of the FasTrack entity. As a result of the notes being carried with no value, the net impact to the consolidated financial statements in the case of a consolidation for the periods ended June 30, 2011 and 2010 would be insignificant and thus FasTrack has not been consolidated as its operations are not material to the Company.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In July 2011, FasTrack entered into a merger agreement with a publicly-traded Company, North Horizon, Inc. Under the agreement, FasTrack will become a subsidiary of North Horizon. The shareholders, noteholder, and warrantholder of FasTrack will receive in the transaction the number of shares comprising 92% of the fully-diluted shares of North Horizon. The transaction is subject to customary closing conditions. Apricus makes no representation as to the likelihood of completion of the transaction or of the value that may be associated with the interests of Apricus following the merger.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;INCOME TAXES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has incurred losses since inception, which have generated net operating loss carryforwards of approximately $36 million for federal and state income tax purposes through December 31, 2010.&#160;&#160;These carryforwards are available to offset future taxable income and expire beginning in 2014 through 2029 for federal income tax purposes.&#160;&#160;Internal Revenue Code Section 382 places a limitation on the utilization of federal net operating loss carryforwards when an ownership change, as defined by tax law, occurs.&#160;&#160;Generally, an ownership change, as defined, occurs when a greater than 50 percent change in ownership takes place during any three-year period. The Company performed a review of stock transactions for the years beginning January 1, 2008 and ending December 31, 2010 as the Company feels that was the likely period that such an ownership change likely occurred.&#160;&#160;Based on this limited review, the Company determined that an ownership change took place in June 2010 when the Bio-Quant notes were converted to common stock as discussed in Note 8.&#160;&#160;As a result of this ownership change, the ability to utilize the current net operating loss carryforwards generated prior to this change in ownership is limited to approximately $1.2 million per year based on our calculations at the time of the ownership change.&#160;&#160;The Company has recorded a full valuation allowance against the deferred tax assets arising from the net operating loss carryforwards.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company follows the provisions of ASC 740-10-25. ASC 740-10-25 provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company&#8217;s Federal income tax returns for 2007 to 2009 are still open and subject to audit.&#160;&#160;In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.&#160;&#160;The Company had no tax positions relating to open income tax returns that were considered to be uncertain. Accordingly, we have not recorded a liability for unrecognized tax benefits upon adoption of ASC 740-10-25. There continues to be no liability related to unrecognized tax benefits at June 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vitaros&#174; - (2011 &#8211; 2010)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 22, 2010, the Company entered into an exclusive license agreement with Bracco SpA (&#8220;the &#8220;Bracco License Agreement&#8221;)&#160;&#160;for its <font style="DISPLAY: inline">Vitaros&#174; product</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>for erectile dysfunction. Under the terms of the Bracco License Agreement, Bracco has been granted exclusive rights in Italy to commercialize and market Vitaros<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#174;</font> under the Bracco trademark, and the Company received <font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8364;</font>750,000 as an up-front payment and is entitled to receive up to <font style="DISPLAY: inline; FONT-SIZE: 10pt">&#8364;</font>4.75 million in regulatory and sales milestone payments.&#160;&#160;Further, over the life of the agreement, the Company will receive royalties based on Bracco's sales of the product.&#160;&#160;The expected up-front payment from Bracco was received in April 2011, in the amount of USD $1,000,000, net of withholding taxes. Of this amount, approximately $669,000 was recognized as license revenue in the second quarter of 2011 in accordance with our revenue recognition criteria and the remaining amount was deferred and will be recognized at the time that the Company receives regulatory marketing approval for the product in Europe in accordance with the Bracco license agreement.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 3, 2011, the Company entered into a license agreement (the &#8220;Elis License Agreement&#8221;) with Elis Pharmaceuticals Ltd. (&#8220;Elis&#8221;), granting Elis the exclusive rights to commercialize&#160;&#160;Vitaros&#174; for erectile dysfunction in the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia, Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen (the &#8220;Elis Territory&#8221;). Under the Elis License Agreement, the Company is entitled to receive upfront license fees and milestone payments of up to $2.1 million over the term of the Elis License Agreement.&#160;&#160;The future milestones are tied to regulatory approval and the achievement of certain levels of aggregate net sales of Vitaros<font style="DISPLAY: inline; BORDER-BOTTOM: 1pt double; TEXT-DECORATION: underline">&#174;</font>.&#160;&#160;Additionally, the Company is entitled to receive escalating tiered double-digit royalties on Elis&#8217;s sales of Vitaros<font style="DISPLAY: inline; BORDER-BOTTOM: 1pt double; TEXT-DECORATION: underline">&#174;</font> in the Elis Territory.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On February, 14,&#160;&#160;2011 the Company entered into a license agreement (the &#8220;Neopharm License Agreement&#8221;) with the Neopharm Group (&#8220;Neopharm&#8221;), granting Neopharm the exclusive rights to commercialize&#160;&#160;Vitaros&#174; for erectile dysfunction and when and if available, the Company&#8217;s product for premature ejaculation in&#160;&#160;Israel and the Palestinian Territories (the &#8220;Neopharm Territory&#8221;).&#160;&#160;Under the Neopharm License Agreement, the Company is entitled to receive upfront license fees and milestone payments of up to $4.35 million over the term of the Neopharm License Agreement.&#160;&#160;The future milestones are tied to regulatory approval and the achievement of certain levels of aggregate net sales of Vitaros&#174;.&#160;&#160;Additionally, the Company is entitled to receive escalating tiered double-digit royalties on Neopharm&#8217;s sales of Vitaros&#174; in the Neopharm Territory.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company received $203,000 in up-front payments pursuant to the Elis and Neopharm licensing agreements and has recorded the payments as license fee revenue during the six months ended June 30, 2011.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In April 2011, the Company filed a marketing application in Europe for Vitaros&#174; for erectile dysfunction.&#160;&#160;If it is approved by the various European regulatory authorities, it would give the Company the right to sell Vitaros<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#174;</font> in multiple chosen countries in the European Union. Under a European system called the &#8220;Decentralized Procedure&#8221; (DCP), a company files its application for marketing approval of a drug in just one European country, which is designated the Reference Member State (RMS). The Company has chosen The Netherlands as its RMS. The RMS then evaluates the application and prepares an assessment report that is submitted to other chosen European Union countries for their consideration and approval.&#160;The entire review process on average requires approximately 240 days not including additional time associated with responses to regulatory review questions. One of the major advantages of the DCP is that a company may receive identical marketing authorizations for its product in multiple chosen European Member countries at the same time.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vitaros&#174; &#8211; (2009 &#8211; 2007)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-FAMILY: times new roman">On November 1, 2007, the Company signed an exclusive licensing agreement with Warner Chilcott Company, Inc., (&#8220;Warner Chilcott&#8221;) for Vitaros&#174; for erectile dysfunction.&#160;&#160;Under the agreement, Warner Chilcott acquired the exclusive rights in the United States to Vitaros&#174; and would assume all further development, manufacturing, and commercialization responsibilities as well as costs.&#160;&#160;</font></div>

<div>&#160;</div>

<div>On February 3, 2009, the Company terminated the licensing agreement and sold the U.S. rights for Vitaros&#174;&#160;to Warner Chilcott.&#160;&#160;Under the terms of the Asset Purchase Agreement, the Company received an up-front payment of $2.5 million and is eligible to receive an additional payment of $2.5 million upon Warner Chilcott&#8217;s receipt of a New Drug Application (NDA) approval for Vitaros&#174;from the FDA.&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employment Agreements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have an employment agreement with Dr. Damaj, our Chairman, President and Chief Executive Officer. Pursuant to that agreement, we may terminate Dr. Damaj&#8217;s employment without cause on ten days notice, in which event Dr. Damaj would be entitled to severance pay equal to twelve months&#8217; base salary which is currently $450,000 per annum.&#160;&#160;&#160;The employment agreement further provides that in the event that within one year after a &#8220;Change of Control&#8221; (as defined therein) of the Company occurs, and the President and Chief Executive Officer&#8217;s employment is terminated or resigns for cause, the President and Chief Executive Officer will be paid a lump sum amount equal to his base salary for a 12-month period following termination or resignation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company is a party to other employment and compensatory agreements in the normal course of business and the<font style="DISPLAY: inline"> Company is a party to numerous short-term consulting and research agreements that, generally, can be cancelled pursuant to the terms of such agreements.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are subject to certain legal proceedings in the ordinary course of business.&#160;&#160;We do not expect any such items to have a significant impact on our financial position.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SEGMENT INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Through June 30, 2011, the Company had two active business segments: designing and developing pharmaceutical products with its NexACT&#174; drug delivery technology and providing pre-clinical CRO services through its subsidiary, Bio-Quant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Segment information for the six months ended June 30, 2011 and 2010, respectively is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30, 2011</font></div>
</td>
</tr></table>
</div>
</div>

<div>
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NexACT</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Drug</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery</font></font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bio-Quant CRO</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate Not</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Allocated to</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Segments</font></font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">871,449</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,094,041</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">216,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,182,217</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating expenses</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,072,378</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,189,553</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6,163,661</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12,425,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,200,929</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(174,099</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,879,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,254,608</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,200,929</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(186,828</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,817,341</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,205,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,080,283</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,080,283</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FOR THE SIX MONTHS</font></div>
</td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ENDED JUNE 30, 2010</font></div>
</td>
</tr></table>
</div>
</div>

<div align="left">
<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NexACT</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Drug</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery</font></font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bio-Quant CRO</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font></font> </font>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Corporate Not</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Allocated to</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Segments</font></font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" nowrap valign="bottom" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated </font></font>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></font></font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,560,266</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">321,313</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,916,679</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating expenses</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">916,743</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">768,488</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,098,664</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,783,895</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from operations</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(881,643</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(63,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,981,514</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(4,926,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(881,643</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(52,499</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(12,581,961</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(13,516,103</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total assets</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,045,423</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,435,240</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24,480,663</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div align="left">&#160;</div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;STOCKHOLDER RIGHTS PLAN</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 24, 2011, pursuant to the Company&#8217;s shareholders rights plan (the &#8220;Plan&#8221;) the Company declared a dividend distribution of one preferred share purchase Right for each outstanding share of the Company's<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>Common Stock to shareholders of record at the close of business on April 1, 2011.&#160; Initially, these rights will not be exercisable and will trade with the shares of the Company's common stock.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under the Plan, the rights generally will become exercisable if a person or group acquires beneficial ownership of 15% or more of the Company's common stock in a transaction not approved by the Company's Board. In that situation, each holder of a right (other than the acquiring person) will be entitled to purchase, at the then-current exercise price, additional shares of common stock having a value of twice the exercise price of the right. In addition, if the Company is acquired in a merger or other business combination after an unapproved party acquires more than 15% of the Company's common stock, each holder of the right would then be entitled to purchase at the then-current exercise price, shares of the acquiring company's stock, having a value of twice the exercise price of the right.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><br>
&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Board may redeem the rights for a nominal amount at any time before an event that causes the rights to become exercisable. The rights will expire on April 1, 2021.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2.&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosures Regarding Forward-Looking Statements.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following should be read in conjunction with the unaudited consolidated financial statements and the related notes that appear elsewhere in this document as well as in conjunction with the Risk Factors section herein and in our Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 10, 2011 and our Form 10-Q for the quarter ended March 31, 2011 filed with the Securities and Exchange Commission on May 13, 2011. These reports include forward-looking statements made based on current management expectations pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and actual outcomes may differ materially from what is expressed or forecast. There are many factors that affect our business, consolidated financial position, results of operations and cash flows, including but not limited to, our ability to enter into partnering agreements or raise financing on acceptable terms, successful completion of clinical development programs, regulatory review and approval, product development and acceptance, anticipated revenue growth, manufacturing, competition, and/or other factors, many of which are outside our control.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company operates in a rapidly changing business, and new risk factors emerge from time to time. Management cannot predict every risk factor, nor can it assess the impact, if any, of all such risk factors on the Company&#8217;s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those projected in any forward-looking statements.&#160;&#160;Accordingly, forward-looking statements should not be relied upon as a prediction of actual results and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Corporate History</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a Nevada corporation and have been in existence since 1987.&#160;&#160;<font style="DISPLAY: inline">On September 10, 2010, the Company changed its name from &#8220;NexMed, Inc.&#8221; to &#8220;Apricus Biosciences, Inc</font>.&#8221;&#160;&#160;We have operated in the pharmaceutical industry since 1995, focusing primarily on research and development in the area of drug delivery.&#160;&#160;Our proprietary drug delivery technology is called NexACT<font style="DISPLAY: inline">&#174;</font>.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 14, 2009, we acquired Bio-Quant, Inc. (&#8220;Bio-Quant&#8221;), a specialty biotechnology contract research organization (&#8220;CRO&#8221;) based in San Diego, California and one of the industry's most experienced CROs for non-GLP (good laboratory practices) contract drug discovery and pre-clinical development services, specializing in oncology, inflammation, immunology, and metabolic diseases. Bio-Quant has clients world-wide and performs hundreds of studies a year in pharmacology, pharmacokinetics and toxicology to support pre-investigational new drug enabling<font style="DISPLAY: inline">&#160;</font>packages. Bio-Quant&#8217;s revenue to date has been derived from pre-clinical contract services, sales of diagnostic kits and housing services.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a result of our acquisition of Bio-Quant, we had two operating segments through June 30, 2011: designing and developing pharmaceutical product candidates (&#8220;The NexACT<font style="DISPLAY: inline">&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>drug delivery technology business&#8221;) and providing pre-clinical CRO services (&#8220;The Bio-Quant CRO business&#8221;).&#160;&#160;The sales of diagnostic kits by Bio-Quant did not constitute a reporting segment at the time as the assets and revenues are not material in relation to our operations as a whole, but the results of that business segment are included in the Bio-Quant CRO business discussion.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011, the Company entered into a stock purchase agreement with Samm Solutions, Inc. doing business as BioTox Sciences (&#8220;BioTox&#8221;), a San Diego-based CRO to sell all of the outstanding capital stock of Bio-Quant, which was one of the Company&#8217;s wholly owned subsidiaries.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Subsequent to June 30, 2011 we will operate in one segment and the sales of diagnostic kits whose assets and revenues are not material in relation to our operations as a whole will be included in the remaining segment designing and developing pharmaceutical products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Growth Strategy</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are currently focusing the majority of our efforts on commercializing and developing new pharmaceutical products based on our patented drug delivery technology known as NexACT&#174;.<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">.</font> <font style="DISPLAY: inline">Our strategy is to continue to develop new applications of </font>NexACT<font style="DISPLAY: inline">&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline">to attract commercial and development partners to license both our NexACT&#174;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline">technology and </font>our <font style="DISPLAY: inline">pipeline </font>of product candidates.<font style="DISPLAY: inline">&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Develop and Monetize Pipeline</font>.&#160;&#160;We are seeking to derive value from our current pipeline of 13 clinical and pre-clinical candidates through out-licensing, sales and commercial partnerships.&#160;&#160;In doing so, we are seeking to find development partners who will bear substantially all of the future costs associated with the development of these programs in exchange for granting the partners the rights to commercialize the drugs, if approved.&#160;&#160;Each agreement&#160;with those development partners&#160;may include a combination of upfront payments, license and/or milestone fees and future royalty payments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We currently have one drug, Vitaros&#174; for erectile dysfunction, approved for marketing in Canada.&#160;&#160;We have filed for marketing approval for Vitaros&#174; for erectile dysfunction in the European Union in April 2011 through the Decentralized Procedure,&#160;&#160;and filed in July 2011 in Switzerland.&#160;&#160;The Company intends to file for marketing approval for Vitaros&#174; for erectile dysfunction in Latin America and in other countries.&#160;&#160;We currently have commercialization partners for Vitaros&#174; for erectile dysfunction in Italy (Bracco), the Gulf countries and parts of the Middle East (Elis Pharmaceuticals) and in Israel and the Palestinian Territories (Neopharm) and are seeking commercialization partners in Canada, Europe and in other countries.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our other four later stage product candidates are (1) Femprox&#174; for the treatment of female sexual arousal disorder (Phase III); (2) MycoVa&#174; for oncychomycosis excluding tinea pedis (nail fungal infection) (Phase III); (3) Prevonco&#8482; for the treatment of solid tumors (Phase II/Phase III); and (4) RayVa&#8482; for Raynaud&#8217;s Syndrome (Phase II/Phase III).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We intend to continue our efforts developing treatments based on the application of NexACT&#174; technology to drugs: (1) previously approved by the FDA, (2) with proven efficacy and safety profiles, (3) with patents expiring in the near term or expired and (4) with proven market track records and potential.&#160;&#160;Further, we have begun to develop new formulations based on the application of NexACT&#174; technology to drug compounds in the areas of oncology, pain/inflammation, autoimmune diseases, and metabolic diseases.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">NexACT&#174; as a Licensing Platform</font>.&#160;&#160;In addition to seeking to monetize our existing pipeline, we are seeking to derive value from our NexACT&#174; technology platform as a means of enhancing the delivery of other companies&#8217; drugs and drug candidates.&#160;&#160;NexACT&#174; can be used to deliver drugs through different methods of administration and can be used as a means to enhance the bioavailability of drugs.&#160;&#160; Moreover, we believe that we can enhance our business development efforts by offering potential partners clearly defined regulatory paths for our products under development.&#160;&#160;Towards that end, we will continue to work closely with our regulatory and clinical consultants, and meet with the FDA in order to obtain Special Protocol Assessments, or SPAs, for our planned clinical studies.&#160;&#160;When the FDA grants an SPA for a study, the FDA generally cannot change the clinical endpoints at a later date.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue Sources</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">License Revenue</font>.&#160;&#160;The Company entered into two license agreements for Vitaros&#174; in the first quarter of 2011.&#160;&#160;Pursuant to these agreements, the Company received approximately $203,000 in upfront license fees in the first quarter.&#160;&#160;In April 2011, we received an initial license fee from Bracco in the amount of approximately $1,000,000, of which $669,000 was recognized as revenue in the second quarter of 2011.&#160;&#160;We will continue to pursue new licenses for Vitaros, as well as the Company&#8217;s drug candidates and NexACT&#174; platform technology.&#160;&#160;&#160;However, the timing for these new agreements is inherently uncertain.&#160;&#160;Additionally, the timing of milestone payments under existing license agreements is similarly uncertain and can vary significantly from quarter to quarter.&#160;&#160;Accordingly, although we expect an overall increase in license revenue in future periods, the amount and timing of these increases is unknown at this time.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Contract Service Revenue</font>.&#160;&#160;During the first part of 2011, a more substantial portion of the pre-clinical contract services performed by Bio-Quant were in support of the expansion of the use of our NexACT&#174; technology to multiple routes and classes of drugs. Our strategy, which started in the fourth quarter of 2010 had been to continue to divert the Bio-Quant CRO&#8217;s revenue generating capacity to our own technology and pipeline development projects in order to generate sufficient data to attract commercial and development partners to license both our NexACT&#174; technology and pipeline products. We believe that if we are able to enter into such licensing agreements they would be expected to generate higher revenue and greater return for our shareholders than we could make from the Bio-Quant CRO business.&#160;&#160;On June 30, 2011, we sold the Bio-Quant CRO business and subsequent to June 30, 2011, we will no longer receive or recognize contract services revenue from the CRO business. Contract service revenue from the Bio-Quant operating segment was approximately $2.0 million in the first half of 2011. The sale of the Bio-Quant business was structured with an earn-out from the buyer that could generate significant cash flows for the Company beginning in the second half of 2012.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity, Capital Resources and Financial Condition.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have experienced net losses and negative cash flows from operations each year since our inception.&#160;&#160;Since the Company&#8217;s inception and through June 30, 2011, we had an accumulated deficit of approximately $212 million.&#160;&#160;Our operations have principally been financed through private placements of equity securities, debt financing and up-front payments received from commercial partners for our products under development.&#160;&#160;Funds raised in past periods should not be considered an indication of our ability to raise additional funds in any future periods.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We currently expect to be cash flow positive from operations in 2011, which includes cash expected to be received from up-front and milestone payments from the licensing of our products and NexACT&#174; <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>technology, with the current goal of becoming profitable in 2012 or 2013 as we anticipate entering into out-licensing agreements for our NexACT&#174; <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>technology with pharmaceutical and biotechnology companies worldwide and start receiving royalty from sales and milestones of our approved drug Vitaros&#174; in Canada.&#160;&#160;We also are actively pursuing partnering opportunities for our clinical stage NexACT&#174; based and non NexACT&#174; based candidates in the areas of oncology, inflammation, dermatology, pain, autoimmune diseases and sexual dysfunction.<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>The successful licensing of one or more of these candidates and/or the NexACT&#174; technology itself would be expected to generate significant revenues for funding our current operations and long-term growth strategy.&#160;&#160;Even if we are successful in obtaining partners who can assume the funding for further development of our products, we may still encounter additional obstacles such as our research and development activities may not be successful, our products may not prove to be safe and effective, clinical development work may not be completed in a timely manner or at all, and the anticipated products may not be commercially viable or successfully marketed. </font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">Our current cash reserves </font>were<font style="DISPLAY: inline"> approximately $7.5 million as of the date of filing this </font>Report on <font style="DISPLAY: inline">Form 10-Q, which includes the </font>$1 million received from Bracco in April 2011 pursuant to the license agreement signed in December 2010 <font style="DISPLAY: inline">and $500,019 received from BioTox in June 2011 pursuant to the stock purchase agreement for the </font>sale <font style="DISPLAY: inline">of&#160;&#160;our wholly-owned subsidiary Bio-Quant</font>. Our current cash needs include monthly <font style="DISPLAY: inline">operating expenses of maintaining our public listing and continuing our current business development and research and development efforts for our current pipeline of products.&#160;&#160;Our business will require additional financing if we chose to accelerate product development expenditures in advance of receiving up-front payments from development and commercial partners. The timing of receipt of up-front and milestone payments is difficult to estimate and we will </font>seek to <font style="DISPLAY: inline">obtain additional outside equity capital as necessary to support the commercial opportunities for our product portfolio. </font>To the extent we sign licensing agreements in 2011 and 2012 for our approved Vitaros&#174;product in larger sales territories and for other products in our pipeline<font style="DISPLAY: inline"> and/or the NexACT&#174; technology itself, </font>we expect that <font style="DISPLAY: inline">our cash reserves </font>could<font style="DISPLAY: inline"> provide us with sufficient cash to fund our operations well into 2013.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">At June 30, 2011, we had cash and cash equivalents of approximately $9.1 million, equivalent to the $9.1 million at December 31, 2010.&#160;&#160;&#160;During the first half of 2011, we received net proceeds of approximately $2.7 million as a result of the sale of our Common Stock and pursuant to a Sales Agreement as discussed in Note 12 to the consolidated financial statements</font>.&#160;&#160;We also received net proceeds of approximately $1.3 million from the exercise of warrants and $0.5 million at June 30, 2011 from the sale of the Bio-Quant subsidiary.&#160;&#160;The receipt of this cash during the first half of 2011 was offset by o<font style="DISPLAY: inline">ur cash used from operations.&#160;&#160;Our net cash outflow from operations during the first half of the year was approximately $4.5 million which resulted from the increase in expenditures for research and development activities as we seek to commercialize our Vitaros&#174; product for sale in the Canadian market and obtain market approval in other regions. During the first half of 2011, we operated our Bio-Quant CRO which contributed revenue </font>for<font style="DISPLAY: inline"> us, yet had a net use of cash </font><font style="DISPLAY: inline">in the first half of 2011. Our net outflows related to Bio-Quant will be eliminated with the sale of the operation on June 30, 2011 and the transaction was structured with an earn-out that allows for cash to be received by us over the next 10 years based on the success of the buyer, BioTox. Our operational structure with a minimum number of employees and limited space need allows us to closely regulate our level of expenditures and to quickly adjust our spending rates as commercial opportunities develop. We operate in a rapidly changing and highly regulated marketplace and we expect to adjust our capital needs and financing plans as market conditions dictate.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Critical Accounting Estimates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.&#160;&#160;&#160;The preparation of these financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities.&#160;&#160;Our accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.&#160;&#160;Actual results could differ from these estimates.&#160;&#160;There have been no material changes to our Critical Accounting Policies described in our Report on Form 10-K, as filed with the Securities and Exchange Commission on March 10, 2011.</font></font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Comparison of Results of Operations Between the Three Months Ended June 30, 2011 and 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Revenue</font>.&#160;&#160;We recorded $1,595,152 in revenue during the second quarter of 2011, as compared to $1,470,927 in revenue during the second quarter of 2010.&#160;&#160;The increase in revenue is primarily attributable to $669,000 in revenue recognized in 2011 as a result of the licensing agreements signed in 2010 for Vitaros&#174; for erectile dysfunction.&#160;&#160;The 2011 revenue attributable to the sales of CRO services by Bio-Quant was approximately $500,000 less than the second quarter in 2010.&#160;&#160;The decrease in revenue is the result of our change in strategy in 2010 to divert Bio-Quant&#8217;s capacity to our own technology and pipeline development projects.&#160;&#160;On June 30, 2011, we sold Bio-Quant to BioTox.&#160;&#160;As a result of the sale we will no longer be recognizing revenues related to Bio-Quant&#8217;s CRO business in subsequent periods.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Research and Development Expenses</font>.&#160;&#160;<font style="FONT-STYLE: italic"><font style="FONT-STYLE: normal">Our research and development expenses were $1,971,832 during the second quarter of 2011 as compared to $477,566 during the same period in 2010.&#160;&#160;Our increased research and development expenditures in the second quarter of 2011 is the result of manufacturing activities and expenses related to regulatory filings in Europe for Vitaros<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#160;</font>&#174; as a treatment for patients with erectile dysfunction.&#160;&#160;We expect to continue to see an increase in research and development spending in 2011 as a result of the expansion of our<font style="DISPLAY: inline; COLOR: #0000ff; FONT-STYLE: normal">&#160;</font>NexACT&#174;<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#160;</font>technology into the areas of oncology, inflammation, immunology, and metabolic diseases.&#160;&#160;We will also see an increase in research and development spending as we begin to prepare for regulatory filings around the world for Vitaros&#174; and our other late stage product candidates; Femprox<font style="DISPLAY: inline; FONT-STYLE: normal">&#174;</font>, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#160;</font> PrevOnco&#8482;, MycoVa&#8482; <font style="DISPLAY: inline; FONT-STYLE: normal">and RayVa&#8482;.</font></font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-STYLE: normal"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">General and Administrative Expenses</font>.&#160;&#160;Our general and administrative expenses were $3,687,041 during the second quarter of 2011 as compared to $2,640,400 during the same period in 2010.&#160;&#160;&#160;The increase is due primarily to increased expenses for severance charges, investor relations activities initiated in the second half of 2010, increased travel related to licensing activities and facilities expense resulting from an expansion of the CRO facility. These increases were partially offset by a decrease in non-cash stock compensation expense of approximately $550,000.&#160;&#160;</font></font></font></font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Loss on sale of Bio-Quant subsidiary</font>.&#160;&#160;On June 30, 2011 we sold Bio-Quant to BioTox and incurred a non cash loss of $2,759,920 during the second quarter of 2011. The loss is primarily due to the sale of the remaining balance of Bio-Quant Know-How and Bio-Quant trade name in the amount of approximately $2,642,000, net of amortization.&#160;&#160;In addition to the intangible assets, we sold net assets of approximately $985,000 offset by liabilities of approximately $367,000.&#160;&#160;The loss resulting from the disposal of these tangible and intangible assets was computed based on the realized down payment received in the transaction of $500,019.</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Interest Expense, Net</font>.&#160;&#160;We had net interest expense of $75,708 during the second quarter of 2011, as compared to $1,609,657 during the same period in 2010.&#160;&#160;The interest expense during 2010 is mainly the result of interest expense recognized on the beneficial conversion feature of the convertible mortgage notes.&#160;&#160;Non-cash interest expense was $1,599,981 during the second quarter in 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Net Loss</font>.&#160;&#160;The net loss was $7,794,092 or $0.39 per share in the second quarter of 2011 as compared to $4,278,647 or $0.47 per share during the same period in 2010.&#160;&#160;The increase in net loss is primarily attributable to the increased research and development expenses, the increase in general and administrative expenses and non-cash loss on the sale of the Bio-Quant subsidiary of $2,759,920.&#160;&#160;These increased expenses were partially offset by the decreased non-cash interest charges as discussed above.</font></font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Comparison of Results of Operations Between the Six Months Ended June 30, 2011 and 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 45pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Revenue</font>.&#160;&#160;<font style="FONT-STYLE: normal">We recorded $3,182,217 in revenue during the first half of 2011, as compared to $2,916,679 in revenue during the first half of 2010, an increase of 9.1%.&#160;&#160;&#160;The increase in revenue is primarily attributable to $871,000 in revenue recognized in 2011 as a result of the licensing deals signed in 2010 and 2011 for Vitaros&#174; for erectile dysfunction.&#160;&#160;The increase was partially offset by an approximately $500,000 decrease in revenue attributable to the sales of CRO services by our Bio-Quant CRO in the first half of 2011 as compared to the first half of 2010.&#160;&#160;&#160;The decrease in revenue is the result of our change in strategy in 2010 when we began diverting the Bio-Quant&#8217;s capacity to our own technology and pipeline development projects.&#160;&#160;On June 30, 2011 we sold Bio-Quant to BioTox.&#160;&#160;As a result of the sale we will no longer be recognizing revenues related to the CRO business in subsequent periods.</font></font></font></font></div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Research and Development Expenses</font>.&#160;&#160;<font style="FONT-STYLE: normal">Our research and development expenses were $3,072,378 for the first half of 2011 as compared to $903,959 during the same period in 2010.&#160;&#160;Our increased research and development expenditures in 2011 is primarily the result of our increased activities in the manufacturing and scale up of our approved drug Vitaros&#174; in Canada. In addition to the additional expenses related to CRO services, we incurred expenses related to regulatory activities in the first half of 2011 to advance our product pipeline.&#160;&#160;We expect to continue to see an increase in research and development spending in 2011 as a result of the commercial production of Vitaros&#174; and expansion of our NexACT&#174; <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#174; </font>technology into the areas of oncology, inflammation, immunology, and metabolic diseases.&#160;&#160;We will also see an increase in research and development spending as we begin to prepare for regulatory filings around the world for Vitaros&#174; and our other late stage product candidates; Femprox<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#174;</font>,<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">&#160;</font> PrevOnco&#8482;, MycoV<font style="FONT-WEIGHT: normal">a</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: normal"><font style="FONT-WEIGHT: normal">&#8482;</font> </font><font style="DISPLAY: inline; FONT-STYLE: normal">and RayVa&#8482;.</font></font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 4.5pt" align="left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">General and Administrative Expenses</font>.&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our general and administrative expenses were $6,593,294 during the first half of 2011 as compared to $4,879,936 during the same period in 2010.&#160;&#160;&#160;The increase is due to increased compensation expenses associated with additional personnel in the current period compared to the comparable prior year period, severance expenses, increased travel related to licensing activities and increased investor relations support.&#160;&#160;&#160;&#160;</font> </font>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Loss on sale of Bio-Quant subsidiary</font>.&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On June 30, 2011 we sold Bio-Quant to BioTox and incurred a non-cash loss of $2,759,920 during the second half of 2011. The loss is primarily due to the sale of the remaining balance of Bio-Quant Know-How and Bio-Quant trade name in the amount of approximately $2,642,000, net of amortization.&#160;&#160;In addition to the intangible assets, we sold net assets of approximately $985,000 offset by liabilities of approximately $367,000.&#160;&#160;The loss resulting from the disposal of these tangible and intangible assets was computed based on the realized down payment received in the transaction of $500,019.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Interest Expense, Net</font>.&#160;&#160;We had net interest expense of $173,452 during the first half of 2011, as compared to $8,589,704 during the same period in 2010.&#160;&#160;The interest expense during 2010 is mainly the result of interest expense recognized on the beneficial conversion feature of the convertible mortgage notes.&#160;&#160;Non cash interest expense was $8,530,999 for the first half ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">Net Loss</font>.&#160;&#160;The net loss was $11,205,098 or $0.58 per share in the first half of 2011 as compared to $13,516,103 or $1.64 per share during the same period in 2010.&#160;&#160;The decrease in net loss is primarily attributable to the decreased non-cash interest charges as discussed above. This decrease in net loss is partially offset by the increased research and development expenses, general and administrative expenses in addition to the loss on the sale of the subsidiary as discussed above.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>There have been no material changes to our exposures to market risk since December 31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;CONTROLS AND PROCEDURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with Exchange Act Rules 13a-15 and 15d-15, the Company's management, with participation of the Company's Chief Executive Officer and Chief Financial Officer, its principal executive officer and principal financial officer, respectively, carried out an evaluation of the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded as of the end of the period covered by this Form 10-Q that the Company's disclosure controls and procedures are effective. There were no changes in the Company's internal controls over financial reporting that occurred during the quarter covered by this report that have materially affected or are reasonably likely to materially affect the Company's internal controls over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART II.&#160;&#160;OTHER INFORMATION</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;LEGAL PROCEEDINGS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There have been no material changes to the legal proceedings described in the Company&#8217;s Report on Form 10-K, as filed with the Securities and Exchange Commission on March 10, 2011.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1A.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;</font>&#160;&#160; RISK FACTORS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following risk factors represent the only material changes to the risk factors described in the Company&#8217;s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 10, 2011.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">RISKS RELATED TO THE REALIZATION OF FUTURE EARN-OUT PAYMENTS FROM SALE OF BIO-QUANT SUBSIDIARY</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our realization of future earn-out income over the next ten years from the sale of our Bio-Quant subsidiary to Samm Solutions, Inc. d/b/a/ BioTox Sciences (&#8220;BioTox&#8221;) may be adversely effected by the ability of BioTox to realize revenue and cash flows from the operation of the joint companies as well as other internal and external factors that could affect the success of this contract research organization (&#8220;CRO&#8221;).</font></font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As part of our sale of our wholly-owned subsidiary, Bio-Quant, Inc., to BioTox, we were paid $500,019 as an up-front payment and after the second anniversary of the closing of that transaction, are to be paid the higher of $500,000 per year or a double digit royalty payment per year over the next 9 year period for a total of minimum future payments of $4.5 million or up to $20 million based on the projections of BioTox as of the closing date of the transaction.&#160;&#160;The annual payments are secured by a first priority secured lien on the assets of Bio-Quant as well as the assets of BioTox for a certain period of time after the closing date of the transaction.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We may not realize the minimum or maximum annual payments based on either internal or external factors relating to the operation of Bio-Quant by BioTox and various other domestic and international factors that may affect the CRO business in general.&#160;&#160;In addition, BioTox does not have a long operating history, it may have difficulties integrating the two companies and growing the two companies according to its projections.&#160;&#160;Also, the success of Bio-Quant may be affected by changes that are occurring in the CRO business in general in the United States, namely the competition from lower cost CROs in China, India and other countries.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">RISKS RELATED TO OUR EFFORT TO ACQUIRE OR MERGE WITH THIRD PARTIES</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">From time to time, we will be evaluating, and potentially closing transactions to acquire or merge with companies that have complementary products or technology.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><br>
</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-FAMILY: times new roman">We are continuously looking to acquire or merge with companies that have complementary products or technologies. In addition, we will evaluate certain opportunities to in-license or out-license or partner our products or technology with third parties.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-FAMILY: times new roman">In evaluating and closing such transactions, we may incur additional expenses and may need additional financing to consummate these transactions.<font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-STYLE: normal">&#160;</font>These transactions may also be a distraction for the management team and take internal resources away from other priorities. Any of these effects could have an adverse impact on our results of operations.</font></font></div>

<br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">RISKS RELATED TO OWNING OUR COMMON STOCK</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The anti-takeover provisions of our stockholder rights agreement may entrench management, may delay or prevent beneficial takeover bids by third parties and may prevent or frustrate any stockholder attempt to replace or remove the current management even if the stockholders consider it beneficial to do so.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have a stockholder rights agreement designed to protect our stockholders from coercive or unfair takeover tactics. Pursuant to the agreement, we declared a dividend of one preferred stock purchase right (a &#8220;Right&#8221;) for each share of common stock outstanding on April 1, 2011 (the &#8220;Record Date&#8221;). In addition, one Right will automatically attach to each share of common stock issued after the Record Date.&#160;&#160;Each Right entitles the holder to purchase from us 1/10,000th of a share of Series D Junior Participating Cumulative Preferred Stock, par value $0.001 per share, for $20.00. In the event any acquiring entity or group accumulates or initiates a tender offer to purchase 15% or more of our common stock, then each holder of a preferred stock purchase right, other than the acquiring entity and its affiliates, will have the right to receive, upon exercise of the Right, shares of our common stock or shares in the acquiring entity having a value equal to two times the exercise price of the Right.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The intent of the stockholder rights agreement is to protect our stockholders&#8217; interests by encouraging anyone seeking control of our company to negotiate with our board of directors. However, our stockholder rights plan could make it more difficult for a third party to acquire us without the consent of our board of directors, even if doing so may be beneficial to our stockholders. This plan may discourage, delay or prevent a tender offer or takeover attempt, including offers or attempts that could result in a premium over the market price of our common stock. This plan could reduce the price that investors might be willing to pay for shares of our common stock in the future. Furthermore, the anti-takeover provisions of our stockholder rights agreement may entrench management and make it more difficult for stockholders to replace management even if the stockholders consider it beneficial to do so.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 6.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;EXHIBITS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.1</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock Purchase Agreement, dated June 30, 2011, by and between Apricus Biosciences, Inc, and Samm Solutions, Inc. (doing business as BioTox Sciences) (incorporated by reference&#160;&#160;to Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K, filed on July 6, 2011).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Separation Agreement by and between the Company and Mark Westgate, dated June 1, 2011 (incorporated by reference&#160;&#160;to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, filed on June 2, 2011).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employment Agreement by and between the Company and Steven Martin, dated June 1, 2011(incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, filed on June 2, 2011) .</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employment Agreement by and between the Company and Randy Berholtz, dated May 9, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer&#8217;s Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer&#8217;s Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer&#8217;s Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 &#8211; furnished only.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.2</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer&#8217;s Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 &#8211; furnished only.</font></div>
</td>
</tr></table>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.INS</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Instance Document. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.SCH</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Schema. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.CAL</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Calculation Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.LAB</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Labels Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.PRE</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Presentation Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.DEF</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Definition Linkbase. (1)</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">(1) Furnished, not filed.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>SIGNATURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">APRICUS BIOSCIENCES, INC.</font></font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 15, 2011</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steve Martin</font></font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steve Martin</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Senior Vice President and Chief Financial </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.3</font></div>
</td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Employment Agreement by and between the Company and Randy Berholtz, dated May 9, 2011</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer&#8217;s Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer&#8217;s Certificate, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer&#8217;s Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 &#8211; furnished only.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="top" width="8%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.2</font></div>
</td>
<td align="left" valign="top" width="63%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer&#8217;s Certificate, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 &#8211; furnished only.</font></div>
</td>
</tr></table>
</div>

<div>
<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.INS</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Instance Document. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.SCH</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Schema. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.CAL</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Calculation Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.LAB</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Labels Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.PRE</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Presentation Linkbase. (1)</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">101.DEF</font></td>
<td align="left" valign="top" width="63%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XBRL Taxonomy Extension Definition Linkbase. (1)</font></td>
</tr></table>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">(1) Furnished, not filed.</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>v230961_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: VF-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EMPLOYMENT AGREEMENT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This EMPLOYMENT AGREEMENT, dated May 9, 2011 (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Agreement</font>&#8221;), is made and entered into by and between Apricus Biosciences, Inc., a Nevada corporation (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;), and Randy Berholtz (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Executive</font>&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS, the Company and the Executive entered into an Offer of Employment dated December 20, 2010 (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Offer of Employment</font>&#8221;), which provided for a 90-day probationary period following the commencement of Executive&#8217;s employment on January 4, 2011;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS, the Company desires to continue to employ Executive and the Company considers it essential to its best interests and the best interests of its stockholders for the Company to employ Executive during the term of this Agreement; and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS, Executive is willing to accept his employment with the Company on the terms hereinafter set forth in this Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOW, THEREFORE, in consideration of the premises and mutual covenants herein and for other good and valuable consideration, the parties agree as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Term of Employment</font>.&#160;&#160;Subject to the terms and conditions set forth in Section 6 of this Agreement, Executive&#8217;s employment with the Company shall be &#8220;at will,&#8221; and the Company and Executive shall each have the right to terminate Executive&#8217;s employment hereunder.&#160;&#160;The term of Executive&#8217;s employment hereunder is referred to herein as the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Employment Term</font>.&#8221;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Position</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the Employment Term, Executive shall be employed by the Company as Executive Vice President, General Counsel and Secretary, and shall have such duties, authority, and responsibility as are commensurate with his position, subject to the direction of the Company&#8217;s President and Chief Executive Officer.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the Employment Term, Executive shall devote all of his business time and attention to the performance of his duties hereunder faithfully and to the best of his abilities and shall not undertake employment with, or participate in, the conduct of the business affairs of any other person, corporation, or entity; <font style="DISPLAY: inline; FONT-STYLE: italic">provided, </font>that nothing shall preclude Executive from (i) with the prior approval of the Company&#8217;s Chief Executive Officer, serving as a director, trustee or member of another business organization or (ii) participating in the affairs of any recognized charitable organizations, non-profit or in any community affairs, of Executive&#8217;s choice.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Executive&#8217;s duties hereunder shall be performed for the Company worldwide, with principal business activities expected to be at the Company&#8217;s offices in San Diego, California.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Compensation</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Base Salary</font>.&#160;&#160;During the Employment Term, the Company shall pay Executive a base salary, subject to increase at the discretion of the Board of Directors of the Company (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Board</font>&#8221;), at the initial annual rate of $250,000 (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Base Salary</font>&#8221;), payable in regular installments in accordance with the Company&#8217;s usual payroll practices.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Annual Bonus</font>.&#160;&#160;With respect to each calendar year during the Employment Term, Executive shall be eligible to earn an annual bonus award (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Bonus</font>&#8221;) in a target amount equal to 30% of Executive&#8217;s annual Base Salary.&#160;&#160;The amount of the Bonus shall be determined by the Board, or the Compensation Committee of the Board (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Compensation Committee</font>&#8221;), in its sole discretion, based upon the achievement by the Company of objective performance measures established and determined by the Board or the Compensation Committee no later than the end of the first month of such calendar year.&#160;&#160;The Bonus, if any, with respect to each calendar year in the Employment Term shall be paid as promptly as practicable following the delivery of the Company&#8217;s audited financial statements for such year, but not later than March 15 of the calendar year following the calendar year for which the Bonus is payable.&#160;&#160;Unless otherwise stated herein, the Bonus shall not accrue until the date on which it is paid, and Executive must be employed on the date the Bonus is paid in order to receive the Bonus.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Equity Awards</font>.&#160;&#160;The Compensation Committee shall consider annually whether to grant any equity-based compensation awards to the Executive in accordance with the terms and subject to the conditions of the Company&#8217;s equity compensation plans.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Employee Benefits</font>.&#160;&#160;During the Employment Term, Executive shall be eligible for inclusion, to the extent permitted by law, as a full-time employee of the Company or any of its subsidiaries, in any and all of the following plans, programs, and policies in effect at the time: (i) pension, profit sharing, savings, and other retirement plans and programs, (ii) life and health (medical, dental, hospitalization, short-term and long-term disability) insurance plans and programs, (iii) stock option and stock purchase plans and programs, (iv) accidental death and dismemberment protection plans and programs, (v) travel accident insurance plans and programs, (vi) vacation policy (Executive shall have four weeks of paid vacation per calendar year), and (vii) other plans and programs sponsored by the Company or any subsidiary for employees or executives generally, including any and all plans and programs that supplement any or all of the foregoing types of plans or programs.&#160;&#160;Nothing in this Agreement shall preclude the Company or any of its subsidiaries or affiliates from terminating or amending any employee benefit plan or program from time to time after the date of this Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Business Expenses and Perquisites</font>.&#160;&#160;The Company shall reimburse to Executive, or pay directly, all reasonable expenses incurred by Executive in connection with the business of the Company, and its subsidiaries and affiliates, in each case subject to Company travel and expense reimbursement policies.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Termination</font>.&#160;&#160;Subject to this Section 6, either party may terminate this Agreement at any time and from time to time.&#160;&#160;In the event of the termination of Executive&#8217;s employment, the Employment Term shall end on the day of such termination.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">By the Company for Cause</font>. The Company may, for Cause, terminate Executive&#8217;s employment hereunder at any time by written notice to Executive.&#160;&#160;For purposes of this Agreement, the term &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cause</font>&#8221; shall mean Executive&#8217;s (i) engaging in fraud against the Company or misappropriation of funds of the Company, (ii) disregard or failure to follow specific and reasonable directives of the Board, (iii) willful failure to perform his duties as General Counsel of the Company, (iv) willful misconduct resulting in material injury to the Company, (v) violation of the terms of the Confidential Information and Intellectual Property Agreement between Executive the Company referred to in Section 11 below, (vi) conviction of, or Executive&#8217;s plea of guilty or no contest to, a felony or any crime involving as a material element fraud or dishonesty, or (vii) material breach (not covered by clauses (i) through (vi) of this paragraph) of any of the other provisions of this Agreement; provided, that, in the case of subclauses (ii), (iii) or (vii), Cause shall not exist if the act or omission deemed to constitute Cause is cured (if curable) by Executive within thirty (30) days after written notice thereof to Executive by the Company.&#160;&#160;For purposes of the foregoing, no act, or failure to act, on Executive&#8217;s part shall be considered &#8220;willful&#8221; unless done, or omitted to be done, by Executive other than in good faith, and without reasonable belief that his action or omission was in furtherance of the interests of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of the termination of Executive&#8217;s employment under this Section 6(a) for Cause, the Employment Term shall end on the day of such termination and the Company shall pay to Executive, no later than the payroll cycle following Executive&#8217;s termination, in one lump sum: (i) any accrued but unpaid Base Salary, less applicable deductions, including salary in respect of any accrued and accumulated vacation due to Executive at the date of such termination; and (ii) any amounts owing, but not yet paid, pursuant to Section 5 hereof.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as specifically set forth in Section 9 hereof, the Company shall have no further obligations to Executive under this Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Disability or Death</font>.&#160;&#160;If Executive should suffer a Permanent Disability, the Company may terminate Executive&#8217;s employment hereunder upon ten (10) or more days&#8217; prior written notice to Executive.&#160;&#160;If Executive should pass away during the term of this Agreement, Executive&#8217;s employment shall be deemed terminated on his date of death.&#160;&#160;For purposes of this Agreement, a &#8220;Permanent Disability&#8221; shall be deemed to have occurred only when Executive has qualified for benefits (including satisfaction of any applicable waiting period) under the Company&#8217;s or a subsidiary&#8217;s long-term disability insurance arrangement.&#160;&#160;In the event of the termination of Executive&#8217;s employment hereunder by reason of Permanent Disability or death, the Employment Term shall end on the day of such termination and the Company shall pay, no later than the payroll cycle following Executive&#8217;s termination, to Executive or Executive&#8217;s legal representative (in the event of Permanent Disability), or any beneficiary or beneficiaries designated by Executive to the Company in writing, or to Executive&#8217;s estate if no such beneficiary has been so designated (in the event of Executive&#8217;s death), a single lump sum payment of: (i) any accrued but unpaid Base Salary, less applicable deductions, including salary in respect of any accrued and accumulated vacation, due to Executive at the date of such termination; (ii) any amounts owing, but not yet paid, pursuant to Section 5 hereof.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, upon a termination under this Section 6(b), and upon the satisfaction of the conditions set forth herein: (1) Executive shall receive a pro rata Bonus for the calendar year in which such termination occurs, equal to the Bonus he would have received, to the extent all criteria for such a Bonus have been met (with the exception of the requirement that Executive be employed on the date the Bonus is to be paid), for the calendar year of said termination multiplied by a fraction, the numerator of which is the number of days in such year preceding and including the date of termination, and the denominator of which is 365.&#160;&#160;Said pro-rata Bonus shall be paid at the same time as the Bonus would have been paid had Executive remained employed by the Company through the date of payment, but in any event, not later than March 15 of the calendar year following the calendar year for which the Bonus is payable; (2) Executive shall receive any unpaid Bonus for the calendar year preceding his termination, to the extent that all criteria for such bonus have been met (with the exception of the requirement that Executive be employed on the date the Bonus is to be paid).&#160;&#160;Said Bonus shall be paid at the same time as the Bonus would have been paid had Executive remained employed by the Company through the date of payment; and (3) all of Executive&#8217;s outstanding but unvested equity awards granted pursuant to the Offer of Employment and Section 3(c) of this Agreement shall vest immediately.&#160;&#160;The payment of any Bonus pursuant to clause (1) or clause (2) above and the acceleration of Executive&#8217;s options and stock pursuant to clause (3), are conditioned upon Executive (or his legal representative) signing a release in favor of the Company, as provided for in Section 6(f).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">By the Company without Cause</font>.&#160;&#160;The Company may, without Cause, terminate Executive&#8217;s employment hereunder at any time upon ten (10) or more days&#8217; written notice to Executive.&#160;&#160;The Company, in its sole discretion, may provide the Executive with ten (10) days&#8217; pay in lieu of notice.&#160;&#160;In the event Executive&#8217;s employment is terminated pursuant to this Section 6(c), the Employment Term shall end on the day of such termination and the Company shall pay to Executive, no later than the payroll cycle following Executive&#8217;s termination, in one lump sum: (i) any accrued but unpaid Base Salary, less applicable deductions, including salary in respect of any accrued and accumulated vacation, due to Executive at the date of such termination, and (ii) any amounts owing, but not yet paid, pursuant to Section 5 hereof.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, upon a termination under this Section 6(c) and upon the satisfaction of the conditions set forth herein: (1) Executive shall receive a pro rata Bonus for the calendar year in which such termination occurs, equal to the Bonus he would have received, to the extent all criteria for such a Bonus have been met (with the exception of the requirement that Executive be employed on date the Bonus is to be paid), for the calendar year of said termination multiplied by a fraction, the numerator of which is the number of days in such year preceding and including the date of termination, and the denominator of which is 365.&#160;&#160;Said pro-rata Bonus shall be paid at the same time as the Bonus would have been paid had Executive remained employed by the Company through the date of payment, but in any event, not later than March 15 of the calendar year following the calendar year for which the Bonus is payable; (2) Executive shall receive any unpaid Bonus for the calendar year preceding his termination, to the extent that all criteria for such bonus have been met (with the exception of the Executive being employed on the date the Bonus is to be paid).&#160;&#160;Said Bonus shall be paid at the same time as the Bonus would have been paid had Executive remained employed by the Company through the date of payment; (3) all of Executive&#8217;s outstanding but unvested equity awards granted pursuant to the Offer of Employment and Section 3(c) of this Agreement shall vest immediately; and (4) the Company shall pay Executive (A) an amount equal to six (6)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>months of Executive&#8217;s Base Salary at the time of such termination and (B) an amount equal to the product of the number of whole years that Executive has been employed by the Company multiplied by a fraction, the numerator of which is the Executive&#8217;s Base Salary at the time of such termination and the denominator of which is fifty-two (52) (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Severance</font>&#8221;).&#160;&#160;The payment of any Bonus pursuant to clause (1) or clause (2) above and the acceleration of Executive&#8217;s options and stock pursuant to clause (3), are conditioned upon Executive signing a release in favor of the Company, as provided for in Section 6(f), and the Severance shall be payable in a single lump sum within 60 days after the effective date of termination of the Employment Term, subject to Executive&#8217;s execution, delivery and non-revocation of a release in favor of the Company, as provided for in Section 6(f).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as specifically set forth in Section 9 hereof, the Company shall have no further obligations to Executive under this Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Resignation by Executive for Good Reason</font>. If any of the events described below occurs during the Employment Term, Executive may terminate Executive&#8217;s employment hereunder for Good Reason by written notice to the Company identifying the event or omission constituting Good Reason not more than one (1) month following the occurrence of such event and, in the case of subclauses (ii), (iii), or (iv) below, a failure by the Company to cure such act or omission within thirty (30) days after receipt of such written notice.&#160;&#160;In the event that Executive elects to terminate employment pursuant to this Section 6(d), the Employment Term and Executive&#8217;s employment hereunder will be terminated effective as of the later of thirty-one (31) days after the Company&#8217;s receipt of Executive&#8217;s notice of termination or thirty-one (31) days after the event, and Executive&#8217;s resignation for Good Reason pursuant to this Section 6(d) shall be treated for all purposes as a termination without Cause pursuant to Section 6(c) and the provisions of Section 6(c) shall apply to such termination, including the payment of Severance.&#160;&#160;The occurrence of any of the following events without Executive&#8217;s consent shall permit Executive to terminate Executive&#8217;s employment for &#8220;Good Reason&#8221; pursuant to this Section 6(d):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The failure by the Company to observe or comply in any material respect with any of the material provisions of this Agreement;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A material diminution in Executive&#8217;s duties;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The assignment to Executive of duties that are materially inconsistent with Executive&#8217;s duties or that materially impair Executive&#8217;s ability to function as the General Counsel of the Company; or</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The relocation of Executive&#8217;s primary office from a location that is more than 50 miles from both (a) the Company&#8217;s executive office that constitutes Executive&#8217;s primary office location at the time of relocation and (b) Executive&#8217;s primary residence at the time of such relocation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as specifically set forth in Section 9 hereof, the Company shall have no further obligations to Executive under this Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">By Executive without Good Reason</font>.&#160;&#160;Executive may terminate the Employment Term and Executive&#8217;s employment hereunder at any time without Good Reason upon thirty (30) days advance written notice to the Company.&#160;&#160;In the event Executive&#8217;s employment is terminated pursuant to this Section 6(e), the Company shall pay to Executive, no later than ten (10) days after the last day of Executive&#8217;s employment, in one lump sum, the sum of (i) any accrued but unpaid Base Salary, less applicable deductions, including salary in respect of any accrued and accumulated vacation, due to Executive at the date of such termination, and (ii) any amounts owing, but not yet paid, pursuant to Section 5 hereof.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Except as specifically set forth in Section 9 hereof, the Company shall have no further obligations to Executive under this Agreement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Release</font>.&#160;&#160;Notwithstanding any other provision of this Agreement to the contrary, Executive acknowledges and agrees that any and all payments and benefits to which Executive is entitled under Section 6(b), 6(c) or 6(d), with the exception of accrued salary, accrued vacation payments, and payments pursuant to Section 5 of this Agreement, are conditioned upon and subject to Executive&#8217;s first executing a general waiver and release (and the expiration of any associated revocation period), in such reasonable and customary form as shall be prepared by the Company, of all claims Executive may have against the Company, and related entities and individuals.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Required Postponement for Specified Executives.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Specified Executive Delay</font>.&#160;&#160;Notwithstanding anything in this Agreement to the contrary, if required by section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Code</font>&#8221;) and if Executive is considered a Specified Executive (as defined herein) and payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by section 409A, and the accumulated amounts shall be paid in a lump sum payment within five days after the end of the six-month period.&#160;&#160;If Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of section 409A shall be paid to the personal representative of Executive&#8217;s estate within 60 days after the date of Executive&#8217;s death.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Specified Executive</font>&#8221; shall mean an employee who, at any time during the 12-month period ending on the identification date, is a &#8220;specified employee&#8221; under section 409A of the Code, as determined by the Compensation Committee of the Board or its delegate.&#160;&#160;The determination of Specified Executives, including the number and identity of persons considered officers and the identification date, shall be made by the Compensation Committee or its delegate in accordance with the provisions of section 409A of the Code and the regulations issued thereunder.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">No Mitigation; Employee Benefit Plans</font>.&#160;&#160;Executive shall not be required to mitigate amounts payable to him under this Agreement by seeking other employment or otherwise, and there shall be no offset against amounts payable to Executive under this Agreement on account of Executive&#8217;s subsequent employment.&#160;&#160;Amounts payable to Executive under this Agreement shall not be offset by any claims that the Company may have against Executive, and such amounts payable to Executive under this Agreement shall not be affected by any other circumstances, including, without limitation, any counterclaim, recoupment, defense, or other right that the Company may have against Executive or others; <font style="DISPLAY: inline; FONT-STYLE: italic">provided, however, </font>that payments made to Executive as a result of the termination of Executive&#8217;s employment hereunder shall not be considered as includible compensation with respect to any employee benefit plans maintained by the Company, except to the extent otherwise required by law.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Indemnification</font>.&#160;&#160;In the event that Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative, or investigative (a &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Proceeding</font>&#8221;), by reason of Executive&#8217;s employment with, or serving as an officer of, the Company, the Company shall indemnify and hold Executive harmless, and defend Executive to the fullest extent authorized by the laws of the state in which the Company is incorporated, as the same exist and may hereafter be amended, against any and all claims, demands, suits, judgments, assessments, and settlements (collectively the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Claims</font>&#8221;), including all expenses incurred or suffered by Executive in connection therewith (excluding, however, any legal fees incurred by Executive for Executive&#8217;s own counsel, except as otherwise provided in this Section 9, and excluding any Proceedings initiated by executive), and such indemnification shall continue as to Executive even after Executive is no longer employed by the Company hereunder, and shall inure to the benefit of Executive&#8217;s heirs, executors, and administrators; <font style="DISPLAY: inline; FONT-STYLE: italic">provided, however, </font>that Executive promptly gives written notice to the Company of any such Claims (although Executive&#8217;s failure to promptly give notice shall not affect the Company&#8217;s obligations under this Section 9 except to the extent that such failure prejudices the Company or its ability to defend such Claims).&#160;&#160;The Company shall have the right to undertake, with counsel or other representatives of its own choosing, the defense or settlement of any Claims.&#160;&#160;In the event that the Company shall fail to notify Executive, within ten days of its receipt of Executive&#8217;s written notice, that the Company has elected to undertake such defense or settlement, or if at any time the Company shall otherwise fail to diligently defend or pursue settlement of such Claims, then Executive shall have the right to undertake the defense, compromise, or settlement of such Claims, in which event the Company shall hold Executive harmless from any legal fees incurred by Executive for Executive&#8217;s counsel.&#160;&#160;Neither Executive nor the Company shall settle any Claims without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed.&#160;&#160;In the event that the Company submits to Executive a bona fide settlement offer from the claimant of Claims (which settlement offer shall include as an unconditional term thereof the giving by the claimant or the plaintiff to Executive a release from all liability in respect of such Claims), and Executive refuses to consent to such settlement, then thereafter the Company&#8217;s liability to Executive for indemnification hereunder with respect to such Claims shall not exceed the settlement amount included in such bona fide settlement offer, and Executive shall either assume the defense of such Claims or pay the Company&#8217;s attorneys&#8217; fees and other out-of-pocket costs incurred thereafter in continuing the defense of such Claims.&#160;&#160;Regardless of which party is conducting the defense of any such Claims, the other party, with counsel or other representatives of its own choosing and at its sole cost and expense, shall have the right to consult with the party conducting the defense of such Claims and its counsel or other representatives concerning such Claims and Executive and the respective counsel or other representatives shall cooperate with respect to such Claims.&#160;&#160;The party conducting the defense of any such Claims and its counsel shall in any case keep the other party and its counsel (if any) fully informed as to the status of such Claims and any matters relating thereto.&#160;&#160;Executive and the Company shall provide to the other such records, books, documents, and other materials as shall reasonably be necessary for each to conduct or evaluate the defense of any Claims, and will generally cooperate with respect to any matters relating thereto.&#160;&#160;This Section 9 shall remain in effect after this Agreement is terminated, regardless of the reasons for such termination.&#160;&#160;The indemnification provided to Executive pursuant to this Section 9 shall not supersede or reduce any indemnification provided to Executive under any separate agreement, or the By-Laws of the Company; in this regard, it is intended that this Agreement shall expand and extend Executive&#8217;s rights to receive indemnification.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Withholding</font>.&#160;&#160;The Company shall have the right to deduct and withhold from all payments to Executive hereunder all payroll taxes, income tax withholding and other federal, state and local taxes and charges which currently are or which hereafter may be required by law to be so deducted and withheld.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Additional Agreements</font>.&#160;&#160;As a condition to his employment hereunder, Executive shall execute and deliver to the Company a Confidential Information and Intellectual Property Agreement in the form attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font>, which shall be incorporated herein by reference.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Non-Assignability</font>.&#160;&#160;Executive&#8217;s rights and benefits hereunder are personal to Executive, and shall not be alienated, voluntarily or involuntarily assigned, or transferred.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Binding Effect</font>.&#160;&#160;This Agreement shall be binding upon the parties hereto, and their respective assigns, successors, executors, administrators, and heirs.&#160;&#160;In the event the Company becomes a party to any merger, consolidation, or reorganization, this Agreement shall remain in full force and effect as an obligation of the Company or its successor(s) in interest.&#160;&#160;None of the payments provided for by this Agreement shall be subject to seizure for payment of any debts or judgments against Executive or Executive&#8217;s beneficiary or beneficiaries, nor shall Executive or any such beneficiary or beneficiaries have any right to transfer or encumber any right or benefit hereunder.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Entire Agreement; Modification</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Agreement supersedes all prior agreements, including the Offer of Employment between the Company and Executive relating to the subject matter hereof, with the exception of the Confidential Information and Intellectual Property Agreement; <font style="DISPLAY: inline; FONT-STYLE: italic">provided, however,</font> that the stock options granted pursuant to the Offer of Employment shall not be affected, except as specifically provided herein.&#160;&#160;This Agreement sets forth the entire understanding among the parties hereto with respect to the subject matter hereof, may not be changed orally, and may be changed only by an agreement in writing signed by the parties hereto.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">&#160;</td>
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Executive acknowledges that from time to time, the Company may establish, maintain and distribute manuals, handbooks or personnel policies, and officers or other representatives of the Company may make written or oral statements relating to personnel policies and procedures.&#160;&#160;Such manuals, handbooks and statements are intended only for general guidance.&#160;&#160;No policies, procedures or statements of any nature by or on behalf of the Company (whether written or oral, and whether or not contained in any manual or handbook or personnel policies), and no acts or practices of any nature, shall be construed to modify this Agreement or to create express or implied obligations of any nature to Executive.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Notices</font>.&#160;&#160;All notices and communications hereunder shall be in writing, sent by certified or registered mail, return receipt requested, postage prepaid; by facsimile transmission, with proof of the time and date of receipt retained by the transmitter; or by hand-delivery properly receipted.&#160;&#160;The actual date of receipt as shown by the return receipt therefore, the facsimile transmission sheet, or the hand-delivery receipt, as the case may be, shall determine the date on which (and, in the case of a facsimile, the time at which) notice was given.&#160;&#160;All payments required hereunder by the Company to Executive shall be sent postage prepaid, or, at Executive&#8217;s election, shall be transferred to Executive electronically to such bank account as Executive may designate in writing to the Company, including designation of the applicable electronic address.&#160;&#160;The foregoing items (other than any electronic transfer to Executive) shall be addressed as follows (or to such other address as the Company and Executive may designate in writing from time to time):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To the Company:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Apricus Biosciences, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6330 Nancy Ridge Drive, Suite 103</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">San Diego, CA 92121</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile: (858) 866-0482</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Attention: Chief Executive Officer</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To Executive:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Randy Berholtz</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XXXXXXXXXXXX</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XXXXXXXXXXX</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Facsimile: XXX-XXX-XXXX</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Section 409A of the Code.</font>&#160;&#160;This Agreement is intended to comply with section 409A of the Code and its corresponding regulations, to the extent applicable.&#160;&#160;Accordingly, all provisions herein, or incorporated herein by reference, shall be construed and interpreted to comply with section 409A of the Code and any applicable exceptions thereunder.&#160;&#160;Notwithstanding anything in this Agreement to the contrary, payments may only be made under this Agreement upon an event and in a manner permitted by section 409A of the Code, to the extent applicable.&#160;&#160;As used in the Agreement, the term &#8220;termination of employment&#8221; shall mean Executive&#8217;s separation from service with the Company within the meaning of section 409A of the Code and the regulations promulgated thereunder.&#160;&#160;For purposes of section 409A, the right to a series of payments under the Agreement shall be treated as a right to a series of separate payments.&#160;&#160;Any amounts payable solely on account of an involuntary separation from service of Executive within the meaning of section 409A of the Code shall be excludible from the requirements of section 409A of the Code, either as involuntary separation pay or as short-term deferral amounts to the maximum possible extent.&#160;&#160;All reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement shall be for expenses incurred during Executive&#8217;s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">17.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Governing Law; Jurisdiction.</font>&#160;&#160;This Agreement shall be governed by, and construed and enforced according to, the domestic laws of the State of California without giving effect to the principles of conflict of laws thereof, or such principles of any other jurisdiction, which could cause the application of the substantive law of any jurisdiction other than the State of California.&#160;&#160;The Company and Executive agree that the state or federal courts located in San Diego, California shall have exclusive jurisdiction to hear and determine any dispute which may arise under this Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Severability</font>.&#160;&#160;The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of the Agreement shall be severable and enforceable to the extent permitted by law.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">19.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Headings</font>.&#160;&#160;The headings of the Sections hereof are provided for convenience only and are not to serve as a basis for interpretation or construction, and shall not constitute a part, of this Agreement.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">20.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Signature in Counterparts</font>.&#160;&#160;This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF, Executive has hereunto set his hand and the Company has caused this Agreement to be executed in its name on its behalf, all as of the day and year first above written.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ RANDY BERHOLTZ</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Randy Berholtz</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Apricus Biosciences, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;/S/ BASSAM DAMAJ</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Bassam Damaj, Ph.D.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT A</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">CONFIDENTIALITY AND INTELLECTUAL PROPERTY AGREEMENT</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APRICUS BIOSCIENCES, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Employee Confidentiality and Assignment Agreement</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In consideration and as a condition of my employment or continued employment by Apricus Biosciences, Inc. (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company</font>&#8221;), I agree as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Proprietary Information</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I agree that all information, whether or not in writing, concerning the Company&#8217;s business, technology, business relationships or financial affairs which the Company has not released to the general public (collectively, &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Proprietary Information</font>&#8221;) is and will be the exclusive property of the Company.&#160;&#160;By way of illustration, Proprietary Information may include information or material which has not been made generally available to the public, such as:&#160;&#160;(a) <font style="DISPLAY: inline; FONT-STYLE: italic">corporate information</font>, including plans, strategies, methods, policies, resolutions, negotiations or litigation; (b) <font style="DISPLAY: inline; FONT-STYLE: italic">marketing information</font>, including strategies, methods, customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or projections; (c) <font style="DISPLAY: inline; FONT-STYLE: italic">financial information</font>, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists; and (d) <font style="DISPLAY: inline; FONT-STYLE: italic">operational and technological information</font>, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions, improvements, concepts and ideas; and (e) <font style="DISPLAY: inline; FONT-STYLE: italic">personnel information</font>, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations and termination arrangements or documents.&#160;&#160;Proprietary Information also includes information received in confidence by the Company from its customers or suppliers or other third parties.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Recognition of Company&#8217;s Rights</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I will not, at any time, without the Company&#8217;s prior written permission, either during or after my employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties as an employee of the Company.&#160;&#160;I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information.&#160;&#160;I will deliver to the Company all copies of Proprietary Information in my possession or control upon the earlier of a request by the Company or termination of my employment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Rights of Others</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I understand that the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons which require the Company to protect or refrain from use of Proprietary Information.&#160;&#160;I agree to be bound by the terms of such agreements in the event I have access to such Proprietary Information.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Commitment to Company; Avoidance of Conflict of Interest</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;While an employee of the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Company, I will devote my full-time efforts to the Company&#8217;s business and I will not engage in any other business activity that conflicts with my duties to the Company.&#160;&#160;I will advise the president of the Company (or, if I am an executive officer of the Company, the Company&#8217;s Board of Directors) or his or her nominee at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company.&#160;&#160;I will take whatever action is requested of me by the Company to resolve any conflict or appearance of conflict which it finds to exist.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Developments</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship (collectively &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Developments</font>&#8221;), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of my employment.&#160;&#160;I acknowledge that all work performed by me is on a &#8220;work for hire&#8221; basis, and I hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Company and its successors and assigns all my right, title and interest in all Developments that (a) relate to the business of the Company or any customer of&#160;&#160;the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such products or services; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company-Related Developments</font>&#8221;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Intellectual Property Rights</font>&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To preclude any possible uncertainty, I have set forth on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Prior Inventions</font>&#8221;).&#160;If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason.&#160;&#160;I have also listed on <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> all patents and patent applications in which I am named as an inventor, other than those which have been assigned to the Company (&#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Patent Rights</font>&#8221;).&#160;&#160;If no such disclosure is attached, I represent that there are no Prior Inventions or Other Patent Rights.&#160;&#160;If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, paid-up, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use, sell, offer for sale and import such Prior Invention.&#160;&#160;Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#8217;s prior written consent.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As required pursuant to Section 2872 of the California Labor Code, I acknowledge that the Company has notified me that the provisions of this paragraph 5 do not apply to an invention which qualifies fully under the provisions of Section 2870 of the California Labor Code.&#160;&#160;Specifically, such provisions do not apply to, and I am not required to transfer to the Company, any invention developed entirely on my own time without using the Company&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either (a) relate at the time of conception or reduction to practice of the invention to the Company&#8217;s business, or actual or demonstrably anticipated research or development of the Company; or (b) result from any work performed by the Employee for the Company.&#160;&#160;However, I will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion.&#160;&#160;I understand that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 5 will be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes.&#160;&#160;I also hereby waive all claims to any moral rights or other special rights which I may have or accrue in any Company-Related Developments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Documents and Other Materials</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I will keep and maintain adequate and current records of all Proprietary Information and Company-Related Developments developed by me during my employment, which records will be available to and remain the sole property of the Company at all times.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, or other written, photographic or other tangible material containing Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the performance of my duties for the Company.&#160;&#160;Any property situated on the Company&#8217;s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.&#160;&#160;In the event of the termination of my employment for any reason, I will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, or other written, photographic or other tangible material containing Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company and to my work, and will not take or keep in my possession any of the foregoing or any copies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Enforcement of Intellectual Property Rights</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I will cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related Developments.&#160;&#160;I will sign, both during and after the term of this Agreement,&#160;&#160;all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development.&#160;&#160;If the Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and appoint each officer of the Company as my agent and attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Non-Solicitation</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;During my employment and for a period of twelve (12) months following the termination of my employment for any reason (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Restricted Period</font>&#8221;), I will not, directly or indirectly, in any manner, other than for the benefit of the Company, solicit, entice or attempt to persuade any other employee or consultant of the Company to leave the services of the Company for any reason.&#160;&#160;I acknowledge and agree that if I violate any of the provisions of this paragraph 8, the running of the Restricted Period will be extended by the time during which I engage in such violation(s).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Government Contracts</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I acknowledge that the Company may have from time to time agreements with other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.&#160;&#160;I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 5, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Prior Agreements</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I hereby represent that, except as I have fully disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party.&#160;&#160;I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Remedies upon Breach</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">. </font>&#160;&#160;I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and I consider them to be reasonable for such purpose.&#160;&#160;Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Use of Voice, Image and Likeness</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font> I give the Company permission to use any and all of my voice, image and likeness, with or without using my name, in connection with the products and/or services of the Company, for the purposes of advertising and promoting such products and/or services and/or the Company, and/or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent expressly prohibited by law.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Publications and Public Statements</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I will obtain the Company&#8217;s written approval before publishing or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information.&#160;&#160;To ensure that the Company delivers a consistent message about its products, services and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company which I create, publish or post during my period of employment and for six (6) months thereafter, on any media accessible by the public, including but not limited to electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer of the Company before it is released in the public domain.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">No Employment Obligation</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I understand that this Agreement does not create an obligation on the<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Company or any other person to continue my employment.&#160;&#160;I acknowledge that, unless otherwise agreed in a formal written employment agreement signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Survival and Assignment by the Company</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;I understand that my obligations under this Agreement will continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators.&#160;&#160;The Company will have the right to assign this Agreement to its affiliates, successors and assigns.&#160;&#160;I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time of such transfer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Disclosure to Future Employers</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font> I will provide a copy of this Agreement to any prospective employer, partner or coventurer prior to entering into an employment, partnership or other business relationship with such person or entity.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">17.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Severability</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;In case any provisions (or portions thereof) contained in this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.&#160;&#160;If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">18.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Interpretation</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;This Agreement will be deemed to be made and entered into in the State of California, and will in all respects be interpreted, enforced and governed under the laws of the State of California.&#160;&#160;I hereby agree to consent to personal jurisdiction of the state and federal courts situated within San Diego County, California for purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[End of Text]</font><br>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I HAVE READ IT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">IN WITNESS WHEREOF,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>the undersigned has executed this agreement as a sealed instrument as of the date set forth below.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Signed:</font></div>
</td>
<td align="left" valign="top" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ RANDY BERHOLTZ</font></font></div>
</td>
<td align="left" valign="top" width="54%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="94%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Employee&#8217;s full name)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Type&#160;or&#160;print&#160;name:</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Randy Berholtz</font></font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="57%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" nowrap valign="top" width="20%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Social&#160;Security&#160;Number:</font></div>
</td>
<td align="left" valign="top" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">XXX-XX-XXX</font></div>
</td>
<td align="left" valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="6%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:</font></div>
</td>
<td align="left" valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5/10/11</font></div>
</td>
<td align="left" valign="top" width="36%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT A</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Apricus Biosciences, Inc.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">From:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________________</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 27pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________________</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SUBJECT:</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Prior Inventions</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No inventions or improvements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Additional sheets attached</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div id="HDR_DIV" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.3</font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following is a list of all patents and patent applications in which I have been named as an inventor:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See below:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v230961_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Bassam Damaj, certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of Apricus Biosciences, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="30%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 15,&#160;&#160;2011</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ BASSAM DAMAJ</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bassam Damaj</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v230961_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 31.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Steve Martin, certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of Apricus Biosciences, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="75%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="72%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="30%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date August 15, 2011</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ STEVE MARTIN</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Steve Martin</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v230961_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18 U.S.C. SECTION 1350,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Bassam Damaj, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Apricus Biosciences, Inc. on Form 10-Q for the quarter ended June 30, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Apricus Biosciences, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="middle" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="middle" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 15, 2011</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="28%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/S/ BASSAM DAMAJ</font></font></div>
</td>
</tr><tr>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bassam Damaj</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>v230961_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: vintage-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 32.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18 U.S.C. SECTION 1350,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I, Steve Martin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Apricus Biosciences, Inc. on Form 10-Q for the quarter ended June 30, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Apricus Biosciences, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td colspan="2" valign="middle" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td colspan="2" valign="middle" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td colspan="2" valign="middle" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: August 15, 2011</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
</td>
</tr><tr>
<td valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">/S/ STEVE MARTIN</font></font></div>
</td>
</tr><tr>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Steve Martin</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">36</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>apri-20110630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:apri="http://www.apricusbio.com/20110630" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="apri-20110630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_0_20110809_0" unitRef="shares" decimals="INF">20022080</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20100630_0" unitRef="iso4217_USD" decimals="0">4215095</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">204890</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">55830</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">2642003</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">199236</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">3676991</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">4000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">343375</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">-212445306</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">4833</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">106693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">70000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">44867</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">14080283</us-gaap:Assets>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">768882</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">67150</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">20012</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">20012080</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">9361785</us-gaap:AssetsCurrent>
  <us-gaap:AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">47860</us-gaap:AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">9140225</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">40923</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">392477</us-gaap:DeferredCompensationLiabilityCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">2210555</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">14080283</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">217992554</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">5567260</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">20012080</us-gaap:CommonStockSharesIssued>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">780983</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">4457778</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">8513023</us-gaap:Liabilities>
  <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">118270</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">730584</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <apri:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">207923</apri:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x440920" unitRef="iso4217_USD" decimals="0">-212445306</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x444581" unitRef="shares" decimals="INF">20012080</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="0">20012</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="0">217992554</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20091231_0" unitRef="iso4217_USD" decimals="0">479888</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">189478</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">74401</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">102211</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">31263</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2316628</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">4000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">209705</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">-201240208</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">188504</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">604343</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">288778</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">18863638</us-gaap:Assets>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="INF">250000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">805788</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">72250</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">18519</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">18521951</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">10477308</us-gaap:AssetsCurrent>
  <us-gaap:AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">29289</us-gaap:AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">9145683</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">68596</us-gaap:DeferredCompensationLiabilityCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">789544</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">18863638</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">212788450</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">11566761</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">18521951</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShortTermBorrowings contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">401000</us-gaap:ShortTermBorrowings>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">5420939</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">75000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">7296877</us-gaap:Liabilities>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">2701512</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="0">816520</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="0">-201240208</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF">18521951</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="0">18519</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="0">212788450</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">857496</us-gaap:GrossProfit>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">1142</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-898714</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-67182</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ContractsRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">2881579</us-gaap:ContractsRevenue>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">12310</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-2665363</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-204896</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">1194927</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-120122</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-27496</us-gaap:IncreaseDecreaseInDeferredCompensation>
  <us-gaap:GainLossOnSaleOfProperty contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-312</us-gaap:GainLossOnSaleOfProperty>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">603000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:NetIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-13516103</us-gaap:NetIncomeLoss>
  <us-gaap:ProceedsFromNotesPayable contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">2300000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-8589704</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">35100</us-gaap:LicensesRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">903959</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">471398</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-437794</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="INF">-8589704</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-99682</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">296856</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:SalesRevenueNet contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">2916679</us-gaap:SalesRevenueNet>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">2592012</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-4926399</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-8716575</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">401000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">3306296</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">3896310</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">3735207</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">117061</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">67762</us-gaap:InterestPaid>
  <us-gaap:OperatingExpenses contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">5783895</us-gaap:OperatingExpenses>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">138124</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">-16107</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">4879936</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">7299284</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CostOfServices contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="0">2059183</us-gaap:CostOfServices>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">-1.64</us-gaap:EarningsPerShareBasicAndDiluted>
  <apri:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0" unitRef="shares" decimals="0">8264515</apri:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0_455296x454932" unitRef="iso4217_USD" decimals="INF">397888</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE4964----1110-Q0004_STD_181_20100630_0_455296x469977" unitRef="iso4217_USD" decimals="INF">12129010</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">APRI</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">APRICUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">2011-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">0001017491</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="INF">17984</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:GrossProfit contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">1170984</us-gaap:GrossProfit>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;5.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;WARRANTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
summary of warrant activity for the six month period ended June 30,
2011 is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="49%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="49%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Common Shares&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="49%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Issuable upon&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exercise&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exercise&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Life&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="49%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="16%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,675,658&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3.72&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.28
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Issued&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-LEFT: 4%" valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(581,332&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2.27&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%" valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(16,684&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;17.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at June 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,077,642&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3.54
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="49%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="15%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at June 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;922,043&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.63&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3.46
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">357633</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-44675</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ContractsRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">2310768</us-gaap:ContractsRevenue>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;16.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;COMMITMENTS
AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Employment
Agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;We
have an employment agreement with Dr. Damaj, our Chairman,
President and Chief Executive Officer. Pursuant to that agreement,
we may terminate Dr. Damaj&amp;#x2019;s employment without cause on ten
days notice, in which event Dr. Damaj would be entitled to
severance pay equal to twelve months&amp;#x2019; base salary which is
currently $450,000 per annum.&amp;#xA0;&amp;#xA0;&amp;#xA0;The employment
agreement further provides that in the event that within one year
after a &amp;#x201C;Change of Control&amp;#x201D; (as defined therein) of the
Company occurs, and the President and Chief Executive
Officer&amp;#x2019;s employment is terminated or resigns for cause, the
President and Chief Executive Officer will be paid a lump sum
amount equal to his base salary for a 12-month period following
termination or resignation.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Company is a party to other employment and compensatory
agreements in the normal course of business and the &lt;font style="DISPLAY: inline"&gt;Company is a party to numerous short-term
consulting and research agreements that, generally, can be
cancelled pursuant to the terms of such
agreements.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
We are subject to certain legal proceedings in the ordinary course
of business.&amp;#xA0;&amp;#xA0;We do not expect any such items to have a
significant impact on our financial position.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;17.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;SEGMENT
INFORMATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Through
June 30, 2011, the Company had two active business segments:
designing and developing pharmaceutical products with its
NexACT&amp;#xAE; drug delivery technology and providing pre-clinical
CRO services through its subsidiary, Bio-Quant.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Segment
information for the six months ended June 30, 2011 and 2010,
respectively is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;NexACT&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#xA0;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Drug&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Delivery&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Bio-Quant CRO&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Other&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Corporate Not&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Allocated to&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Segments&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Consolidated&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;871,449&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,094,041&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;216,727&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,182,217&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Operating
expenses&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,072,378&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,189,553&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;6,163,661&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;12,425,592&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Loss
from operations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,200,929&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(174,099&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(8,879,580&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(11,254,608&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,200,929&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(186,828&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(8,817,341&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(11,205,098&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;14,080,283&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;14,080,283&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;NexACT&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#xA0;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Drug&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Delivery&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Bio-Quant CRO&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Other&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Corporate Not&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Allocated to&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Segments&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Consolidated&lt;/font&gt;&lt;/font&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Revenues&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;35,100&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,560,266&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;321,313&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,916,679&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Operating
expenses&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;916,743&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;768,488&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4,098,664&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;5,783,895&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Loss
from operations&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(881,643&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(63,242&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(3,981,514&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(4,926,399&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(881,643&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(52,499&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(12,581,961&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(13,516,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
assets&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;15,045,423&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9,435,240&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;24,480,663&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="INF">1318461</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">15204</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;8.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;CONVERTIBLE
NOTES PAYABLE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
2010 Convertible Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
On March 15, 2010, the Company issued convertible notes (the
&amp;#x201C;2010 Convertible Notes&amp;#x201D;) in an aggregate principal
amount of $4 million. The 2010 Convertible Notes are secured by a
first priority mortgage on the Company&amp;#x2019;s facility in East
Windsor, New Jersey and are due on December 31,
2012.&amp;#xA0;&amp;#xA0;The proceeds were used to repay the 2008
Convertible Notes (see below) then outstanding in the aggregate sum
of $2.6 million.&amp;#xA0;&amp;#xA0;As such, the Company received
approximately $1.4 million in net proceeds from the issuance of the
2010 Convertible Notes.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The 2010 Convertible Notes are, at the holders&amp;#x2019;
option,&amp;#xA0;&amp;#xA0;payable in cash at maturity on December 31, 2012
or convertible at any time into shares of Common Stock at a current
conversion price of $6.29 per share (with an initial conversion
price of $8.70 per share) (the &amp;#x201C;conversion price&amp;#x201D;),
which price is subject to adjustment upon certain dilutive
issuances of common stock.&amp;#xA0;&amp;#xA0;The 2010 Convertible Notes
have a coupon rate of 7% per annum, which is payable at the
Company&amp;#x2019;s option in cash or, if the Company&amp;#x2019;s net cash
balance is less than $3 million at the time of payment, in shares
of Common Stock.&amp;#xA0;&amp;#xA0;If paid in shares of Common Stock, then
the price of the stock issued will be the lesser of $1.20 below or
95% of the five-day weighted average of the market price of the
Common Stock prior to the time of payment.&amp;#xA0;&amp;#xA0;Such
additional interest consideration is considered contingent and
therefore would only be recognized upon
occurrence.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The conversion price at June 30, 2011 was $6.29 per share which
represents an adjusted price from $8.70 at issuance due to certain
dilutive equity financings since the issuance of the notes. At June
30, 2011, the conversion price was above the current market price
of the Common Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
Conversion of 2008 convertible notes during
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
On January 26, 2010, the Company agreed to convert $397,988 of the
then outstanding 2008 Convertible Notes into Common Stock at a
price of $7.50 per share.&amp;#xA0;&amp;#xA0;As such, the Company issued
53,333 shares of Common Stock to the note holders in repayment of
such $397,988 principal amount plus interest.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The remaining balance outstanding on the remaining 2008 Convertible
Notes of $2,592,012 was repaid in full on March 15, 2010 with the
proceeds received from the 2010 Convertible
Notes.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company recognized a debt inducement charge in interest expense for
the differential between the original conversion rate of $30.00 per
share and the various adjusted conversion prices in 2009 and
2010.&amp;#xA0;&amp;#xA0;Non-cash interest expense recognized for these
conversions was $1,200,000 during the six months ended June 30,
2010.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-4506770</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;6.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;LOSS
PER SHARE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;At
June 30, 2011 and 2010, respectively, options to acquire 916,818
and 156,771 shares of Common Stock, warrants to acquire 1,077,642
and 250,895 shares of Common Stock and convertible securities
convertible into 636,257 and 466,200 shares of Common Stock were
excluded from the calculation of diluted loss per share, as their
effect would be anti-dilutive.&amp;#xA0;&amp;#xA0;Loss per share for the
three and six months ended June 30, 2011 and 2010 was calculated as
follows (net loss / weighted average common shares
outstanding):&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE THREE MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(7,794,092&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(4,278,647&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(11,205,098&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(13,516,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted
average common shares outstanding&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;used
for basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,817,009&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;9,140,451&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,475,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,264,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Basic
and diluted loss per common share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.39&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.47&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.58&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1.64&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">1145733</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">1628934</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">286975</us-gaap:IncreaseDecreaseInDeferredCompensation>
  <us-gaap:GainLossOnSaleOfProperty contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-920</us-gaap:GainLossOnSaleOfProperty>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-534343</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">275990</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-11205098</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">49510</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">871449</us-gaap:LicensesRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">3072378</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">417477</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-2759920</us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">25990</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-2759920</us-gaap:GainLossOnSaleOfEquityInvestments>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="INF">-173452</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">2741403</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">176710</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:SalesRevenueNet contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">3182217</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-11254608</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-18571</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:ProceedsFromRepaymentsOfShortTermDebt contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-401000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;3.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;SALE
OF BIO-QUANT&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Company sold all of the outstanding capital stock of Bio-Quant,
which was one of the Company&amp;#x2019;s wholly owned subsidiaries, to
BioTox on June 30, 2011.&amp;#xA0;&amp;#xA0;&amp;#xA0;The Company received
$500,019 at closing as an initial payment and will be entitled to
receive earn-out payments calculated as a percentage of the future
gross revenue of BioTox&amp;#x2019;s CRO services
business.&amp;#xA0;&amp;#xA0;Over the ten-year term of the earn-out, the
Company will be entitled to receive a minimum of $4,500,000 with
the right to receive amounts in excess of this, depending on the
gross revenue of BioTox over this ten-year period.&amp;#xA0;&amp;#xA0;The
earn-out obligations are secured with a first priority lien on all
the assets of Bio-Quant as well as the assets of BioTox for a
certain period of time. After the sale, the Company does not
beneficially own any equity shares in Bio-Quant or
BioTox.&amp;#xA0;&amp;#xA0;The Company evaluated the sale of Bio-Quant in
accordance with ASC Topic 205-20, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Discontinued
Operations&lt;/font&gt;. The Company does not expect to recognize
continuing direct cash flows from Bio-Quant after the
sale.&amp;#xA0;&amp;#xA0;However, the transaction is structured with a low
down payment and a payment stream over 10 years that is contingent
on the operational success of BioTox. This payment structure was
negotiated as a means to improve the likely cash available for
investment in the growth of the business, which was expected to
have the effect of&amp;#xA0;&amp;#xA0;encouraging higher revenues for
BioTox and potentially greater earn-out payments to the Company
over the ten year earn-out period.&amp;#xA0;&amp;#xA0;The Company does not
have any vote or influence on the execution of the operations but
retains a significant amount of collection risk depending on the
operational success of the disposed CRO business.&amp;#xA0;&amp;#xA0;This
continued exposure to the operating risk of BioTox and the extended
post sale earn-out period indicates future continuing involvement
in the continuing operations of the CRO. As such, the Company
determined that it would not be appropriate to classify the sale of
Bio-Quant as a discontinued operation in the consolidated financial
statements.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company also considered whether BioTox should be consolidated as a
Variable Interest Entity (&amp;#x201C;VIE&amp;#x201D;) under ASU No. 2009-17,
&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Consolidations
(Topic 810): Improvements to Financial Reporting by Enterprises
Involved with Variable Interest Entities&lt;/font&gt;. The Company
determined that BioTox is a VIE because it could potentially lack
sufficient equity at risk to fund its operational activities
without additional subordinated financial support. The Company
determined that it does not have the power to direct the activities
of BioTox, nor does it have the obligation to absorb additional
losses and it will not participate in any residual revenues thus it
is not the primary beneficiary of the VIE. As such, the Company
will not consolidate the financial information of the
Buyer.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The estimated fair value of the earn-out payments expected to be
received over the next ten years is approximately $2.3, million
which represents the minimum payments of $4,500,000 discounted at
13.0% over the ten-year period.&amp;#xA0;&amp;#xA0;&amp;#xA0;This receivable is
carried on the Company&amp;#x2019;s balance sheet as of June 30, 2011 at
$0 due to a reserve of $2.3 million established at June 30, 2011,
based on the length of time over which the payments will be
received and lack of measurable external inputs available to
determine the fair value of the minimum earn-out amounts due. This
reserve increases the loss on sale of the Bio-Quant subsidiary and
is not reflected as a bad debt expense. In the event that actual
future cash receipts from BioTox differ from our estimates or we
adjust our estimates in future periods, our financial position and
results of operations could be materially
impacted.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following represents proforma results for the six months ended June
30, 2011 and 2010, respectively, as if the transaction had occurred
on January 1, 2010.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Pro
forma financial results&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
As Reported&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Bio-Quant&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Adjusted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
revenue&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;3,182,217&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,094,041&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,088,176&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(11,205,098&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(2,946,748&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(8,258,350&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Basic
and diluted loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.58&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.15&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.42&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted
average common shares outstanding&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;used
for basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,475,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,475,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;19,475,598&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Pro
forma financial results&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(Unaudited)&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
As Reported&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Bio-Quant&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Adjusted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Total
revenue&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,916,679&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;2,560,266&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;356,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Net
loss&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(13,516,103&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(52,499&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(13,463,604&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Basic
and diluted loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1.64&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(0.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(1.63&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Weighted
average common shares outstanding&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="64%"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
used for basic and diluted loss per share&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,264,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,264,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;8,264,515&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
unaudited proforma condensed financial information may not
necessarily be indicative of the results of operations that would
have been achieved if the sale of the subsidiary had occurred at
that time. The proforma adjustments are based on certain
assumptions that the Company believes are reasonable under the
circumstances.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:RentalIncomeNonoperating contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">222962</us-gaap:RentalIncomeNonoperating>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">2741403</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-5458</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-79550</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;14.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;INCOME
TAXES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company has incurred losses since inception, which have generated
net operating loss carryforwards of approximately $36 million for
federal and state income tax purposes through December 31,
2010.&amp;#xA0;&amp;#xA0;These carryforwards are available to offset future
taxable income and expire beginning in 2014 through 2029 for
federal income tax purposes.&amp;#xA0;&amp;#xA0;Internal Revenue Code
Section 382 places a limitation on the utilization of federal net
operating loss carryforwards when an ownership change, as defined
by tax law, occurs.&amp;#xA0;&amp;#xA0;Generally, an ownership change, as
defined, occurs when a greater than 50 percent change in ownership
takes place during any three-year period. The Company performed a
review of stock transactions for the years beginning January 1,
2008 and ending December 31, 2010 as the Company feels that was the
likely period that such an ownership change likely
occurred.&amp;#xA0;&amp;#xA0;Based on this limited review, the Company
determined that an ownership change took place in June 2010 when
the Bio-Quant notes were converted to common stock as discussed in
Note 8.&amp;#xA0;&amp;#xA0;As a result of this ownership change, the
ability to utilize the current net operating loss carryforwards
generated prior to this change in ownership is limited to
approximately $1.2 million per year based on our calculations at
the time of the ownership change.&amp;#xA0;&amp;#xA0;The Company has
recorded a full valuation allowance against the deferred tax assets
arising from the net operating loss carryforwards.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company follows the provisions of ASC 740-10-25. ASC 740-10-25
provides recognition criteria and a related measurement model for
uncertain tax positions taken or expected to be taken in income tax
returns. ASC 740-10-25 requires that a position taken or expected
to be taken in a tax return be recognized in the financial
statements when it is more likely than not that the position would
be sustained upon examination by tax authorities. Tax positions
that meet the more likely than not threshold are then measured
using a probability weighted approach recognizing the largest
amount of tax benefit that is greater than 50% likely of being
realized upon ultimate settlement. The Company&amp;#x2019;s Federal
income tax returns for 2007 to 2009 are still open and subject to
audit.&amp;#xA0;&amp;#xA0;In addition, net operating losses arising from
prior years are also subject to examination at the time they are
utilized in future years.&amp;#xA0;&amp;#xA0;The Company had no tax
positions relating to open income tax returns that were considered
to be uncertain. Accordingly, we have not recorded a liability for
unrecognized tax benefits upon adoption of ASC 740-10-25. There
continues to be no liability related to unrecognized tax benefits
at June 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">174422</us-gaap:InterestPaid>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;2.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;ACQUISITION
OF BIO-QUANT&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
In connection with the Company&amp;#x2019;s acquisition of Bio-Quant,
which was consummated on December 14, 2009 (the &amp;#x201C;Effective
Time&amp;#x201D;), each outstanding share of common stock of Bio-Quant
was canceled and converted into the right to receive 60.93 shares
of common stock, par value $0.001 per share, of the Company (the
&amp;#x201C;Apricus Shares&amp;#x201D;), as well as a promissory note (each,
a &amp;#x201C;Note&amp;#x201D;) in the original principal amount of
$2,771.37.&amp;#xA0;&amp;#xA0;&amp;#xA0;In connection with the closing of the
Merger, the Company issued an aggregate of 266,667 Apricus Shares
and Notes in the aggregate original principal amount of $12,129,010
to the shareholders of Bio-Quant.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Notes accrued interest at a rate of 10% per annum through their
repayment, with all principal and interest accrued thereunder
becoming due and payable one year from the closing date of the
Merger.&amp;#xA0;&amp;#xA0;The terms of the Notes provide that the
principal amounts and all interest thereunder were payable by the
Company in cash or, at the Company&amp;#x2019;s option, in Apricus
Shares, which would be valued for purposes of conversion at the
fixed price of $2.52 per share.&amp;#xA0;&amp;#xA0;The Merger Agreement
provides that if the Company repaid the Notes in Apricus Shares,
the total number of Apricus Shares issuable to Bio-Quant
shareholders could not exceed 19.99% of outstanding Apricus Shares
at the Effective Time unless the Company received stockholder
approval to do so in accordance with applicable rules of the NASDAQ
Capital Market.&amp;#xA0;&amp;#xA0;The Company received stockholder
approval at its May 24, 2010 meeting for the potential issuance of
shares in full repayment of the remaining amounts owed under the
Notes, and, on June 21, 2010, the Company repaid the remaining
outstanding principal and interest accrued under the Notes in
Apricus Shares.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Intangible
assets acquired from Bio-Quant of $4,160,000 consisted primarily of
developed Know-How and the Bio-Quant Trade Name. Developed Know-How
related to Bio-Quant&amp;#x2019;s pre-clinical service expertise
including, but not limited to, its extensive inventory of
internally developed cell lines. The Bio-Quant Trade Name
represents future revenue attributable to the reputation and name
recognition of Bio-Quant within the pharmaceutical industry where
Bio-Quant is a known expert in pre-clinical services. (See Note 3
and Note 7 for the sale of Bio-Quant and the write-off of these
intangibles).&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
At the time of acquisition, Bio-Quant was a revenue generating,
cash flow positive CRO.&amp;#xA0;&amp;#xA0;Bio-Quant was expected to
continue its revenue growth and cash generating CRO
business.&amp;#xA0;&amp;#xA0;The $9,084,476 of goodwill generated from the
acquisition of Bio-Quant consisted largely of the ability of the
Bio-Quant CRO to continue to grow its revenues and generate
positive cash flow to contribute to the pharmaceutical product
development business segment of the Company.&amp;#xA0;&amp;#xA0;As
discussed in Note 1, the Company shifted the focus of the Bio-Quant
CRO from growing revenues and generating increased positive cash
flow to largely supporting the Company&amp;#x2019;s research and
development business segment which designs and develops
pharmaceutical drug candidates. &lt;font style="DISPLAY: inline"&gt;The
Bio-Quant CRO allowed the Company to increase its active
pre-clinical and clinical product pipeline from 4 drug candidates
to 13 drug candidates&lt;/font&gt; utilizing &lt;font style="DISPLAY: inline"&gt;the internal capabilities of the CRO. However, as
a result of this internal&lt;/font&gt; research &lt;font style="DISPLAY: inline"&gt;focus the cash flow generating capabilities of
the CRO diminished over time and in connection with the&lt;/font&gt;
valuation of the future expected cash flows and the goodwill
related to Bio-Quant at December 31, 2010, an impairment charge of
$9,084,476 was taken in 2010 to write off the entire value of
goodwill&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;font style="DISPLAY: inline"&gt;from
this acquisition&lt;/font&gt;. &lt;font style="DISPLAY: inline"&gt;During 2011,
the Company, considered the significance of its enhanced
product&lt;/font&gt; candidate &lt;font style="DISPLAY: inline"&gt;pipeline,
the resources needed to further develop each of those product
opportunities and the value being derived from the CRO business
with diminished cash flows towards operations. Based on&lt;/font&gt; this
&lt;font style="DISPLAY: inline"&gt;change in strategic focus, on&lt;/font&gt;
June 30, 2011, the Company entered into a stock purchase agreement
with BioTox to sell all of the outstanding capital stock of
Bio-Quant. (See Note 3).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">12425592</us-gaap:OperatingExpenses>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;1.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;BASIS
OF PRESENTATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Apricus Biosciences, Inc. (formerly NexMed, Inc.) and subsidiaries
(the &amp;#x201C;Company&amp;#x201D; or &amp;#x201C;our&amp;#x201D; or
&amp;#x201C;we&amp;#x201D;) was incorporated in Nevada in 1987.&amp;#xA0;&amp;#xA0;On
September 10, 2010, the Company changed its name from
&amp;#x201C;NexMed, Inc.&amp;#x201D; to &amp;#x201C;Apricus Biosciences,
Inc.&amp;#x201D; The Company has historically focused its efforts on
drug development using its patented drug delivery technology known
as NexACT&amp;#xAE;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The consolidated financial statements have been prepared by the
Company pursuant to the rules and regulations of the U.S.
Securities and Exchange Commission.&amp;#xA0;&amp;#xA0;Certain information
and footnote disclosures normally included in financial statements
prepared in accordance with accounting principles generally
accepted in the United States have been condensed or omitted. In
the opinion of the Company&amp;#x2019;s management, all adjustments that
are of a normal recurring nature, considered necessary for fair
presentation, have been included in the accompanying consolidated
financial statements. The unaudited consolidated financial
statements and statements of operations for the interim periods are
not necessarily indicative of results for the full year. For
further information, refer to the consolidated financial statements
and notes thereto included in the Company&amp;#x2019;s annual report on
Form 10-K filed with the Securities Exchange Commission for the
year ended December 31, 2010. The preparation of these consolidated
financial statements requires the Company to make estimates and
judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, the Company evaluates its
estimates, including those related to bad debts, intangible assets,
income taxes, stock-based compensation and commitments and
contingencies.&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s actual results may
differ from these estimates under different assumptions or
conditions.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
December 14, 2009, the Company acquired Bio-Quant, Inc.
(&amp;#x201C;Bio-Quant&amp;#x201D;), a &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;specialty biotech contract
research organization (&amp;#x201C;CRO&amp;#x201D;) based in San
Diego.&amp;#xA0;&amp;#xA0;The acquisition was made pursuant to an&lt;/font&gt;
Agreement and Plan of Merger (the &amp;#x201C;Merger Agreement&amp;#x201D;)
dated November 20, 2009 by and among the Company and BQ Acquisition
Corp., a wholly-owned subsidiary of the Company and
Bio-Quant.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline"&gt;Since that time, the Bio-Quant CRO
allowed the Company to increase its active pre-clinical and
clinical product pipeline from 4 drug candidates to 13 drug
candidates&lt;/font&gt; utilizing &lt;font style="DISPLAY: inline"&gt;the
internal&lt;/font&gt; research &lt;font style="DISPLAY: inline"&gt;capabilities
of the CRO.&lt;/font&gt; The Company used the Bio-Quant resources to
advance its product candidates and expand the uses and routes of
its NexACT&amp;#xAE; delivery technology. As &lt;font style="DISPLAY: inline"&gt;a result of this internal&lt;/font&gt; research
&lt;font style="DISPLAY: inline"&gt;focus&lt;/font&gt;, &lt;font style="DISPLAY: inline"&gt;the cash flow generating capabilities of the CRO
diminished over time&lt;/font&gt; since the Company was using the
capabilities and resources of Bio-Quant for internal development
activities rather than for external customer growth. In
&lt;font style="DISPLAY: inline"&gt;connection with the&lt;/font&gt; valuation
of the future expected cash flows and the goodwill related to
Bio-Quant at December 31, 2010, an impairment charge of $9,084,476
was taken in 2010 to write off the entire value of
goodwill&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;font style="DISPLAY: inline"&gt;from
this acquisition&lt;/font&gt;.&lt;font style="DISPLAY: inline"&gt;&amp;#xA0;During
2011, the Company considered the significance of its enhanced
product candidate pipeline, the resources needed to further develop
each of those product opportunities and the value being derived
from the CRO business with diminished cash flows towards
operations.&lt;/font&gt; &lt;font style="DISPLAY: inline"&gt;Based on the
change in strategic focus, on&lt;/font&gt; June 30, 2011, the Company
entered into a stock purchase agreement with Samm Solutions, Inc.
doing business as BioTox Sciences (&amp;#x201C;BioTox&amp;#x201D;), a San
Diego-based CRO, to sell all of the outstanding capital stock of
Bio-Quant, Inc., which was one of the Company&amp;#x2019;s wholly owned
subsidiaries (see Note 3).&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Through
June 30, 2011, the date of the sale of Bio-Quant, the Company
operated in two segments &amp;#x2013; designing and developing
pharmaceutical products through its wholly-owned subsidiary NexMed
(USA), Inc. and providing pre-clinical CRO services through its
wholly-owned subsidiary, Bio-Quant.&amp;#xA0;&amp;#xA0;For periods
subsequent to June 30, 2011 the Company will operate in one segment
designing and developing pharmaceutical products through its
wholly-owned subsidiary NexMed (USA), Inc.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Company is focusing its efforts on new and patented
pharmaceutical products and product candidates based on our
patented drug delivery technology known as
NexACT&amp;#xAE;.&amp;#xA0;&amp;#xA0;&amp;#xA0;The Company continues with its
efforts to expand the uses of
the&amp;#xA0;&amp;#xA0;NexACT&amp;#xAE;&amp;#xA0;&amp;#xA0;technology into the oral,
subcutaneous, ocular and rectal delivery of multi-classes of drugs
for these and other indications.&amp;#xA0;&amp;#xA0;The Company is also
seeking commercialization partnerships for its product,
Vitaros&amp;#xAE;, which is approved in Canada for the treatment of
erectile dysfunction (&amp;#x201C;ED&amp;#x201D;) and its additional existing
clinical and pre-clinical pipeline of product candidates such
as&amp;#xA0;&amp;#xA0;Femprox&amp;#xAE; for female sexual arousal disorder,
MycoVa&amp;#x2122; for onychomycosis excluding tinea pedis (nail fungal
infection), RayVa&amp;#x2122; for Raynaud&amp;#x2019;s Syndrome and
PrevOnco&amp;#x2122; for liver cancer and is enhancing its business
development efforts by offering potential partners clearly defined
regulatory paths for our products and product candidates under
development.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
June&amp;#xA0;21, 2010, the Company completed a reverse stock split
pursuant to which each fifteen shares of Company&apos;s common stock
then issued and outstanding were automatically converted into one
share of the Company&apos;s common stock; no change was made to the
per-share par value of the common stock. The authorized common
stock was also proportionately reverse split by a factor of
fifteen-for-one. All share and per share amounts in the
accompanying consolidated financial statements have been adjusted
to reflect the reverse stock split as if it had occurred at the
beginning of the earliest period presented.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Liquidity&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
accompanying consolidated financial statements have been prepared
on a basis which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of
business.&amp;#xA0;&amp;#xA0;The Company has an accumulated deficit of
approximately $212.4 million at June 30, 2011 and recorded a net
loss of approximately $11.2&amp;#xA0;&amp;#xA0;million for the six months
ended June 30, 2011 and has principally been financed through
private placements of equity securities,&amp;#xA0;&amp;#xA0;debt financing
and up-front payments received from commercial partners for its
products under development.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company&amp;#x2019;s cash reserves of approximately $9.1 million at June
30, 2011, are expected to provide us with sufficient cash to fund
our operations into the second half of 2012.&amp;#xA0;&amp;#xA0;This
projection is based on the monthly operating expenses of
maintaining our public listing, continuing essential business
development and research and development efforts for our current
pipeline together with the receipt of multiple licensing payments
from commercial partners and from possible future cash earn-out
revenues resulting from the sale of
Bio-Quant.&amp;#xA0;&amp;#xA0;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;To
the extent we sign additional licensing agreements in 2011 or 2012
and receive up-front and milestone payments for&lt;/font&gt; one or more
of our product pipeline candidates and/or the NexACT&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;&amp;#xA0;&lt;/font&gt;technology
itself, we expect that our cash reserves plus those payments should
provide us with sufficient cash to fund our operations well into
2013. &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
change in any of these assumptions or any unexpected expenses, may
change these projected cash reserve amounts and/or
timelines.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Company currently expects that it will be cash flow positive
from operations, which includes cash expected to be received from
up-front and milestone payments from the licensing of its products
and NexACT&amp;#xAE;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;technology, during
2011 as the Company plans to enter into out-licensing agreements
for its NexACT&amp;#xAE; technology with pharmaceutical and
biotechnology companies worldwide. The Company&amp;#x2019;s cash flow
positive guidance assumes the Company does not commence any
clinical trials, which would be expected to increase our expenses
significantly.&amp;#xA0;&amp;#xA0;At the same time, the Company is actively
pursuing partnering opportunities for its approved and clinical
stage NexACT&amp;#xAE; based candidates in the areas of sexual
dysfunction, oncology, inflammation, dermatology, pain and
autoimmune diseases.&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;The successful
licensing of one or more of these candidates and/or the
NexACT&amp;#xAE; technology itself would be expected to generate
additional revenues for funding the Company&amp;#x2019;s long-term
growth strategy.&amp;#xA0;&amp;#xA0;To that end, as discussed in Note 15,
the Company, in December 2010, entered into a licensing agreement
with Bracco SpA (&amp;#x201C;Bracco&amp;#x201D;) for its topical
alprostadil-based cream treatment for erectile dysfunction
(&amp;#x201C;Vitaros&amp;#xAE;&amp;#x201D;) for sale in Italy and in January
2011, and the Company entered into exclusive license agreement with
Elis Pharmaceuticals Ltd. (&amp;#x201C;Elis&amp;#x201D;) and Neopharm Group
(&amp;#x201C;Neopharm&amp;#x201D;) for Vitaros&amp;#xAE;.&amp;#xA0;&amp;#xA0;Under the
terms of the Elis License Agreement, Elis has been granted
exclusive rights in United Arab Emirates, Oman, Bahrain, Qatar,
Saudi Arabia, Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen and
under the terms of the Neopharm License Agreement, Neopharm has
been granted exclusive rights in Israel and the Palestinian
Territories of the Gaza Strip and the West Bank to commercialize
and market Vitaros&amp;#xAE;. The Company continues to be active in
discussions with other potential commercial partners for other
territories. In April 2011, we filed a marketing application in
Europe for approval of Vitaros&amp;#xAE; as a treatment for patients
with ED. In addition, the Company expects revenues from the sale of
Vitaros&amp;#xAE; in the approved territory(ies) which would also
increase its cash position.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Effective
January 1, 2010, the Company adopted ASU No. 2009-17, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Consolidations (Topic 810):
Improvements to Financial Reporting by Enterprises Involved with
Variable Interest Entities&lt;/font&gt;. The amendments in this update
replace the&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;quantitative-based
risks and rewards calculation for determining which reporting
entity, if any, has a controlling financial interest in
a&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;variable
interest entity with an approach focused on identifying which
reporting entity has the power to direct the activities of a
variable interest entity that most significantly impact the
entity&amp;#x2019;s economic performance and (1) the obligation to
absorb losses of the entity or (2) the right to receive benefits
from the entity. An approach that is expected to be primarily
qualitative will be more effective for identifying which reporting
entity has a controlling financial interest in a variable interest
entity. The amendments in this update also require additional
disclosures about a reporting entity&amp;#x2019;s involvement in
variable interest entities, which will enhance the information
provided to users of financial statements. The Company evaluated
their business relationships to identify potential variable
interest entities and have concluded that consolidation of such
entities is not required for the periods presented. On a quarterly
basis, the Company will continue to reassess our involvement with
variable interest entities.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
April 2010, the FASB issued ASU No. 2010-17, Topic 605 - Revenue
Recognition - Milestone Method (&amp;#x201C;USA 2010-17&amp;#x201D;), which
provides guidance on defining a milestone and determining when it
may be appropriate to apply the milestone method of revenue
recognition for research or development transactions. The
amendments in ASU 2010-17 are effective on a prospective basis for
milestones achieved in fiscal years beginning on or after June 15,
2010, and interim periods within those years. The Company has
adopted ASU 2010-17 effective as of the first quarter of fiscal
2011. This ASU did not have any impact on the Company&amp;#x2019;s
consolidated financial statements upon adoption.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
December 2010, the FASB issued ASU No. 2010-28, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Intangibles &amp;#x2014; Goodwill
and Other (Topic 350): &amp;#x201C;When to Perform Step 2 of the
Goodwill Impairment Test for Reporting Units with Zero or Negative
Carrying Amounts&lt;/font&gt;. ASU 2010-28 is effective for fiscal
years&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;beginning after
December 15, 2010 and amends the criteria for performing Step 2 of
the goodwill impairment test for reporting units&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;with zero or
negative carrying amounts and requires performing Step 2 if
qualitative factors indicate that it is more likely than not
that&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;a goodwill
impairment exists. The Company has adopted ASU 2010-28 effective as
of the first quarter of fiscal 2011. This ASU did not have any
impact on the Company&amp;#x2019;s consolidated financial statements
upon adoption.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
December 2010, the FASB issued ASU No. 2010-27, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Fees Paid to the Federal
Government by Pharmaceutical Manufacturers&lt;/font&gt; ( &amp;#x201C;ASU
2010-27&amp;#x201D;) which provides guidance on how to recognize and
classify the fees mandated by the Patient&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;Protection and
Affordable Care Act as amended by the Health Care and Education
Reconciliation Act (together, the &amp;#x201C;Acts&amp;#x201D;). The
Acts&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;impose an annual
fee for each calendar year beginning on or after January 1, 2011
payable by branded prescription drug&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;manufacturers
and importers on branded prescription drugs. The liability for the
fee should be estimated and recorded in full upon the&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;first qualifying
sale with a corresponding deferred cost that is amortized to
expense using a straight-line method of allocation over
the&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;calendar year
that it is payable. ASU 2010-27 is effective for calendar years
beginning on or after December 31, 2010, when the fee&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;initially
becomes effective. As the Company does not currently have a
commercial product, the effect of this guidance will be limited to
future transactions.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">1037295</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;4.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;ACCOUNTING
FOR STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
value of restricted stock grants is calculated based upon the
closing stock price of the Company&amp;#x2019;s Common Stock on the date
of the grant.&amp;#xA0;&amp;#xA0;For stock options granted to employees and
directors, we recognize compensation expense based on the
grant-date fair value estimated in accordance with the appropriate
accounting guidance, and recognized over the expected service
period. We estimate the fair value of each option award on the date
of grant using the Black-Scholes option pricing model. Stock
options and warrants issued to consultants are accounted for in
accordance with accounting guidance. Compensation expense is
calculated each quarter for consultants using the Black-Scholes
option pricing model until the option is fully vested and is
included in research and development or general and administrative
facility expenses, based upon the services performed by the
recipient.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
December 1996, the Company adopted the Stock Option and Long-Term
Incentive Compensation Plan (the &amp;#x201C;Incentive Plan&amp;#x201D;) and
the Recognition and Retention Stock Incentive Plan (the
&amp;#x201C;Recognition Plan&amp;#x201D;).&amp;#xA0;&amp;#xA0;A total of 133,333
shares were set aside for these two plans.&amp;#xA0;&amp;#xA0;In May 2000,
the Stockholders&amp;#x2019; approved an increase in the number of
shares reserved for the Incentive Plan and Recognition Plan to a
total of 500,000.&amp;#xA0;&amp;#xA0;In June 2006, the Company adopted the
NexMed, Inc. 2006 Stock Incentive Plan (&amp;#x201C;the 2006
Plan&amp;#x201D;).&amp;#xA0;&amp;#xA0;A total of 200,000 shares were initially
reserved for the issuance under the 2006 Plan and an additional
133,333 shares were added to the 2006 Plan in June
2008.&amp;#xA0;&amp;#xA0;The Company received stockholder approval at its
May 24, 2010 meeting to add an additional 1,000,000 shares to the
2006 Plan. The Company received stockholder approval at its May 16,
2011 meeting to increase the number of shares reserved for the 2006
Plan by 2,500,000 to 3,833,333. Options granted under the
Company&amp;#x2019;s plans generally vest over a period of one to five
years, with exercise prices of currently outstanding options
ranging from $1.69 to $48.75.&amp;#xA0;&amp;#xA0;The maximum term under
these plans is 10 years.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table summarizes information about options outstanding at
June 30, 2011:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;
&lt;div&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="12%" colspan="2" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="45%" colspan="11"&gt;&lt;font style="FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Options Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="25%" colspan="8" align="right"&gt;&lt;font style="FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Options Exercisable&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="12%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Range of&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Exercise
Prices&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Number&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Outstanding&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Average&lt;br /&gt;

Remaining&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Contractual
Life&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Exercise&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Intrinsic&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Number&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Exercisable&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Average&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;Exercise
Price&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%" colspan="2" align="right"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Intrinsic&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"&gt;
Value&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;1.69
- 5.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;870,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;9.6
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;4.36&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;109,990&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;4.01&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;85,391&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;8.25
- 48.75&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;46,818&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;4.4
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;14.61&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;46,818&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;14.61&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="8%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="11%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;916,818&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 4px" valign="bottom" width="11%"&gt;
&lt;div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;9.3
years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;4.88&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;156,808&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;7.18&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"&gt;85,391&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;A
summary of stock option activity is as follows:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Weighted&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Average&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Average Remaining&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Total&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;Aggregate&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Number of&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Exercise&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Contractual&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Intrinsic&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Shares&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Price&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Life&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Value&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at December 31, 2010&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;107,604&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10.37&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
5.8&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-LEFT: 9%" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Granted&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;842,500&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.44&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-LEFT: 9%" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercised&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 9%" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;(33,286&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;11.50&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Outstanding
at June 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;916,818&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.88&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
9.3&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Vested
or expected to vest at&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;June
30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;892,431&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;4.88&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
9.3&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td valign="bottom" width="38%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Exercisable
at June 30, 2011&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;156,808&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;7.18&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
7.5&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;years&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Expected Volatility.&lt;/font&gt; The Company uses analysis of historical
volatility to compute the expected volatility of its stock
options.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Expected Term.&lt;/font&gt; The expected term is based on several factors
including historical observations of employee exercise patterns
during the Company&amp;#x2019;s history and expectations of employee
exercise behavior in the future giving consideration to the
contractual terms of the stock-based awards.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Risk-Free Interest Rate&lt;/font&gt;. The interest rate used in valuing
awards is based on the yield at the time of grant of a U.S.
Treasury security with an equivalent remaining term.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Dividend Yield&lt;/font&gt;. The Company has never paid cash dividends,
and does not currently intend to pay cash dividends, and thus has
assumed a 0% dividend yield.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;
Pre-Vesting Forfeitures&lt;/font&gt;. Estimates of pre-vesting option
forfeitures are based on Company experience. The Company will
adjust its estimate of forfeitures over the requisite service
period based on the extent to which actual forfeitures differ, or
are expected to differ, from such estimates. Changes in estimated
forfeitures will be recognized through a cumulative catch-up
adjustment in the period of change and will also impact the amount
of compensation expense to be recognized in future
periods.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Total
unrecognized compensation cost related to unvested stock options as
of June 30, 2011 was approximately $3.1 million.&amp;#xA0;&amp;#xA0;That
cost is expected to be recognized over 3 years.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
Compensatory Share Issuances&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
value of restricted stock grants is calculated based upon the
closing stock price of the Company&amp;#x2019;s Common Stock on the date
of the grant.&amp;#xA0;&amp;#xA0;The value of the grant is expensed over
the vesting period of the grant in accordance with FASB ASC
718.&amp;#xA0;&amp;#xA0;As of June 30, 2011, there was approximately
$839,000 of total unrecognized compensation cost related to
non-vested restricted stock.&amp;#xA0;&amp;#xA0;That cost is expected to be
recognized over 3 years.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
2011, the Board of Directors awarded Dr. Bassam Damaj, the
Company&amp;#x2019;s current Chairman, President and Chief Executive
Officer an option (the &amp;#x201C;Option&amp;#x201D;)&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;to
purchase up to 300,000 shares of common stock of the
Company.&amp;#xA0;&amp;#xA0;The exercise price of the Option is equal to
$3.89 per share, the fair market value of the Company&amp;#x2019;s
common stock on the date of grant (January 31,
2011).&amp;#xA0;&amp;#xA0;The Options become exercisable over a period of
three years, with one-third of the Options vesting immediately upon
the date of grant and the remaining two-thirds vesting quarterly
over the two-year period beginning on the first anniversary of the
date of grant. The expense related to this Option grant will be
recorded in 2011, 2012 and 2013 based on the vesting
period.&amp;#xA0;&amp;#xA0;&amp;#xA0;As a result of this Option grant, the
Company recognized approximately $429,000 as compensation expense
during the six months ended June 30, 2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
following table indicates where the total stock-based compensation
expense resulting from stock options and awards appears in the
Unaudited Consolidated Statements of Operations:&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE THREE MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
FOR THE SIX&amp;#xA0;MONTHS&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
ENDED JUNE 30,&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2011&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline"&gt;
2010&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Research
and development&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;110,783&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,284&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;136,420&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;10,284&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;General
and administrative&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;415,557&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,040,090&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,009,313&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,184,643&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#C0FFC0"&gt;
&lt;td valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Stock-based
compensation expense&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;526,340&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,050,374&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,145,733&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,194,927&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
stock-based compensation expense has not been tax-effected due to
the recording of a full valuation allowance against U.S. net
deferred tax assets.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-45013</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">-5100</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;7.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;INTANGIBLE
ASSETS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline"&gt;The intangible assets of the Company
at December 31, 2010 and through June 30, 2011 consisted of
Know-How and Trade Name related to the Bio-Quant CRO segment. On
June 30, 2011, the Bio-Quant business was sold to BioTox and the
intangibles associated with the business were removed from the
consolidated accounts of the Company. During 2010 and for the first
half of 2011, the Company amortized Know-How over the expected
useful life of 10 years and the Trade Name over the expected useful
life of 20 years.&lt;/font&gt; Amortization expense amounted to $59,509
and $179,924 for the six months ended June 30, 2011 and 2010,
respectively.&amp;#xA0;&amp;#xA0;During 2010, the Company took an
impairment charge of $1,083,646 to write down the fair value of
Know-How to $1,637,000.&amp;#xA0;&amp;#xA0;&lt;font style="DISPLAY: inline"&gt;Such impairment was derived mainly from the fact
that Bio-Quant significantly changed its strategic focus in
2010.&amp;#xA0;&amp;#xA0;Rather than serve the greater CRO market,
Bio-Quant was primarily performing&lt;/font&gt; internal &lt;font style="DISPLAY: inline"&gt;CRO services for the Company&amp;#x2019;s own
pharmaceutical product development segment&lt;/font&gt; (NexMed
USA).&lt;font style="DISPLAY: inline"&gt;&amp;#xA0;&amp;#xA0;As such, the ongoing
revenue, profits and cash flows for Bio-Quant were significantly
reduced from the initial projections for Bio-Quant when it was
acquired by the Company in December
2009.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;13.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;RELATED
PARTY TRANSACTIONS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
Approximately 63% of the Bio-Quant notes payable described in Note
8 were held by executives of the Company.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
FasTrack Pharmaceuticals, Inc. (&amp;#x201C;FasTrack&amp;#x201D;) and
Sorrento Pharmaceuticals, Inc. (&amp;#x201C;Sorrento&amp;#x201D;) were formed
by Bio-Quant in 2008 and in 2009 Bio-Quant spun-off its
pharmaceutical assets to the two companies to enable it to focus on
its core business of pre-clinical CRO testing
services.&amp;#xA0;&amp;#xA0;&amp;#xA0;FasTrack subsequently acquired
Sorrento&amp;#x2019;s assets and liabilities in March
2011.&amp;#xA0;&amp;#xA0;FasTrack is a privately-held, development stage
company of whom two executive officers and one director of the
Company are minority shareholders.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
&lt;font style="DISPLAY: inline"&gt;On April 4, 2011 the Company and
FasTrack entered&amp;#xA0;&amp;#xA0;into an Asset Purchase
Agreement&lt;/font&gt;, &lt;font style="DISPLAY: inline"&gt;pursuant to
which&lt;/font&gt; &lt;font style="DISPLAY: inline"&gt;FasTrack sold&lt;/font&gt; to
the Company all &lt;font style="DISPLAY: inline"&gt;the rights&lt;/font&gt; it
had &lt;font style="DISPLAY: inline"&gt;in&lt;/font&gt; certain &lt;font style="DISPLAY: inline"&gt;back-up compounds for
PrevOnco&lt;/font&gt;&amp;#x2122;.&lt;font style="DISPLAY: inline"&gt;&amp;#xA0;&lt;/font&gt;PrevOnco&amp;#x2122; for the treatment of
solid tumors, contains a marketed anti-ulcer compound, lansoprazole
that could be &lt;font style="DISPLAY: inline"&gt;used alone or in
combination with other chemotherapeutic agents.&amp;#xA0; The Company
believes&lt;/font&gt; PrevOnco&amp;#x2122; &lt;font style="DISPLAY: inline"&gt;can
be optimized further to increase its efficacy in combination with
our NexAct&amp;#xAE; technology.&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
In exchange for the PrevOnco&amp;#x2122; back up compound portfolio, the
Company loaned FasTrack $250,000 in the form of a secured
convertible note and restructured the existing outstanding demand
notes and interest payable due to the Company into a second secured
convertible note in the amount of $224,520. The notes are due on
April 4, 2013 and bear interest at the rate of prime plus 1%
(currently 4.25%).&amp;#xA0;&amp;#xA0;The notes automatically convert to
common stock of FasTrack if, prior to the maturity
date,&amp;#xA0;&amp;#xA0;FasTrack completes a material round of financing,
or closes a merger or acquisition transaction (&amp;#x201C;M&amp;amp;A
event&amp;#x201D;), or completes a public offering at an offering price
equal to the financing or M&amp;amp;A value at that time discounted by
10%.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
In addition and separately, the Company granted FasTrack an option
to enter into a license to the Company&amp;#x2019;s NexACT&amp;#xAE;
permeation enhancer for the combination of two to-be-determined
specific drugs chosen by FasTrack and agreed to by the Company. It
is understood that these to-be-determined products would be outside
of the Company&amp;#x2019;s core focus and expertise and it is expected
that these drugs would not be candidates that the Company would
likely pursue on its own. Under the terms of the license, the
Company would receive $500,000 in cash, plus milestones of more
than $5,000,000 per compound, and product sales royalties following
the exercise of the license option by FasTrack.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
The Company considered whether FasTrack should be consolidated as a
Variable Interest Entity (VIE) under ASU No. 2009-17, &lt;font style="FONT-STYLE: italic; DISPLAY: inline"&gt;Consolidations (Topic 810):
Improvements to Financial Reporting by Enterprises Involved with
Variable Interest Entities&lt;/font&gt;. The Company determined that
FasTrack is a VIE because it lacks sufficient equity at risk to
fund its operational activities without additional subordinated
financial support. The Company has a variable interest in the VIE
related to the convertible notes due from FasTrack even though we
do not currently have a direct equity interest in
FasTrack.&amp;#xA0;&amp;#xA0;In the accompanying consolidated financial
statements the loans and Notes are valued at a zero book value at
June 30, 2011 and December 31, 2010 for accounting purposes for
lack of marketability of the FasTrack entity. As a result of the
notes being carried with no value, the net impact to the
consolidated financial statements in the case of a consolidation
for the periods ended June 30, 2011 and 2010 would be insignificant
and thus FasTrack has not been consolidated as its operations are
not material to the Company.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
In July 2011, FasTrack entered into a merger agreement with a
publicly-traded Company, North Horizon, Inc. Under the agreement,
FasTrack will become a subsidiary of North Horizon. The
shareholders, noteholder, and warrantholder of FasTrack will
receive in the transaction the number of shares comprising 92% of
the fully-diluted shares of North Horizon. The transaction is
subject to customary closing conditions. Apricus makes no
representation as to the likelihood of completion of the
transaction or of the value that may be associated with the
interests of Apricus following the merger.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">6593294</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">4143679</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CostOfServices contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">2011233</us-gaap:CostOfServices>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <apri:StockIssuedDuringPeriodValueDirectorStockAward contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">108438</apri:StockIssuedDuringPeriodValueDirectorStockAward>
  <apri:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">1318461</apri:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <apri:DeferredRevenueAmortization contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">133670</apri:DeferredRevenueAmortization>
  <apri:ProceedsFromPaymentsForSaleOfSubsidiaryStock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="0">500019</apri:ProceedsFromPaymentsForSaleOfSubsidiaryStock>
  <apri:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0" unitRef="shares" decimals="0">19475598</apri:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <apri:NotesPayableDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;9.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;NOTES
PAYABLE&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
Former Bio-Quant Shareholders&amp;#x2019; Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
December 14, 2009, the Company issued $12,129,010 in promissory
notes (the &amp;#x201C;Notes&amp;#x201D;) in connection with the acquisition
of Bio-Quant as discussed in Note 2 above. The Notes bore interest
at a rate of 10% per annum, with all principal and interest accrued
thereunder becoming due and payable one year from the closing date
of the Merger, or December 14, 2010.&amp;#xA0;&amp;#xA0;The terms of the
Notes provided that the principal amounts and all interest
thereunder were payable by the Company in cash or, at the
Company&amp;#x2019;s option, in shares of Company common stock, which
were valued at the fixed price of $2.52 per share.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
January and March 2010, the Company repaid $2,230,201 of
outstanding principal of the Notes through the issuance of Common
Stock at $2.52 per share, which is the fixed payment price pursuant
to the terms of the Notes.&amp;#xA0;&amp;#xA0;As such, the Company issued
1,003,210 shares of Common Stock to the note holders in repayment
of such $2,230,201 principal amount plus interest.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company recognized a beneficial conversion charge for the
differential between the original conversion rate of $2.52 per
share and the market price of the Company&amp;#x2019;s Common Stock at
the time of the above payments.&amp;#xA0;&amp;#xA0;As such the beneficial
conversion charge non-cash interest expense recognized with respect
to the Notes for the&amp;#xA0;&amp;#xA0;three and six months ended June 30,
2010 was $1,627,101and $6,139,741, respectively.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; TEXT-DECORATION: underline"&gt;
2010 Promissory Notes&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
January 2010, the Company raised gross proceeds of $2.3 million in
an offering of unsecured promissory notes (the &amp;#x201C;2010
Notes&amp;#x201D;).&amp;#xA0;&amp;#xA0;The 2010 Notes accrued interest at a rate
of 10% per annum and were due and payable in full six months from
the date of issuance. The principal and accrued interest due under
the Notes was payable, at the election of the Company, in either
cash or shares of Common Stock, par value $0.001 per
share.&amp;#xA0;&amp;#xA0;The weighted average conversion price of the 2010
Notes was $5.55 per share, with the conversion prices ranging from
$5.40 to $6.00 per share.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
On March 17, 2010, the 2010 Notes were repaid in full with the
issuance of 415,504 shares of common stock to repay such $2.3
million principal amount and interest.&amp;#xA0;&amp;#xA0;The Company
recognized a beneficial conversion charge on the differential
between the original conversion rates of $5.40 to $6.00 per share
and the market price of the Company&amp;#x2019;s Common Stock at the
time of repayment.&amp;#xA0;&amp;#xA0;The Company has recorded a beneficial
conversion charge to interest expense of $0 and $660,819 during the
three and six months ended June 30, 2010, respectively, as a result
of the conversion.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</apri:NotesPayableDisclosureTextBlock>
  <apri:StockholderRightsPlan contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;18.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;STOCKHOLDER
RIGHTS PLAN&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
March 24, 2011, pursuant to the Company&amp;#x2019;s shareholders rights
plan (the &amp;#x201C;Plan&amp;#x201D;) the Company declared a dividend
distribution of one preferred share purchase Right for each
outstanding share of the Company&apos;s&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;Common
Stock to shareholders of record at the close of business on April
1, 2011.&amp;#xA0; Initially, these rights will not be exercisable and
will trade with the shares of the Company&apos;s common
stock.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Under
the Plan, the rights generally will become exercisable if a person
or group acquires beneficial ownership of 15% or more of the
Company&apos;s common stock in a transaction not approved by the
Company&apos;s Board. In that situation, each holder of a right (other
than the acquiring person) will be entitled to purchase, at the
then-current exercise price, additional shares of common stock
having a value of twice the exercise price of the right. In
addition, if the Company is acquired in a merger or other business
combination after an unapproved party acquires more than 15% of the
Company&apos;s common stock, each holder of the right would then be
entitled to purchase at the then-current exercise price, shares of
the acquiring company&apos;s stock, having a value of twice the exercise
price of the right.&lt;/font&gt;&lt;br /&gt;
&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Board may redeem the rights for a nominal amount at any time before
an event that causes the rights to become exercisable. The rights
will expire on April 1, 2021.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</apri:StockholderRightsPlan>
  <apri:CommonStockDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;12.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;COMMON
STOCK TRANSACTIONS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
April 21, 2010, the Company entered into a Sales Agreement with
Brinson Patrick Securities Corporation (the &amp;#x201C;Sales
Manager&amp;#x201D;) to issue and sell through the Sales Manager, as
agent, up to $10,000,000 of common stock from time to time pursuant
to the Company&amp;#x2019;s effective shelf registration statement on
Form S-3 (File No. 333-165960).&amp;#xA0; During the six months ended
June 30, 2011, the Company had sold an aggregate of 674,466 shares
of common stock under the Sales Agreement at a weighted average
sales price of approximately $4.26 per share, resulting in offering
proceeds of approximately $2.7 million, net of sales
commissions.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
2010, the Company had sold an aggregate of 518,264 shares of common
stock under the Sales Agreement at a weighted average sales price
of approximately $6.73 per share, resulting in offering proceeds of
approximately $3.3 million, net of sales commissions.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</apri:CommonStockDisclosureTextBlock>
  <apri:DeferredCompensationPlansDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;11.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;DEFERRED
COMPENSATION&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
February 27, 2002, the Company entered into an employment agreement
with Y. Joseph Mo, Ph.D., that had a constant term of five years,
and pursuant to which Dr. Mo would serve as the Company&apos;s Chief
Executive Officer and President.&amp;#xA0;&amp;#xA0;Under the employment
agreement, Dr. Mo was entitled to deferred compensation in an
annual amount equal to one sixth of the sum of his base salary and
bonus for the 36 calendar months preceding the date on which the
deferred compensation payments commenced subject to certain
limitations, including annual vesting through January 1, 2007, as
set forth in the employment agreement.&amp;#xA0;&amp;#xA0;The deferred
compensation is payable monthly for 180 months commencing on
termination of employment.&amp;#xA0;&amp;#xA0;Dr. Mo&amp;#x2019;s employment was
terminated as of December 15, 2005.&amp;#xA0;&amp;#xA0;At such date, the
Company accrued deferred compensation of $1,178,197 based upon the
estimated present value of the obligation.&amp;#xA0;&amp;#xA0;The monthly
deferred compensation payment through May 15, 2021 is
$9,158.&amp;#xA0;&amp;#xA0;As of June 30, 2011, the Company has a
discounted accrued balance of approximately $839,500 included in
deferred compensation. The remaining amounts accrued in Deferred
Compensation also relate to severance amounts due to former
employees of the Company.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</apri:DeferredCompensationPlansDisclosureTextBlock>
  <apri:SignificantAgreementsDisclosureTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;15.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;LICENSING
AND RESEARCH AND DEVELOPMENT AGREEMENTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Vitaros&amp;#xAE; - (2011 &amp;#x2013; 2010)&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
On December 22, 2010, the Company entered into an exclusive license
agreement with Bracco SpA (&amp;#x201C;the &amp;#x201C;Bracco License
Agreement&amp;#x201D;)&amp;#xA0;&amp;#xA0;for its &lt;font style="DISPLAY: inline"&gt;Vitaros&amp;#xAE; product&lt;/font&gt;&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;for erectile
dysfunction. Under the terms of the Bracco License Agreement,
Bracco has been granted exclusive rights in Italy to commercialize
and market Vitaros&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#xAE;&lt;/font&gt; under the Bracco
trademark, and the Company received &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#x20AC;&lt;/font&gt;750,000 as an
up-front payment and is entitled to receive up to &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;&amp;#x20AC;&lt;/font&gt;4.75 million in
regulatory and sales milestone payments.&amp;#xA0;&amp;#xA0;Further, over
the life of the agreement, the Company will receive royalties based
on Bracco&apos;s sales of the product.&amp;#xA0;&amp;#xA0;The expected up-front
payment from Bracco was received in April 2011, in the amount of
USD $1,000,000, net of withholding taxes. Of this amount,
approximately $669,000 was recognized as license revenue in the
second quarter of 2011 in accordance with our revenue recognition
criteria and the remaining amount was deferred and will be
recognized at the time that the Company receives regulatory
marketing approval for the product in Europe in accordance with the
Bracco license agreement.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
January 3, 2011, the Company entered into a license agreement (the
&amp;#x201C;Elis License Agreement&amp;#x201D;) with Elis Pharmaceuticals
Ltd. (&amp;#x201C;Elis&amp;#x201D;), granting Elis the exclusive rights to
commercialize&amp;#xA0;&amp;#xA0;Vitaros&amp;#xAE; for erectile dysfunction in
the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia,
Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen (the &amp;#x201C;Elis
Territory&amp;#x201D;). Under the Elis License Agreement, the Company is
entitled to receive upfront license fees and milestone payments of
up to $2.1 million over the term of the Elis License
Agreement.&amp;#xA0;&amp;#xA0;The future milestones are tied to regulatory
approval and the achievement of certain levels of aggregate net
sales of Vitaros&lt;font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline"&gt;&amp;#xAE;&lt;/font&gt;.&amp;#xA0;&amp;#xA0;Additionally,
the Company is entitled to receive escalating tiered double-digit
royalties on Elis&amp;#x2019;s sales of Vitaros&lt;font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline"&gt;&amp;#xAE;&lt;/font&gt;
in the Elis Territory.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
February, 14,&amp;#xA0;&amp;#xA0;2011 the Company entered into a license
agreement (the &amp;#x201C;Neopharm License Agreement&amp;#x201D;) with the
Neopharm Group (&amp;#x201C;Neopharm&amp;#x201D;), granting Neopharm the
exclusive rights to commercialize&amp;#xA0;&amp;#xA0;Vitaros&amp;#xAE; for
erectile dysfunction and when and if available, the Company&amp;#x2019;s
product for premature ejaculation in&amp;#xA0;&amp;#xA0;Israel and the
Palestinian Territories (the &amp;#x201C;Neopharm
Territory&amp;#x201D;).&amp;#xA0;&amp;#xA0;Under the Neopharm License Agreement,
the Company is entitled to receive upfront license fees and
milestone payments of up to $4.35 million over the term of the
Neopharm License Agreement.&amp;#xA0;&amp;#xA0;The future milestones are
tied to regulatory approval and the achievement of certain levels
of aggregate net sales of Vitaros&amp;#xAE;.&amp;#xA0;&amp;#xA0;Additionally,
the Company is entitled to receive escalating tiered double-digit
royalties on Neopharm&amp;#x2019;s sales of Vitaros&amp;#xAE; in the
Neopharm Territory.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
Company received $203,000 in up-front payments pursuant to the Elis
and Neopharm licensing agreements and has recorded the payments as
license fee revenue during the six months ended June 30,
2011.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
April 2011, the Company filed a marketing application in Europe for
Vitaros&amp;#xAE; for erectile dysfunction.&amp;#xA0;&amp;#xA0;If it is
approved by the various European regulatory authorities, it would
give the Company the right to sell Vitaros&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xAE;&lt;/font&gt;
in multiple chosen countries in the European Union. Under a
European system called the &amp;#x201C;Decentralized Procedure&amp;#x201D;
(DCP), a company files its application for marketing approval of a
drug in just one European country, which is designated the
Reference Member State (RMS). The Company has chosen The
Netherlands as its RMS. The RMS then evaluates the application and
prepares an assessment report that is submitted to other chosen
European Union countries for their consideration and
approval.&amp;#xA0;The entire review process on average requires
approximately 240 days not including additional time associated
with responses to regulatory review questions. One of the major
advantages of the DCP is that a company may receive identical
marketing authorizations for its product in multiple chosen
European Member countries at the same time.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Vitaros&amp;#xAE; &amp;#x2013; (2009 &amp;#x2013; 2007)&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;&lt;font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
On November 1, 2007, the Company signed an exclusive licensing
agreement with Warner Chilcott Company, Inc., (&amp;#x201C;Warner
Chilcott&amp;#x201D;) for Vitaros&amp;#xAE; for erectile
dysfunction.&amp;#xA0;&amp;#xA0;Under the agreement, Warner Chilcott
acquired the exclusive rights in the United States to Vitaros&amp;#xAE;
and would assume all further development, manufacturing, and
commercialization responsibilities as well as
costs.&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;div&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;On February 3, 2009, the Company terminated the licensing
agreement and sold the U.S. rights for Vitaros&amp;#xAE;&amp;#xA0;to Warner
Chilcott.&amp;#xA0;&amp;#xA0;Under the terms of the Asset Purchase
Agreement, the Company received an up-front payment of $2.5 million
and is eligible to receive an additional payment of $2.5 million
upon Warner Chilcott&amp;#x2019;s receipt of a New Drug Application
(NDA) approval for Vitaros&amp;#xAE;from the FDA.&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</apri:SignificantAgreementsDisclosureTextBlock>
  <apri:LineOfCreditFacilitiesTextBlock contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;10.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;LINES
OF CREDIT&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
March 8, 2010, Bio-Quant entered into a Loan and Security Agreement
with Square 1 Bank for a revolving line of credit (&amp;#x201C;Credit
Line&amp;#x201D;) in the amount of $250,000.&amp;#xA0;&amp;#xA0;The Credit Line
was secured by a $255,000 cash deposit from the Company which was
classified as restricted cash on the accompanying consolidated
balance sheet at December 31, 2010.&amp;#xA0;&amp;#xA0;The Credit Line bore
interest at the rate of 4.25% per annum or 1% above the Prime Rate
and expired on March 7, 2011 and was repaid in full at that
time.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
On April 12, 2010, Bio-Quant entered into a Loan and Security
Agreement with Torrey Pines Bank for a revolving line of credit
(&amp;#x201C;TP Credit Line&amp;#x201D;) in the amount of
$250,000.&amp;#xA0;&amp;#xA0;The TP Credit Line was secured by a $278,824
cash deposit from the Company which is included in restricted cash
on the accompanying consolidated balance sheet at December 31,
2010.&amp;#xA0;&amp;#xA0;The TP Credit Line bore interest at the rate of
2.6% per annum and expired on April 12, 2011 and was repaid in full
at that time.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</apri:LineOfCreditFacilitiesTextBlock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x440920" unitRef="iso4217_USD" decimals="0">-11205098</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">209138</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="0">676</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">674466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="0">209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <apri:StockIssuedDuringPeriodValueDirectorStockAward contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="0">26</apri:StockIssuedDuringPeriodValueDirectorStockAward>
  <apri:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="0">582</apri:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <apri:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">581332</apri:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <apri:StockIssuedDuringPeriodSharesDirectorStockAward contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">25193</apri:StockIssuedDuringPeriodSharesDirectorStockAward>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="0">2740727</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="0">1037086</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <apri:StockIssuedDuringPeriodValueDirectorStockAward contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="0">108412</apri:StockIssuedDuringPeriodValueDirectorStockAward>
  <apri:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="0">1317879</apri:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:GrossProfit contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">448976</us-gaap:GrossProfit>
  <us-gaap:ContractsRevenue contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">1438377</us-gaap:ContractsRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">-4278647</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">-1609657</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">32550</us-gaap:LicensesRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">477566</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="INF">-1609657</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueNet contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">1470927</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">-2668990</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">3117966</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">2640400</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfServices contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="0">1021951</us-gaap:CostOfServices>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <apri:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_91_20100630_0" unitRef="shares" decimals="0">9140451</apri:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:GrossProfit contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">588927</us-gaap:GrossProfit>
  <us-gaap:ContractsRevenue contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">926253</us-gaap:ContractsRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">-7794092</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">35774</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">668899</us-gaap:LicensesRevenue>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">1971832</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">-2759920</us-gaap:GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="INF">-75708</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueNet contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">1595152</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">-7829866</us-gaap:OperatingIncomeLoss>
  <us-gaap:RentalIncomeNonoperating contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">111482</us-gaap:RentalIncomeNonoperating>
  <us-gaap:OperatingExpenses contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">8418793</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">3687041</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfServices contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="0">1006225</us-gaap:CostOfServices>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
  <apri:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE4964----1110-Q0004_STD_91_20110630_0" unitRef="shares" decimals="0">19817009</apri:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <context id="eol_PE4964----1110-Q0004_STD_91_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_91_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20110630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20100630_0_455296x469977">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">apri:NotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20100630_0_455296x454932">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_181_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20110630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE4964----1110-Q0004_STD_0_20110809_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001017491</identifier>
    </entity>
    <period>
      <instant>2011-08-09</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>apri-20110630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:apri="http://www.apricusbio.com/20110630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.apricusbio.com/20110630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statement of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" id="Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
        <link:definition>109 - Disclosure - ACQUISITION OF BIO-QUANT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Role_NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <link:definition>110 - Disclosure - SALE OF BIO-QUANT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>111 - Disclosure - ACCOUNTING FOR STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>112 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>113 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
        <link:definition>114 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>115 - Disclosure - CONVERTIBLE NOTES PAYABLE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock" id="Role_NotesToFinancialStatementsNotesPayableDisclosureTextBlock">
        <link:definition>116 - Disclosure - NOTES PAYABLE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" id="Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
        <link:definition>117 - Disclosure - LINES OF CREDIT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock" id="Role_NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock">
        <link:definition>118 - Disclosure - DEFERRED COMPENSATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommonStockDisclosureTextBlock">
        <link:definition>119 - Disclosure - COMMON STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>120 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>121 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock">
        <link:definition>122 - Disclosure - LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>123 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" id="Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
        <link:definition>124 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan" id="Role_NotesToFinancialStatementsStockholderRightsPlan">
        <link:definition>125 - Disclosure - STOCKHOLDER RIGHTS PLAN</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="apri-20110630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="apri-20110630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="apri-20110630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="apri-20110630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="CommonStockDisclosureTextBlock" id="apri_CommonStockDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredCompensationPlansDisclosureTextBlock" id="apri_DeferredCompensationPlansDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueAmortization" id="apri_DeferredRevenueAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" id="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="apri_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LineOfCreditFacilitiesTextBlock" id="apri_LineOfCreditFacilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesPayableDisclosureTextBlock" id="apri_NotesPayableDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesPayableMember" id="apri_NotesPayableMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="apri_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromPaymentsForSaleOfSubsidiaryStock" id="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAgreementsDisclosureTextBlock" id="apri_SignificantAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholderRightsPlan" id="apri_StockholderRightsPlan" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesDirectorStockAward" id="apri_StockIssuedDuringPeriodSharesDirectorStockAward" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueDirectorStockAward" id="apri_StockIssuedDuringPeriodValueDirectorStockAward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueStockWarrantsExercised" id="apri_StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="apri_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>apri-20110630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsNotesPayableDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommonStockDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholderRightsPlan" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="us-gaap_RentalIncomeNonoperating"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_SalesRevenueNet" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfServices" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_RentalIncomeNonoperating" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_LicensesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_ContractsRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredRevenueAmortization" xlink:label="apri_DeferredRevenueAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfProperty" xlink:label="us-gaap_GainLossOnSaleOfProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.3000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="apri_DeferredRevenueAmortization" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfProperty" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>apri-20110630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsNotesPayableDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommonStockDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholderRightsPlan" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" xlink:label="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="us-gaap_RentalIncomeNonoperating"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="apri_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RentalIncomeNonoperating" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractsRevenue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfServices" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodSharesDirectorStockAward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodValueDirectorStockAward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodSharesDirectorStockAward" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodValueDirectorStockAward" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredRevenueAmortization" xlink:label="apri_DeferredRevenueAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfProperty" xlink:label="us-gaap_GainLossOnSaleOfProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableMember" xlink:label="apri_NotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apri_DeferredRevenueAmortization" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfProperty" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="apri_NotesPayableMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableDisclosureTextBlock" xlink:label="apri_NotesPayableDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_NotesPayableDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_LineOfCreditFacilitiesTextBlock" xlink:label="apri_LineOfCreditFacilitiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_LineOfCreditFacilitiesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredCompensationPlansDisclosureTextBlock" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_DeferredCompensationPlansDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_CommonStockDisclosureTextBlock" xlink:label="apri_CommonStockDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_CommonStockDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_SignificantAgreementsDisclosureTextBlock" xlink:label="apri_SignificantAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_SignificantAgreementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockholderRightsPlan" xlink:label="apri_StockholderRightsPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockholderRightsPlan" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>apri-20110630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" xlink:label="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_lbl" xml:lang="en-US">Debt issuance cost, accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" xlink:to="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in-capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITION OF BIO-QUANT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital lease payable - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Sales of investment in consolidated subsidiary:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_CommonStockDisclosureTextBlock" xlink:label="apri_CommonStockDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_CommonStockDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_CommonStockDisclosureTextBlock_lbl" xml:lang="en-US">COMMON STOCK TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_CommonStockDisclosureTextBlock" xlink:to="apri_CommonStockDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value, 75,000,000 shares authorized, 20,012,080 and 18,521,951 issued and outstanding at June 30, 2011 and December 31, 2010, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractsRevenue_lbl" xml:lang="en-US">Contract service revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US">Cost of services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServices" xlink:to="us-gaap_CostOfServices_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Issuance of common stock in payment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredCompensationPlansDisclosureTextBlock" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Compensation Plans Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Compensation Plans Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock_lbl" xml:lang="en-US">DEFERRED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_DeferredCompensationPlansDisclosureTextBlock" xlink:to="apri_DeferredCompensationPlansDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Debt issuance cost, net of accumulated amortization of $47,860 and $29,289</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredRevenueAmortization" xlink:label="apri_DeferredRevenueAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_DeferredRevenueAmortization_lbl" xml:lang="en-US">Deferred revenue recognized but not to be included in current operations cash flows.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_DeferredRevenueAmortization_lbl" xml:lang="en-US">Non-cash write off of deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_DeferredRevenueAmortization" xlink:to="apri_DeferredRevenueAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">ACCOUNTING FOR STOCK-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" xlink:to="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_lbl" xml:lang="en-US">Capital lease payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Payroll related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment and leasehold improvements, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">SALE OF BIO-QUANT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DocumentDocumentandEntityInformationAbstract" xlink:label="apri_DocumentDocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_DocumentDocumentandEntityInformationAbstract" xlink:to="apri_DocumentDocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xml:lang="en-US">Non-cash loss on sale of Bio-Quant subsidiary</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xml:lang="en-US">Non-cash loss on sale of Bio-Quant subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfProperty" xlink:label="us-gaap_GainLossOnSaleOfProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfProperty_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfProperty_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfProperty" xlink:to="us-gaap_GainLossOnSaleOfProperty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_lbl" xml:lang="en-US">Loss on sale of Bio-Quant subsidiary</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_lbl" xml:lang="en-US">Loss on sale of Bio-Quant subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:to="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Decrease (increase) in deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (decrease) in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Decrease in due from related party</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Decrease in due from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Decrease in due to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in payroll related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase (decrease) in accrued rental income and other assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase (decrease) in accrued rental income and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Decrease (increase) in other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (decrease) in prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (decrease) in prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Release (deposit) of restricted cash</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Release (deposit) of restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">License fee revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_LineOfCreditFacilitiesTextBlock" xlink:label="apri_LineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_LineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Line of Credit Facilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_LineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">LINES OF CREDIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_LineOfCreditFacilitiesTextBlock" xlink:to="apri_LineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableDisclosureTextBlock" xlink:label="apri_NotesPayableDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_NotesPayableDisclosureTextBlock" xlink:to="apri_NotesPayableDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableMember" xlink:label="apri_NotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_NotesPayableMember_lbl" xml:lang="en-US">Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_NotesPayableMember_lbl" xml:lang="en-US">Notes payable to former Bio-Quant shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_NotesPayableMember" xlink:to="apri_NotesPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="apri_NotesToFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Accrued rental income and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash interest, amortization of beneficial conversion feature and deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash interest, amortization of beneficial conversion feature and deferred financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Capital expenditures</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes payable, net of debt issue costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock_lbl" xml:lang="en-US">Proceeds from (payments for) the sale of subsidiary stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock_lbl" xml:lang="en-US">Proceeds from sale of Bio-Quant subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" xlink:to="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayment of short-term borrowing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Reserve for related party note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="us-gaap_RentalIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalIncomeNonoperating_lbl" xml:lang="en-US">Rental income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible notes payable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayment of capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayment of capital lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term borrowing from banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_SignificantAgreementsDisclosureTextBlock" xlink:label="apri_SignificantAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_SignificantAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">Significant Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_SignificantAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_SignificantAgreementsDisclosureTextBlock" xlink:to="apri_SignificantAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Statement, Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockholderRightsPlan" xlink:label="apri_StockholderRightsPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_StockholderRightsPlan_lbl" xml:lang="en-US">Stockholder Rights Plan Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_StockholderRightsPlan_lbl" xml:lang="en-US">STOCKHOLDER RIGHTS PLAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_StockholderRightsPlan" xlink:to="apri_StockholderRightsPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodSharesDirectorStockAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_StockIssuedDuringPeriodSharesDirectorStockAward_lbl" xml:lang="en-US">Number of shares issued during the period as a result of reissuance of treasury stock for Director stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_StockIssuedDuringPeriodSharesDirectorStockAward_lbl" xml:lang="en-US">Issuance of compensatory stock to the board of directors (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_StockIssuedDuringPeriodSharesDirectorStockAward" xlink:to="apri_StockIssuedDuringPeriodSharesDirectorStockAward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock and compensation expense for employees (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodValueDirectorStockAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_StockIssuedDuringPeriodValueDirectorStockAward_lbl" xml:lang="en-US">Value of reissuance of treasury stock for Director stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_StockIssuedDuringPeriodValueDirectorStockAward_lbl" xml:lang="en-US">Issuance of compensatory stock to the board of directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_StockIssuedDuringPeriodValueDirectorStockAward" xlink:to="apri_StockIssuedDuringPeriodValueDirectorStockAward_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of stock and compensation expense for employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Value stock issued during the period as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="apri_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="apri_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apri_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apri_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding used for basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apri_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="apri_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>apri-20110630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.12.8 -->
<!-- Round: 42b408c5-d22b-4f55-9678-c71c4150ee83 -->
<!-- Creation date: 2011-08-12T21:20:39Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsNotesPayableDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommonStockDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsSegmentReportingDisclosureTextBlock" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="apri-20110630.xsd#Role_NotesToFinancialStatementsStockholderRightsPlan" roleURI="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DocumentDocumentandEntityInformationAbstract" xlink:label="apri_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.2800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.2900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.3100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.3400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" xlink:label="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" xlink:label="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="us-gaap_RentalIncomeNonoperating"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="apri_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RentalIncomeNonoperating" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee" order="1.1800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractsRevenue" order="1.0300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfServices" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodSharesDirectorStockAward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueDirectorStockAward" xlink:label="apri_StockIssuedDuringPeriodValueDirectorStockAward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="apri_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.0500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodSharesDirectorStockAward" order="1.0600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodValueDirectorStockAward" order="1.0700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.1000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockIssuedDuringPeriodValueStockWarrantsExercised" order="1.1100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredRevenueAmortization" xlink:label="apri_DeferredRevenueAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" xlink:label="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfProperty" xlink:label="us-gaap_GainLossOnSaleOfProperty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableMember" xlink:label="apri_NotesPayableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" xlink:label="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.3200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.3300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.3400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="apri_DeferredRevenueAmortization" order="1.3500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.3600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfProperty" order="1.3700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments" order="1.3800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" order="1.5000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet" order="1.5100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses" order="1.5200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" order="1.5300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" order="1.5400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1.1000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.1200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1300" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.1500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation" order="1.1600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.1800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.2100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfShortTermDebt" order="1.2200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.2300" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock" order="1.2500" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0400" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0500" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="1.0600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2900" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.2700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="apri_NotesPayableMember" order="1.2800" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.4000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.4100" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.4200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaid" order="1.4600" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.4700" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.0300" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesPayableDisclosureTextBlock" xlink:label="apri_NotesPayableDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_NotesPayableDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_LineOfCreditFacilitiesTextBlock" xlink:label="apri_LineOfCreditFacilitiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_LineOfCreditFacilitiesTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_DeferredCompensationPlansDisclosureTextBlock" xlink:label="apri_DeferredCompensationPlansDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_DeferredCompensationPlansDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_CommonStockDisclosureTextBlock" xlink:label="apri_CommonStockDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_CommonStockDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_SignificantAgreementsDisclosureTextBlock" xlink:label="apri_SignificantAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_SignificantAgreementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_NotesToFinancialStatementsAbstract" xlink:label="apri_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="apri-20110630.xsd#apri_StockholderRightsPlan" xlink:label="apri_StockholderRightsPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apri_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="apri_StockholderRightsPlan" order="1.0200" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001144204-11-046337-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-046337-xbrl.zip
M4$L#!!0````(`'DR#S\E3*.4^HT``")M!@`1`!P`87!R:2TR,#$Q,#8S,"YX
M;6Q55`D``\;R2$[&\DA.=7@+``$$)0X```0Y`0``[%UK<^(XUOZ>JOP';79[
M:J8*$M\OR?1LT4!ZV#>=9`@SW;M?NAQ;@&>,S5IV$O;7OT>V"388?`DFD+B_
M=/!%>L[1T;G*TL__?)I8Z`&[Q'3LCR?L*7."L*T[AFF//I[XI*D1W31/$/$T
MV]`LQ\8?3V:8G/SSE^.CG__6;*)NYW.KCVYLR[0QZC6_8,\UG]`W'5O8U3RX
M9--7=8PZCNY/L.TUT+U&L($<&WW[U+]"W"F+T-CSIN=G9X^/CZ?8&&ENTPD:
M/-6=R1EJ-N>=_1'B/$=(.F6Y4R5VJ^_XMG&.!.Y>8!1=;!H<=]\4AJ+85"59
M:>HRJPNLR&"L\+&WVB[6/&@1&8#U''$,RS89I<ER`XX]YYAS7OU/_&EG.G/-
MT=A#/^H_P<.,V*1O)'C0`(KU4]2R+-2GCQ+4QP2[#]@XC5IZNG<M!%RWR<>3
M&-WT\JGCCLZ@7?[,C-AV$CYY3N]:&YZ'KO^B?'U^GEY(//_(!T^SJJJ>!7?G
MCYK$$3A6W@0F?.*Y;6*FM0R/LF??OES=Z6,\T9K+%&A3-_D:O:#[Y-YT@F&F
MG&0DGID_K\.`>N[L^94`$L'ZZ<AY.(MNGH4#QC9Y=OZ:@<WT5^!&RN.F_8")
ME_Y&>"_E)=NQ;7^2SC##<\^\V12?P4-->`H#D<_O9;^4?`'FWTC3IL\O#35R
M'[P0W4C!!G=H2R3UG>!.RDL4B+'$MVA(I;/P9N)1+_51,7S4.P$I1RB0<^N<
M!-+0QT,4"-TYA?#QA)B3J45%([BFN;KK6#B?>`=OC%T\_'A"):@YEYO3)V*4
MD/[\$^LL)`ODZ+QK>Z8W:SN3B6/?>8[^U]U8<S&Y\;U`3X+N1+IC>_C)ZU.<
MV+&^WW8%51*:\(\%O,W?&(81OM\-.M^9[P$%"J-^!]GW;3-\AP0MGB`#Z^9$
MLV`\>]>7)[\`)HZ#AW\^RX<CQ!R)RWE;(^.6;=#_NO_US0?-`H5,6EY;<]T9
M//V'9OFX('2&,C\!/5(7WW^_Z\3Q,R>_P&614<6?SPH!2M)PXXVQVR($>^3:
ML77?=>&5PNS.CYEC!$5E%I!3^T]"[.`AALO&I6E3#=AV2/S9:UPE7%%4^!C:
M3"A+R$TR=8AF?78=?PJ&S/*I$,%5"MBT?6S<3*E=!Y/9LT'$1N:]A2-F5$H6
M)PET.L8(>Q'2TE2W],#T``\]3$!RKQS-)GVL8Y!=Z*!:)H#VXGBI%`^R<2=9
M<F5J]Z9E>B8F[<JG&"_)DJJR"\)6>U_28PZ89M>C0WKEV*,!=B<!8;?:C%)3
M(52!"?[%--AF*.F*H8\?,`S/#C@K\+PLKJJ#)(`DR#[V-'!DC:[FVB!.!$3'
MG_@6.,@&O&[J9I6`FQS+"8+(,S$QSP94>CH'RCSB0J@<JI0=A2^GP%91)@F^
M=?%4,XWNTQ3;!,/LCMFHZF4,GI74&&$YT"P+'(&@48?AK,(_*4**G)S;!8$E
MJ9IKW(22K7XT!$&1Y`4)FU`LX:U:_%D(S!E.B4E*FBS/-10XM51^`OF?FX-9
MV]((,8<F-G;B^LF2HBC<JO;,C6VC]M\)"9(,'O=:_;\.:2RBJ'K*T:P!%S>G
MR9Y7<9G>))A[,!L#13G"M@Y^PG8A/A'SW#8A+O1<?Q'ZI8!\>>"WC&-]X,>&
M@5\>%&E3NWK=H_(2*ROB\@1/5S<+(]Z:..!`_2\T=<.%3*;%+E5J3EF1F(3F
M+`.P^H"[T(B`TN6XEP7<11V5!7]B;GRE+CE$1>7]JE2X:^?[K>;>N'<>E8J`
M5;?8#2;?-NG[#OB^KZH!_N07YA2T0*H&6(>KB'&M/AI1.4&6\]K3-5HC<&>B
MZ`HD&:Z`BC9V&J]R',N(HKCJ9>6`M3;,AI>"D1P[EH%=0F>G-]NI.Y8%9FDH
M#,.D`Z99M^#M]^RV-C4]S8K)9)4CP,JJRHFB$!N#3#Q)_#MEMBA*,A>W+EG<
M73'N/4)`GE[1NP@!E#8-MZX#?WJS6TN#(-8V*-'32>7I4%EA5*6<==B$>#G^
M?A7:!$&495F)1]YY$:^,;LOWQHYK_J\Z$9/%U=396A!KM62%[%1$EF>X='WX
M,H]H-_A95N%DIKPCM);<[F1J.3.,^SCPAG=J:F6>$968EL_$$D*GE<$RZ?$5
M`QYEL:H<-XZ1`P=VZYBKL7??!9%3&?%)H'YW^:1NE@'<4F"]0"N("EO&$&;$
MUMMGZQ+0W*F33(YN&ZG(2ZI2UEW+=("V'SDS*LOQ;.YL@*HHRHL"YVU4JID"
MD%E%%>+NP"M4JHO`E4&#L*O!8,Y*=>3>7V&-X)M[RQP%.G%'C&8@`HS'X5E8
M<D$O9TR+X.993N(S86<%JM7CA"<EB5-2/;$=U(.+0-V#>G`ASC*JS+QV/;@(
M8+J\BQ,8,,GEZ\';+X\6T\J*R`CQ(&VORJ-%2)$8@1?X^$#L1WVTT`Q0E$3,
M7'&!M*"D2+S$Q\&E%$@#<5F@)=5S+72,Q:2>6P]CM_7<(@Q6&%&.^W1[4L\M
MY#1QW.[KN<6$6&35W==S,R#NK)Z[BF--H`E\XEA53*_F5%C/+>;G"K+,,RL*
MZ14+NH54O<HI:D+3[V=!MPA-*BN(DL*_*"[=?CES(P4'5<XLY`XIHBKEM2:[
MK686,BF**@K"JD?TVL7,E[E.KUS,+*2G6`[<$B%NUW=>S"S$;%:4)%EB"R3S
MME+-W*9M3:MFWHW!*M"`_9/CNLXC#2TKS1RP"8<ZI??*JHQ%<(H"QZB\&@]@
M=U]ES#WTKU)E+.;`JY(27P2SMNR6\ME*]RDJ"'UV'./1M*PJM9+,L&*\OI`'
M3[6%PT*Q'BN)7$P,<A8.MZU02U7+5E->55?+5M#FJY:M*MJJJV590','II57
MRY:1%JF6K?@#66@_NPXAH)B'19*QK,(6_8!3$64A[O/&^ETQ5CK&!KETG<D=
MQ"0WP[5FHU+`+"MP"=.5%U62')K=@@@+GGXP#6Q\FOU.,+AEO>`+<9#RENZ9
M#P5-1PEJFHJJR&S,5\^/:]FVZ"XM^W1P^'_/7LV#5DN))+-*PKAD`UJI^7BN
MIM,'@MQ7I7`Y16%%.9'72O:^G+*?:K,@K74SG%>!UE3;JI5^4$&)[YERP\HE
M_M%2E-V)/R=)H$;Y3/E/`98E_QT?4ZT0N0>WFEO*32E%%/W`7-HT%39A2_$#
M/M']5>)9B(HUK"JHG+SD`JQ@R*M_-F4=JAT'EOI=N532)HR9<I:2):I8OI(F
M.Q^D)?=",^TKL/0W=M)J5@N<CT<?ZR!D\3M9HZP4L,3PB<@S"\R*CH47G`FF
M5%8LZ;S(2BR3U*.+SM=[<N46592QM_Q2%+\.Q1(/'=N9J_Z0GJC,7K%7)BJJ
M'*_QK\6QG''0@X6:N_!@8,CC_%SJ>F7%`=9<G=85.G#?<@*/>!>L5!E>%=6X
MQ[(!R7(Q8.I"4X'V@K\M'*R1M1.UGDJQ"S++JXGJ<C:@+.VU7&6O5HX%7I95
M89,"6\:SDK'"$/U["9&/SX5"F<JB%`09B=6YF`=4#N=PX+R":ZBJTN8@:3VP
M)24>^?T#IZ5#A.OBUXG&:>Y3C/DB^6$MN;G@`LQ55Z4R%6!F)2D>^BUUOC[R
MBRT%[.#[BE&**I=8#;X!R-)ZHJ2AJM[[@&A!XM480U,0I"QYHE5Z<)IV:=9E
M5A+CN^>LQ;'>8XH/PW.%IW)I6*XMY4*TG@A:+*/K(:@DE2B(EO%6>$;BXE%+
M)ISUZ'<Y#7F(Y!,IEPU`\BPLN<6NZ1C+>K]:$F1>Y)A8/%\$698AC1:_SB/.
MU$6P%6<K9"9>N2X',=WMH:7Z:@-,69:X5<^&]KM&IQ?_?*T$+%%60.[%%(6>
M_B7:*L_7%^>J%09>8;F-_NYZ8'GS/+N([9HTFI?SI'A2P[W/V(;QLFAH8DQ,
MVR0>';V'G1A909%5-;ZG80:87'GI</G>[O+2,J>JG))=EDG!M5S3(!Y89>P^
M0'A>+6:.$54VL9`PT?=2(3_ZTF*^#.^31DR=QN2FY7M%%G/D`;IFO2!'Y?Q4
MBG\+O!E5[$O@KYANQ8V-%MA?;82O_<D]=H/'HV=?4#]?2](J";2`RDF"R(K1
MU[[%<2WG/.Z]T*N@VZ)'_@65-)@UP6;KK0E-6+-EJ?DNB"*X84^"**@\ES,$
MYU592:ZRSP?RE4B35%66<Y+&<BRG,BQ3ECBZ9_-\'_Q+D^B:%;I1EW"M^'2?
M?V3^RV]<N!WTVJ87O0]<C8K1W6QR[Q18/;3<8^NVWPO[3#2XO$-V'X\"!6Y[
MU]JDN"%)=-?^_0Y]ZMW<M7O=ZW;WKH%ZU^W3^#;8R<X64%K`$B-@BZ45G]?/
M&(8@!CCL+]'B,LV7IH7=-G@+(\<M7B!Y[NX.Q`X:0A"NT70A:"1:GM'L69SD
M1%_K1.S?6'-?*&#T[S01>VYZM>_!;/J"`:<WDQW2]E9["66\"SJ?GC7Q(OJ:
MC-3DF62GB>:7![J-Z1(`JV<;^.G_\`N&&FZP#"L+*IO8U3W9_*+W*,&W&($7
MDP\/<$T^ZGU=\[E2U8M/*4K&<KDWS@CUL:PJV?GJ95#;6SI5;'L6F4F@7;MV
M:G6Q%ZUXT3U`+(?X+AX`Q$]6F13,\XC_8'D7AOGPP\B[.#Z*?B#BS>@A#(/N
MMT&S=]WI7@_.$3/U+E"G=W=[U?KW.;JGO5Z@+ZW^Y]YU\ZI[.7\BNM+O??XU
MO'2"-,L<V1]/+#ST3F@_M)<AX)UW\]RH&9R;<H$N;ZX'S<O6E]X57!R8$W"`
MK_$CZCL3S8[NWO7^TSU'+&V?-BF>_J!-IA=_?VHQ%[OXZVNKWV]=#^XH*6>4
MECE=9[OAY9\^\<SA+&3G`M_N`%0YF*WC(^)/)AH836>('C676G*DA9'2#`T=
M%\%D1L1\0A/H>8RF@7)&8(HA`OF7;V/$,XWC(RKFR"1((_".93F/Y+P>KT4_
MZ7>\H*(?84B,G1>,G0UCYZ:/'=*Q99&II@<G1C'A[ZEF&//?CZ;AC3^>@./]
M(=ZC&_O;0`\1KGO'\YS)\TN"^J&$O&5B3AF0A'AX1AYP[#YCDS[`2#AT8&P:
M.[\^T+B`MZYZGZ_/42"$&[B+;.?1I<<?A?_O`1&[E(3HPM=N.*\AO#+F\Z<2
M\:A8%^F8IJMWRJ=Y>B5#_Q^$I%8J#>*'6@)B/^*FJ393M7*JA$]A[1J%&=Y:
M0]4R?(`R'-4M:NE]K_:UA`#4YO6UI?%=J*9@D1A-:OA3QZX55"W#!RC#W2?L
MZB:I[>N[M:_SSXQ]S=J6C8T0W[8ZG=[UY^:GF\'@YLLYXJ9/:P5D;G_#-EX]
MA5@$.EL-\JU(<X3DTTV_T^T_4W-O:?I?E"9$',LTUE-6J\#"*O`"%92=`]&+
M]<1X=Q/CUC7U>E94*49OUJFX,H<OB=C1_0AFE^-^/'D<FQX^2?"\CN#K.FY=
MQZTEX>`E07QU45BK=O_>9BXOVTQNQ;MA-=`^K1++Q;S8IQ#'1YJ'.EC']*,)
MQ+,-1%?W%W2)-HAJ=,>E%>37EH5RLZVRF+V,&Q8''O(TG^>U9>AL0Y+%AB0J
M[UN]O;IVVSN)_L>!"3)_*G/O6X8//$`+FA1..>7X:(8UM]`:D"(AV5)R*"1:
M^+`QV_N67(9PJ_?:+ZC]@DW0F^];E];^P)N1Y#J"/\P(_KW;Z7FIKS;5M8+;
M"/U'46$;/'_(T<]/M:%^MX$[=\K)!RRZ;]LR9\?/L1KYHG#^[HQUFV[`:%EE
MOZTKNN!@/PWYYI4%%ZBH@CPXHO)IT2I<`%9J2(I05HWNX8J7G&[!_JST>KMS
M)K=#<1!3A95/.?&M392=KP+;1U\E3Q8A[_+NM^2;+*\1F.\-0]<'L+6_LM>Z
M]XWZ*VR#D>6&))3.6;P=15R[+K7KDK\XKM83YIVN7X\6N8A"Q<LCZA7K;R(+
M?+#5C+I<6XMT+=)O4J3KW,'!Y0ZB10ATYY`Z=W!@P<\;S1VH'-=@!+X.A.K,
M09TYR)TYD.H)\\XS!X+TTLS!6;`M>NQW\KW47[%S8O,>XY#K3+.>_8")][(S
MS8H<5\&+LL3SF4>:I<#*.BBDI>OT2"2R.$:Z4D*:@B#%#W'-`VCY5+9P$Z;2
MY[07@<OQ+"-+2OQ<MF3OR]@F$],+CG.E9W3"LS`6V-9A'.H#0U;+,-*.3PQI
MWWSYTAM\`<[<'1^UKCNH#:C`M'2OV[UN?8Y(%6,<'ME)9P1P?.1B'$R.FM45
ML/HKQ,AC[0$CS4;XF>U(FW,='`IOC#KN*>IH$^W/!G)\%[7'FNE"DPVZAQ$F
M8$SH*[8!-TP\1!"`ZSX]\!/=#(>FCN'E6]^E!SY[R'.0-]9B'4`;CQA-M!D"
M3V)BVO04K.?N(G:#%E,O2!P?1>7X'M(UGV#DV/"R?7QD:#-P*AP/^FP`3]#C
MV-3'B.I<;]$F>G1\RT#W&&%Z2)>%#0!U?$0PW0?7UC&:`A;\7U^S`K"/V`)"
M@N-J2!P.NJ>G.!/-HJ?=A!V9Y/@H.J7*FJ%_""+3`&5,#[D!YMC^)$-Q#<8X
M1N+QT6(,AKY+#\%"T]!RDY"%0"`]32<D+[A"N0)7'1LCZC5!$T./=HX6P-L7
M,'A@7N@!/8%9<JS%S<X%^E$C8,R&($T&;=W%IOT3?1;^#O8[I\?7(4<',DDC
M&'(*8:,0'!]%4K!V,$VR&'L#.2ZBS8UL$AP8%(QP(^P_E[`!%RR+#B\]`AIH
MM_S)%!%_`MP(SG%<C.T8.HZ/(NU.0RS73!Q.%)Y`%"Q$F:,T0>">808_3_="
M.6U?/6P*6%[M_*.#4[(5-'E\1-7%?$+2L[)`WEUO1N7:"91%7)O;]'S?"3U]
M6?,<=Q;3+62N1FP'-#H]3A1F=J`=[GT"V`AYGN495(1KRE,!@>[#KN,31,:.
MZS7I-`)-Z=C$MX)C,6D/,)E`98$6C4&C2JV!1N%QTM:L`<K`AID-[\Z7KJ-I
MPK#@0)$0"I_X^CA.9\H,7?^CGKOO<TY]!3_(!7O@W_^)]4"FP*!X&DP1"X]@
M=H`!UC&FJQ*?YXWCPD\M.":6SISCH]C4237XT(?A4"\%X:<I[87.%RJMR/0P
MR"XU3(%#!CX)<-$$HT;EVX2)!0]3RP,>V#`\AIQ"<HBYQ@)MR)=DY#V*A:1+
M1U_B$7WQ^=#;.H9-6\^]VQCVKON9!K#'1[WKRYO^E]:@=W.]%UKOK853@S'8
MN1$8GD31,7!?GXWU6`-[^NB$YV+BA9TEX<0AYQ#(!)[EW#0:X.);SI3^G(XU
M,-,Z!H]7#_61X>M@*8,HS?0@`+G&3ZWV8,[8[@4R7'\$35C0ETN#+'UL.Y8S
MF@5-AQ%%T+*+FSJ03=L%3[]_`WC<!W"HJ1D.B*+M4]4(+K@)"J^!/IE.\S=J
M?/?#^WUKLA0ITN,CTQY2YRP(.U;.4"5+IZ<&`A>,+=U*#Z)K<*RHF8'AMV;U
MH:KK@HIDI^MCC_0[^W;VZB&7?J(+*9L>@^E"@U^[Z*[W#7V!9W[-RKX6/5"A
M8+'M;7*Y"]@[Z%^_7W=++9HI77U[<Y-P%VN=JEA?>$!0XYLI[VT)/WME2`KR
M/5GU4DM++2VUM-324DM++2U[L/@]C:A<*_W2/<:]&I!`KO(M7-PC"K:PE#1C
MYJ1'6%&387P4=?/BJ*LZOFZ_R;PX5R*\*$&X/+[9+84`9.;#!?JCVQ_TVJVK
M^3#09'[3<Z;K^ERD(ZOI-TMX2["IX_JCC))*_LQ9+:UEI;43):Y+#\5V5XP?
M@F6O#4EM2%Z:!'PN[:!V_Z:>;O5TJZ?;CBWAR^?P#5T&5KLPAS=P;<>=.BY=
M"'WM>/4`'MX`MBS@8+"8V7/J\3N\\8M67J1\<5)[0;475'M!E=D].^`[U9RU
MIMPV=W?5S\#Q-*O6G-G%C/A./NW+RW;[)$'YFB_[1>YM[=83?1)=Z`O_4KME
M[=5N(GNR/5D%YZZH%0)69+8A"*7W$SW(#4!J"7]/$LXU&%5H,$+*DLM:QFL9
M?QLRSDH-^;V<GU5+^#N4<+[!*ER#8]^#C&]AG^ZW%M+<3+&K><&.$?037YO4
MT<V;VWRY6O7!R%R#EY5WH#YJ87_WPLXJ:D,42^_U60M[+>R'(NS_S][5]K9M
M).'O`O0?%D$*)`#MDA3UUMP5</UR<9#:J>VT=Y\"BEQ9VU*DRA<KZJ^_F5V2
M(B5*EFS+EN3IM3A+(I<SL\\\,[,D=UJ:T6IHK1:5]P3VO0>[86J6V=2:W5WN
M\D[W=AYAO,]!%-5K?3B"!:HF"GPJA8A#5I?\G:F9NJYU']Y$;@LX9.66T`3R
MUPERHVUI>I<@3A#?6XAWM$X;ROR.3B`GD.\KR`U#,YN6UM)W>>7V'I2O<[\G
M%2I[5&^^'E'?=$>+]=Y(2=1]N9+H@L?UF@=U$95!Q"Q4!A'(">33\-EI:1US
MCV,G0?RU0QS*(*.M-7;Z^4X".8'\WC)(;VIZ=X^I_,GN]VQ(?+I+2]ZZ!0;?
MLKNTA'9".Z&=T$YH)[03V@GMNXOV1]R&R79,L*IV3-C3)]'DIA3UFAU%_-Y&
MT@_?[6:918TM*O4JM[T!X9D;)#V/E_>]686)-J#5RJ_\K:7,2NRT`6T.'DI)
M:X-LRWB*_(?\A_R'_(?\YT7]Q[`TO:-K9N?!K]F1(Y$CD2.1(WUX<(/'RG:/
MZRER(Q6YX$_7]WYQC5O]R[8UF7R&NIPZO>ZIE><[O58\G;^93J]K^]WN>"2U
M?=W\\CTUVWOI*=A*,Q-:7EQV0@NAA=!":'G2NYN4;A'(X\4UV&ON]["6G-0+
M]F%FHEZP6X'6Y^H%N_WQ\94&&G*HU1?W-MW!E9QDXZ*F2\+;D(Z]7!1XO">L
MTP>5&.:%)XMZG^[X!%+OT]V>O^?J?4KY`R79.^*!RZ+5*AU+R:*K6_2YKO/(
M+J7[R7BTB76%\:A!*37^6E7@1E,S]%W>XI1>MB6`+Q/8U)HM73-;+<(X87Q/
M,=XP#:UA4#\J0OB^(MS4ND9+:[5W>3=9ZD_Z8--1?]+M8(U=W6@%R:-M48`D
MJ.\]U-NMCF9U=GD?4X(Z07TER;$%54=KM2P".X%]W\'>U-J=AM;I-E\!V.FN
M3H7QJ#4I4<CC)'_7Z1A::Z?+(.KD0!!?"O%60S.M76[?30@GA"]%>$/K`HTW
MC5VN>@CD!/*E(+>TKMG2&OO<89K:DC[*NM26E(B%2B"*G03Q68@W3<W:Y\!)
M"'_M"#=,K0D\WFU14U)"^?ZBO`%5?DLS]#W.5J@I*7GK7GCKJVKE16@GM!/:
M">V$=D([H9W0OKMHIZ:D:YF5FI+>VY*%>EE14\5GC<KD/^0_JVIC-#7=:FJ6
M^6I[P9$CD2,]Q0NEFM5H:J;UX)USR(_(C\B//IB69G5TK=6Z)R`]40O/53[]
MZ\<D.KBU[=%/Z<:B5WP4A+CYP(F('"^(DI#?\._Q+UB:_5RO,?:O[(0O8>!P
M[D9GH/$?=AC:?GSZG8>.B,`2#N@&IUWQ_K_?\,#[]N74ZK:L`_C',`S]X#==
MUZUOUS<GWXR.\<W4X;M60_^FOV&)+]19(@HLTVA_^WI]\H:YW!%#VXO^_>;\
MXNS-ST;#Z%@M8RK\,EG*4H-^]D3NH'K9_QSXMS<\'![;(P&EWF=N1_RR!Z!0
MKQMM3@D=5&B:NC558`VQROJ<\%Y<,54/EOWGM%S?WMK]1KK:!5_:9+9S6"#$
M9_CK^/)"-CSYY?-IO79Q>7-Z#7'A?T?P\9Z%@S6LF]NJ%[(?'SW:]LS5O4-*
M54Y.CR^OCF[.+X'`$]_E(?Z6+C%A:U1V'/AW'*@+VXU>!''5IBE/,@WK&>[/
M)(I%?U(5HY]YYO89(>L/6:]=^NQ7.W0&#.I$V5Q78_&``XR&(]N?,!%%"7>1
M1W-4^8@J]@Z.RA>\X;SC#PO@EQ]Q\N$]2,IL^/?V-N2WN'W^*!2^(T9R@7$8
M)*!;T&=O+384G@<L?\AN0);J@9D=<A9Q!_C>9;T)L^NUO@BC&,<,0A%/V!!"
M^*U]RUG@%W6:2M3]$+&^[0@/CP;13NTHKM?^$+X;!:$F;?>)AQ&'P7U77L]-
MY&@GW.'#'@]9P]"DWYF51(O"C]*8S,8<SD\BN>4\"S'02:%,7>_(+9IGM'L7
M<<YZW`O&[_$XGP5)',4@!R0E*"N>.[5CE`SK-32=>=C*C5<ETE$$QSJ#\B2'
MH(ZXXRY,P@CD_0[Q.>;>A+TU#O.IP&OZ/)[J(]]*QE$0(K;O<)PZ"8KJ^3I<
MAXB(EEXY+2WW>XW9L<3>(/`@!D9%EP8_&&&&J%7!'[Q.-N(&,#MV-,!A`.N)
MI(L9O\;+FS!86"(_.`$]!@L=&`0\.1J`/!%B'[QI"&-<QYAXXG$,N"F$9+9>
M4R-$Z$;`3LI5WK8.S2X;P<7D$.S=6,0#9$<!:;.P/38]J5Z;GM4Y;.O3L]Y+
M'F9%&IZ]5HF`@:W&`P%LKP84R`:]/[D3(RG9+OH#IM\L&<'I#BAM@Z5<X24Q
M\$.]EKFZU-=1^D:H[T+ZJY[#>FU@WW&T4""O)%NIP)#M'Z1JMN\G0XTI24'&
M;-;4I"-;5A"YFO5\9I'`17\Q[R.7X8'U6L_V)'W!A3P>17`*3,+;1DY\*=3D
ME(.,:86BX974Y$OF+<Y^I37.\53A3D^;Q8SD9)CK6$8-D1.JLG`6B<<@%<0%
M^0.*"^9"6!B'IJ["!6A>KW6;/V1G]V'F#ER(-F..!3\,`:8/95A4!PSM\"])
M[*+`X24PRXB*"*FP0Z6NUQ!B()BXKL`Y`2P+;!_`(3@#.B/AIEM9H,FS+U22
M@24WX@_BG#1$R/L!^,8X2#P7'!1B$J@.X2JX]<4_<`JB!\SO*$]S^%I!YGG"
MR@8(=\DBUTM$40IB2X+8'/4#G7Q*?,X:N@PQ!AO;T5PPD-17KT&:"%Z#ZR$R
M;9;\#*A7`\D$3,4#&#//PC!%!5=-R;M>R]B;\;\3#'-]X<-QX&?`_0)/J,CA
M5(Y_R(Z4K/5:)JS*&^=T0A7L7G"G!DO#7HE8)$>F9%S@2?+6E_/6K5S#.)Y"
M"P"#Q5%%[>E"PH;[PF)RL7T0HCIBBRCXTF>?;#^QPPDS6U4+'#:4T*HF3W$&
MJ5^WK74[G3P7FBN_)2SG"Q-9#\Q5`<7DO7W8+"3OJQ?H*O>KUYH-K=%H+*HY
MT@0-?20KC##;#+-%=3BA7L/!IRKFZR\L77X9>4F49VO$SY1-;8\K8S85\B$D
M->B#6=56],MTG6]ZT*RCUFO*4^5*F=;LFAK4^#)[02=1Q5D_@0(KF%T59;(Z
MEW20KX!ERV;3I;#9:C>]'OG1GN4Y-X55B&(Y:C.7]R`7]]W$X9)R':#J6[G>
ME)?`Z6[VK(^%.J+&%?T^QXP95WUZ/!YSKH`<A.)6^*6EH'RIY&U#/]1E,`%.
MES4#KE'C67<VE.O`XGFY,)NNRZ@`KM%593:"MC(4703^@5Q+F1.]H'(?5P8&
M4*045[DB5=08&EQ%TT%,E;&IU0SQG4',B@<1XY#\N7DUE$FR&GJF-XT7W/LM
MWR"^X/$QJ/(E#.X$7/27R=>(N^=^WF3@R($:2<1BDS?M]3<_'UA-O=5NZU/I
M5Q>LK-"I'2+%15]X>(W33_>\4]]L/?,][\^7U]?UVI?3*W;]\>B*;G3?.T%'
M<;U67@%!YE*9.;#,B"/BN3?1TB7=2*Y-.W\G`D@.NSITC$Z]AN<8S9;6;AL+
MUU/'ZAF8T@"&IK?;6LLRU1!F4\<-EA<NX_OE>Y_R?J/TQHSNU/<R]6\U6IK9
M;,N3K%8+R6_1N'@S$/N:.%[B%A,(Q_:<Q%.+HW".7+N!WW'/JVG=H#$;5ZFY
M`.KG$#J<.%T@[6$0B,5!MN13Z0F?2V-E_(V1"`HA*?M"AB[/EN3X3&`,?KA5
M<>!YP3AB[W!Y74K]X_RZ<W;C(%L\GV9P[W_:,_>97J?Z%_E46R;#>H_2,8=[
MV"(9E_(PMLC/(UQS3S]GCR7J>O'-L=++3W/;*[S\8YD;%RC]HJJK[X.EG':K
M;CU'Z::Z,3^K;<XNK]C-QU/X[^KTE/T*1WV\OB]3V^*&PYL``4%UNZ!Z??Y?
M`NK<ZZY5FLX^NV]6/+O_\I'A185]$E=<]I0^J,&BP!/N/,SVWF-/0?83]NGK
MQ2EFF4_CK?-OI%0!9?-OV#PE<`CZ!/U7!7V*7=OV9MPJOFKNM*^N,N3TA8N*
MW4CWQG\)Y`3R]1^R(9`3R'<1Y,3D!/*]!SDQ^0J5Q=8A?-L%FO6EK>"#K5B^
MI9FFF::9IIFFF=[[F5[2UD(_.SO6WU2IN5+FM*<;RSZRF]\ZIC.FEE.[7FT-
MSI=7+7NP^]@"75YJ\[%W;:W=M32]^^!^T2N6.]O6=8<<AQSGD>UYS79':UEM
M<AQR''*<-7JZX6LP30@Y'?(<\ASRG.?LAKBCGK-.BY)74BW^D;Y%4J]5OD92
M?`]XS7IR!S:IIO9&6VSP+;NS18@F1!.BM]O`A&A"-"&:$+T_B'Z"IHJOZ=[7
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M=@(K-PR3OT%IQEUL7,?]2'49VF2W,\.PFNU&8RIJM0QE.<]])^1PR`E7_W_N
M'SD.]B:-OM@3M-.1[\(W8<+=S\+N"6_S7=N,EMGI-JRI'@^3\3X]3WB?A^$S
MSH_9:77;S65J58E45N,_MO"QI=2E?VU[_++_)0R@SH\GFVVCUS4++?06B7"?
MO:]X%(?"B4$]['*X48&;#0O^M\S496G*LLON@-A8\2P(3X*D%_<3+T/<9A'2
M;G:[!5,O$V2NX2+H&`RY[#>V4=L:AJDW]6ZGU%1Q>O$9N0(_R'HKJF-.TZ:6
MFY31ZC:-8M/'14*49?TL'/PRNN)WW$\V*V&G;5A6=RKBS+7+@@%6.;;'!9H[
M@=^]8(3-3I_#D`V];3;:A:E>*DI9ZA,^"F$L26+PM\?Q#V3J81#&XI_-\ZUE
MM*UVN]BY]'Z!EK.M["9X[E\GO4BXP@XGE^'IWXF()[_R>!"XY_X=L`K?[)0<
M2))81L@K2GD?7U_&`QY>R:;+&&,WS'QEXKM?FN43I?15FB)`-TR)]T[)G#RS
MQE<=?TOD5&0M8-C-:7!^<8:TWFY83;,X!??+-)/R2MQ%$:1A)[(!,:3((G!_
MM[V$7_"Q_&73\=,R++V8`:\BTDSPMR=RAFZ"(]7#-,MOOGBV'P-=X%R.5+?I
M32;![5:[&,-6%VMF4@!_6539*(HP6A@=$WXIF+]\\;)DE^60_"R)2]-JZ85H
M5B'"C(S(.@!Z[,O]?.G+@=%IMHV"F(NDF$M;'<[=Z`SJY"L^2@$#\6``\>V&
MAT-LW;WA?MNZ`>>7$MC[19I)&T0T"B+;^T\8)*,(U/42W&4$6XZ#Y`*0Y*;3
M%OA112/RU]Z0N_',#;FOCSZ?UFN79^R7\\N#W[X>7=S<<Z-Y=YL*[QP6-C!D
MO78SX-A=>V3[$US6=$$1#[MG8T/MPK9`S+%'(K8]N#9Z)1SPBP@.?DL@6FGU
MVG@@G(%L:1WX/#L['37%%KAF]T/$QH/`\R8L&/O<95&6TPH>:2P.ZC48]";X
M#J.4VV;?XP1%'4*95.(KP&^;NJ[!59D--`FT@EJ`A+8/]A*Q`%U2!I.O"(\%
MZ-WC##Z+V`/A4)QT,`9%DG\`ULC.F&G=S6Q\/`.[5.#62JGZ_21.L$_Y;8BA
M,$RK4&4XT+%LEN.K2Q;Q\`[JQJA>ZR4@+(^B2K4O[[AL.LYB[A],0#+X(QQF
M5\TDU51?\LPJ%=IEE@+AAV"082+'>&MITFRZ#N?$`^QLSM7:=NF4H5H]$3[C
MWT'D2%U>P"RZ'&*91`Q,HI1A@0%8H!01T523D<SG*M6^P:'R>0AZX&XJ:#!L
MQ"Y;RW-7R@P*]448P63!8"$DZLP3W$=Q`-I*(3N*>!R54(S3..9@)=4>OGP(
MBHMOE-OUF@-9&I0#J:A2;W"T0W;4C]-Y@6C'M:(',#?`)>\@AIGE/N\+J%I3
M)V#X,Y?E1+87%XP]%2H(,Y]89)3\(OP.TF`)R$R(LG["K]=LQPE"U_8=KBQU
M='W,;H*1<,#+F@<F>-LLQRC2N/G?9V`-]'_A%/BQT""E&-`A?N0AO10]#ME-
MA54`0B/N9/@*;GWQ#TQU.AH"R87\&'['?(GUO6`<L3XD(,6IRVQ?KZ'>E:;Z
M&(P!@:&:F#BT_<AVY)H%X"^*P\2)BP""J]1K+DY0D2/L_!.<P>VA@K"A,P0O
MP@:81JBT%^2&X^HUY00LR`R"#)HXF<ND4PMF@=,*8RMID%#K-9_?!L!6.=,,
M.<B.QA+#40@"R/$]\1<'1$D3V7>V\+"J1LC6:R(O4Q%:>#`XY!BT3!DC(QN-
M35E<S4A*@@,[O0CO]W$>@GZ5?3EDLDEHW^*$#8`OP#"IRT=*CM2-T(ZC($8B
MDDYP"X;$V9NG6%"QX$1@R@+Q28L7SEG*&Q5^*'7"K^Y`%/`R,$T?BDATC'3&
M^'>@%`F0+!CFF`:3Q1@;D`=P1B*(_`*\6D)1,B.>XT"@XPIBH8C^JB#&!:#`
MB[DR;88)P,"P-!P@=')O@1-@ZF0&G9DO+_"5%%,^PXE0BH(]7?1:.#%6Q#%C
M6+"."^K%.)4RJK&"=P*^`N^.#R7<4X05?BZ8+<L+KBZ!+B-4>:"5I]CE&,N$
M+TD,G2EFXR"!I`1I`L*7/0+(`ZV#**B?XP%+B_ZDR'@2:%-*M]&44^ODTK"I
MI/)FKO2OOO"!&P&7P",Q?"-Q>#B?`"]Y['+W*XYEM_QW7[N;8E8$A6X@$2!<
M+LE_P+$VSSPD&DCL]690@JBJUWZ'K%62;+:RQDXQMYJP=]/,[OC#[^>GTX\G
M']Y#V0V7@KC[E5T$AQ!U]>Z!T=;FGS)?->X>YY*AB]5K[U0X[QCZ^Y_8N8H0
M.9V>9?AF4+WC*CGX9V^"@O,0O"K"W/-<N7,:"1=H"?GZXL`^[\:I/06Z(U@$
M+.K82<31O1UIXF)`P(<LP/^2/N9)&+72]`C&D0P&>O3!BG!R5`JK&,[OI&A0
MCX#L2%^VZXJ<8'N0^H`!2HX.7X_0$O<H`(+FV4H>#D>0480H3IJ?R*RQ($1.
MM1J<%ZH!1.'\:0Z+@]B]*`A[!8E5>P\>2:)&(L04'@48V3!SCA@A"0J50<+,
M"#<!=?*0&P\2O!HPLI):"AR*H1U.6)Z$PM\I)\.L+.+D_+H%)U`%3FY$")Y!
M.+0+T1)8.)GPL(([:?%@SQ8/@!0`5M*K;!'BLT,)GZU&ITE=(;,$'.85MLOR
M[,Z'A"1/\2))&ACUO\N+`#^\-0\;&I2LG@=PRY8>0KP9&"F>@S&R@C:_;+FR
ME2D!I&E(YN`B1N-0_X$%<W7UDJRRG'^E=;$D2IF-V6$H4"=_\4)(S_9D'18-
M.)>9"HA86O.0HKT%81.9Z]CHY#R\D[9%&V0FP`F`*PL8"-4I#P*1I8=/#&6B
M>-R_35-_F&&EL[*@)(C,7.ER06%ZD(3DXV]P*E0@D&%*;3%Y#'U)`:,$3IS6
M'E@YY#2J^&(.'MDTY3#)UA5`9U44H01*:Y'>0U03+%^)P5=ATC(7OYOF??FZ
MT@3ESCDPY'U/@4\FACW;A:2\I^I//X(KGJ>I_QV&'4G\P.<)4G&6]F)])6TR
MBJ=5*,8V5T!Q%*JOH`[*O2+"XF(,EK3=/Q,(G^7?@+[3D176H`C#`Z;,"BFY
M#`=*#[!%XBDT%])J)\M2<,Q0!E%0&2"'JCY/]KH5Y+RI;+$/A5PPEA74E&6`
MD63,8]F<X/*0+$/$=S8$*0;`=5A627^LUZ9>#8Z$O60U/!.Y$-S+FV@(2=&?
M6YP8`$8#QTGP,3*YF/#)]A/$M2&'TY\\P):3_Y<*K^6++H["U;_(!T)+B?3*
M#Y\RAWO8S\^!Z<9[8/+S").R]'/V**RN%]\/??4]<-,O_CA5L]L+/'?]=W07
MME8T].?(OC;697JQ<<XNK]C-QU-V??Y?]BL<\_'Z/H;>XH:/C\<`]94FGWJT
M<4Y!]A/VZ>O%*6;!Y$_D3^1/CS$.9JWD1:MYT8XL&*WDNE_"0&ZC/K0+]6A:
M[:R)AVWGFKWQ8O5&X%??3EP!Q7_%:W0[X[>/V6.F2JE57G1\>6"^J+!/$B!7
M>G5V'E&Y!YH[[8"+37@4I3?=N/LT7KGBN[L;?V'W*5%#N-\[W.>K\H1Z0OVK
M0?V1O-M#5']/HE;<'/SX[.SXN+P=X()]*%K6?FWY=Q/$>(\Q?7;C<;55Q08Q
MS]2*:T6JV)*M0U?>`V8[=@QM:$;'U$SCP3N*;<&F+D^R!2Z!>G]`;6IZU])T
MZ\']FPC4!.IM`[6AZ9V.9K1;KP#4ZVSMO"27VY`6%SQ6S]"29Y)GXKKX_]O[
MUJ;&C6W1[Z[R?U#E3JHF5<;Q$^,D.U4,,-GL/0,$F.3F?DDU5AMK1Y8</7CD
MU]_UZ)9:MHR-!X,-?>J<D\&V6KVZU_O9;-9:C2X(G95[3&X`;2YN)VFQ^4U@
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M>M+62"4)BY:*;&ND57V<&\=K7@T5<Z**;8U4`I1MC62;9=C62!N.-1;O7QW>
MV]9(%NO?'M;;UDBV/LRV1EK-N+#%![,;;M7ZS=W:;J^_CF/>L+BC1>HW@]3=
MW4:MM?L6NLA8I'XC2-WN[M8ZS?8;0&E;,?:8;DQ6B7OSK.%]LUWK@AK7;&PS
M>[#UT!:;"9N[K5JGO\T&B<5DB\F:+W=VV[7=1N?U8K/UO)6<F>W,9/G%*ORB
MOON*.87%X[>"QXUZ8YO;DEL\MGBL^?$KMJBMG\UV9MI`)K&M-9QOJNN'Q6B+
MT1:C-_N`+4:_;8Q^P@$S7ZO2O6"#I;7@/W9M<E9KVF2=?I8WE>Y\K];:[=2Z
M6]W3VF8M6>RVV&VQVV+WZ\7NC6C?M*BUTR9Y'B_I]$_@],\?J-4825`K=8&U
M,XE"+I$?A($K`U(WLV)Y+Z#O$B\,G+&X!_Q(JI5`#F0<B\CS[YTK";]QO0'\
MY$8ZX=!)1E*7V..?(>BG]'@,WXC$N0U3WZU61@)^?25EX(C!R),W\%*/GXV%
MGZT3IU>QYWHBNG=&PG7"P2"-(OBI@$W0:HAM=0<`RJ$05+8TE@&\'[1B5)OA
M"=C^0$:)\()J1<1Q.IX8>\)7'83CB0@0'A^WP\]&4L1A0*VX4CB;"']9K0R\
M:)".T3D+QU!?I&FKOW[Z/HUWKH68_'#HQ9,0H/PE"M-)?!P,_!2=O/`Q7$#B
M!:ET3[-#PT]!S4\C>2GOD@^(2#]7*X[SDU[M'``5/JP2CN5)&*CC#J[Q-A-X
MY%P.__6-#/T_SXXZ_=W.#OQ/L]EL[/S::#0Z?UY<'O[9W&O^V6K`9[OMQI^-
M;P!2CY_RXK#3:O;^_')Q^(WCRH$W%GZ,'<1^;K5:_=U6#M*\312W>A:%`RG=
M^"-PAF.X`SR_T^$!>;TO$H!LO7ON=9J=1CO?],+M%'=_(.+1?N#B?X[^3CW@
MH8AB9S+R0A<@1U21AY+_NU9`=KJ=[EX.QF/V581H^MOCX"R2$^&YAW(HD<Z.
M[B;(#V#U4T#\:#^.)1#56F'K];O=1@[<:EN<`1/0\E+<E=#2RL#\K+C_EHN"
M9J=N",)G^-?QR<'IYZ-JY7+__QXM:A2WMA-%`>$-[Q?J`5MYI23=M30;B1B6
M4E(3W47P?`P?H-`>2)*!->=VY`U&#DGD:QD@Z\:H9"`3)Y<FY&H:B"BZ!RE[
M*R*7A+N8@-B]`_)-)*@"[]J[SMCS?=05X%?5RE""S`0E`GU6("X3>BO0HI.(
M.V>21B`&)8I@$(37(P=H7(ZO0,BVFS5NV52*FP`?,MC"5E!6BQOA^22JDQ#V
M-@1&X`S3!*@==`5Q1]^HU^-^Y-W$0^U`7GM!@!!Z@0/O[&3;:35:_2(8)9LO
MW>$QEFH'\,`Y5\.";N'")B[D@-2H]E[+F?AB@#J&XWMC+V'U"OX7%9$T\7SO
M'_71T-$O#[`LX\'[N!VA-@4/W<(=QB-OX@Q&(KB6-0>0P)6@T^&U7MT3`+ZX
MK;$^50[#+X0(OG]?F[=DM:+6U.NH#3C7P*D3TI7@R6X#'918O:X>Q7/.EL.;
M^0O.@8[#<=,(04.\A4N0<N=>B@@?!TG&2IY&:_@,E3W4!*GFV`.2@+.*28E(
M(A'$8L#Z'3I.\51QJ=BX[?^(($6UDE&ML<<X0='V`B(B3C3P`$T=<2BEK]59
M_JI:\;V_D`9XM_Q=G`)9E9R>P[^%ZU3Z;.D-?-!Z:S+R8L83^)N!K9G;P8N`
M\Q[C7?"+R]Z9A.%?ZISA!OZ3!I)!PTM#95HZ69<+5/+A4FYE1(K,C<2&+TA5
M.D&!CAF1"@1J&N,V4:T^@:><O5)8]A'5V2A@U1X@FL4I.D=Q!>B?W./KF!(D
MP4H'A5M;P)6JE8R%@4G@X>V'_+X2]'.,@TU">'>1G37KK8R?H9>=T#$S)\(T
M@E?[@]17Y@T;)9)L$FW`3`,YCZ,Y!L-&C!Z$D8O8#1S,]]%>3YDA`$6&MZBH
M.N(:;)F8;1=7*4-$V8)4(``F\F(\HR&HM_2K14>WR)*QXOBKQ?$PQ/MC9@*H
M=@,WA)@#R+)_<>#T.HT=T#E;W7KQSVJ%?NO"RQ`SKD&-1EP81("XD2>(=2%Y
M^83U8]"30>BA`>R,0?#X+,320-F_++_"V%,&,#!@0.8(!2((*";T*ZD^]P)#
MZB%B@CP-XJG]P:O!\(BD8HDB6WUV<:"0XNJ"ML/KXA<*P'^(I]`Y9;Z(:H5T
M"+;L2=9X"5+P.(PT2V69`^PKM^NSO2C'PQ5Z%6(\"'A%.H$OY)T`WLGTI:2C
M2)-1",?K@81W+LWS4GZ'L92\_)R7PV&,0M\EQ23!K:I;<3&>1T(.[_]*,[M;
ME0O&"I4`L:'/`7^+[_%%="UCX#!B'*8!<U'8UQ4PNZ&GP(6SF)*]W^JMP<^O
M)*R%5RA\.EZ"'1@RL3L'>$;BT]D6)*TB1Y`4_1]CYR/K(M6*H0DIE"!!"X*T
MA^@#_^T3Z$#7P+Z`Z02L`Z97_P,T8%Z+WJ<YZI.#S<I9-YUE6N2:R5D;$@>R
M>1;PI`CZ<6B\JG"_"BF(1<,_[O$!N!(6-(1RK#+R<DMP:Q<NG&DC)RFB1+JX
MD&$O.2Y6'I2$C8&VHYPX,E(%.AN@)("U4!&[E:RD(XH9(L+W-!HI0C=HR,"1
MF&]<N.%$ZY933`<@P]/07JA8<0(`,'^%YC(HGN>]""XW80VCW2`%JOEX)]E#
M1ONT>0\(#Z1Q)CQWK;Z)9J_3:;7,+>8O+F[I`]*XC&-`DRN%>=;W,-LZXYE=
M#_L'OWXYOCB^/#X]J59./SH?CD]W?OVR?W)I]9XMQJ(U+%FM@`@"X@R4P7[K
M)2/3X"H*13$`Y4?I&,!3,RL*#$MVK*")B$P^'8^)=<+O,@NSV:FQM'R/Z^<+
M'_QX-!SBZV^`(>.F\Z\.?_RNYDC4$8P,<<X`PO<7;#1S/[`=W`@:#S[*C<`U
MC#LO(#-)<EP3N3OP=HD1G=U&O=]6.>E@L19?4',F8!*A>2*==XUZH]',TY%J
MV@;2PO(]V7<FC/L@NL&`="YH]2D0!5J@H#V(F)6EL1?'8401*.F\QP.`$Q:%
M,T,+M+"*UB%!EP/#7_AH$H(N.4&?E-:CJI5WK5JOUZRW>PL8TARL0+Z.5\#@
M5BN?):AJ4<%$!]4L3NG0P6X#'>T:52[X?6MWM[:[VW.*!\'%G"=DA"L`C*<>
M``5,UE:MV>K7P+`G98)B:+@F*J-@B!80HD0HOS037`-[>"#2O/TB="W,#Q5<
M1CXQ&$0I<P?2=!RR[B*%O$TP+Y#:11"DX\QM"BCG16AF3,0]FA,U)A3A%S`V
M,!=5;\'XC:0P*UIIP&:0J-R4W;6P&GEPPX!U\]RMH<G/5=LR:'"N_H[NLECS
M)X95F=B9X4AV18'`8C:T?3_?>KYEUN7U+M&,-.U^H.*!B(%C`ULHQIN+LB14
M'GGXO6()U0KS!.VE)RL6M7)BNIP8FGG2B3LC2X]S6Z=:&7IW[`P;T/F\:]6[
MK9Q-SSTC/D)G'Q@/V86&%X*MS2)WY["<<:`Y#(JMU91[##M%.H`R*/_0""G\
MB#BE]N(;LJO`Q09T"&@&R3L,X3K-?KW?_Y;2#0R9.,-5^>0SR4H$`9J_#ZKZ
M%"PD^UP6<OQ6Y1V$8\>=N6!AAN2_(`.-/'*,YY.)[PT(@"CU98YD^Q>'^[\"
M1HB)A_!_%M%?LMS^O5Q^)W@-@)>?Q;W3ZBA?-;HFR#A6GN\)W`88=!B_4$%N
M$GJJRHPL7M]W,GK-4SC&8(&2JT)A?WB+7H,\#8*N&<,#&`'0+F7E,:_-PXUL
M6=`EC*M:P!JRMV:X5:T4;]<*LU>6I`36M0BN/2`D2MC!Q`/2M-'-3;P_#U<@
M4^O4FKN-&EC,[$^)E?]_S$E*B/"NO)%^.('/_QN$MSO_#F\)UXJ1C\M(@`PX
M$9A5=#CS`(JUS/V1-P4OL/!))'<&`#0P`=^)972#;!?=GU'BQ9)<9YSO4W.N
M4@JU&"&(&I&SO`.*C9%!><#,03./&`)/Q14!H!P8'.[GX"''[+@K@X7$,1`)
M>4Z5@TMUZ@46DD0>[$3S7";22:J"DGA$@5HB=SV;:B3Q/:6F3H`6QV(@TX3`
M]P(7"`)V?\N>I?P9#Y7ZO^!8`W4VR(C*C@Z@>G\AF>Z==JX9.[V,P>F$L7QU
M?:^WZ"'?"8=#Q=3X_#5>Q=\]8<3#&O$;I\?N&[Y>S%7([?2:B;V"8Y-,#2IX
MB.19K9#*-O2!4;!O%PCRX/RT/%A;6,\(I>3N5"+M[#U1>(O:`AKA^);\O?@*
MT'^5!W&N@O`.C+R]3JW3VT78KL/0O457>Q[\U/HQD,P<!X7!*2FZP&$"LC:5
MLU=KT_DCL#D.!"N8X-\(B@D;J\EZ(]HO?B.=_#C5"L1W,J8SQ3M`PW'309+Q
M;=)-]+$`=[@VE16E:,R)/<,:1J":V4>SJ*'$(V^8L`T"?`75"K6RH8(B['2J
M"#'>5!G`G$G"R6JN4X`=-'$%O#[N.)W@-!4=XRDU"9!MBX@2"=P%A\$6`BCH
M0*^\*?5S.(&ITW6C]!I]0:Z'9A,PV044F(<RB[A`\6AU;OHLDS`[`<(+H=Q8
M!?9.F*__4'?M3+R)Q+?Q,7>F=TDNC69[^N,"$U=)`WBDRX"$^]9B%9:<,.9[
MN=Z.!.^`Z(>#C#CK92:103]?W$=V;\ML@U&.K-F,2`R$FMH8VU%X_"YH#H$7
MC]"K>(,:LJ>RF[Q25U5AA]5*GE:@@%6J0<:^LLW$F4C5G*9<%4*#9"9[AC*(
M/,`-+QJK/"!`?_:\Y5R,$FET5)@,&5B8!#@F<]&[T8R)E.5+C^O-/*^JO?`R
M*2I)J&&PWL(RR]';(>=#8>1'V<Z*Q&I&T)!5(*!X;^@-E'7'6F0PPC]=LMN1
MO(KXF='/4EO1E*GV`<@=IM&`"CVDRT@P3"-TAVB>HUS4>'-A+'-V'A++PW";
M)W.TXCNE$#4L$)')FWEX$-,ULZM6")D-Q#>0-`E59F*6/E]W=!I5$7J\G875
M.01YGC8$FBP<U[4W8`E1FUZT6BG$/(L"AL:W:$>[4.[Y"9SA"-FDR)TL!!X0
MU&5XAZ<:DPL<@^@JH<@PF@?*EZ!]_09S+FC-97KNLK;C;&1VN>!F,2!ZJB/X
M*EU[O4GDS5:GU>WVC5#MS/NGMA==BT#E7!X`UN#`'_H#>RO&I\,SMIWX(P7^
MH8P'D4?^NOW`Q3A]BCK1]1D\/`#4MF%>G6+^S&'>#_L7QQ<4X#T[/[J`\]G'
MB.]&>(2L>;A)YJ'R'P+/C(%@L9:KYAP'`V"=E%L<@8)^(N\^8X(S?OR=3F'B
MBC0/]=&9J.V,"G_X(Z:_F3\!P3GU=3$H>CL5PKSE%/XP`KDI$F7"R!OA"OQ7
ML[]7'K8\#3#C?)*H.'.CS"_+LLTE=0&=/"JAJA!2-4Z@L&V0366A7/,T,8X^
M]=14JJL#8C@)(S0"_'L6JVH[<@B7@$YG`(/T?=/RX10Z_-E$H',;GE&_\4%S
MB,`$D8-1$/KA]3T[F="%B)>Y?W"I3^CH1^LRWGK9LK;XYR#3`@K5L$8":E[`
M.L'P!NIVTU$_4.]BLHJT6Y4"0LA%(GF=I8TKQ>Y+_:).-2)IE*O&1W=*_<2J
M1"_&L%XIL1^HU%ZC6I==I<,P3"AAPLU4-"!U_`T2'/NB5=YC"9!DLS-L9:&N
M3.?1X1L$[UH7CJ#C"4N,\DS>+P&YN2]P??,`\[IC8)7AV$O@5W7@.&QKA!/0
M]',;M=1)`K<IKB6'FU%9-FN`,5B)V?#L!%3`8V`MC<B\`A4VQ6P5PZ32]<V4
M4>D,!0:T)X8.6#,V;YXA^<[@5&B'J@8W0R,,Q,X>,3OM\V+L<L0KI#YGU53\
M9['&6CO%R2GAC54]2LQYKAAL,&NWBX7;NFA;+T%Q08RUUYV/5`:E##P#R6KP
MT%!&&L$74@TC)9>74.R<?46%`RQ/L@J"E&X-C4<2"K"E,5#MSG_A19C/E*7C
M&"140CX:NFJ%L@AD@&^><5GHDG)$?M-#$LLEKM1,AR]XQ<;B+^G(F#.N8W;H
M_2]UKW,\=03%IG40AB8MY_'7H:KMJ&7YN!Y)V8(?4BH+IZ88#3MI<O)720)(
MMBA*LVH1^+&Q:MTYY5JR8.<Z1$S&YE/QE$G+_B,,Q^(*&6`U)XMQ*>/?<!5=
M"?1*7B7T*QV)T7"9B>6X#AFV.UQQ@U0%@.51*<Q#\Y*,)+2C':!"\VM19'TZ
MAR]A]&(*&`LLJO*&B-K:"Q&;5\?Q:/Z%.L6LHP"2"G(T3@;?#"5CK3+X#06E
M4:F>R=TL4D46I,X304EY!F/!U)=+HL><];C('5>^L7@BD0LE]\Z5%Z+VRP$6
M@1ZWS!,=&FX.I[";@_/3HM'!-`<<^4(@R)Z\#N=2E!E?0F-EC&%G4_<1TWZR
M+*>("/G,%\1?5<+1C$TUG8A4V"G0*;&6D_"&;Z754!FUH(U1OM8X+(97Z-,/
MOSK[^;9198LF=3S]VU$(NLL.UNVY9ON1J5Q68C@/95)^71P9GKF*G.]?BDML
M,86NQ2)8QD]\057U65.:VE1B"45UEX^6.=/!,I`ICXR6.7FP#$/93Q0MR[-0
MOB+<9<:S**=<1]J*:YK.`G(,%(\T#T)0/9E[0Z8)>074"1F'H50C'6](8VV)
MA6FB@FKXY+2/H,RE4'?VXZ7`?&2D<#D\(R=)88':TI'.98*+^BY0`9H-+A9W
M'BN<SZ\)^3][9PA7"FNS/JKOK)")@$IY%H8U/#UH0P(Y\/.PWY$N;1Q23:F.
MVX*M!UICI+(JV'1<"@\7A$CSPNL,2Q\1(C747C-L_J@0J9'GP?4;;R=$NLPZ
M^18X5DIM0Z8B;ZN$2HWH:!;Y=)8,?((E5!;Y=)8.?()561;Y=!8'/K,&(3.&
MQU(LPN@X@;2[=.#3F1_WA,-8+O#)T%V(\=BY"/V40-"*L\L6J#X'$>OXZ(7R
M-#O3JC5\.:-7YYJLLBCA<&M?$6+EW65Y^2*FVH2'O%2L6U)/"+AD,Y+@O(^?
M)%J[;8KF&KC2)=>AE`;CC1*1V:S1*;QE2E)NJ=M0)UG%AFG2_E$E6W'7FBS=
MBAA1>3I;WNW(2^*YQ@8'7<!B_'*Q_YT*2E$1#!5@L,/54`^12^AT67-]+$`L
M?4'-+`(KL>H^AKKM3LQX*O].)=MRA5,MBGY5ZA]QGR>B!G5HF+=6?DYSLOZ6
M`T.=DV,<T^LPQ,R8T):'G]85H,D+*UDHZ8!@'C>D'K1<.L8QPODTJ6AKVF8P
M6_W`P\N%&BE'<#;4^&#*PF5175'=%T@BLFM5`47-+(HVC,H&+%MU>A-EOS%V
MGY4`AY'P:T3W@Q3DH`Q)Y&.?HTCI\(.$U'1U`L!$Q]A'!!B2B%49&IX1;%PY
MVV-.2@Q5^("##J2C+#@,U`_]&-1G$(]_<4!E#(H^NKJT'VLBHD3U6.+0A6$`
M`A2_@?B.PC@_!2VP<6DJHV(6?R`"C*CKV$>"?514AC&</X+L@;QP[^-A&@QF
M'6A'AT7_&>5@(F:I1B9P7O+.BQ,2#84DV`(GSTQZ.,(2A,2&8AC*+N79<HS-
MJPS3E6)7<HQR+I9WZ-^&DTACO#HOQN8A$9S/Y_M!^)O0FV^V6OQ<&-P/1N$8
MOHP]S&?/_/FP.0&R`59PW@?"\T'[#:ZY)<R032G@Q.?BOF1-^!3#7$6=Z.(^
M<"/5DZ]:.8ODS6DP"&>>)53CXG5&0D]K[9KP\P1!,U-`4\X5HNE04L`O+XC3
MN.,,?+#`J:Q&=<E3`5JLO`&Z'S%F8<>O13Q#U:\:>]B,","FI!F\`@W3Z,R`
MVE`.>GGQ(P:N?$F!/*H8B&*IS(EXXGM85FNXRIDWD0$YQ(H$F8\#'.9&Q22,
M?XP+C1A("`1YFP&W8,50;;)(DQ"CMIQK,]7Z`90U51(Z8\',ONQ';`FDS,/,
MX<_"`Z"1T0XOE+>&4$N::W"$5?79^H?C>V/TL_#14%4.]G$"$J,2"6"AU)0O
M.T$\._+Q.T,Q2)`ZAQB.I3/;`6K=`9#JSC[HI+P;HE==])S%5+U`U\C,B=HO
M2O[@3`/5NRF20S\/W\Y<-5JN'GH<IIN9\Q[RYI3JO)`G>5@&JYI*JA0$[!>Y
M"5SD%77J4Q_\?L1OO`I]5^F:G[R_4[`VDGM[Y&LQUK^&]G1R$ACKV$B04A04
M!Z6<:^"[0F6:.-SV+LOET!7%K$H#UX%OXB$WC<7OC52(F60#E:>B$HD&H!7$
M[&M=6+1G9CX*2JA*QZE*T`#-8^"QNCG5AA2TH'HG:T0ZW5I-J^2Z&QSU":;F
MGK/]F9O->JML;T;39N4CO7.`&8/>@_X[7'?VE0A#5K5/<R"D3B(C3ZORPL!/
M;LB-BIUGLX0E3)!)[D$MU:DZM;)M89Z(Q@'4F_&UZ61G&"$2JG8%<=XB@;RF
MN8&0:W?**LB\NUG^QH-*VELC[RUF(\\2]/VZUJ]%JX=<]RC-HQM91JC]>G.:
MX*N5W)<IS`A4$F:]:U+E-(C3(7(3BB3AFRA(@?856C!&LF!F\@,AAD33/I7*
MPUO*F_-=4MD4O.Y_*FSF&5X27(BX!OJXLY:=.A^-.!OV_DA46Q&RIM(KWQL`
MMR7+N*:='_1<'"LKK=RR4]'$K#;6*3/[M-6FND?#UK6!G837DMP16=X@\9%)
MDKDS0&F'C0VP$P,:C8K=J.!,&9NA?%O\$C3FF-+:5+"0[@`V&NR`4FZDZW%T
MN-"C67FE"[DE9:ZC-8CBD--MJ?D$MB:E2)GIP,@/(XO:Q"H2V72H^VNSQ4Q:
M]X[+F#5^"/@,NBQZA3/6#==3#"11!"6BIKH4<34L[MPW4HSJ?Z]DEO)VK<^T
M/7I4F+.P5J_Q[8_.;T?GE\<'^Y_T*"ZL"=M)PLE#]G/NGJ/T!.D/J0LLTSXG
MFW`;<I.=3'RJ):;8HS[I>,3=CY?D%,X4HZ!&?,@M*,#:7EB^NLHY[YLA1]22
MLI3;8G8E?0<,4?._/.&5TC9UNWMZ4G$J'2Q51V3V\_H>TS4QLX%;J"SPU;RT
M%V<C\CBM*O*2`0\ERD#&,@7H;FP)!^"NS"P?W7Y"":V<H#,G..?>*X5DJ@-\
M0;&N5A8R<RW#<CFATBNTVJVZ]TR')5;)=UW(+VMJF@AGA$P/\`!K).!P"F8G
M*!=8FNR4B3B.8I0FAQG1$^*F4_$E<FFK?%SU,[9TT:J\#2/?O05>_$"_]>PF
MC2XJUZG'-3C$%:>*#-R0RGL2UD_H5QC+SN(+200:RVPO0?/BLV1$%`&:MX*!
MG*7-`.J5]UE)E`8SED8&I!G)(:<I%@:1QY.U*M*="%<*Z3'ZR+,0C=DOA*IA
MKN7L?:A*@5P_T#4Y"!$-B*$X""B2>1P'LUD&"F6\8.B+L2YM`1,1_JF^F@B2
M2BXVKD]";SQ&@]CU8CRJ>%&NTJ-P&+$A3@=8I3-,?1PL8Y"3H2`9)2EE"M%L
M$-)$5U8FRC$@;]UC*'^9TDI1I31P'VQ:XX?!]0XVV:Q65*<CE4-4CCJ7(3,Q
MB:T$I^;*J'8]W>D.&)[119F=[E.91B6TK+LK1.AR<BXF^U.)0_1Y,9"G$1$4
M-48]X0-&`OZYGJ\K4P"[QD;$D'(32R*&4Q4`,Y')V1>3-0"`'B?"O]=]7=3D
M(IWJIJ/!I8TF*'!'G>3X-*83KJJ5(["]G+,"WXJ=3XE;GXIOPL]F(YPG,B26
MY]`HRRGX])>S8,U`7HH47_).DX5VK;3C3PJ<K"B@QI^C5XH\4=>1X)A_?@34
MVIIX@BI$W(_$E7,T]B*N6CH%"5QS/HA1!+1><WX5L$O`N@LLS:/?>J+F_#>]
M%1Z\[9.\$@%RB8O["#__#Y5&UISC2/Q-9_,';HLY1MZ]LMAW5I]>"3#9=S0/
MR(3(*0/H.(Z$]#-<.!,HG8%98LK;I8PB#XNL\_3>7\0_PKD`83#)'OD=XPP?
M1/"7GO.DH^R2I?:8^I667%TA2WMZ=(1*9L=VG8JFV9Q`*N1L@#P8.\]S1[\C
M'-!@8((O-7?UE3_D5JHB0*'V253/G5C930$;.$HC4(!HR:Q_*IS'#$3<<+Q(
MSA-8AG4!VOK1(6TAGU)2($"EEN4<<\:XGWVG%E1:W&EH[]\#O-\5Y#4G1!1J
M!DA/T/-'-B/>G.O8#S@U7U-H>'X(Z5S2^+M"N708A#CEA13,UY&S]EP1]VQN
M7TFHG6;;(&._^`)J0YWJP'::O=D""7[)Y1^?X"V8W^L-#."-C.A",Z#8>7^)
M6H"SUVQ\]T.U<CPF8E75NZ'S,8M6G4O=UN_JWCE"@0S,"GV@Q\%-Z-^H:F7@
M`P)D!SH*]2@9_#$IP,54>(Z5PXM<(P+EX4`?E_2T2/)@/U6_L`JD<Y31O]$%
M20,J;R2K._`V+_Y+5W-PORUC#!ZQ2SV/D'(/B'5%^D0H(=Q+4($;.J3(43",
MRQ5#WR=OJ#%]7)T+C>U^>5[V]*A]HU!`U54AK'Q`JL="D(\$T^U14)ZY^*/A
M?7;`A`,*Y]3S(V7S3L);KM!WO4@G)QA5-1A\P%:`"A.G=\'3SD#A=0H6(!6K
M#%3B`O^T:`%@0"$<`[&H49ULL@+.O&]^QUF&5W"XC#)4OG45A]&5'O`5YM4L
MV(8T<MZW^*F9\23YS*E,S/)3=6??.#L]'VW*Q9%UB*Y6`--]A>B9)X7,+)FU
MBR=;8/KD9U%[68R&W\P<NUYC`<ES;HSJ,V#XZ%G-TGT^Q%68TL"&*=0HWI3'
M/(ET'22S.:C@&3,(\'A4S8QJ-F&T'5$N9AX1%JNA(_-;7TQW$W#)SO.BO-Z#
MQZD!_Z443W11J#LPE,=Y9*3C]Y0T`#>B6DT0.@Q,YD[>`4JOS)[S8C5I37<=
MUPWU54N-/!V'FB4X@$%1@FVC0&&?[99`AV;VS47U+4;XT-%B7@++AOG7\$J2
MW-?;/)[[>_F&DO!Q_^*#3I#+%81F@Q0$%NR[C:ZSHZ<VD^*6=3S?<3YG+L_/
M,AF%;M%`_G*QKU>;JCQ2_#D;GI$Y\&!5RC?E<9"Y1Y6#F:8$I5&7&#V])Z,*
MF1H`)[AW,MHY]QQ\S988\PZIJ8L"QFS?CIAL=`4HA$[-Z<E$H3ARTF1#>'8*
M4@Y$9_R1LG#0.S)1'W!&#DTES/:&?L"1)V]TUZ$8_9+3TYE#&AHJANB<I=03
M\O_H2DEWIKM-UH(>@UX\NG&ZU1AZLW+M4`.0;UYD4F?H14!MBIJ9><7D^J%)
MA@[&P&D-U^,9),1;R,?),C&<W\>&.H,LR&\J3&FTM+X4K4]Y`A\D]];>ZO9`
M/I3"K`/K_.C\DK5%1O0\)=>&LA;:7;`6"@TM?D>"!LH]8]7(N4CDQ&EEW=;U
M6LYQ7A!\B0*`DN@S68Y.+.5*^7\R"I%@3G!$&)E)!SC8F6;@<*ASRI[(2*"U
M1UI10<71Z$YT],3V1$[B1-QF-Y6NGK5.33N`XZB&V'K*\9"+TO#$\/GLT-@O
MG!5=&U74B3ZT7`'"^,)3PT17\`]?0;42J#O@V=KF_!RVF%1KJ%E(O&%1">6T
MYEC7R\@LSC=GY#%/)GYBV(31\-LX6:IEF>6QS@R+!?PR66Q>1E_.8YT%+)8W
M\3"/7:8+F>6Q:^:Q7^%S^2AA/S3,5R6G95.G?\$V%`'//KB?"EHXGT60(LF`
MY1---3EY7^Q4>O&%50G8Y52G5;)N2A6U$0]NR`8>ZY8LH,*C(4(HC?N&$V2\
MXUZ0``<YCI^8*L\BC"GK3FB@ZF*ZFTO6P@&J9/L#JC4@+IKOY=]2^,"I#G0U
MQ)&;#I3-AIHN4(GOL2V$S[_7&7)\U843'"3%8)#2$^GSIX44R#VDZD'5`1#,
M?,E2BFIDX.(!1,'3O^?ICP6/81,+.;,A?5>@[+J2*RMT-V^J77QB,,8F<K*.
M@)`A\Z-2U;G[4#RV,.*;M00\!\[JHOBM:DWG%M/!]70WXG=/[QW,N+C/'A',
MH_=U=U#@PQ&`,PDY5NQBH\B("GWB?%X]R$80S/^H)BDJW4!UD!$4-$:'SP[E
M_>5&#?914I$=9`E<`?NTH!4PBT6KDKT*?4PEJC>K1!6>CPO%/09NEC2"(6M/
M\9.G)B8T_[@U*\W7E,:FJ:E1>2I)EG#$4AAMF#Q2IPIMV?'&S2MUMZ.,?VIW
M6C[G#)N)4FILP=I<LG30:.N_SK[]Q1$!%UC&=4RBCEO-G)'I^1O6M]$$0FJ>
M<F`VJ5SKB(-&N]?J=_.C>/S^BO#E(QQ.A^:OSKF'T0$0;9RO<Z:2ONR0`Z4@
M=9Y]EOW!Z9>3R^.37ZJ5CZ?GSL7EZ<%_=S[L7QP=.@>GG\^.3B[LV(.U5JUE
ME:WHFXT\"BIPK2<E:I#[6,?%4`>C5"$MAU%UY*G%JA^2'LX[UZ@YX-K9"^Y#
M%&3M;#*+BMXZMYN+ZE^DDJAU*@EF"(TG?G@O=3MBCA&!V4E)%;FZ6^B^J\7T
M5:%?%"VZ0]$)[)BM2G]SQ:2D@WB6\L#>3"X%5#%R+3UJF49#.]&]Z$9&SIKJ
M?4.UQ\#SZL[O^7M9E.;[P>(S:L_%.I;``.;,>1(H>1\[YX,O!G_M7`Q&(4WT
MY4?QSO`'X]"5?IUO!ML&\1'CIF%MC0ID(O'8.ZSYH$])#V>`572!HISSNZSK
M(ZD[!V77@:4Y!L81F-K")I7$>/<<V/3^B\`Y^'Z?HW837?:#>N6]<R-CK73B
MZ\U>WG.+<V`KJDD\^WI<ZFB&^8&<JBP&K.KFB?U%XLE['2DGBM%Z'_#$FWA/
M6]#W)HSZ9K^_6YY,@9\QVSF=9,VW/V&"YR4E>!X'F-Y"PS%-K*2NOC.]?/,?
MX_<S&87LRS/C+OBR<TEAOHS]%1>AEQ2'EI@+S+RG/'E9C27'L?;M=JW=;F<3
MLJEY0BS1HL;*F;RE#78%HT3RTA6/`Q[+#8J/2EV]R$=XQR9S-Y.<C5ZPJLI8
MSTG/]J.*6/)XY-1Q\(D5#X#B1-BB0,'8;="LY'D;YU'>C<9\C*#LXFPP#/UV
MSN68]X*+X4^KE4??2HMW[)B78M@S,X>2S3K/DR]ID]D1B:`0-U>W7E@?OI>9
M%RI_V@M4029\M+?2!'=G:H![M5(ZP1TOS9W:J=/$8S"/0C?>R#98=,LN\W["
MU.9N315+&._/T+&`B\X\5,PO%SERJZ;P#%=JU_;XB.N*C^1JB#%3OE3WX6J-
M;+`("1U6`X1NC:%2X[%\C80(6=TUEJ#R#HU5J@;S5.?9W*8UVZ0HV0W8A$$>
M79;YKEG?[>/*[SI[]5YW[H6/Q9TW3L>4XZO;`*DJ--H_R$RX6PY.OEZUO-5[
M8;U\&&*3;4)?\O+%Z1A3?/ZA:I`L347EQFAMS<0"G!93:'?PP^N]K57Z$!;?
M6UZZIXZ^I'`^H8O$UGQ1^4720/MX(E#]1%<'_3U!!JC^OO7<9/2O;YJ-QK?F
M&R/CWZY^]=G^X2'8R#L?3B\O3S\#=D[NOD%#@/9\%29).,X7;'T++POQW?!E
M*SL$2CE;`6470KJHZ#)QRT"B&U8EQ'CJ/SJ/`A)@#,+;2$S^]0W_]XDAZZ\,
MV&/!6./UK`[$A]/SPZ/S#(8K-*X0$H=\DS\ZYNT-J%1G+HR=KHF/S68IC(\'
MZ;D.:6$']E5>]90KSD_8U_K):2X5%M146+I]U70[%YY6@4;WE@#.$NP:"?:(
M-7U4/KZ>8%=$B>=4(U;']U?&C;XOJ']%57#E>UJS<JW$__.^:1TJ[//0^/;N
M_)P:TH3#Q["D^=;F-IZ!XLL2&SRC"^8Q\"[)P+:'5SW`DC9..[*\T_+.%]WY
M";F<WR[G7-X$?;-,T^":S]5`[$78CV5TKYG1;>_.?Y<H]:6[,I-^Q>Q[6_>]
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M)S\ME`MKJ%8&7RVHUW71_?JN,<'@->9D;A0_6(.4VUO??CM6N%ED?BW(O&,Q
MV6+R"ZAI:T3I9J-?Z_??AI9F$7M#6/0ZS8Y.O=&TV&RQ^75@\UZWUNZ_`7R>
MZW6\'7F)W&"?XQ.(_4<VA%+@K`'7ZJTN^B.I]^ZJ*+?EW:W>5*^]8H_,96AH
MVV!:CG&O00G9K>TU]]X\#3UAB]97Y"_MU#NK^4LM9WHKG&EO74`U._7=E=7)
M5\.7+`59"GIV'["E'DL]FP/3"U&/58PM";T-$EJ?<6EU.$M"EH2L$O>VDGNW
M-0URO8&RS4*O!Z.2+[XUB\X;?]Y;@\Z;@,^6U%Z>U-:8F64IS6*SQ6:+S1MP
MO!:;+39;;+9*O47G#3Q>B\YO&9UMXJSIC.V\2.+L.F;"/@C)IB'A_*C,(C"V
M)RH#D#ANF%[Y\A6%9>8!]5)QF7[SB?,#MI2,RI):5^%UKR!;ME]O/VFVK.5(
MZP%JZ<*J)V1$ZTM3JN]9)F0IQU+.2V966+*Q9+.I*O#Z"C2ZH`$WK/"Q5/1Z
MA<_Z[,=>W1J/EG0LZ:P`S==UFM@PXLG;!J_B1O\^H?$R^=\S#9056(1W):\I
M^B4>^&OU9LRMWL/=F/.M/>I0+^E03^!0S^<?ZGZU$J?CL8CNG7`(Z\+NG'"2
M>&'@B$'BW7C)O>/%CHB=8>C[X6W\PP+7S=IZ4O\OC1-O>+_PCM:V@>P:YN..
M(BU$.;V'Q^&Y,Y`^-OD?>,'UO[YI\-\3X;KZ;TUUC8;I%2P$CN8&1=M/KND^
MFC:?,6+[E'MK%*<OO/Q&-R[6N>F8H#XH&ZVP%O18,R]:6X/^U<YIN]KHKQT?
M+`)O(@+/GQQFT=<$H+_)DMB2UB:2EI4-#V9R6>5\$\AN`W?_2M'_E2/2\_'O
M5R@I7ME[5AE'NZ;AHO,V^3QO66[BZEM4!BPWM#SJH2'%SKD<"R_P@FM+/-9,
M?8N$;5G(IK_G,DR$;W6<)<<COT5&;5T>;YJ%/]<YG:3C*QDYX=!2G<7?+<3?
MHSL9#;RX1()8]+7HN_'H>P#OB,0@2<NT08O!UCZUU/45YW0,Q.4%L3>PM+7(
MI)B3'_]0!]_V&II(?47NWB.;#S^S7^&)6T7/A^Q-$/;%2$1RQ:+W#6];_=1X
M9,GB[9#%6>0-GL@2LE1AJ>*54,4G;VB)XJF)HF]U/TO.+T+.OPD_M?1L`T<;
ML3=;R&8QP6*"Q02+"2]TVF\N*F"Q=&.Q=*4)<H_UN#_0/6&]71K6<+"G:1(G
M(L!F#-6*2)Q#.9"4CM)NUIQ6H]E83<W?H/&7ST0(:S/%O[;Z:DXO\B4\"VL`
MIMGHU78;G54O8`.MQ>UUEVPW42S=WFJ#::'>[EE*>!VB8G-')3\34`\WAENC
MC?#PDHI;=.LEC1<MV2W/`U^3SON$[?JW1VP_:N?;8IEN.SFN,!Y)`\Q4A)3Y
M1BS57R(1/+[5T=8I$ANB7J]SN-HZ`]=[G5:MVRCQ6KPZ5]>&.STW"YU7MQ9?
M!(L[]<[*/A*+PJ\3A;>5([^I^(.-DMDHV>9CZ5=%R=Z<X:'K6ZWI807=0SM?
M>;;8%G&.#9<A%I$W_\`M1EN,MAAM;9!-I#9K@[R\#;(X]&'$>O(`T)LS2PY$
M@).45AW^8-,N-H_];%':Q?MVN];:VUV546UJX/:[90':WD2`+2"9KQM=N6&4
MTFS6NRO'(S>53MYRPNNC[V1C[F!C4V%M)I!M`;`U.]\68W#;2<+6<GUE+==_
MTD`Z[0;5<96,SK96X@:IO*_32NPW=VM[S9+4^[?!P5Z#:-P"VGE5YF*GOF?I
MQ<H=*W?67Q36K[=G@;9D9XO"K)*\F<SJ50GZ-^L3?DSDUW;+LWE#-F_(8K3%
MZ*TX<(O1%J,M1MO<3DMMEMI>`;79".0C#_8W&2?2K5;"R)%W$SF`/YPD=&[@
M8T<DS^)=V6#,MXE#&P;*:_"F6$*QA+*9EV()9?/N9&/NP!+**R.4S3(Z+(EO
M%B26Q#>*Q)^F^/+-F+7&L2[Y+TR]K59L[NU6I!6\SARHO7ZKUFF7X-[;8'&O
M01?8`MIY52DY-O?6RATK=VSN[<:3G<V]M<S*"GJ;>[OFB+;-OK6Y)C;7Q&*T
MQ>BM.'"+T1:C+4;;[%M+;9;:7@&UV2#E*F,JQ)4O;?>?+7.NO$Y/<+.[6]MK
MV(B*I2/KI%P!F%[==LZRM&-ET#-$(WOU[BS0ENQL--(JS)O)K%Z5H+?12/X#
M35?C[R+!%?YZ!%]9`<9+@O$$8#Q?#<:-V^O4DOR;RS\^P8^\!+!E8.RD(!B/
M=!7O;Z$O$L_WDOMZ`5[G<B2=@W`\$<&]D\:P%Q$(_S[V8B<<.B,O3L+(&PB_
M6KG)5L"2X`$\DB;22>#QK%38^`D\["4Q;!B.I5H))XD7!G']Z8[Z<>+F?VF<
M>,/[LHM_G@VL*.^>"SLN930NP8N\!AR^=P`EKD0,?X6!$\L;&0G?&8H!($A<
MK7C!P$^Q<[6!,TYX%<OH1M#=(T;(\<0/[R4NS"-9G8E(8.T`%G#3")].<G14
M%]5J-/L_QFK9>T!/5^UK=MUJ)5OX2H[$C1=&`#"M.4R3-)+.M7>#;QG`@YX+
M$.`2B,[PDVH%/DTB`"B%K2/$M#8^3%B\P\"+6Q&Y%I,W#)//O?BOG8\1H-9Q
M`%>'_0K.12(+MU0GG/;T]W#Y$CF>BR@"(C?EMNMTO05<1PRX]Z0/=Y_0'RA#
M$36N(P%[A7\(YTO]HEZM7$92Q"D@:2P'@,[`!F^]9`0HZ\B_4P_>(>'WD1P+
M+R!<GZ$ZBT@OC4B'P"!<"3SF#[SQ$OS1LG(D4(T"+@@\S'.=@8A'CJL>CFN`
M2+"&&Z*N%28.8$,$=^_?$_H%U%1C(NZGGR+FEHS2&%>')>(X'2/+<1K?9K]B
M5+1HLUEH<Q;)'6R>@F3],8R&TD-Q$T_ASQ'\8`QLAP3+!!ZY48^P?E2M#/-'
M'0'B*N-!&NM0\D6>#`:RB(VWG@\JFG#Q>DCQDNI5^"9SU1`Q%IE8A"PI]N`7
M**.]`<@_7#ITBXQ/WB7(M`!?;T?>`'@9BT=S2=<;#F54<\((=A#)0N<8_=T0
MK`TG3F$!O;&X[AR,1'`-"P#_U9^ZQ3-`L$"4PV8'X77@_8.+CJ(PO8:-`%&-
M4]0W;R3043(8[:03?01CW+.2_`HJ.(<!O8^(C!86?APZ'AS@@/FZ&(=ID("V
M.B3U5@8QZP<(4``Z!<!3W`N\@?4*?796+U@+75Z&"5H@:6"<?>&&!B$*=.D+
MA79I<$.=C%AS4^0%)!73Y18BJ\XM,'(QF43A'6$@\.AW[7K3&0.&P$/ULNK0
MRY%(4%U$6HL+^%[$#R*VMD,.*8L9S\&Q9Y8D4`Z/#D[/]R^/3T]^`-0`O=_@
MW`<:C]"XN!@A`SL&N8O#64N<B/;^GIBRT>Y"Y9L$%>KE8#GFA$L:-FGC8$X.
M4J9OED_IA"44T*$?QBA$^9$)+""UX59J2<*'8WCV@ED#"PD75B;>@'_06^<0
MOG2RW68_U4P@B!7-5ROXG1;NN0`RG@A`D@["R$4\8ROAX_[%!V?_XJ!:Z37W
M2M^^3WI#@7O5<$U`V1DF5JV\VVOW:XU&@UZ,#-19FG]6*T$8["@6.GTI<SFB
M4\X0JQ7+$9^1H@[)CU*M9-CA?`C!I$4L./3@)M!=PTX,N([#J.Y\`#-#C)U#
M,1;_JS%%E9*-LF%0:_,B>'W-`:47O2CP&:I4!R-/#IVC.S!]42>K5DZ'0R#%
M",U?%L#.>]Q.ONK!CZ?T>?[)(0_P?:0.K@[B]R,^Z:O0=Q]R\2)^3]((M$'0
MZ=()8FF[T2!2B9'_$Y4-F$DH_6%8.)>YK"%W:YE,B($DPOB;7$OP?E`Q]OK(
M&?B5?%%#.%AG+**_9%+D,F7W@?J'N<6<C^6NB??_$4$J0*ZUFS7&B._F[OU4
MZ4A70*SC#!1TZ3/1BIR/(7M#5PM1<8VY5QC(G63D16X1ZCCC@MX83%F/%2SD
MW<PCB_ME\U>:+I+;D)?-%X(SC!(0X<#B,F,&?X:[T7N\DM=>0`NH<QEZ$;:P
MA,_@D1B/1-]I80?US.V)^KZA4,(>8GV1O%=EFC!W(V("GLY$!_^_1;#`/]I%
M<TH!H>V%TMLH,'R!_#?U$][OU":*Y&IJGE,*;:?%H@"D1)EE4_"^QMZ=`WB5
MC`!?`X2K('`LTUZ;&C0,?3^\I6L@LO,"UQN0M^"69#PA.@ERTQ]MWB?ZOS7J
M(M+@6FQY%\V@0+NQ$4^0B)6M7*U\"43J>HCT!_!+#+$2!5PD\!\TJHDWGDZ4
MYSS^P6)#_I[R;_@N36&V="C6&4@?Q]0.X![_]4V#_YX(U]5_9Q-M&V;.>B'M
M>J:JX.6S%-:^H7GZP*/J!J:#\-G$X-WGR(\92`Q3/.O9?#P]=R[_?03_=WYT
MY'R&7_W[8K4LFL7Y)25I#$]=;[$.)+"HNEFH>G'\?_-CLA@[77%3!NDR"4<O
M+R)>=+-/0I-+I:_-HMFK)]TCV/NA\Y\O)T=H4CP-M2Z91K?VW+FG1!R+^A;U
MWQ3J6]FUL1GC#]!J:ZMI]1$5)N5%N*^&?BV26R0G)"^I9;!(;I'\=2&YY>06
MR5\]DEM.OH1EL7$8OND;FJ:EC>`'&^&^M3=M;]K>M+UI>].O_J:?I`MWM_6Z
MVFZ<RUB*:#!2I6_R1OKA!'.&'JEZ;D'CG`WI@KET$XW-:'[9;#9JO;V2L2&O
MKO.EQ>)7C,6-6FNO8Y'XI?=FD?AKD+B]6^NT5NY;9+'88O$F8/%;8<5K[J3]
MVBR17V2`S8G8$!'NV`N\.(FH4\`C;9$5#M.V!=Q8H%YL+&FS6^MV>ZLRJFWO
M$FCIR-+1T\C[6J/3J#7Z;[;?IJ4D2TE/14F-?JW=7-D99RG)4M)&`?5RE-3<
MZ]1V.V^6DIXL%O;R:+<%)+$ACB([?VT+*--BM,5HB]&;?<`6HRU&6XRV&/UZ
M,/H)8E6=-Q2KNLA;>5%'OYG>;+.GO4K$ZJ$C72?1/I'1#]MWW#"]\N5&N#*^
M;GK5/&!>RH71;>W6VITG=*HO0+8-8UB6:"S1K.1![S9J[=[*Z2>6;%Y^YY9L
M7L!=WNG6>NTG=)=;LK%D\P;(IM^I]5M/F$.T763S')-&MZP#<6$#C[J9Y5M2
MSVLTG;5(IREH8>)<21DXB;C;D<,ASWYP4TF=[KF?.[9(IW;L."QOF/H^-;CG
MM02VO:8Y&.):>$&<T#0]P)RD6G'E4$81]F`7=XZ(8YDL'!NA__KI^S3>N19B
M\L.A%^.,D#22I\,#`XIS[N]^$,9)3)-?/B"@9^*>.EU?RKOD`U[+S]6*X_RD
M%SL.!CCE3QY*_N]Q<*2F3ZKE/GGB"F>@>A*;K0<)+',NA__Z1H;^GV='G?YN
M9P?^I]EL-G9^;30:G3\O+@__;.XU_\3&)(W==N//QC=.&GC\E!>'G5:S]^>7
MB\-O'%<.O+'P8VS^_/-.I]MHMG,H'[.Q12`=JF,_ES<R@(M<*QS=9J/Q$!A3
MFYG>>R*":P_XP3YA1W[7V?VMO/N?%?UNKHMI*4KN+9@R\-3_.CZYW#_YY?C#
MIZ-J9?_BXNAR45/>528L7T7.]U^]VE>W?-\Z7%C#D@N54BU.X$]-JXJ53\TW
MJ59$X@#=R_$53@GB21H--16$I_X51[?1&%\:4H1#2?X+JLK.O\-;>N`R$JYT
M3L1X:HR'=#YXX<ZO*8[P.#@_=6)YC=R^[IP&U<KL:"7CUU=I#,#$,<U:BD.?
M%H2O+\,[/;@$QR!K$'':7!P./'HUC4C!Y?)%<*)#),?A#7Q-,QKT".)\Z@).
MB$J#F6.J.SSC)S^=81CE4TZJE9'PA_A,#H6>$"+&8930@)#LL+(9*GIJ4[62
MQA)$M.-[0YJ,`B^A22_9>!;C;&>>=OCA:D4_W6J437MR]GDG16V"!S#R5;WK
M]FO=1I^+.-XU>WU0?SL9I`\/*='#5QHU',\2X\Z\&^F7#^XQ#K-X6$D8_@4K
MP:7"WUY$,R4'H"9<$USOFK7&7KNVV]FEX9@13M)TP]L@G^2C1_@8F(EP-6N[
M[1Y.8REGRTO0T@7.T30VA0CIRLA#5,+!.?Y]AE$TH!N5,*"L')5CX#/>T!L(
M&DG+8S%=-:\=QR)?>P,XZ4&*<T&XEU3I7L\%#A^#UXB`AHA*->!,PA(141</
M,X);R-^-FYU$(/XC#]X]D1%<Z1@NH(@>-*4Y$+ZSS'DP'=,0TSC#D-(95G`_
MU<H$[G`L!C)-:$CY)`K==)"8'0LT5RCNZ?V)O/N,]/'E8O^[^C(;FS/3!^>@
M,JJ%P75(XX`BUFUJN)LA7@1B,$T''H)RS%`99XC,HW")N`)`8?`2V`>H>@S?
M_Y``</++U#(C4-H]NA(@L\'?J8>:]M5]@0J\(&/)B`J-?HG^/?^/!RRS63U]
M"5VNJ/PIQ?9,1,D],"50ZQE.JP265/P^LQ9X?O1I__+HL%HYVS^__,.Y/-\_
MN=@_P!F<5AW<&*Q8BSJX7Y@]MMO^5NLO.><)0AQK-1'W-!S)E?$@\JYXA-I)
MB),X]YC'C:1/#$GJJ8(SNM!C^,^VNF(><I)M/V=:"PY^%#$(!&#[9P5A']><
MXV!0=]Z;0RCU;PMC*%$`5RL7(<V\#)=91O^VN`RA,:HXJ#@`)N<T0.,"&WLD
MZ?G??5-%FZ3!3C@<HE8VH[(HZTD9-,EM2,XY$:#+"3Z4`<^/H['MK,?A;#A4
M*P9A9!@A:@K]`,Z9UD5%*M$3"K5&M4!N9"<=IU>Q_#N5I%-J;2(_PJ(BIB!`
MV'W#7P;G\)E[2/&LP8?>Y^%P1-`D;XC/[""KJ!65N$1<2TZJ044&@+T=H6X$
MQY7Q$_B4AI3R5D*P(5PU)'5ZZ*>#DZ%!40U!T[_GJ9TC,`)EZ1Q;RX,L#UK*
M+7(:./N`P[[3499KP5I'%I3A.W45EFX937C(HL`(([79.5.S;4$2@RTF9PR9
MVE)&U22-8N)$Z,2_'7F#4=$:6F:-G#<`I10?UZ&!#%9_.5N/P@D8A2L.9P=F
MAWX/=ZDUO*#X+-!_`F;S4L]>`3@[Z808;I@&+ME4H.2"`7<:#,(B<2B6UVRU
M?GRLO6BNDRUNK)?9N0F:V\3OT--`SB,G2<=A!$(*;1Z,J`"C9$L<G4I!XNVD
M/@YFUC#4'!]LIW`2B7]"7RIOP2!,4?>22YU*B@$BX2/_A&VATP#6OO("=N_P
M@&#R%0Q&<DS_$A,29@ZPZ"`Q90Q-X,T<@E?2]X"E3UUVZ8$LL\\!NG,`)IR$
M.B8_V#"-V(D1PN\XXD".$(ER00S(_IV&I5H)TPCH_VY_D.B-'P%*R\$H"/WP
MNN!G6M58MH+BS0B*8_2`LA<N(^M2%$?FXQC,QYF$43($D@^G)D'[H0@`N3/^
M^Z[5Y0'GGO)/@D+*L=@8%*&(<X^#&^"#Y)U'\XP4H@B4P2@=)"F%8,G-Z_$4
M[C!-0+\***CKRC&)*K;J6)]%614GN8E'T>`IQQ(*+=Q`"$_,WX?:,ON&R?/:
M:G5JW5:#AW6KET;\#M1S38':INU<X6CP;$_`W$B*J,'?Z(R4SL0'+;GY;;7R
M7LVY!R6V4V]UOYT_,5V].4W@;DDO1U\J[Y[$V_0(^5QS':*?SPLC?23P?(IJ
M)4\CKSVH]N+=^Y+>C,_)"'U\$6$#O&,(?"K`><$U8%+`;OTPYE_*Z!JX''Q$
MFGGL$3-+<I]9T9;Y3'_@_^U7*^B:3`I630T7,C<R2:]\8.:@3$MRI@N<M9[_
M"<`.`#O!.H"]*IBSG>):QON4VYPN"?\?7H[KQ0,5&;B"0VHVOK4ZMV6E<U@I
MSL?FO!)B*Q,1D8%8C.U<`^8G)H=$=)WP#'6RH#&"H3@48#9%IXK\JVC/HC)P
M<)DK`V"R2[#Y57@K&&%Z2Y0Q=U.A0#,3+-(DW+F2.R[0$T9#D!%BV`K]^XX;
MI==@N8^`E`-TAAE[!J4+57P*F!7]]G7G&#1BL)&!,8"-FH2AJPAJ)`F6XNMT
M%"1V;K7>AQS><X%LBQZW(MSD3V`7`^X&`WG`NV.6'EZ"1GH>5S3>SS#QNSA_
MR!F@-'%IWKW^879=]$.,*?Z%+D4R39#7DZ86W@9UYPM"R?HP0)1Y"=7534E'
M?BV8^1(]`.^ZC4PV8L2EQK)@[/D@+$"CI<5`GV;%.(#?XZ_IB4E!B4:0=3`I
M%A@!CL)[X9-C`X2T']Z27X7%J(P&>$S%?2H4-"_9,CK+Z,H8G6$E<1J$B\X!
M#.F1.9-;WB--S\74`J#7:N4W`=H#*EK'6C<Z`NLPN7?>_W9\]!VS#F?_XHMS
M$M;)0;G3[,UZ#WB#EW]\@AUZ"1SHP+@+,TR;;8!BD>\OPPEPM[UFX[L?@'&/
M@71NR%E!/LR/K!Z`OG`N4<M%10'(X@@W"NH$:C7'P4WHWZCLBKG`>%/&8]TT
M,!V#`R+3,=PMY%Z$8X"C&XB4K$('<X,Q?(NVH8<F-V@T>%S`K6!+?Y'6-TP#
M#J6'P!T(5'388@("NSAQL\!:,S$%W\;I%:5'"N*2PPSR.)T@Z,4=8\:E`"5)
M`9MIM4I-AAUC++B0\3*M4L>D*E.@./<NW6`"YXB2;&Z!U;DA\>5<&1X)X)5"
MN4<UX,;;\Z,K59B/E18_4.Y8O,\"1F9@8]8I?*(P`9DC&#,L7DXR79^41)?T
M3.<?&8'TPV0-K3I.9?+0L[-Y14/2ADFQ)"4UC2:D+9-#A]+`D?&3WX0]U/>:
M79L^.?BX[NSCG<!!I'Z2^8WYI*\D02JBR--Y0$'(&V6-))`)Y7(,$G5=4TE`
M!CKDQZ(N>R!8A`CC*$F%T8H&H*`7N@_GR.02WPN,G`).O$E&(`HS<`O9OM/\
MI(#S=$MT!KF14M2?'B78WDI.MXTIS]?K_Y,"%^*4MFF?N-;4E94KM-N;Z0T$
M'=NG_OU.@JEKKL;!&G"4"'[Q[S#R_@D#%=7+=<ELH9HA&&X]WT>A$(Z1'V+4
MRW,]$1%S*"Q'?!NXF1$JJA'_Y3]88;P%S@#4QA\5O`3X'F3EK*4JBC<M=N(>
M*?$T>(Y>$Y,Z"K((F4Z_]2WYA,G:3GV`WO7\%*E5_;9TPX57>#'L/[W"_"$D
M7U#ST=D!L*)C0;%P%F-QG0(9:`B,Q5]8^!'BYB?P'C@_E>B?A2Q)D?=&:)3`
M)I0G05M#>&CF)K)8G.+O9!V,Q3VRK)(<2TK")*E$$.I=91HX>UP(4[Z"!\UF
M+STB&:F8Q:3:5>\'[GZA5_61RHI<9_+];K??;O4[.10+-E/<^8E,#L!B.@/-
M#?1/]\/]EUBZQ\%'[=K9S]6>=0+1:7;:N[U^#L3R^RK"@Y4@I\,+G4JXSCWC
MSUMMHWRC^.[BOHY$%,"VXS,9Z3H5;P!7=*CH^4DW^B?(\#^90YA[;GWS\TZC
MWMW+=[Q@5PR"`/+[@9I<',=@M+N<;7M&>LEO2,Z'*MY.O]D'=OC$X$R=>[.Q
MUVD#$"OL:TF`Z+O?F:W'1\K07S-0[>9>9[>Y!%3EFS,@FRJV*:1IKQ<$(.&&
M@N"!31A;!?(>2.G&'\&0T45;'^'"A"^!D#*Y3""O=>]=>+C95WM_S*X,8'Z7
M&-26[CY8:N):GI!<)XI2Y$0D%I\:89>O!VF6RO$F^IU>M]O7-/+XC1E0D<%V
MQC$@FY0[H]?VORHG]^3T\N@"\VO_V/_PZ6@C7(,O:C.]A"U#H!P>'9R>[V-J
M\P_L,S,&<7_$U#\SZ?[",`=,7SH[-S;/V_L*2YNQU"MS!S4I4-SH%^-#'HE/
MYUVS56NV^C5TDX`%-@&>#M^$T;UV[[S'A\S(*=]B(064,DB"@&LP\E(P(Q!+
M,98<1;"<!YAE&L=Y2K33<L15>"/91F-'V!4&7[2Q0\5S(HMJ-QO?4GA"!&`B
MUI0A[&,UB`<J\`1]DF:<7@P&4<HQ&OB`';]DXU)\/^5XC@[F8YH/UG3EM2;:
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MN8,XC`=$FR-ZQ?7-PYHF,(Z):N)Z0CS=,LFT3M2^-&/4V#+C.J`410&<.)`8
M<H+KX%A.3.88UZ(J7W^UXGJ8;X,A"8$.RN26>G)@E6'D77M!\6$M)S(L5H[*
MK,B7`Q\YJYJ;`E!`-L&,E]-VU%,DMS0I/(CA7"*=`:N3P4QH@S#8(7Z=B2Y=
M/&R<&$D[5?B;$1N3MSJMLDT`Y4N&?VYU,1?#4@TKUO&V>K5FHTD%RKNU9KM?
MZW6:-:=8<6PI91/5<KK&LTR=L\KW\TOO$IDMR%-V'84Q*7WD1U%,JHT).3[%
M)`(,3>;)A?!]&JCT44-#=^8HZ/A:I5@6U/2Y&BFABHH\LY9<2"5EE9N$:$'G
MYNB.5'FIIOH,PI<Z(!E<!A5I9IRNXLM:]6!]OZBUSVP#WT`8SFOP9JG0GE^I
M-5M'^LH**3)T4FJEAQHS\%S6AN>H$S584[<V>->H-U!7R(3'W#.\54XD1[`7
MR91$!0ECW`YSV6Z]VRTH6=I\FEXAAGL(KA$A^##AR4Z#&B[LUE6JUE/KV-M*
MV%O,0-827#Y558<.9C?E;,D@?-6MA4P*3;Y&O-$P$VC69Z-C4$\A#1SPD11O
MK7#7V]6*9FPS.K=IH<\EK:Q49GF-4<6.37T1JV(6*XS,C.<0EDX865UU5*%?
MI3IF!LHBT"DMA5O,3<%>ID!2H<^4ZHA0<2>==[N[C=I>LP\L-5*Q8N2I"Q5#
MA3:FZE>C)#N5%90Y1?(-/4GP>1DO^W3<BHW`<RJB._/%ZG&=5^*%;^X]<VN,
MB\O3@__^^_33X=%YM4+`7C@`Q,G+)[^^-GT3/;W*0]317;V,PM;YG,E,VE'U
MIM7*!(EE1J%$$BHZ?$V=UI4#7T3$E^`$/5=BH92+:17>5:I5,72H3B+=ZI+M
M\(FJXG6(4,ENE6(P*OJP^*?3+'82QC_&SY>F7?2,P:D6#H\X.?)FK8-231)^
MG+<A4$70Z,QRI@K_G6-N8Z0*.&)=_<MI6*IT0*73DW9-E6CT)>5ZY0IC+I%G
M#TL):=7PU+IA%Z+"E]S:0/QGA4G=S#6G$/GWA50Y\XX\3%D%Q2&FT$>$%E\Z
MT3TC8E-Y"6]AK7CD32BFT?T6#1.LQ9CNSE"\1Z5L@:8F"NELB"YB0HGFNL_5
MS`H?0A&Y=8?RE06V2DNX36V-R,_)$_4$P^N\#]ENHN*0++##=6\$XG?Z'#A=
MV.?$;$W?>=0!_E^PHQ*N\PH1TJ)JA73Q4M42R]]OJ/8N:SSG)+>H@14*3@I*
M&0&`L(+NIM:OX>44_<Q9,P\^T+R4D$NZ-1D7:[[%,"%+&.S2[,0GF!J77S/=
M(YT:7>SB"YVY@@P&E<.,)PCG7*V4';3F/P\><W:VC-OY50Z*VU+[6>;(06[,
MGOD,A]'\86;*U?;S"O)K$UE1UB8@DI1CDV%0(CX0YYAL#FW\H/USSX[D*SD,
MV<"@.@55&DIE&;&Y$%;!S7`;]J!H&4ZD"'J_%\E,[C@D=EK-Y3M+SU>F#66;
MY2+]RN:^S&K=K6?6N@]./W\^/0$U!;7OU]R/;DUZ-)-*JVFZ2+20F,K#OZ#J
MQ_U"&CZP`&"D(`Z=,P'*+Q#`!?IL.3OX((PF(5>.S"K8M!KJ\8$`P3.E:H<<
M"%7%OJCU&?%;WH=Z$.UQ8"'8;Z2&312H%VLCJ^6<]M1P;@-R'[03J$7`=/BV
MU'+@!OB8LA^/I(_*[[5*HJ:E50D/-2K`W"#G8J?MO/_H^9**[-KM]DYSM]O?
M;9@.:=WP-RGI?%O:M3CWC+C<JA@XI[B&^[A6[N7=7J?6V=U5\HZ\$P7HTZP&
M8OHNR>4][<\%Q9E^EDDZ4>@!^*Y3;^V:7EQVBB!(7N[)1T&9^_RG5FC5>SH"
M4*.:*0Q:,V+@Q@$)J`C!FM!/3?J,>APQ6Q*YNLV]6FMWU@>JS*O'(I=CX!9A
MZA1J[-9[[87(9<:3@`L45VCGX:4B<CF/P*TI[>!AZ5^2<6U.ID!-PG:Q+5$:
MRGL"KN]?AT<?C\[/L8TMJ`]G1Z`RH,9@0TAKTC$^RJN(@\,4B6FT'E(SP!B@
M`2?,.30/014_&3E_U)W_A+&<C)S/8<TY&]4/ZS4V&Y!M<<%L0EY`R:V0ABBR
MJ5-]C2,9II^04[L.HSJLIFQ-;G@NXC)OTL'(D\!ECK(NDZ?<99*TE#/@3^@'
M+(]KY,6'.7"HM>A"Q&P3(BZX$[)!.84Q/6BP4[@\2'/+*FO#@VY'4">P.1O;
MIG%*1S$"FQ]G_B`/5'EVU<I5&*1Y=_7V+IA?/B@@(M+:R`1+%5VMIG`<.U`G
MQ_E)I5O4>4'$:F6`+<S-BD-NS8>M/\8>EQ'&&*T>^"F]2D%VPTU+,^5/YQB0
MLMKHL>J'O1&'5.^HBBG+T&=NL$GO?FI*KY>W,:9SP-[[<$;-O88^%P47I2I@
M=QGJ-Y#U?LGW4#Z<@&Y[2L/,MTV=V_6*7(8-:^;9MEV"OUN><Y5P$)):3A4;
MI.@$@_(;X^$'S=Y>K=GO.3P<*IUP4+%:P9L8TV94[:?A&\'0XA5P$EIG[DFK
M<UR`,-E=?Q;W"M!6DPI6W_5KS6YY3&>?SN=!A9D:8Q@-I_197`$M!*7*[5X;
M)U4T%%82>YJS=^6*D#BD@;!7)R]G"1W.889FICX`_#<.U2`3\K!+5(UH9)9:
M0C58HT[#$=R"&OVT1+_LAY28Q^@F9I@Q;R.0Z796G2E19\HI<WW_^G1\`#K,
M\<DO8,Z?'#KG1Q='^^<'_W;PC\.CWXX^G9Y]AF-S]G\Y/SK"?SVA;\2J.DUZ
M)7WP^Q&_\0KL)Y6%\AO(MRC426G84'3'>4^=.G+VW_Z1G"_?;<2M/%N`T>9(
M;42.5*96M%J+?8#4TM1/8]1^57<S0XWEJ.R'"-OO.!>3_6+WR6D'H/K=)[U,
MWM;:]`66\3M4Q;`OS8(C(1AGZ4\U<YO!Q<6'NQQ>4TP?J\P][+KLWL?#-!BP
MGC"GGUWQ)'+'"4Y8XJ]0@:'V/+K#87X-*D@"2L9Q(OQ[4J]1-XTPTNK]HQ*X
M5/*6/HVO`?>H"*[A]^'-4IL/;!X;_57+Z@Z,`@A)$ZV^9@NMQOY!<1,]U0@7
M]3Q0T]+)SC#"Q;5623EW1=-*MV!AG_'3;J=3[W4+F<V1O$Y!RPM5>1-[H;)>
MA`]747SD7M8UFLK&`4P]A2TI=+,I]E;$B)B&,>]82'I]M0+;XLO*(I^T([6D
MHI"YJGP^%4Z=<[6B#YK\ZPII;SF!C^_;TU$YULZGV__B^*U#FK[&COO,88<L
M!:-Q9`>*.QG7P>R&9S&`30_79OQ^N[M]0@;U_BQ],LX:,JJY7&H7:$-2MV*P
MH*.$8]`DH='.'F"2"^GDW.\\C;*GU=I<ZCG`47&1)S*,G[8'U#PW93]0&CGG
M#Q1S/%4TFR(4T_TRU6$B5!J=JA6F;'H/1>3!;L[ZA*FVE0#'41J%$UD&$1V`
MNC%]/H;=O''%$R^HG[P.<$^-:HUVF;4\%?:;00J*Y649#23+CWR@QQGY50SJ
M$;;1#Z?&[E0KGQ)W:NP._J[P>(U%'^(YK<&Y&%-"4/?GSH1?&0>;U0A,B>T8
M`IM8-[[H"U`Y',A^)*Z<H[%'2=,UYW2,*5(?Q"@"0J\YOPI8M^9<B-3UZ*>>
M`-[TW_16>,";/\DK$6`@XN(>N$3-^0\18<TYCL3?Q`W^P".;#9,BL-7*)7`-
M#^F]6-QB*!3E-S!=7%K,H<E%($M+?=-#J1J^STHH8M4JS-JJ-S,AETT,U8[7
MZ3T9^MU<N3),L26]V:,7\R`33^\V9WH9J]/<5@Q&.%%"3<S(9G_X.#B(`X]9
M*(LFD&?R;HY&].'T_/#H?.?#Z>7EZ6<@GDGBN&%ZY<N9)J@+R]+FZ$WEGJPL
M'\R_KQ5'J<Q17V0,)"383>H1V?(^=USO&J>GY*(?;JE(57U3[K_8.6!CMQQ;
M,D2WV9J/"JW4L`=#&4;-C!\JY^ZF%3?;_4*&-*IL*0Y/LB%[XA?*`7U?MMH\
M]IX]RX[G61[OK,;B8:TR'D^:&&88DHT`C.)&>#Z7U\W+!J&4!M*L4'),4-,C
MQB7_)P;(HEATE&WL.(Z$S+A6M7*&Y`=0>V!9:]3W2AN0J$.9*PH>CCK-O\'E
MN,P\"4%E3K,B0B?B=.KM[H,BPL"4F9T]3DQ@A=&TG'`>)R8X"\&4$[/L,<.H
MEV#?LY13RL)SK-?V37;(ZV"OU@,\M]<#F[[O6HVV'D4P[9F(9PI76.&COMCZ
MUICJR,3+XBZ$TH42.;+X]*H8032(-;-9W?DI9\5V"`O39E\?AFR_:7><)W3.
M6'5#SZ=ZI8*_`%`D2RE0+@*2E,O;2.5MX8<\)40KZOG\<>QP'Z:Q>ID("MPZ
M348AIX[6:(`YCP>Y]M0(>@U)7A]`,5/??YQ;<R7?0)G2.L9\M`D<AQKB0K'E
M2`T\)5+60(+]F+M_1;62?1'?QXD<8]*%KRC8%/KHFH<52<W!#)-P((%^I2GX
MJY7WAP=GH#X)7<M`%\U]V\T+QOLK<16AQ*M6<&X+;AK1D_)'L@TR3/=&&R17
M8CMY'D2`[.Y<4KGQ`#N#41SA`K-AG??GGR^^FYUQH([JDJ42^C5]@>,65:=Y
M>(B?@7]PW8?$/`,U/D86("+U8X+UQ!$I(S1]-HY)MD<T78(]:!YVH;D:>XF:
MG:!'%N)&C*N@.S+N4#G1O"@;Q&&\5I]?O:B9H(2GDO(;#]"*<A.Y$$[G/$:2
MJV2F?9:M3L-QQ3WWX3?R8/+R(/((YGVQ53X45B;#[GA`L$%*:@=_IZA=4AOO
MTR#S&(_%_Y#&A7L#8@=VE?E]`9.XT14E;&I\XNH.U:\<,YS0:5/P.S+=_J-&
M!.CHC.%]G*(4X]05SN3'KER>L1BS%W3CQ=#7F:7;J>P\)MQ="'._IWG84Y'O
M1F\S(M\/ZQIEIVC.R`G":"S\$K=(X603.MD`3C9:$)<]P;DYE.ZEL]U,&8@\
MF,((,P%92NN>"LG^+J(`5CH8>?X@3)*\00Q.1J@5S7/^+:BQZL=%$Q^)^V'E
MH!CR?-@L-6)74UL$$'1Y8JFG5TE8Y9@ED4,\<&9OK$IS<B>PSQ2Y*&@,>D"L
M,5F\!IPN2(<"YV+BJ$7F]*:O@06`XKE>-MY<8"<1WR>=>Q#&<\)XBU%\220$
MW,@2:MME74Z-S$$.%I:@!44A0RZN=+[40>H:57LSAYCO"HYX&D$6W'$ATCUW
ME/5TFT=E.HE9BTFWM]-^!;Y@-*^!I&D8DF%>B\"4H7-7H#S'*0PL&MFTX"3A
M"F%DC(>H,NWGZ@@H8B>'^]\5@W`S!YFU5OUXN%]?)$NF"Q.73+\S,O8^`0,Z
M'1X`%7G)1S%0"&L3]72B7GG#VJ]+Q3O![MVG'YV#\Z/#X\LM$&S;=V]Y_X\]
MG;*4MUF>\F]_"@6[=E5=XGWN8%0Z]`6&_:73=#Z(X"]5M0SZ<^A3$3CND5R%
M1$1%4<F$5:T@F17%9,ET8\Y0F=_UB-?'I6!?(%)T[SLPG`4^3O,IN:FQ"]9-
M["5YH^8LZ8.,-$H?'_@@[8!=<.(#37SV*&>#&\$MF-M6K>C$Z'@D)55PS4Q:
M6P84:F:=C^Z9'M),HYB-YGJ88O^MZBR*OSNC(<[GU(E/#2(EE2#4K;UZQM0S
M3O<H-/-2XX:Y^]3&6Q(V_?$%TA]5JX#6XQF)H;VPEGT91I&\=\ZP;\8RS`14
M!I.;7)Z9E/,P/ZE6%C*4XG)."4OI[=7V6AW5&G(!3_%BLQ!BFI]00MF##,5Y
MD)]P'>JRH!0:Y$^Q%%BIOCO=K]-@&X7KGL<WJ.E^-J?\Z3JZ+5#'9J9P@746
MCN4G[)NZHJ;V9Z?;ZC>Z=YU.H]]:;NP-+-AJ=!O]O<+@K7PKQ5W.F4K$TV/T
M_*ABI<G7P]+I[C4?G'=S?/(19W'UFVT#BA6VNA2L-($)6`U]\P0W-07=`U/>
M>KL+H2MN[A%WMSZ`YES7;J_3V5T,T-3NEK^A9T+&AV;#]9>[KH=P\1D'KZT"
MXN[VC&!;`;SN7NLIAK$]S(B>!\@Y1`@_:K<7`/G0/I>%\AFP=)Y4Z#;[[64`
MG(>FSRL-NNW=_MYRM-?K-'JMWCHDPCKYY_(`-AOM7F-O29&W:3ST,6#N=9K+
M\)E-XZ./`+'=[.WU^E_)2[/9MCA8X"P*AV`?+`U#GT!H/&8<;6>O;RI<QFNG
MQ\UBS'Z0Q&K.Y3HWU>RT]]J]GCEOMOCR)[$I'K^OG0Y8E[N=WE(VQ$D8J`GS
MP37_YM$SDE?887.WT=_MFCN<MXWB;E6>XG/<;KO5[3;R#4Z]N;BM<QE+=(GA
MI-X\IO4,!]GI];JFWO[@1HI[/E8V?.&TS6L`I%G;UDD;F,6"9?8T)30Q_U+=
MR3HW3.3>`SO>E/'%=Q<W=EK$YK73?&MW=Z_?-Q"V9`-S=JC.>:W[:S>;O;Z)
MJ3-O7],`]\=OM;7;:70:C17GMZ\Z[WP%?&RTFOUN\YG'G2^QSP>GG9MB:?EI
MY^L<Y3P/HM))SOTF($>W^96#G)]`>WK4,.V]O0+C6IOV])A-]5N[K6[[692G
MQVQKI]?KH[_V>96GQ^RPW>WU.L^M.3UF@R")0!2]A.KTF%TV^[WF7KNUDN[T
MB_`"Q(;30,V@)RLJR$?1GT9'?Z=><O]9)J/0/0ZPF9I<*S@[K5ZWWV^98FNU
M3:Y?2UP:+-82>]U>8^\%=<1'(547)'*W]7PZXN-8VUZKOU>JA,UC<.=``<+G
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M6?\LKUL^$QZH80=BXH'`XW5_^K[T=3_#3:C]K(;KS1?&]0?CB-M\FT:/^K=Y
M@Y3KM,TW>"ZQ+8%TM3Q_2]>X65)G<XZGD6$YH/GN76>WW^_U-AS++P8RP()O
MQNZ9J;9K1.O&<O?V#-K"]+UU._UV:ZONS7"/@E:>8(W56[W%S6).&W`\#3J<
M9JO=M`KQ8U'=XUDE?$7-UDX;H52?K?N*K):[F==B5==-NYL79_G/"'.COW$P
M-_KKOF?KSOE:4LRLG^>Z(BN]-O-:K/3:M+O9($Z^?I@WQ4@K2.RUW_->H[]9
M,,,][^U@1&]YF#%&2`"K&*%^9"P%]C;YF3_^Z7O]-R^!3TT];T9WIQ=1W_T`
MWSUN)3/^JA=UO1LXHQQ^?.XD'6,,/LPYU3)OY[,I?YZ6/91!2`U]RA<N.YM\
MS=F'?_K>V'L&.O,X^,?_!U!+`P04````"`!Y,@\_=8ASB#,-``#7K```%0`<
M`&%P<FDM,C`Q,3`V,S!?8V%L+GAM;%54"0`#QO)(3L;R2$YU>`L``00E#@``
M!#D!``#M7=U3XS@2?]^J_1]\V9>[J@U)8#ZI8;<@P!15S$`%9F_J7K8460FJ
M=:RL9`=R?_VU_(&=Q++E)$86<R^$.&JI?ZVO5G>K_>GWIYGG+`@7E/DGG<%!
MO^,0'S.7^M.3SK>[[NG=\.JJ\_MO/__TZ1_=KG-Q_OETY-SX'O6)<]7]0@).
MGYSOF'B$HX`X]^B)^6RV=(;(PZ&'`JC6N:;^7V,DR*^._.LZ\.C[V>C:.3P8
M.,Y#$,R/>[W'Q\<#XDX1[[*H\@/,9CVGVTT;_B-F\=AY=S`X//B0^V7$0M\]
M=MX<CM_T/^"W7??P<-Q],WG[MOOQW?L/7?Q^@-\,WO8)^7"4HQIR$C/G`MO'
MSF%_,.CV/W0'A_>'@^/#_O'1Q__D2[/YDM/I0^#\$_\+"O??=B7%BCA^=:Y\
M?."<>IXSDD6%,R*"\`5Q#Y*:O$0.#LC<%R>='/2G,?<.&)_VH.ZC7EJP\_-/
M3ESX^$G0%8+'H[3XH/?]R_4=?B`SU*6^")"/5PAE946D@X\?/_:B7^/2@AZ+
MJ)9KAB/1:##H*$O(;]VT6%<^`MEVCP8'3\+M_"8;_,291T9DXD0\'`?+.3GI
M"#J;>Z23/'O@9'+207-.(W'WWQWU)?TOYPR',^('Z2?RW0L_H,'RRI\P/HNX
M[SBR_F^CJQ48LBX<BC%ET0`+DN':DV5[6M7V=F5^!)1_W@4P[&0;-Y-+ZD.7
M4>3=,D%E$T,/"4$GE+A;8-"L^"51W").MNF.&K4'#R2@&'G[QP5SFLW(;MPG
M=>R'-TR[N:KO'@#^`_-<6!XO_@YAK)[Z[@V(@P_9;`X_$5_0!=D'BGI-[;TC
MAD@\7'KL45SY+N4$![NAV:QN/QQ_90$1]^QYP#XW*6[X%/GTO]$J,F2^8!YU
MHR]G2%!Q,[GEL%W`HA,]"@7L*$*<$X$YG<M'(.Q3C&&O"V!KO@5B3*$A\A2<
M>0S_M84P3'':M)Q3CF!4CN%7R=$Y%=AC(N2D&8%I-MDT<FASS@3R/G,6SF%@
M8R^4>IQDA<G."(E[,Y=Z&O`GFI;)SLR\@+22-F$U@!4,EJ^(F1$!M96X0R8"
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MR%1^CLB<\2`Y+S4Z!#3:>\'316PYESM+4R>)7`L)+IRY*J2G8@4?R(#XKK3$
MQD]E.WLV*,=,]-:X:)HU33MQQ`8P`N-@I7%/^@@87^WXI.W($3!!8AQY`T+1
MG2(T[\D!T2->(-(GW=CG,DB<`K\DC_],;$>I2AE;DWA(W&N*QHG&-0RYM/JF
MS7MH3+R3SC8U]`PB'!%,Z$*R^)4$>I`*28Q@<-UHK,"H0=2]\H=H3@/DY?0E
M%9)J0B-XHG.HBN?X1W-\50R.E3(FN$PZ\9H@06[&'IW&9KURMBN(6H3C*_/Q
M-E!R=&;0B`>IT\"'-)\MD!=I.<$0<;Z$O?X/Y(5$B4B'U@BJ;*4H!;!>S`RO
M_H*`7@7K]37SI_>$S_+F$B7KY50FD!09`-+M=)DI#)4SI7X][4.[`\`68(K5
M/1+Y%#(Q@SI1`4A-9Q+-B"R('Q*]/EDKW`*^M>?+9GD3W%_`:8\M"4GL0]H:
M>36="33K7@@8RQ=/B9_R,V/N(_4\!2`M4A.8<J)5L)XO89A#4#`V?7S5;!>3
M&<92/@%:,N*C<)UDQ%:M/,5EC7&=G7Q%Y6FYA,`$_[><S.&L>_$D%0*21DWI
MG.QT*,T@8G/04)?2C!8`6W(*SF>E:D0IB0D,(R("3K$,K]CAG%2W%C-(`T1]
MXJ;Q!:<8A[,PVHE!O:"8JOI,@]`$GKL'Q@-Y*CICG+-'R9D"0%%)(QSK[G)E
M^UK.&'S*5UE''*<5PK\;EN#5T.RD1$^$L]@$W:4!F:7T$\YF&Y:OM#&F,CHY
MC`/+T06"=_U^QWDDTLP>?8=O<TX9!RPGG<..$PI@CLUC&V!;T94O<!G8]Z\!
MK)X>G('^\!I`*U2A#.7'UX!2X]#_C'C0MPWQFO*4!ZZYIV?=/7A%X,L=3!GF
MPU>$N>R0D"$^>D6(:RNPF1C>O"(Q:)VN,NAO[8%>8,O)`R\R/F2+N46:207.
M2B=*!MHBS:0"=(F=.(-KD8I2U<?5CM=GV(<6Z2F:O5S#JY:)P2*-1=?FJUC>
M\J@MTEFV05U4*@-OT=E:;1I?@5MDRLD6.#N'N(9FKA7<ELG!SD%?(@<-1V*&
MWB*E70^]RGF=0;9(0=>#7!4AED&W4T'7Z.WR8)),`!8M\GI[VF;$5K:C632W
M]<#J!,9F\"V:YWKP=7Q-&?QMYGI+0^57\Y`8YS1)PV$FYC'@"$OK8[2[J8,<
M5XN9B<\4,K,)X0N*E0$S:X5,\/D9YM0U$^+&OT,>`6;D7+SR[\*QH"Y%?'G#
MXRGYA00/#%:=!1$!48E^V]J,("<^X<B3BK([HSX5@4P9L2")N4^%L(+*"!(.
M(K_E;*)TM^=+&(J'(QRZ.EX[$EE]A?4ESM/A3]71'5JD9B*TL&2E8C%:+V6"
M4Y!0+#TY-15\KI8QPF6N3U<Z6\6QLKR12+*4E80)E9PWRQGEMG)<%)4T$VGD
M@ZX;,Y'O>65\D:*XH7@P`OJP=*2=PS+@L2C>HWQTE],8B32"'3U=QM3+]7HI
MHP>+@HUQQ42XCLA*;VX%R'5%5.&J[;8;9.$6MN*D+UK1K`Q`J81:LE%::=FL
MW/C7(LHT-$DK[?RUY*#>#ZVT[2O5I[6PE+)]U,I`42W@E4=5*\-&]:!O:Y]0
M!)6V?)\K4<Q7I)+?\ZV,0-($6C!&%'&T+>]8A?:\&I:P9E"P,H14`^BF'7>W
MP%&3UO!ZN:N-L[N9G+HUV2-N"?0S+."82T_N.8D_59;S.E74.RUO)IF23]8]
MZZ<SF=4JSF2]QF-E<3.WPV$P8AHQ`/][)%H40*%0XZA%V@;?13S_8A4@2LZE
MZ:78I&L#FO2BD":(Y^)F[/NK4^[*UPE'4EK\MZJL7;BS^P*U4>9(VX&I*,Q$
M&U4A<;MPE7MPJNE:@B8DEZ")Y1*L5N8.J%E):W#>LYU1JJIH!T9U$*,VQI(J
MVH$Q4I*S^//2-'FZU"U"EKLP5@]4GK`=>))[4.FR5W@?2ANC5F7MP+UZ#4X;
MX1J9(8^_;!MTP@6%8^/9\IL@<"Y*@LS\Z2D.Z*)L/:E108OPQ2K\#OB**F@1
MOF=KV+;XBBKX?T1*:78@N<>`)'4B4M3EC6322=_EPTXQ''`Y46:>4,"I48&A
M3$&8$%=(?35WD5.^&$4%J(3"-((K(4*91R%Z2U-%HN-J.M-H-%*1*HOOQ5J7
MKST=QY>,)SZD9^=1D93KTYN6]@@TJIA%:8].KKUIS@,UK6E4JV8M[46K1@VF
M$?X;<8ZD`YMP3-4A@Z4DAC`LJ'QG,LR(<Q:.@TGHI<8K-08UB9F8O&S<Z^T>
M912F$:39"Q1WX3005=5@)AM;^EY"#<NCHK!17^@VCJZ52*\:QP`K<S<T)*#"
M<Z"5-P,;$E"A(>!90$<6!8[5MW2L)>-3Z*Q67J3<GS`V59/=KE9:+Q#%^<S*
M!!K[D\J&YI3)PZ)`Q/W)H^0DEDG&HE12NTFF5,?.Y&%3&-_^!%*ILF?;<?_5
M"V@+FTTF'HN"(^O[+50K3:5UQ,JD9CO*IX;%6Y'LS,[9I2F?:@^G(AF:G5(I
M\9:M'9$*[XS9%'2]FP3*[7E6)O7=32!ZP;)6WA;=33`E'E%K[Y5N(8[J@'`K
M[^3L-C94UEHKK^7M)@IU*+?BHMZKG"4J:12$Z=MY66\WL>C%CMMYVVW?DMF,
MJ%1<[?_!Y%(>\ZVX!?^#R4@O>E5Q:_X'DY4B)EN15N('$X[>E28K,^WN6U1E
M]Q>LS,?;P,*MO,1B9;[>O0NH\,Z9E2\A:4HTF[?GMWI+R8M?1X\<[??L.>/M
M\_5T<<.GR$_.T$/F"^91-_H"QTHJY#F*")GW)GH4"NH3(<Z)P)S.4PM-O$:#
M5&^!&(-,[X'9,T^Z#-J&-D4`0WP,OT;&)BJPQT3(27O9!A[G3"#O,V?A7,#P
MC%_G)UEG4O*P(29#&WK0$D`)CY%S_WFY29;GZ,UVF7'CV<G06CR;Z;1E61MZ
M(DWM?4MX)/#V<KK^8DL;I"O][C;PF0_$LH%?:$BN'+`CT^`2X431;2^_1:J5
M])!:,8AST5<VL)M3\9?W'&2,L#7[8NS@N4=/-C![1Z<^G5`L'?U33M9W]O8R
M+@<TC>W@,M`W4J&FQ)>JJPWLWY&I_!R1N71_Q6I@ZWG.%*21/"H)N?JIN?S4
MDZV/0?F#+_\#4$L#!!0````(`'DR#S_!O_,0?A<``++"`0`5`!P`87!R:2TR
M,#$Q,#8S,%]D968N>&UL550)``/&\DA.QO)(3G5X"P`!!"4.```$.0$``.U=
M67/CNI5^3U7^@T9YF:F*+"_MOMVN[J347KI4X]MVR;[)35ZZ(!*2,:$(!:"\
MY-</P$40*8($*5(`9?1#VY:PG.\`.`MP#O#EKZ\+K_<,"478_]H_.3KN]Z#O
M8!?Y\Z_]WQX&HX?+\;C_U[_\\0]?_FLPZ%U??1]->G>^AWS8&P]^A0%!K[W?
M'>A!`@+8>P2OV,>+M]X5G"$?!:S5WBWR_S4%%/ZYQ_]W>^RCW[]-;GNG1R>]
MWE,0+"^&PY>7ER/HS@$9X+#M(P<OAKW!(.GW;Q&%%[V/1R>G1Y\VOIG@E>]>
M]#Z<3C\<?W+.!^[IZ73P879^/OC\\9=/`^>7$^?#R?DQA)_.-FI=$@A"XEQ&
M]47O]/CD9'#\:7!R^GAZ<G%Z?''V^9^;I?'RC:#Y4]#[;^=_6.'C\P&OD>+&
MGWMCWSGJC3RO-^%%:6\"*23/T#V*6_)B/O08RWWZM;\!_75*O"-,YD/6]MDP
M*=C_XQ]Z4>&+5XI2%5[.DN(GP]]_O7UPGN`"#)!/`^`[J8J\L;RJ)Y\_?QZ&
MWVZ69G2XP;KX)EGGP^C+J#1%%S3L\Q8[(2,5X/2D)?A?@Z38@'_$1F)P=G+T
M2MW^7WB'7PCVX`3.>B'%%\';$G[M4[18>K`??_9$X.QK'RP)"@?G^./9,:__
MIROLK!;0#Y*?P'>O_0`%;V-_ALDBI+[?X^W_-AFG8/"VG!6=(AQ.QR">VT->
M=JC4['!7XB>LYL^'@$U2WL?=[`;Y;(`1\.XQ#5?7I0<H13,$W1H8%!O>)XI[
M0&"=X:C0>O`$`^0`KWE<3`+@!=R-^KB-9FAST&"CZ8<G!O\)>RX3IM?_7K&Y
M.O+=.\8.<HD72_85]"EZADV@J-95XP-Q">C3C8=?Z-AW$8%.L!N:[>::H?@'
M#B!]Q.L)N^Z2WI$Y\-%_0BERB7V*/>2&?WP#%-&[V3UARH4)G?"C%67ZA](K
M2!V"EOPCQNR1XS#-&#`]?L\J.XAU!%^#;QYV_E6#&;HH;9O/"45L5D[9MYRB
M*T0=#],5@>TP3+'+MI&S/I>8`N\[P:LEF]B.M^)&'R<%\\%80?=NR8TZ1A]M
MFR<[$[,';L5],FG`)!@37R$Q$^BQ(NXEI@$-9=XW;N+>@[>P5FO,VHF6MGGU
M$+!>4K*?EVU["JGWVC;^:T!\-GGI/23A,+2#5]Y+V_C&W-B=HZD'1Y3"H'7A
MH-)?Z^L?3H/6A:"DC[:QA=\P,0$8A]O&6-97VUAOF>IE4I-`%P4WP$$><Q#:
MLHS*^FI_SLX@(5PA"!UQ[X$]:/,J';?-!4;$`ONA=F@;=TE7;2.-]3_S<8.W
M1\+8#9R]&&]5^FU?-W&'\A&\MJ^4"CIJW<)"<Q_-D`/\8#0G,&L6MF1@J7:Z
MCQ6-@O!7YCU>A@["'/K<<=S'"J_0=>OS`,[YSPE<8A+$_E*K4T"AOSUZ%]$^
M.]<L;7D2&SW$N`!Q5*%)MKN3C72^SWT>(@:>U^_%#6]B6-="?C!TT6(8EQGR
M"BW2P[KBVW/8'[AP!E9>4(VZ[>K[H14O`/)KDQK5;I/2L(?!`BZFD%0D,U6U
M11J?6!/$64WA8,V9:I3F-1#3ZZY/!/F!8(IF)CR@[_(CC.A3WE3#)S$A#8P*
M)J-277O\_`J37'Z%*"ETCN;X>>A"-.1RBO\RB,X+3^(CJC^QCWZ.6-<N[_[&
M`_.D.0],H?>UO_W]L'5Z+E>$GW7<,!$-O']`0*Y]]XJ)N!S2I$7;IS(9LZCO
M>T@0=F_89S2'3'G9?=/)>:1&I2BY/QHWICUW0<=,K141FEM\?]1&XRB?G/GE
M]D??(VNV@*SPZ_:I"04:WSW@&R<YY*2_WQ,];Y>,`01X8R:[7_\7OLGHVBJW
M-_J$0Q[ND=*[5<`C)/C9@IS8HDK[HOPJ-F8D-%YM6BOM4W.#/$@NV;J;8R(?
MY72I?=$V@7-$V>SR@Q]@(5T:V6+M4W<+Y\"+^AZ]HCP!G"W1/DV/!/!9_/"V
MF&(OAZ+T]VMZA.4V(FG*F-F7-!-;@&K.2UQG1O!"01DE7>(\6=?#A#EJ7_LG
MQ\='Q^P?*QT:M1?<,X7NUWY`5E!\R%QV9FU>>Z&KQZSER*/M]YB!B0D;B:_]
MTWYO11D.')Y/@];XD/$'=N%(6E<E##DZ/N'LZ#2RC%4MH)UV'IK$`!(0SPX&
MXI;5+$!^.#"0*1=&P#SO/,R,[A#0/G8>6KXA(1#^<B`(M\QU`?%3YR'*]SL$
MRL^=1YEKCZ\!GAP?",!BQTW@U63@Y&Z39E'GNNP)S"WO0$Q276.XM9&>!23Q
M:-(CESBN5?%\&:;WAUO>,U:,?*_MD<T`G89L7M'!'(!EY)9!+Z#))UG_+/[X
M9QP-FP3)1/&QS(5Q;Q&8QC$DL:S+>'!U6JCO<^Z.<`(=B)XYB3]@H`8IMXH6
M#*Z+HOE[#Y`[]B_!$@7`VY!;,B3E%;7@"2/K9#1'7^JC:S3EAIDCG1WI0OKH
M+)G$J3+:J51B:K:L#JKC)7(+`85W4P_-HS#P8F:75#((QP_L.W6@;-33@X8^
M\1@8]H.'6S\#+XR*"2X!(6_,3/L;\%;9[=AJ=;6@D@?XR+`4U-"%(-8DA4.0
M+::'5O\9DH"'=M]B?_X(R6(S0%A*>G$M'4CR0EX3<^M-&)2E:[UZ.^:AW0&@
M`9@B=P"&632"S<S<+`$DKZ<3S00^0W\%U<8D4]@`NI77RW9Y'=1?+Y8>?H,P
MCHA6]MC*ZQW*N7-]WF:S@-C*NGZ-\P2_8^R^("][I%FIZF&="-?G\\;DD[!S
MLX1F"IG%M9WW5TYV?C43L90X:<K5-6,K%G^&[$MMDZ'.?1/\Y`URA!Y4AY!3
M1P>*\)*(6$Z7:?_\LMJH%KN3M'1'LZ""#OKO"5P"Y%Z_<J,<)G=UJ.QJJ=34
M@P@OF9?XQI,W`D86%XC+1:$I7UA%!X8)9`L1.3RI?X?=EJJMZ$$:,,,2NDE6
M^\AQ5HM5:`WSF\0<)!LSA8HZ\#P\81+PG8EOF!#\PBF3`,@KJ87BY$1LZV@V
M2_!V0:WTYH5$2PKIH5/1/C7$(JUL@ZI8G7L+-TB?7F0IYT?5)6<AZW/K4_-"
MMM3!%2L_@=&\V"UUC&H;`@*K>5%<ZE@E1K$`9U[\ECHXA9U7`=2\$*ZJ(F<#
MS9EY\5HEXG$;E*)E*C";%Y1>&7-Q!(N`:EZ0>F6H18ZM`&I>J'IEH)5]+8'>
MO!CVRNB5_'^!V'3;2&4-R[#ILHGTQE_J&*NJF]^;PU>T66MREE##V/,V>DW.
M(&H8OMF91$V`+0Q(,CF_J`GP1:5-3D!J>)9+3CE-3E!2/U-+C7?>KJG)24KU
M8%8*\3<Y>ZD>?(4H&9,SFNJ!E@5D:<]E:AQI6;BV0-P)ZZS"V!:'0PK<G3#+
M%'`7K]Q.V&/R0(FT$582IRQ0=T(5JZ$NB,44>#NADQ5'N3P_0^#NA#*N-LX5
M8M?%?KPF_;QUB4SY,7;:L4@?'A_@'3+5&)(]O!`3W5S/4@V9N@\F,&OR*$O3
MRHMC'PS.+5<9S*J[(NDD)R&1S+6CJV%423$6J,VUI:NA5@D$$ZC-M:1WW>C:
M1*EF21MY@T+ZP3T]EPTD\V>TX+>61R^5W<V$.9,7?R")=:K;FN9$4#8*=R0<
M,#<4E\F;01*4*C4U(XINA1FM@B>V*/XCYK`<R58-(Q",*5VI4Q^7-H)R^56J
M2E4.):&M!6I^GMIDM/<8E-Q:/$'RB,.FG=+!@((F`R38&M./R&YB-+R)4=?6
MZT+`B!H+E(R^+@2(5(:[;1%V(32D)LS$;.Q"`$A-B/DW/NH*]C!E:TZ?DQ\_
MU:[GEJ!PXX3&!U%2=R-33(^;1!FO'B!Y1D[!E5&I0EIN*LF\'LP?:W=&OGN%
MO%4@=4C+:AGE1FGAZW?6\2VF],Y_`!YD@\P%VMA_6$TI<A$@;W<DVM_[%3)%
MY8[]9T@#*)O2=5O3@ASZD`"/!S.Y"R:-^&9G@)YA'%(N0UA22PL2PEA^3_!,
MFG2\64+373B0J<@@DLDQKYB1RY/^``\0E>>X*U6UVP_)V:'#V5.B>+*E=%#*
M1BT:42XN)'2FRVBA<F.>I2:@C&)I>:.H+TF0+J^GY<:2A*28&-FLV2YG!+4E
M/)>7UTI]Z1K-*ZGG/@X_X"]%<"(VYZ^$;&EQ3;>F0.:W\1R^*R:2/1QFOA=+
MFN(Z6K:2F<67J!2Y.L^6LIOT)MP<LOVH-?_DY]\A?TX:NJ-GMCSF\,>*;YJ$
M/E3L0)6=K-5MI0L[\@;LQRML9BG;`)F;*A3,]2[$A]>"+]<E70@6KP6YP-#M
M0F1EJ;6529PO4K?:HRJ;QENZT=&%9(!JB.MN:G4A3:`2)W*<)NTI`?84N>F`
M\<RFSR&=#F=/4@[G*'C+7SJDX]_TH=+AG/JFMMJU'_(V!JM`IW0A:;\BR,U-
MK2XDZZO!4[#[NY":KP@V?7S0A?1[-6"EY]Q=R+\OAEI[:TE[(KX-J@E')9TE
M%%^]QI-QV5><*\]07^R-)`GMU]1L57OB,JZC.7FAD/+M<C:B)9J6?#IBGP?0
MYA%:7+:35-LDC([%%F031PL7NJ2PGI<"U+*IFDRA:N#L++-H:,[\5:MC3RQ-
M.+'LVEL'DA/6:&<Z#(Z_6A&V2)C=CW!L_%XA`AW64EAH]`)(-LRU5A/:^"RC
M\0=\";^2SVFERL;A2ORW]$4U=4!*6FI_!H9?_AT0`ICTNWYES@^B6\'6M9MI
MD_XP@VBG!21KP:!Y%I)8<_EDZIJ&JHG%4]10ZW-OYZ53U(J^K9U"/T62'Y58
MMEV()%#&5[+1T(4H`F6L,E=%?^#`H05T%>?`5W)J4KO*^2-M$MZ<\6L6KLV@
M/\#8A\+4VZY'/Q3?H=[Y^(<ZOM/AQ$C4,7Z['T=1;].C^X$6M5S5PPF]4-W_
M.9QH#$6/O?L1&?4WD;H?M%%[$Z#[01RE@3CO/$3#1&"*_E0,]=3\:!3^XN&-
MAU_HF-G^7'_JB3CYOQ6-'KQZQ!/(O"P'A>]KBG7QB#FE]P0_(P;[V]MO3`B,
M_74\XL@)T'-TX7=QDG`K76F);U%[L3*7"6IUS4$5J0,V0H2_TW`%HY^5P$F:
MT(61+SE^0QW[-4J=X1/+CZ^H2TVR*T3Y5L2*E%TYL'.S>J*TUJ^L;+ZN4A*Q
M551'!XHK.`TBJKA.B>GC0H-Q=L5ES6C!'_\ZD0!2KM[(B4OFB9?-6Q/SCE:*
MBNOA]9*I*102P'[W8&@=^&X!CDI5M6!"=(DI\+X3O%HR&14]:,^7:/CV(S.+
M8^W#R(W?D0MG/J/]%@,__2:U#'RC?30S$ZN3M/5\GN0FD^;;-WQ>C/T`^',N
M$Z-G71J9"'F-&LZ'*)`Z?@`I)'IW-N2TV04NI-[,;80'FRUV@0/B#N#F>9'?
MMN%<84X-^S5XN_<`F\J^RPWD,'6_$7%1V+J-JL^FU$=;!Y&='CJDDA$HKV<"
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M:$`+/H(="%W*=P4VX@3X";L,4$$-W0AX2"1_LO!NEGH!OA1'?CW=:#87L`*(
M5/%&Y,QFZ\D\OL$DON!V?;-M'I>KU]?-[0GSZR(2^953F`2/D"P4UX&\KFY4
MZ<,#9:%5H07=".-0YR326::&"ZMHPO",>/P26Q%7>#4-9BLO.2*08Y!7T7.?
MD)CW:MJCJ(9N!+?8G_.%&^\WWO+MD+NIA^;AH89L4*JTH.7&`P?Z@"#\FT^7
MT$$S!-W"F[[DY3M-_4YWE>UX<Y7RG1)-W!OQSF]_2B:`REU;J;+VSJH".E?+
M993"#;PD;'KLSS!91,&`Q<Z\:FU]>4=MYE-L9L$4Z_QUOL^9N5GD^^*46M2R
MX)BYF>G[XEC!/HM@D[D9[&VSJ3R47W#)W$SW?4VFTML`SLS-BM\7C^0!?8)+
MYB;1Z^)23A"G8)>Y&?C[8E>5.!K!-W,3^9O*W4O9!LUF_ZS9^,'<Z:>9C7E)
M(H)M=O;5RAY8,_#<W+LH-#,P-TE+\,W<BRR:Y%L+J7^"A>9ZFB:(/$D^E&"?
MN6ZG">R3,,U<)[1Z%'.Q[9:7+=*%^Z::YL-V1'$7+J%JF@O%&1Q=N)JJ:8ZH
M169WX>:J5E;,=G:!]KNN-`K1XE3#+KP,WS1GBM*(NO!L?`L"5IHZUH6+X!OG
M1VYB9Q>NB6^+$]MO.MMKY/<VJ/6S-S)GJ)((23&FYEK6S?-@._Y-\,%<V[IY
M/DAB?]?,.'U/"V,K&$^PP5P;NGDV%,3T"H:8:TDWPY#"($W!!G/-YN;94!KI
M*=ABKO6\&UMJ!/@+IIAK0C<S5ZKDT0JNF&M.U\^SE$G6TKR"+KR:T1!;*J2(
M=>$UC6:X4GX=01=>V&B&%U72N+OP`$?]-%^5:_Q/.^>U5`3>3BR1B`;JG*-3
M?>(H9]$+KICK]Y3FN*3?N"R\`%RL(G/%AQ)>::*[0*AIE\>^I]?X<R[UA=T'
M<X7=3N@++0R!WF"AM@OZ0G=-H#=WYT8-?;7'.P1N<[=J=L&]]12+`&RN"ZD&
M.'V?F<!EKN.CJ,M4\P(%9/W';4JO'.>ED::0RVT8_4=QU5XXK@W5B->-[>-K
M%1Y?2P]UU4?7M,BA:IG'62VS6P1L)YYUKL\@]5>8JKX`O>?G^4(W\1''HPJ\
M]7RG=V0._#C#DP&DV$-N^,<W0!'E&]B0<M:%'ZTHTW647D'J$!0"BF+-.!/X
M&YNLLL-FRB,C]IO'3T0.Y(6&P[H#M=TA3V/>3Y_V_H^6;]*PD5UVOVM_3E/+
M`DJ[T6**16Z,$9(,XB5>3-FWO&]A;39@3=27FHJ4Y4M3Q<J'\H[585E)5K];
M_6[U>ROZ756H6D5MFJ).Y3?3X@1G:H@*WYGF?%&Z<[-6[5NU;]6^5?OO1NWO
M+HBM06"@01`/4YA5MDZBC7.,+S$-J+@J<1T(KMD>V(EDJ3FP4ZO6&K#6@+4&
MK#7PGJR!W<2P-09,,P;"+,@G[#'R:72++2_;Z#:`5796V36B[/9*I^JRD$%0
MK6]5N57E.H*<U2>X5=JF*>UK0'SDSWE216AN:?7-Y<3DBT9Y>>M/6Q/#^M-6
M";\;)5P@.JW2-4WI9J_M/V`?N;[P56%2OD16J6E5LE7)5B5;E=QN4G.Y`+/*
MV33ES+/^3(E=DY"2+_5DI:TO;!6O5;Q6\;X;Q2L5FU;9FJ9L-R\P.V`OV!35
MQ4<I[/?XX]EQV.O6-7+E]H92%:M2K4JU*K7S*E5-/%B]:II>Y8-Y-[LDT$7!
M#7#B5Z^L7MVO7BT;A1R]6E;%ZE6K5ZU>/0R]6BH>K%XU3:_FO1C(G['8_0A7
MHD(J=9BC3RK5MSO%=J?8JE^K?M^'^JTF6JTN-DT7;SQCV9;V+>DB1]^6U+`:
MUFI8JV&MAGT?&K9,?%J=:II.C=.O[P$)WAX)LX6`T_QE7E:5M:<:J@Q@OMZH
MTH)5UE996V7=>65=2WA8Y6V:\HZ>1WT$KP>LK7?))RK@3KY4+JQB+0ZKCZT^
MMOJXU0RB(I%E%;!I"O@!S7TT0P[P@]&<P.P=F0>GC$U19)+=>^7AR-G'5ZYK
M5:Y5N5;E=E[E5A085O>:IGOY60,*PE_YT]GAE>)SZ#NIITNU9O-6I#!?2E9L
MQ)XW6Y?9ZF^KOP]>?]<5LE:1FZ;('Z)9.(%+3(+X@1#K/W=!JRD,G$1U*-2T
M>MKJ::NG#T9/*PD+JYR-4\[BKN\)FC\%E`?,6W5LI#I^3\IKIV."W#F==R:0
M6]`J4*M`][Y1G3]EK;Z4Z\LO0][%%%#(_OA_4$L#!!0````(`'DR#S\1?ITN
M&"(```7(`0`5`!P`87!R:2TR,#$Q,#8S,%]L86(N>&UL550)``/&\DA.QO)(
M3G5X"P`!!"4.```$.0$``-U=ZY/:2)+_OA'[/]3Y-F+MB*8?]GC&=LSL!4W3
M'FXQL(!G9\YQ,2%00>M62*Q*M+OWK[]Z2"`)U4,\*LO[8<8T9%9E9OVRGEE9
M/_[7TRI$CS@A01S]].+F\OH%PM$\]H-H^=.+SY-6>]+I]5[\UU_^^(<?_Z/5
M0MV[C^TQ&D9A$&'4:WW":1(\H5_G.,2)EV(T]9[B*%X]H[XWPR%!_2#ZQ\PC
M^`*Q__LHCM"OM^,^>GUY@]!#FJX_7%U]_?KU$OM++VG%O-S+>;RZ0JU67N<O
M0KH/Z/O+F]>7[PJ_C.--Y']`W[V>?7?];OZVY;]^/6M]MWC[MO7^^Q_>M>8_
MW,R_NWE[C?&[-P6N3H*]E!:(?"KQ!_3Z^N:F=?VN=?-Z^OKFP^OK#V_>_T^1
M.EX_)\'R(44OYZ\H\?7;%N,H6>("]:+Y)6J'(1HS4H+&F.#D$?N764EA9@=$
MS1V1GUX45'^:)>%EG"RO:-EOKG+"%W_\`Q+$'YY(4&+X^B8GO[GZ]5-_,G_`
M*Z\51"3UHGF)D156QWKS_OW[*_ZKH";!!\)+Z<=S;AH#`9&4@OW5RLE:["MJ
MV]:;F\LGXK_X"ZOPQR0.\1@O$)?A0_J\QC^](,%J'>(7V7</"5[42Q$FR17C
MOXKPDC:@SVIXUZ*5B!K^,_OZ!6)$G\>];2F\A`VYVI#6TO/6HI"0X30OZL65
M$(]_R:!;$A`_I3CR6<GB6\:O,)0HGMF8%\J*C>>E`D-F[3BI59F7M?#(C!>8
MB\R0=X7#=*M$2Z#W)E<^^_KW]GQ.?2,E(^_9FX6X'?GTFV2#_7[@S8(P2`-,
M.ILDP5&:5\^5_NG%(25<;35D991T3#")-\D<-S(:*^5XL7X/9ZR454C+8+T9
MCEJ?)R_^DI>`UJ((Y$4^\D0A"#^M<40P^5$(4=*KG92;STOFN9#THT:QC.)J
M'E,?7:>MDHZ+)%X=9OE<H/AP"UT!PG.,YSAX9&(.<&J&QUH6``#6R:%#W([G
M`E&N"Y3QU:'M:"7HH#Z+">Z?29=DR^."KZB`5.<<4HV!O&&SVH1L!&JOXB0-
M_L4'X>%B0`T@9+O#"TP_^/=!Q`;Y3DQ2(F_4@TJSZT.'B"B!Y!V>I2@@9,,(
MT9Q27K#^/*\!>84J@+%Z3#-78'RP`4$0[OL!$]`+1U[@]Z*.MPY2+^S$JU4<
M3=)X_@\94O2,-G&KE4;6:VX9Z:PC\.EDO347O*"`-&Z5$O;,C.`0S#[AU0PG
MS=HTXX$'EQ!$CRO&U.I%J.,LKLK-8`"I@NHP:/J_#4E7M"\ETYA.&*CB`9\O
MT,5^O,+]F-#O.QYY&"7Q8T`7AK?/GPFFX@_7;#,DB);M>1H\\@EW>T;2Q)M+
M)[?GJ,HJ=D\OOQ3RVZI0&K-IJ*@,13A%(:V(?<L^SVEU:,,VG8((Q7D]=&:0
M5P3K(N?#5MFSSM0PASLDP?/+9?QXY>-`^"+]4'5!^M7O;2JUSR2_#[UE!7?[
MOUL`^UZE,H3F-(@10:!,:CX&C7HU0#I80K!\&2-^M-F)\1HEC3J-Z8"$/$YR
MEN5ZRBI0+M:/$<]:OU9JTE)/M!,?#FNZ8;A,9!U[NJ'/D>95#CC[BL`UMV9'
ML41CO;'5^VS"H;.UO`/]SFFDM8M3U3[@GE+@*#7JFZJT4*C5]%0=-Y&@[[CJ
MU(-`QNV&!!$FI!.O9D'$-_?N`C*GZYM-@J?X*;T-Y9MFALP6L6,FD6S8Z_SM
M<V_2F_:&`S2\1[>]8>MOG]N#*22LFK5/$6<-3`$!O&SKI8\]@H>S,%AR"34C
MJ8;)(M#4DLAZ*\&$0L:U/19N;<>S-=MAAST[,&N6(LX,+.$0OG;G%LT:ML`'
MC[*=,$V`YB"L]EO#`%D5[6'`11[:D<_^Z?YS$SQZ(=OX:J<=+TF>@VCYBQ=N
ML+1-37BM@LQ`("G0R`./:^&;H'C'?I8EQ!HG0>QW(U^UC#B+.A<(TV_C!1(B
MG%&[2>HE*8!^,[P,HHAM7"NUM-=A-/"P<J=A:AYW.HX1-W<OFB>LJ[O#XM]&
M[2\I`KP;J9=+`L\!3E&0D:*7?D;\BIVKS*UV--J]"H>4A?5(-73UCJDP&91_
MWH?Q5S;'H!][T2,F_'`JRN);2@=5N_649D_EZ&(M^_$QLDK@/J'M3=C8$O`"
M^;$5@SJ=T,5AX/,`*K*9D<`/O.3Y`S323P&"*OJ/MBJ(1\2K52`.=IGWQA&3
M&E-YL>Q`3<5A$\=R,62SHQV'Z'V+/*"`U+=!"6L:S1V#D?E^8\-"W`";^?YC
M%7^E8M"N'/2%E81X4?\+%=)]&HV'GS[UII^Z@^D$M0=WJ#,<3'N#C]U!I]>=
M..IQAMNO!]BGF5]ZZT2$LUQ__^::^QK[YO=">*3>L4PX3NQ%?CS?,*OPO9SF
MXBA<)XX0YT+^ENTLSE'7#QPA.76!X0!-IL/.7]%TW!Y,VAUV`@$"_P8(8E@W
MU1IJP,G$4H;E[M-9'C9*E1O`&[I;K#5JM>?;5PH8`R,O&2:3E"TS^`X077=.
M'KQ$NLEBP`F#$YDX:N00QGJ!UEZ"'AF7(R#2M8H$5DH;``.-"T+:F_0A3H)_
M[2[QREMTCP,&6%4QC`!%.!/RMER.`$O6"A)`U>KN!)!ZA&S,09110P)(B&`$
MGH"3.H68LKF5:"DHZ@12AIN4)69@"35,VZK(`HF9@AQ&P(EW]$ZAIZ8)E!"J
MZ@V,(^6I=94,!B_*P\T21OYT>7U]LYOP7*`?WEY<7U^S__9'K0OTFOYR\_KB
M^MTUWWJY>7?Q]O7-Q?NW-UDOQ;\MX`YY*?KO3831F^L+GMF%$]SA.9_QHC<W
M_%OZ&ZUHC=G&+@Z?'0&K_.RTSM`PH(SXKC<9XT<<*4!9(;,*RG+=4E`*,L32
M]`1S3/'`R6&A4&_=,A1JU`."PB-.TF`6XGX<+:<X60WB%.=91^2MH^2R"Q25
M*'+<Y%R(DZ.,_@+MXI_@]GZ/52GB*KD0F&8&KXIK:+4']I2B/)K=+Q4/C)?L
M"]+41QP!E+P5)'"2:`X#)I(.%Q,Q:,E/>DM$5N%2K%F*#Y*RB(-LZ`4^PJVS
M9QD'>RJ=_^YS%J5]'Y"Y%_Z&O:0;^7=>6AU6E:26;D3+ZM?<#!+TB#&@+INB
M4Q:HJ](Z:^>WII6J0O0&+/.1Z*=8@LRLQV*W]TF:\-.\]HIEN[J1>*LQN\4>
MQ%0F";QZ>1HHVK_,"PM/%M-$IS4\O(G^Y--:(+N=I@U7[)`:60@*E>;!(S)J
MRY@S/QGFZ<8<B_IHID%G./BE.Y[V;OM=-!A.NQ,T:O_6IG]!NX1A#(=*6QC`
MBU1KG7C%LH?R$(H\V>9S)_0("18!]K5WG)J78]5)&@HG=1]1#BH6A+8E7:!=
M62ZLJ4^N]KQ0$*R_'0C:LB<>8AWW?/0(MW3-$YNCT*V;KDT:RAR*!Z-/$LY7
M5]N(FMH@:K8YO^U0OR;"->KE>2%6YT[2H,!_(QT5H]C)5.W>=\?C+HL$_C3J
M#B9M%@H)%@EYB/-MXR(;6P-RM"HF[]T-H@.L&ZKD?`#CE%28!OF<64)'NFZ7
MI75FO_WINQ\NWGTOSHG_]/K]Q>MW[UT8Q[1-6#>(J4UVTA$L.T@LII%6=2)U
MY%#C4XTLNJXZ.^;E:4.7$8LQ0+--RLZ]6-K0&697/\.-+Y*&YK.B+'EH3/MU
M?O-S$<9?R27,>&6N,\5-BXO[-0E2MB&V$#M?94N`=^(*_.WUV3+E(;OH3":S
M)42%&*`S+DN@<Y>,&ORABL.D=R"F0XV2NJZ_1D4'X&V\=[5/#P=R\TV9+<[=
MV7!JK(-[:#?;.ZI7%`;S:SHO"$1.-KP.,?O`WD^2SXT:L5KU!+T\4D#M6,7;
M6(Z\G]*D><I`,[0%".:VJ\[AHK@D'6.^RN$K`!Z5?,O>3QR)(TRB/50[LE2;
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MFU.K&DEE(:A;RNSY`WYZ]8W,"Q2M?.!$0&8XQ^$^3!]PDK\&H7JGZK@RW03[
MOJ`G&_EYT?EQ`I*_:.38$L'8(J,$LQ=>MP_)BPO*7&EWGL<YB1\<V!](+/DM
M=`=Y.)D\Q^8Q)3K<%13$/'%'4"C9\FSX?+9P[I6'$^#\&&>O6NQ;</7=:=3I
MG;Z^;(?=OU;@$W<$NSJ^P3ZAB8'H(I#*$:)$[,FC4*VMJWV$TD&.Z2WDMG2\
MWQ@E+$XL?6;!I"E=X[-L^NN5.ESS1*6[V7>H1)8XQY:$3YOY`/H0ASX*5NLD
M?L0K\2;*M[.<-L'$@<ZBM2ZXNQ"U`@T2C!]=+)2#'""K[)V&=K_KS.N'IVIF
M*?0/M=MICI.R(Y7\7]H5=:D$Z7,O6L3)2FSIUC\LTIS?^G%0`^%D4[R,%;70
M]B/KKD4YJ%`0^I(79?MVCT-:VCGJ.`"SNZ.,IM8Z?P*47!21:T.\1G1/OZNN
MP=2TEE*@2`7002M+@B(X$&>!RH&B-7B>!$6MK&UDL"PL9KC848*@8EN](29X
M8AR'$+%GZ'H\E-6TAX9"3]4/(MQ+\4H%B5IRR[BHDT$'CM*HP[@09P,9=TS-
M7P6*5&][:!GE#Y9*<FK5TUG&1ZER'3"R(00ZDY;2P%4@["MH#P%36JS"]OQG
MR^W-ZM0U,Z.!;MNBZ:I-NM4!8O.AZR7LH5R2/SMQZY%@WJ;P"L*-?*]7QV5Q
MZT`CB@0<G(HO37Q!A^C*F+"W@K<9T%AAD/L%ABU3W`XPL84+(--M7<GI`8&E
MVVSJ#R<3-.J.T>3G]A@T*YC6W"K,P%]LZ*[68?R,<78!HW"BH;XOK.>SB1Z=
M,-_629=QFY2@962#\\]?^+X,K75:DV1]_W=+,YA2I;*3G8P&?>%48"N66@/F
MTYA]12RUZ','L[S^82_R\=-?\;/,R'MT-ENX6KFJI9]11HPX-:+DH"TN,W"I
MY6L5M(8`\X>##)GL8J/YXT$Y4`J/*%X@P8R&L$\)-6N6"HC.]YQ0,T3=Q2LO
MJ!X"[?UL%26B3C4>O@@BV!&B8KQR"Q>TL-66]T&(DPZ=>BSC1#XZE*FLMFRI
M:G4#<U*4T\(V<ZU=RZV]KYFM1A_C9<!.W:)TX*VDL[TJF=5F+]>M;O<=+6+$
ML`U?;]MRR]<H![*(_.=&#"OK..*GM#7=NIK6YF*Q3@!%M)>8``ABT*[?R-JE
M):%44PB0?*25]V-"AM'$"_%P(:3K18^8B-?N)>VEY[,('JTPNE1W?.>3[7A2
M=I;M[C:(6W_;L!Z';&8D\`.O?L`QU^K@F&(PW6PYCC$"BTYD9A47'"J/MS1L
MWBTYH/OD,LAV>3-`^7G(/@75(GABJ55/<"WO9(YR!BV@7***(94GE-1VP0'X
MBK873;:=S3`1WOH)IP^Q+WP6RUY^/+0T0/<Q%%&#RV]@*()1%,H)&^)8Y:--
M#`?BPCC"B1>RA!/^*HCX8H8]>9SEG9#!0\-ETR75HD@0F7&)Y(4E/E`<FC5&
M"6\&ZH/@*J%.0`>H12`[P"Q2V,3+KEH9-A@%$B1GB4E/X]0+^R>0<2V5T1IB
M]YNYA,Z*(A!([$7S>(4G*1WM^--W]=<R=-06$2H109I+AE&C+3GP50-#JQ=!
MHM(7#C!3[\G\]IF2Q3ITZN60X6?0&7[JHFG[U^X$'C!JJ^^C1J$J$'02=B/U
M#HM_>_+$7OJD`0<69A=N!T@H[\AX(>BEGQ7WBKVPX>6IXM:%/(!>E@<0*_(`
M6@3N$6U>@?2AYG0+[+LDGHV!4V!U`L@[>:2YT'/8!E$=;!-EWE<+2WDPW>`=
M<!^'9NY6,8P;SE7W*IEQD]<R@SI8G43-8+A]I\B5]U*;M9D:BE+SN`7&[&6.
MQJV>\SD!P4R89O,2%U[):MP^9I@KVL,1N&WP/=4X"ZT>>8D^/KYA(;!`5$BF
MZQ,9%#<8,4!LP^C7M`2HDP-`[0#=S0"?&M_3&<D91YS&1[NAK`AH)Y3(90C2
M-'8<HIJ6TP)491XWX"F_@V,,`T41H/"4R]5LWK)V\\K5(6VI!JS&8&X`-LM7
M%2VSC+#ZTPG3`D#!*I-*E@[W@?Z%"8-GG'-FL3DBRY^K&-4UGQJA2BLY@L]R
MODUEFGM3;EADUHG4>$>:;SXS?B]DST&S`[A=$G?0T#C'-`9T315R-7XIM9A#
M3KG;HVSHCT5&>%<L2--L]T\@S\'=]?.K!>Q4-<@S\*>J1=QPI>PMCGSG*XN:
M:D<^E[GA<&=4&*C+F4C8<#DA?\S$L7'0$=WAG+<)UM4.;6Q*-YQ\C.F\.IBS
MYVT]\F`,F`H;J..699'`E*YT<Y2N8Q*DKUBL=;+E1.R.D#/N>%:-X)RL'FMJ
M=ZHQ!8SCE)]A:Q+^IN>TZCY:<:3!<-/VX&/OMM]%[<FD.P6.B#-NCS*^S+1W
M`6(#G':?LC3N'^/8_QJ$IHU:RPH(LCIY&CW_R+HVNM#>K#9B8]9;Q4D:_,N!
MJ`;S-E/A4&H@("!B-HZ(*-)L`D.7_-OM1_F++$:L=H&HE4<.1,Z:SV#!WTUI
MTBP5K)G9`!)K(SIEUK0A)P'`#JM7^E0=>4!\F;.($[KJ$0PN@*1HSSHP;)4Z
M?S*6/IW\AB(C2/LIJ$LK7J6PE(*E4JWL?B:CRI^M^,((P5(K22R99UVITP?"
MI_4GRT`'Q_ISX6G,7YX\U0MZA]YQ.Y&@MCH=S?&S"Z?+!1G:D<\O'K.7T7!"
MQ(UC?4/4L\&@MU864Z3PG3A28/\SPKP`<*S;4PO`,Y2PD[B+W"`N^I`F/L.8
MW2&?TL1F]"OPFY3@UW4>?JJ0C$:F`8:C.LP2-OVW<;YOT:/EK_BZ-`<YH=P`
MR%=$<IX\#_DIT6S>G5890-&M"V=S'2>&?6*=ML"X*43E&$.GA@<&/?N"2/,E
M14N4XF3E((3D+2!!D41K&"#-^4&]^M9:E<HJ6$I52Z=DG`HM,';A]IG$JF4X
M[.MUDH=X^T&$AXM.@OT@O??F&>1DYY5&++:?V]7((\5`Q%.I"3ZT8T1?&"OB
MO):?U#U0D]Z@.V'O5G?&W;L>R*/53:"T?1+71%N(3FZ`4[9G/TKBQ\#'_NWS
M9X+]7G0?1%XT#Z)E>YX&CZJ=RP8%6.P:S:629<G%*8\785FS>!%H]HP6.3OR
MMOPP:Q%8_6R-%<W!61Q&&MK(;>_33&`/*,A);]2ME1AB%V'\E8A+OM\N8%73
MX0/-Y1"`1:+2(X:/N@+@`5LCE:)[Y6`=%;K7EZP4%$2OT+8@U'9S(&FFZ=Y`
M\G*3:QIL-77:0Q6`-?!,F;7<]LC#AA1504YZ:,,AY=L%[`%#BLY<#@%X>_WU
MT"&EK@!XP-9(I>MHL[ZU>/G9S4'$@F[`7J@`I8'WR>SCMM<=-FRH"G+2"QL.
M&]\N8`\8-G3F`@*PB.=E[RG(6[]`8Q=VNXH5?2![D@FL"S>2L"^1T"*N]YNY
M`MF*(B!H+$23E\+,9>:7TMM$J4P(99R#N,*:97EXF=T->`6$XC-K8`WE.OB4
M$*]4VBGTZ^8.6CX7O$$S,QA^.VA2#OU&ZI_D6'80ISA/6JZ_1FK$8OM85B./
M]"E&RH4R-K3C`SR5/5"1X;0[0:/V;^W;?A?L3-801]LS61-=3P[P3W@UPXG.
M]!D5)(R%"$;(_2)H`:%J(&S^(D0:L[MI*]I'%QZ6>_`2G`7S.@'?,DIJ$5M0
M^70@G<;9*9,7;I_8D:WX3;E`0*P428D3BH\MZ^ZA)*)Y*>G,,+>MCCW`&R&N
M[`!Z8T!,>K>;(MD\2;8)L4]G<5*[5[DZA#TF64Y-U=,YYU_6G4-J6Y-O*2R*
MD^UZ!9U`L6;))J>'1+5N\]9MA*B696I501&CW7ZMHX1`B7:CD[]`7-S6CR/H
MGN]D,EM'M7J[5J8@")*3I1=E.70ZU'QQ&/C\CUN/!(2]H(Y)/O&\W9`@PH3<
M83)/@C7[2KRWQIZ$HNJ,*/-<$5QNITZ;WG5.1228OVU/>CP8?#3N3KJ#:7O:
M&PY`06\#027W.;O501QQEQAR=Q](AKM:6IO`KQ-``MBV\ZFQE:8O(4^J-AAB
MF!P>>3`Y;Y/3VT9.G1#2!7W4XE$R>5ZEBU+:-W;!9X8CO`CX6I\V]B-."/MA
M@;V4;2LSH&U?(MO%3O,%$U"J3^=M8-7Q5`C><SZIU<`<L)"UFT6.Z/OM>@;;
M+E@KA?)TSXV,ZWJ;[V%&KBH$:$;>,]^[F\;M^3\W08)'"5N\I,\C:O.43DY8
M8HWU2@ZB!@58!)6Y5-+@,O["B]B=\`/6;T'US]9TL>4TS3%7=**&Y@!Q*I%N
MO3;-NKI+-N&TZ49Z<228RSA1QLK'?-%QM[,,NAG_639UZ(QC%A.LVM8Y7K6:
M5P3RA#/PBX@&$"PYEZ%58+PJGF/L$_;L9H?/*E.6K/@.S^3>).>PZD52,:00
M$QS9?1A"-G2.S-,'S'?\*"H>JF]34ONT6,Z"X6?4!DU61I_:4-"HZV4-,5QT
MXM4JCG@",H-&K^<#0F"M,$8X[!5P*'A%<CFX+OPPK7HE?^)Z\!R-6Q>*%W1Q
MZL22U!A],C>2VP7:F8J!-`8-7"('<IVB#*?KN5W!5UV#R&"U9XF3Q#\5:\BG
M^?=Q,O%"BM_)9D8"/_"2Y[INMSF_[9BH)L(9@>OE.BN%!=.]0G2BA@@MC&&-
M;(L3/=NEW7BIDZN:ZU4(%]R6`A8[=0A:MU%4C4T$W5V/<0XW*M]#G*13G*P,
MY]YR7J".7"J0]%FKC)X[%V-H\6Q_LSA)XJ]TIN!*'ZYM)5F'KK8(-/B$6S3>
MFFQ0`A`0-6(UZAP7P1-[A<B!K8?&#2=#I8EYH+'Y=R])J%S=)YS,`WG,J9(%
M"'U5.8S@AC-J!KFOH@!GX"9K"QF^:@T`!*AZB,N?M5*RV`645`X)H.X+/17X
M$U8FIJ_@1ZTO$'X>`W;(3N>0=_%FEBXV8196I.B0Y"QV\2.50SH=(SAYQ/R!
MJP2+U_?6'FT3OK!VY&C8I$DJN%+;`0)78V'=$3/NE':5A*76B*,&3XTV*<$B
MZAJ()0-AM]^>=N_0J#V>_H:FX_9@TNZPZ$?0-T@/:+`B")N:!0:3+')/Q-P4
MKTA+6UI";A5M]3)(^[=";"(LFM2F+D-'H2,,3G9+6K/S0A6'5;1(Q3#9GVBT
MT6RNR,'Q*S;5L><86FR5?4-M`FCW8.]7L`V?+%*HSYXY'\["8"DNL1@TK*X$
M(/?1B&6$ORQZ2CQL'^^8'7`GV^I!N)<A-F7N9F(B&/<CF%KD@:X@[_`C#F.^
MAE2'S*MYK+J80A#%HHWQ9.'?6RY8G!DT0AE9.L6!L)0FP9SV&2Q5()6-_</V
M)1Z]D%_,3SM>DCS3R=@O7BA]1J=I*7;QUD0T.0*S4GBF4V#@'=)B%2@VM@D,
M.%,OB+#?]9*("D/:\_EFM>'+S#M^240^&]<R6H6@3AHIZ@0CRCG1RP(ORIC/
MDZW/((CJ8+V*2OB"$M:C3&%6=B(C[5WPF]JL51IB0/]0IH.J<0"7L+.?^LE`
M2PB,L//1_(TV^4E1E<HB*BI5*Y/&*%[&.UI&;9:'$PEJ"[&2AB]"M4XC$(S.
M<>0E0?PY(FL\#Q8![5KC%?4B64M(Z6WB5B:$!!@Y_04J<*`O@@<DO9>Q^4N8
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M.F>!=\L$BZRSANGJC7EMWPLR%4P&F1T[VO&[D<G^2-7ZO4YW,.D-/J+VX`ZQ
M_'+M<>=G_L==]Y=N?SCB\^+VQW&WRSZ!!%X=!,SM-:!&%@+I9//LSNQD(7UF
M$[`XXL<+3X&TNU7RV.QX58+(_"GGN4"""^W8T!?&"+N<-VF/4H>LM0$HK/I!
MA'OTHQ9+.T((`&UKUZ$&?6&DB-.Z`90]"]>BHZP@*"2&"W:2><\>]M-DOE:R
M0,"D1@XM8%@R!;8^YUS`;P(T:8M:&,D,``RH[6,%HY@$/.NJ,;#DK#``D\IC
M`K3=,Q0YMWN`T[:5!'AJPP`#D-_CSEZW$0.Q.0(5O#`0E`MD@L$B]Y_S.99S
M*-0WF`2&&N.`XC`_WC&9NY=H(7!6%$`_5\^I79JBUYF[%C5[JH*B9*K(R%,A
M@L#%5)%]IS`-YV1NX&`JRZA3H]-I]LEV?=`X6#ZDA-U5K=V@J26TO@-6)X6T
MA;>T2!`C1EW8[[*\Q=5$]NFP\]>?A_V[[AB->Q]_GD[0J-\&.<S5PV2W1275
M$*:7J@ZOTOYBC]!J;U6M71E11$IS(LP9`(_A3(4OG\.!GKV9BKQW^`84;G8>
M?-@;VF1>6![>:I5TH]O0KK_<6'0U7FGM`^6#6TA1KZ,<7#Q516*Y#QN$H1GS
M@^)*(I0$9G]OC\=MH`.W@QM&#325`4XW*6?I6+%_MV'994=B:./Q%'=!@N>T
M)$[4_NHEU=N?!Q4!,I$WET\6L;9A,?4BTQYC%,FL?>3S(GF>2S$K0!Y!'J(4
MFY#O+"6XF&\U3;!'FS++@,ESQ>0B9%]Y3`AB.3?F:6Q426$L@N+BK;)IS,TT
MBVD)/"=X5BZ!#C4ZQA/**Y*&)@0;.F1R#O!7_I-\(\Z(V?:@H97H-#FWH7%Z
M6!/NC3!FUG(.F\WBH0\HR174-HJD+D(X&T`BOS:LF@\V>+4.XV>,OPTL-XC&
M/M"@YY]$\1^SE(XDS^G8?"(E*<:IR52]C*>>4+%?ZM)]NC1E:F0)V2B$-FON
MO?NJ0COOL:@WFS0IC'A.M^6)"8Y:^LA*<,19)>))T,FIO_6%3#.5#UW'N.:*
M&B3KO%!E-(=FAUS,`Q<N%5[X&6!9(-5^*A+,2'`CP7Z!>`$7B!8A"(Y,"'9X
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MR\R43PN$C>*"C39T@.13^-G63'YFIC`FA$VA!!O8G.%P+]G.&0XTK'"33/$^
M+9'^3?^B'ZBQ,/WC_P%02P,$%`````@`>3(//W7%709=&```>NX!`!4`'`!A
M<')I+3(P,3$P-C,P7W!R92YX;6Q55`D``\;R2$[&\DA.=7@+``$$)0X```0Y
M`0``[5U;<]NZM7[O3/^#COMRSDSE:Y*=9))VY%M&<[QCC^S=[O8E0Y&PC%.*
M4`'*L?OK#T!2(BD"('@30!K[82>Q`7!]"[</P+I\^>O+TA\]`TP@"KX>G!P>
M'XQ`X"(/!HNO![_=CR?W%]/IP5__\L<_?/FO\7AT=?EM,AO=!CX,P&@Z_A6$
M&+Z,?G>!#[`3@M&#\X("M'P=W6%`0!`Z(6UW=`.#?\T=`OX\8O_W1O1'OY_/
M;D:GAR>CT5,8KCX?'?W\^?,0>`L'CU'4^J&+ED>C\7CSY;_%,GX>?3@\.3W\
MF/G-#*T#[_/HW>G\W?%']_W8.SV=C]\]OG\__O3AEX]C]Y<3]]W)^V,`/IYE
M:EU@$`OG4;D_CTZ/3T[&QQ_')Z</IR>?3X\_GWWZ9[8T6KUBN'@*1__M_@\M
M?/Q^S&KD]/'GT31P#T<3WQ_-6%$RFE$=X&?@'28M^8D>1E3I`?EZD('^,L?^
M(<*+(]KVV=&FX,$?_S"*"W]^(3!7X>?9IOC)T>^_WMR[3V#IC&%`0B=P<Q59
M8[RJ)Y\^?3J*?AN7)O`SB5JY06ZD&@4!1\(2[%_C3;$Q^Q'5[?CLY/"%>`=_
M81_\@I$/9N!Q%,GP.7Q=@:\'!"Y7/CA(?O:$P>/7`V>%8:3NXP]GQZS^GRZ1
MNU[2X;7YTPF\JR"$X>LT>$1X&4E_,&+M_S:;YF"PMMPUF4,4#;`P&:]'K.R1
M4K-'386?T9H_[NG4`.P;MX_7,*!=!AW_#A'(/G'A.X3`1PB\&A@4&]XGBCL'
M@SK=4:'U\`F$T'7\]G'1.8V6H)GT21OMR.;"<:;I^R<*_PGY'ET>K_Z]IF-U
M$GBW5!WX`BU7]%<@(/`9M(&BVJ=:[X@+ASQ=^^@GF08>Q,`-FZ$I-M>.Q-]1
M",@#V@[8[2?)+5XX`?Q/M(I<H(`@'WK1/\X=`LGM8W;+/%\3NJ,0<@F(B^&*
M_8@J>^*Z=*\+Z=Y\1RN[D'X(O(3G/G+_54,9NB3M6L\;B>BHG-/?,HDN(7%]
M1-88=*,PQ4]VC9Q^<X6(XW_#:+VB`]OUUXS(,5$0ZXPU\&Y7C*A1^4C7.FDL
MS!ZTE7R3K@9T!:/+5R3,#/BTB'>!2$BB->^<D=8[YS6JU9FR&LG2M:[N0_J5
MW-K/RG8]A-2_VC7^*P<'=/"2.X"C;N@&K_@K7>.;,K*[@',?3`@!8>>+@\KW
M.I__8!YVO@@*OM$UMN@W=)EPJ(:[QECVK:ZQWM"MEZZ:&'@PO'9<Z-,#0E?,
MJ.Q;W8_91X`QVQ#2/>+.=_:PFU?Y<-=:H$(L41#M#EWC+OE4UTB3_9^><</7
M!TS5[;A[(6]5OMO]WL0.E`_.2_>;DN1#G3,LN`C@(W2=()PL,-BEA1T1+-6/
M[F-&PS#Z*ST]7D0'A`4(V,%Q'S.\PJ<['P=@P?Z<@17"87)>ZG0(*'QOCZ>+
M^.:<[2Q=G20R7TAPK3+7&>RI(@>0*@$$'KN*C7_*/M3RC7(D!96#ZCKW:9_=
MPR.<5V[RY>BRG0#W<(&>CSP`CYB^V5_&\4O&27+5_B?ZHQ\3^FF/??[:=Q:;
MYGQG#ORO!\7?'W4NS\4:LSO;:SK4'/\?P,%7@7=)NXHCFK!H-2F+0Y+]Y(=*
M]TSF),0.NV[,"5>]?O=ZW8@1:XN>(B'RKNG/"$>QXK+[EI/UJIJ4:<G]R9CI
M24;^IW1!D0G*+;X_:>-^%$\G?KG]R?=`FY6(%?VZ>VFB.<K.;>S(RA$G__L]
MR?-Z016`'7]*=YN7_P6O(KD*Y?8F7WH4BFZGR.TZ9*_-[%97+*RLTKXDOT1+
M!P9"&9-?[TN::^@#?$'GW0)A<2_G2^U+MAE80+9=!>%W9RF<&KO%NI?N!BP<
M/_[VY`7R%N#=$MW+1,_%;!3?OR[GR.=(E/_]5IXLVYS@O&P.=C<-T;\6J&;>
MPB(I<;2*'L#'[A/TMRSU$:-E'8ZRD0;Q%L(1PI0_1U9"]+^#$6T=8=K0UX/3
M@]&:4%E1]/[GZ$&KNFMOP.7WI!3;R0"P[3#^%-SI`,`)R$X*\FQ`(`L<.87Y
M;G`P<T>6%.C[`0#=V2U2<!\&`(Y/'E*,OPP&8X&DIR`_#@"D^&8FQ?EI`#BY
M3'P+\60(]$;ET)8B-I7T<(_J&XB%4X'Y!%6*1]Z]&W#'Q^;"$YS3\F-R<QRO
MVEM?CG9OZCN_OU>TIJY]UGQTR#S2\9J,%XZSB@^<P`_)YB>[)\_DQS\2"\N-
MX45L<XG7P+N!SCRQ2TA6\YVS:9T6ZI^FFR.<`1?`9R;B=Q"J0>)6T8+!\V`\
MAN\<Z$V#"V<%0\?/K,HB).45M>")K+5$,L>_U">7X*E&4$B?G"6#.%=&NY1*
M2MTMJT/J9(K<`(>`V[D/%[%IL5S9)94,PO$=!6X=*)EZ>M"0)V970?]@)KS/
MCA]96H07#L:OE(3^S?'7NQ?-U>IJ024V&A%AD=30A2#92:1=L%M,CZS!,\`A
M,Q>^0<'B`>!EUNA4*+J\E@XD/#/*#=UZ30EEZ5ROWHYY:!L`-`!3?!P`D6=&
MJF9*-TL`B>OI1#,#SR!8`[4^V2EL@-S*\Z587H?T5\N5CUX!2*QLE4]LY?6&
M\J)>7[>[GB5T9EV])+YGWQ#R?D)_][&V4M5AO777UW-F\`G4F2VA64+*N(J^
M9.5B\ZN9B*7DD*9<73,V^?)GR+U440QU[9MP3LZ(D^Z#ZA`X=72@B`(/).MT
MV>[/+ZM-ZO1VDI3>:$HJZ)#_#H.5`[VK%T;*P2;^@\JMEDI-/8C0BIX27YE#
M0$C%8@OB:BFE\M(J.C#,`)V(T&6.X@UN6ZJVH@=I2(DE\#:>TA/772_7$1NF
M%!^Z4-1G"A5UX+E_0CAD-Q/G"&/TDTDF`,`KJ47BS8M8X>%Y5^!B0:WR<E[P
M2C8]I:I:,?$,V`6%],BIR+D-8=F5>;4*D][C"WS^389GU%ORPK-]D3\UT>1.
M'9Y\4T]1FFA[IXY2[:HC16NB%9XZ6@'A3^&9:'^G#D_A7CF%:J()7M7%)X/G
M++'_251P$R^R0EDB04+$WCI92<,U(;@CR"I$D;6G^C+16J\R:KE]3PKVM/K@
M>`9XC@@8R/"071JD:C+1Z:$RU,HGV12_B=X0E?$KW:^DF-^_]:DAU,R'0>TH
MG9O6ZNGFJJ\:V9Z7W<*;[>[6,GK>';[9KG`M*X#C$C>0:=^&HJ26:F:[V+4!
M7U;:;!^\EF>)X`F\X*,WW*FC0">XU_%F>_C5`UK)>\1LU[]Z"E`PP3+;';`>
M;)&]7\$1<'!'BFIZ*O,E2/75$X9986S(K753Y#VAE@K(Y;-_\)Q2;`64)Y(E
M1OBIQFI0B;ZM(6HZDY@II]KZ:+4E773Y6NL)%:DV3BJXA:2/034>3WHQ?L26
M)L4;0,ZA[L3D(ZT:-O6C7XK:Y*-L%5N<_"$^;^_2C]M-OI5.3V-7E(.2#6W3
M0U>H&P#M7JWE72C31=GD%]IJ*%5"&*2X33X.5<.M8FJ:XCX;[";<[+8UJZ.N
M#U+&QH?)IZC4$TIE,W8G2Q;G/\[M=_N8,DJ>_9'`ZK%N:YK=W&DOW.*HP[QH
MN=YDV1*@5*FI&5$<T6NR#I_HQ/A/.H;%2`HUC$`P)62M+GU2V@C)Q2&PE:H,
MQ5UW6*ZMUL6AYRX.UC)G3W<O=6E%/PQTU)2@Q##Z89!3&7"1@)@=G;HAT`U/
MZ8?93$V0_`"Q1IO(V'M%>Z_8BQBR<89)'3<`S/"/30.2/$4*3RL[Q?2<L@C5
MU3W`S]"5Q-/+%=(2QFDG7?>Y0Z`[";Q+Z*]#X7FVK-90SH3U]?J-?O@&$7(;
MW#L^H)W,-J=I<+^>$^A!![_>XOAR\5=`B8<W#9X!"8%H2-=M30MR$`#L^,P<
MSUO"(,JF$,)GD/B#B!"6U-*"!%.5WV'T*(S(D"VA)U`86XNWBW/)05E46E.(
M,T"WJS"6*>EE>N1B/L\.,^\6ARY1JFKO@3;/[RY33\F6N5M*AZ2TU^(>90N=
M0,Y\&2U29L99;@"*)!:6-TKZDI6CO)Z60%0;D1)A1*.F6,X(:4MT+BZO5?K2
M.<HKJ2?,$CT*^;$0V?$K$%M87%,P+$#/G<QY^)(NR3Z*`G_(5QIY'2WWWY2K
M;K84\7:^6\J^EI@0/$F0;/SO@&6>!][DF4Z/!?B^7LX!CDY_R=&O[$FQ;BLZ
M[W5*6'9_;^,&^O"CS')V`A$I'$CZX3E22P'B_;+@1C(<T!(Z7S#"'ICS3"D?
MW8EI(B,D_3#=KH2X]!JKX"HT`,QU+RW5'($B#.LMN8EG2L0+C@*Z"T77S4-0
M(^=<6O#Y&=ABHNH+LG,9-2P;BMW7J2$93!3.<D./5Z+:Z?EGOB%95>2>/PI&
M%&^RNR7;@-F)PFO"S%[V%4*(O,D1H'#*Z$>H$46X^4>90CB1-SD&2FTFS$Y)
MK@:V]G5?/\**6`.TWAJ@16,N[\Z7Q!AEH0?HK^AR3`_J^NS4!-ZFOP(V>P27
M]?(ZFOV$I)(7RUGKKWA8LN&(`N9`P!-47M;:K_3)*F37SUHZ802%]:3N47,`
M;-/K3X.T/T[UOM+N3''"F6]J=>S;>"5/PAJY<%3J#O/%ORTY^YXN25G>RJN*
MP*8B?F6)W+(NUY@N5_1<"5%RM+J$&+BTI:C0Y*>#=TWR:S6A3=,B&;^#G]&O
MQ&N+4F7C<&WN!_)AT>J`%+34_0B,?OEW!V.'[D)7+P"[D!0<0VHWTZ7\D?]J
MHPDD:L&@<1:)6'/Z[-0U#54;DT?64.=CK_'4D;6B\Z))>KX5>.9NSD3]"&ZH
MC+#DLJ<?EC'*:$4'7;.-809JYZATOLP]7/"[N6=HI6\S4O__&EG85C&%"1T<
M#N'I2IX^HT8`P"'JIRJ9'U*\D#I\;`A&+_5.XCT++5(9N?`$-21K%]6+B7[D
MT&D^S;F0:YBM]B0V;+-5073$ZT?BG88K0SGX_MJ_E%I`]<*ZI1I7_G'*\7"J
MS@:O`J_/DUYZX]\LIT[?]*/RA-9?]T=K"R:[/DA@G@X&YDU_3=Y8!O%K'_TD
M4[I.,S:NQZSM_]8DSL+Z@&;`18$+HWSWZ?[X@)BD=Q@]0PK[_/4W2@>FP=:<
M?.*&\#E.!2-_A^_D4UJ,Z-0RP'.5H%9WD*@T&>SP98L)+QUYF"7UN@3QGY7@
M"9K0A9$M)2R\,?UK[,/))DR0Q#?.39Y+2%P?D34NBQ#4N%D])J[;=(#9-(`E
MYJZR.CI07()Y&$M%6,:.6#ZV&%+-KJ.`%4N6)_=$`$BY>BO/I3O9!+,AMWGO
MHK+B>G1--WP71@+0O_L@HCJ!)\%1J:H63)"L$''\;QBM5W2-\M?L+,BF:)1H
MG1[\DUV5BIND7(Y&/I7]!CD!H?LSH`O=W)<$^6GW&^V,Q.HB%3)-"P*/M=^^
MX>-B2AEPL&!K8IS*L)6!P&O4<#W$7BA)KLQ(Z.9JX+39!RUD\CZVI(-LBWW0
M0)I`HGU=\-LV7"OTL$;_&K[>^0X=RH''"'(41Z:5Y4+:NG5)VHWM$E_ZQ#P]
M.F@+>J"\G@EH-IVO"&);7%/0YMPQ<"K>_\L7CIJ-F84[97>546:JFH&)EP9;
M&16WLEFXY(&DR^L9@F8-KC%:SD"4^.G.P6Q67&SRDJM"DS5B#$YV@=H0I:@)
M,S!>+5<^>@4@D;'.FBEIP@R,VWOMQ+RX/-*_:@.&X,N36NG92;6V0<C27:HB
MJ&Q%,_#<8;!RH+=9UC?1;Y((#!4[3JDQ,W#/*-_%T*6K`[OJ5D:X4TUGJ@WF
MGR"4.U/$AAZ(E4+/C;PG1LYSAD"K%1HP&U]9=HCJ#1F$-WVJJMF?O`;,QE>O
M/V4-&8278P)0#2>O`;/QU>M/TVPEN@[U(G@'*GWY%972DH9EPW2C-_;R]$/B
M\CJDI_I+;'HF[K_7$`/AG:T`3H4&M.##R`7`(^Q6(&,GP%[818`D-70C8$;?
M+-_U[6/&BU<!![^>;C39":P`(E>\E74FV_IF'%\CG$1:WX98YVFY>GW=VI[1
M<UTL(HO7AW#X`/!2<1Z(Z^I&E7\\4%ZT*K2@&V'BS+'QY1!MP](JFC`\0V:_
M1&?$)5K/P\>UOWDB$&,05]$31"X=]VJ[AZR&;@0W*%BPB9O<-]ZPZY#;N0\7
MT:.&J%.JM*`E7(D+`@=#]%M`5L"%CQ!XTN".XO+:`N@I!U1I(VC*FP]!M[7<
M5X\\5ZRB%<-F"*L$+<R5M6'R)'*N5RL_DL'Q-_T]#1X17L8&@26#1;&V3L><
M+KU%LNX]\IU_ZZMU9K*[YKYTI6:]G.K,Y+0U^]*9Y,8E593,%;3'6:^ZUG&Y
M1T"J8I-#B^QK+)8&8#DS.0S)OK0DM@U,]?2+G;!MJIAC3)KJ>J`I`?>EZRK&
M0*G234X]U)8+8H[:M.O$M%7DNQK)KGH1^$9S)_`\95*E#S7:D&:ERQTPMNI_
M;W+`!\TJY'JZI9HS.=Y1FYKKP(,R5:(L3&>/"8,)*Z[`)RW5O2SHD]5](]T+
M-#[0NX/J-NQRTLOS%5)+26J5*#%&5XOP:%6HZ#FDEB#5JK.B.T$AH*15J\)$
M+_K3%*)76CVJ[3IRS]Q"S,PWH1N9WUTA2N:;T(C,V[(?:4]:UPC7&[H?25&Z
MTL76@]HF3='0J_6]GG:L#@26Q6FGFAPEOGTM%"U'4TV8_!C1OB8$=O-;=9S*
MC@9]OMUN7Y4%,]A4B2;?M+:O"(D]?:H2DTV<VE&)U$0Z5<1`+S';UV&ID7:J
MTX%>4S;3:0W'GE2C)I\#VAEJ53SH4[U\J+X]AHB-WCYNC@K>V:(]H=0;J1]Y
MR5I23`77TD*^LC>RJ%54:7D,E$+Z,ZO("LL@-_!$(;':VU@&*]K$B9(RG?;P
MI%D1>C=FAZGA8`_O;JH/'N6X(:E>9`]/_9V.I?Z,^63>TG0)Z2PT\3JS$F)A
M8)`4H\FW>\J9[>JO$^],7B<:X9=N[BE^D^^?&N&7GO%2_"9?-JGAKY;M)T5>
M(R]B'W:"!CHK9'Y*E54[2>)@4HJK)KS**$UV+!U(9DFIRO(1*U.]F/Q:K)A3
M5-7O.P5M-)E2"'0PH/R@O%`(.7AB;MDSI&\T$VJ^@[=90@>#[Z9)"E1-Z*I%
MRMC=>9L9_:<#W&BZ6U]%ZKD#4U6HV3AJ2)@;'=@?4-*WCK\=]N06+YP@"2I`
M01+D0R_ZQ[E#(&&/**E0YVM"9PDAEX"X&$:@8K-/I@@Z8NYH99>.EP<J[+G/
MWO0&DEO(E.C=LCBMW-X51,M1K:4ECFNG`S*OA_U\T\8%ZS@ZE37]K`NGXO(Q
MH`.+]"S:\1K4$^[TQD\\C4X$1G&\S1"]0,LY_2W[=DKI6R!K]9=]1<GXVX%B
MY:$DN+0DU-(G2Y^,VE4L?>+2)]55W?(@`T$-F`?EPI(0>5P28@A#:BPS?R]H
MW*QE5995659E695E5?MB5<UW`LNW#`0U;+Z5#,+(X7L;YB*)`W*!2$C2P-U;
M/R7-=*N1R$*VU:A52[8LV;)DRY(M2[;V2+::[0.6:QD(:L!<*XJA\(1\"H+$
M.2=8V58OL2R7L%SB#7")O<JI.FE%$%3K6Z9DF5)'?COJ8]AR(@-!#9@373DX
M@,&".:Y&7%WKS9)8&/[:+BYO;X,L@[,,SMX&68ZS+XXC6;LMIS$0U(`YS6Z6
MM0'?\-3?/524Q-]25&I:QF,9CV4\EO$,F?$HK:"6^Q@(:L#<AX5D,,4L6R`*
M?]D6E;8W.9;76%YC>8WE-7NSZQ&MVP4N,[@<1)8'#84'9<,O#_C^IP^L0M(+
M(DHAJ6+9CF4[ENU8MM.4[:BM3_;ZQD!0`Z8M#,GMXP4EU3"\=MPD([:E+?NE
M+66]P.$&954L;;&TQ=(62UM:H2VEZY.E+0:"&C!MN4QN`K-N@"QU9G/3&\%.
M6.F#G#VQ4GW[!+6_RR++;BR[L>SF3;.;:FN[?92R-*DO-(F.Z"4*(F_`KHA1
MR2<X&VA)#4M^+/FQY,>2'TM^]D)^RM9O>[-C(*@!4Y8DF-.=@\/7!TQ).)V0
MHN"9EBE8IE!QYZTRO/C;<I46+!>R7,C03<9R(:XM<J7UP7(C`T$-F!M-`UH:
M/#@O`R9#31S,)=KA;RO2*I;0]8'06;ICZ8ZE.W7ICGS-M/S&0%`#YC?W<!'`
M1^@Z03A98)"8^@R7ZUB>T$`ZY<'"D5&YKF4TEM$8NE-81E-\S%)?$RRU,1#4
M@*D->V:%83PS`^\B2@ZW`+00,"6I:44)^<M\Q4:LK<];(G*6'EEZ9.F1W@N?
MJJN\M7:V'*LO'.L>+-B?,[!".$RR\-J;(TLXFF[@"L-*L*LKU+04RE(H0S<3
M2Z'XR;54U@-[OV0@J"%SGS3CVPPNGD+"'!@MV[%LQW(#"3=H]/[(G7&\QT9N
M0<M/+#_IX@6,/RHM'3$0U![HR)<C]K6Y0P#]Q_\#4$L#!!0````(`'DR#S_9
MB,X4?0D``*9+```1`!P`87!R:2TR,#$Q,#8S,"YX<V155`D``\;R2$[&\DA.
M=7@+``$$)0X```0Y`0``[5M;<Z.X$G[?JOT/.GXYNU6#;[E,XDIFB]@D0QW'
M>,%SV?,R)8/LJ!8+KR1RV5]_6@(GV"8$<+8F4\<OB4']M;K[:UV1SGZ[7X3H
MEG!!(W;>Z#3;#428'P64S<\;GSS#]/JVW?CMP\\_G?W+,)`UN#)=Y+"0,H)L
MXYI(3N_15Y^$A&-)T`3?1RQ:/"#/OR$+_`Y-L2`!BACZ>N$.4;?90>A&RF6O
MU;J[NVN28(ZY$6EU33]:M)!AK*KZG!C50\?-3K=YDBEQHY@%/738G1ZV3_PC
M(^AVI\;A[.C(.#U^?V+X[SO^8>>H3<C)00;5YP1+4(@",+2'NNU.QVB?&)WN
MI-OI==N]@]/_9J6CY0.G\QN)?O%_!>'VD:$0:P%XAVSF-Y$9ALA5H@*Y1!!^
M2X)FJDGH*""(,1/GC8SC=P?-B,];H+?3^GH]3*+5^/DGE,CV[J<\I&L(]6:%
M.6A1)B1F/LE`P*(_"Q"J6)&1K60+DIK5.3T];>G2C'0LC#G&RT?Y&193+9T6
MM)*(=HR#SCI*/BR)R(7IDGP<7O)U_]4+/Q93&NE$4:#V\4$[`V$18_$B/P2!
MY"U56PN$#)`BH"P+?1FWA5$R@7R$9:-]U$H*,](^Y*SD#^OB@OC->73;2@OS
M(Q$0FH^"@GP$9;=$R'Q04K:)DYC/B1SA!1%+[)/2@8=FOR!,7D9\,2`S'(=0
MZU\Q#NF,DJ"!L(3N81I+LB80LR>1#TK+&68LDKIQZF?U9KFD;!:EC_!")6./
M1R&9`!M(_?CDVD5VRK0G:BG9UB#R8V7IZC]F@<4DE0\VU,(7NNX&HL%YHY3D
MHUTKRP(RHXQJ#SKM#C+0"I[]":I0H@MEE)VU-C5L*H^A"W78!_W;QZ$?AQHX
MA.<4G$H4`9<<^B8F:R"?+'L>E[Y=$?1JO'E@L$XQ9W9)&?1X%(?C2&AK^B$6
M(LTTQ9P+@&\E`<4$PK"!'A4A-1@P$854#1P!NL"AZGF1=T.(%'OV=F9OC#F(
MW!!)(3R5J=3H%_@\+,\G^F7-G%_W_);C%V9"T8+DLY>6%7-T5,318X%`T0PY
M2S79!-B^]95DQ[N!I+Z)P@#FU-9?,8Q`)@L<2'+>CQ;@W0UA@MZ2+1)]:M36
M4DSW<2FZ%=O]&\SF1"#*X'WD_YD:\&^4F+!/@7(IT,?BYC*,[H3-`LJ)+_/;
MZK98,8_ORS=;I1IIW7O."C@;19*(2?0XY#T%T>%SS.C?VI^G.,/#!194.+-Q
MQM^+6,`*58@!$3ZG2_4*&JOIZZ4&+.['`/8I5$3NY44(S2J3#M_+@N),.U%3
M:2K\,!(Q)_!P87JVAYQ+-'8MSQI-S(GMC/:I52NU5F1!1SZ%4F7>4ZRKY4A)
M5<5DGVZ2;?9__V1[MJ)847YA.\;OG\S19,]W+;XAMLM(X/"*1_$2^GH_C-66
MGPIYI%IG#/8]SK+J9L+.E13F2*>]F2.>.;3VR?$JR9$&%>8#,+.#:9WVS26A
M&M;[D9!"SP4OU.;N&#]H5.7<V*F.XM3H;'<??>?3:&*/KM"EXR)OXO3_8\``
M8@U0W[D>6R-O/WK43YCLO#R9E2O9NMU&>6W%2=#=3((OINM"K^#M6:[%LH4Y
M@^Y;C`G7+;,:J\^CBUD\V&1QZ'@>&EO0B#^:KK7GLA:7MMK8GM-I2$PAB*P]
MQ)?14\SOX2:_-LSD1U?V!8SEIN=9^^9:=Q0G4UE[YO8,MIC*HTTJ^\[HL^5.
M-)<C9V)!NS7_,.%I3VDM2G4)S(4PM+>ZU+ZDHYCBXTV*][3N3BO8HF;!G`14
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M-0M6N*H6Y%X=*EOW"J`J/2I57>$-K.>JU57F7OEJD5"*1UW&DZ[JT=^Z;54J
M")LH%8E3%?[.\2XF9"Z*530C8J-ZEA1=J=N!&/6F*B\OW4\K-"</MWK8R9"-
M*V^EC%AAU(^=*M^^.E>J_@PL_?V,%>EE.FT&3"E*;"&KGOO;2X+)X)-<CNS)
MU7L;YK)J;M9`>"HDQ[X\;\QPJ(<7=?>T!\,.C8*)!@<Q3V_(,1J&ZLOA>4/R
M6'60,:"IC%6I/N9WWDC@%/3G.U;]HXAVLQKLK3KMDEO"8F(NU(+P[\RUPS4?
M<Z42EY**@'`B,7^HZ5!2-DTN/D$!F5+Y.FYF3WP6'_A,#X*O/D4G1\.AWL"Z
M5_P2D8W+JZK=.9#)3$-NQ='77U]?)Y`E;J&:J:790%6"90,![R"D>6%(?/B'
MV\>PS"=P[>*+DF^MZ9<ZM*%=>U'R+;MV3193PI_Q9E6XYD`0+3!EW]GZW`V>
MG)951O@-M:<QCWQ"`G')H\7J\/1EQ#T<0N/Q0!\-*'1[>M:0\;(:[$<8D:I]
MW-%!*`]Y:^VQ8$LS\2R__$VZ80L!H_8@5LUHK&O2QX:!"'4K$7)2"9EWF`>;
M#E9!KC59+?5&W=:%7S#G6)VEOB?<IX*4=OTY]`_@_F<<QJ0.Z<\"_[ENZQ4G
M@$5.U<V%0O`/$94O1'5;)#!O8;H_)Z-832O4W5-_0,,8"I)T=V*I9NAJD9")
M2AWP=VP@9ZUD=P%^_@]02P$"'@,4````"`!Y,@\_)4RCE/J-```B;08`$0`8
M```````!````I($`````87!R:2TR,#$Q,#8S,"YX;6Q55`4``\;R2$YU>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!Y,@\_=8ASB#,-``#7K```%0`8````
M```!````I(%%C@``87!R:2TR,#$Q,#8S,%]C86PN>&UL550%``/&\DA.=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`>3(//\&_\Q!^%P``LL(!`!4`&```
M`````0```*2!QYL``&%P<FDM,C`Q,3`V,S!?9&5F+GAM;%54!0`#QO)(3G5X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`'DR#S\1?ITN&"(```7(`0`5`!@`
M``````$```"D@92S``!A<')I+3(P,3$P-C,P7VQA8BYX;6Q55`4``\;R2$YU
M>`L``00E#@``!#D!``!02P$"'@,4````"`!Y,@\_=<5=!ET8``!Z[@$`%0`8
M```````!````I('[U0``87!R:2TR,#$Q,#8S,%]P<F4N>&UL550%``/&\DA.
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`>3(//]F(SA1]"0``IDL``!$`
M&````````0```*2!I^X``&%P<FDM,C`Q,3`V,S`N>'-D550%``/&\DA.=7@+
B``$$)0X```0Y`0``4$L%!@`````&``8`&@(``&_X````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts', window );">Debt issuance cost, accumulated amortization</a></td>
        <td class="nump">$ 47,860<span></span></td>
        <td class="nump">$ 29,289<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="nump">75,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
        <td class="nump">20,012,080<span></span></td>
        <td class="nump">18,521,951<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
        <td class="nump">20,012,080<span></span></td>
        <td class="nump">18,521,951<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of accumulated amortization of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 17<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EYOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fee revenue</a></td>
        <td class="nump">$ 668,899<span></span></td>
        <td class="nump">$ 32,550<span></span></td>
        <td class="nump">$ 871,449<span></span></td>
        <td class="nump">$ 35,100<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contract service revenue</a></td>
        <td class="nump">926,253<span></span></td>
        <td class="nump">1,438,377<span></span></td>
        <td class="nump">2,310,768<span></span></td>
        <td class="nump">2,881,579<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
        <td class="nump">1,595,152<span></span></td>
        <td class="nump">1,470,927<span></span></td>
        <td class="nump">3,182,217<span></span></td>
        <td class="nump">2,916,679<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of services</a></td>
        <td class="nump">1,006,225<span></span></td>
        <td class="nump">1,021,951<span></span></td>
        <td class="nump">2,011,233<span></span></td>
        <td class="nump">2,059,183<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">588,927<span></span></td>
        <td class="nump">448,976<span></span></td>
        <td class="nump">1,170,984<span></span></td>
        <td class="nump">857,496<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">1,971,832<span></span></td>
        <td class="nump">477,566<span></span></td>
        <td class="nump">3,072,378<span></span></td>
        <td class="nump">903,959<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,687,041<span></span></td>
        <td class="nump">2,640,400<span></span></td>
        <td class="nump">6,593,294<span></span></td>
        <td class="nump">4,879,936<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee', window );">Loss on sale of Bio-Quant subsidiary</a></td>
        <td class="nump">2,759,920<span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">2,759,920<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">8,418,793<span></span></td>
        <td class="nump">3,117,966<span></span></td>
        <td class="nump">12,425,592<span></span></td>
        <td class="nump">5,783,895<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(7,829,866)<span></span></td>
        <td class="num">(2,668,990)<span></span></td>
        <td class="num">(11,254,608)<span></span></td>
        <td class="num">(4,926,399)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
        <td class="num">(75,708)<span></span></td>
        <td class="num">(1,609,657)<span></span></td>
        <td class="num">(173,452)<span></span></td>
        <td class="num">(8,589,704)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental income</a></td>
        <td class="nump">111,482<span></span></td>
        <td class="text"> <span></span></td>
        <td class="nump">222,962<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">35,774<span></span></td>
        <td class="num">(1,609,657)<span></span></td>
        <td class="nump">49,510<span></span></td>
        <td class="num">(8,589,704)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (7,794,092)<span></span></td>
        <td class="num">$ (4,278,647)<span></span></td>
        <td class="num">$ (11,205,098)<span></span></td>
        <td class="num">$ (13,516,103)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
        <td class="num">$ (0.39)<span></span></td>
        <td class="num">$ (0.47)<span></span></td>
        <td class="num">$ (0.58)<span></span></td>
        <td class="num">$ (1.64)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">Weighted average common shares outstanding used for basic and diluted loss per share</a></td>
        <td class="nump">19,817,009<span></span></td>
        <td class="nump">9,140,451<span></span></td>
        <td class="nump">19,475,598<span></span></td>
        <td class="nump">8,264,515<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_WeightedAverageNumberBasicDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) on entity's disposition of equity in securities of subsidiaries or 50 percent or less owned persons. Reflects the difference in the parent company's carrying amount of the equity interest in the subsidiary (or equity method investee) immediately before and after all stock transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 9<br> -Section 04<br> -Paragraph 13<br> -Subparagraph g<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of nonoperating interest income (expense).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestIncomeExpenseNonoperatingNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RentalIncomeNonoperating</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;SEGMENT
INFORMATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through
June 30, 2011, the Company had two active business segments:
designing and developing pharmaceutical products with its
NexACT&#xAE; drug delivery technology and providing pre-clinical
CRO services through its subsidiary, Bio-Quant.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Segment
information for the six months ended June 30, 2011 and 2010,
respectively is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX MONTHS</font></div>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30, 2011</font></div>
</td>
</tr>
</table>
</div>
</div>
<div>
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" align="left">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold">NexACT</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold">&#xAE;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#xA0;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Drug</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Bio-Quant CRO</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Other</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Corporate Not</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Allocated to</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Segments</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Consolidated</font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Total</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">871,449</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,094,041</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,727</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,182,217</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating
expenses</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,072,378</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,189,553</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,163,661</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,425,592</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss
from operations</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,200,929</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(174,099</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,879,580</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,254,608</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,200,929</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(186,828</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,817,341</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,205,098</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
assets</font></div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,080,283</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,080,283</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
</div>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX MONTHS</font></div>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30, 2010</font></div>
</td>
</tr>
</table>
</div>
</div>
<div align="left">
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold">NexACT</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-WEIGHT: bold">&#xAE;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#xA0;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Drug</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Bio-Quant CRO</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" colspan="2" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Other</font></font></font>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Corporate Not</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Allocated to</font></font></font></div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Segments</font></font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Consolidated</font></font>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Total</font></font></font></div>
</div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">35,100</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,560,266</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">321,313</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,916,679</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating
expenses</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">916,743</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">768,488</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,098,664</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,783,895</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss
from operations</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(881,643</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(63,242</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,981,514</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,926,399</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></div>
</td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(881,643</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(52,499</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,581,961</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,516,103</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
assets</font></div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,045,423</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,435,240</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,480,663</font></td>
</tr>
</table>
</div>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 131<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SegmentReportingDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E4GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 09, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2011<span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">APRI<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">APRICUS BIOSCIENCES, INC.<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001017491<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">20,022,080<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;LOSS
PER SHARE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At
June 30, 2011 and 2010, respectively, options to acquire 916,818
and 156,771 shares of Common Stock, warrants to acquire 1,077,642
and 250,895 shares of Common Stock and convertible securities
convertible into 636,257 and 466,200 shares of Common Stock were
excluded from the calculation of diluted loss per share, as their
effect would be anti-dilutive.&#xA0;&#xA0;Loss per share for the
three and six months ended June 30, 2011 and 2010 was calculated as
follows (net loss / weighted average common shares
outstanding):</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE THREE MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,794,092</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,278,647</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,205,098</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,516,103</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted
average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;&#xA0;&#xA0;used
for basic and diluted loss per share</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,817,009</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,140,451</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,475,598</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,264,515</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic
and diluted loss per common share</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.39</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.47</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.58</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.64</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DEFERRED COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_DeferredCompensationPlansDisclosureTextBlock', window );">DEFERRED COMPENSATION</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;DEFERRED
COMPENSATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
February 27, 2002, the Company entered into an employment agreement
with Y. Joseph Mo, Ph.D., that had a constant term of five years,
and pursuant to which Dr. Mo would serve as the Company's Chief
Executive Officer and President.&#xA0;&#xA0;Under the employment
agreement, Dr. Mo was entitled to deferred compensation in an
annual amount equal to one sixth of the sum of his base salary and
bonus for the 36 calendar months preceding the date on which the
deferred compensation payments commenced subject to certain
limitations, including annual vesting through January 1, 2007, as
set forth in the employment agreement.&#xA0;&#xA0;The deferred
compensation is payable monthly for 180 months commencing on
termination of employment.&#xA0;&#xA0;Dr. Mo&#x2019;s employment was
terminated as of December 15, 2005.&#xA0;&#xA0;At such date, the
Company accrued deferred compensation of $1,178,197 based upon the
estimated present value of the obligation.&#xA0;&#xA0;The monthly
deferred compensation payment through May 15, 2021 is
$9,158.&#xA0;&#xA0;As of June 30, 2011, the Company has a
discounted accrued balance of approximately $839,500 included in
deferred compensation. The remaining amounts accrued in Deferred
Compensation also relate to severance amounts due to former
employees of the Company.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_DeferredCompensationPlansDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Compensation Plans Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_DeferredCompensationPlansDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ACQUISITION OF BIO-QUANT<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION OF BIO-QUANT</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;ACQUISITION
OF BIO-QUANT</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
In connection with the Company&#x2019;s acquisition of Bio-Quant,
which was consummated on December 14, 2009 (the &#x201C;Effective
Time&#x201D;), each outstanding share of common stock of Bio-Quant
was canceled and converted into the right to receive 60.93 shares
of common stock, par value $0.001 per share, of the Company (the
&#x201C;Apricus Shares&#x201D;), as well as a promissory note (each,
a &#x201C;Note&#x201D;) in the original principal amount of
$2,771.37.&#xA0;&#xA0;&#xA0;In connection with the closing of the
Merger, the Company issued an aggregate of 266,667 Apricus Shares
and Notes in the aggregate original principal amount of $12,129,010
to the shareholders of Bio-Quant.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Notes accrued interest at a rate of 10% per annum through their
repayment, with all principal and interest accrued thereunder
becoming due and payable one year from the closing date of the
Merger.&#xA0;&#xA0;The terms of the Notes provide that the
principal amounts and all interest thereunder were payable by the
Company in cash or, at the Company&#x2019;s option, in Apricus
Shares, which would be valued for purposes of conversion at the
fixed price of $2.52 per share.&#xA0;&#xA0;The Merger Agreement
provides that if the Company repaid the Notes in Apricus Shares,
the total number of Apricus Shares issuable to Bio-Quant
shareholders could not exceed 19.99% of outstanding Apricus Shares
at the Effective Time unless the Company received stockholder
approval to do so in accordance with applicable rules of the NASDAQ
Capital Market.&#xA0;&#xA0;The Company received stockholder
approval at its May 24, 2010 meeting for the potential issuance of
shares in full repayment of the remaining amounts owed under the
Notes, and, on June 21, 2010, the Company repaid the remaining
outstanding principal and interest accrued under the Notes in
Apricus Shares.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intangible
assets acquired from Bio-Quant of $4,160,000 consisted primarily of
developed Know-How and the Bio-Quant Trade Name. Developed Know-How
related to Bio-Quant&#x2019;s pre-clinical service expertise
including, but not limited to, its extensive inventory of
internally developed cell lines. The Bio-Quant Trade Name
represents future revenue attributable to the reputation and name
recognition of Bio-Quant within the pharmaceutical industry where
Bio-Quant is a known expert in pre-clinical services. (See Note 3
and Note 7 for the sale of Bio-Quant and the write-off of these
intangibles).</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
At the time of acquisition, Bio-Quant was a revenue generating,
cash flow positive CRO.&#xA0;&#xA0;Bio-Quant was expected to
continue its revenue growth and cash generating CRO
business.&#xA0;&#xA0;The $9,084,476 of goodwill generated from the
acquisition of Bio-Quant consisted largely of the ability of the
Bio-Quant CRO to continue to grow its revenues and generate
positive cash flow to contribute to the pharmaceutical product
development business segment of the Company.&#xA0;&#xA0;As
discussed in Note 1, the Company shifted the focus of the Bio-Quant
CRO from growing revenues and generating increased positive cash
flow to largely supporting the Company&#x2019;s research and
development business segment which designs and develops
pharmaceutical drug candidates. <font style="DISPLAY: inline">The
Bio-Quant CRO allowed the Company to increase its active
pre-clinical and clinical product pipeline from 4 drug candidates
to 13 drug candidates</font> utilizing <font style="DISPLAY: inline">the internal capabilities of the CRO. However, as
a result of this internal</font> research <font style="DISPLAY: inline">focus the cash flow generating capabilities of
the CRO diminished over time and in connection with the</font>
valuation of the future expected cash flows and the goodwill
related to Bio-Quant at December 31, 2010, an impairment charge of
$9,084,476 was taken in 2010 to write off the entire value of
goodwill<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font><font style="DISPLAY: inline">from
this acquisition</font>. <font style="DISPLAY: inline">During 2011,
the Company, considered the significance of its enhanced
product</font> candidate <font style="DISPLAY: inline">pipeline,
the resources needed to further develop each of those product
opportunities and the value being derived from the CRO business
with diminished cash flows towards operations. Based on</font> this
<font style="DISPLAY: inline">change in strategic focus, on</font>
June 30, 2011, the Company entered into a stock purchase agreement
with BioTox to sell all of the outstanding capital stock of
Bio-Quant. (See Note 3).</font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51, 52<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1500-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7000-128479<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6927-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e7008-128479<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1490-128463<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6911361&amp;loc=d3e6996-128479<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Appendix F<br> -Paragraph F4<br> -Subparagraph e<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1383-128463<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1392-128463<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1497-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 67-73<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1524-128463<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 88-16<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6909870&amp;loc=d3e1486-128463<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;CONVERTIBLE
NOTES PAYABLE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
2010 Convertible Notes</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
On March 15, 2010, the Company issued convertible notes (the
&#x201C;2010 Convertible Notes&#x201D;) in an aggregate principal
amount of $4 million. The 2010 Convertible Notes are secured by a
first priority mortgage on the Company&#x2019;s facility in East
Windsor, New Jersey and are due on December 31,
2012.&#xA0;&#xA0;The proceeds were used to repay the 2008
Convertible Notes (see below) then outstanding in the aggregate sum
of $2.6 million.&#xA0;&#xA0;As such, the Company received
approximately $1.4 million in net proceeds from the issuance of the
2010 Convertible Notes.</font></font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The 2010 Convertible Notes are, at the holders&#x2019;
option,&#xA0;&#xA0;payable in cash at maturity on December 31, 2012
or convertible at any time into shares of Common Stock at a current
conversion price of $6.29 per share (with an initial conversion
price of $8.70 per share) (the &#x201C;conversion price&#x201D;),
which price is subject to adjustment upon certain dilutive
issuances of common stock.&#xA0;&#xA0;The 2010 Convertible Notes
have a coupon rate of 7% per annum, which is payable at the
Company&#x2019;s option in cash or, if the Company&#x2019;s net cash
balance is less than $3 million at the time of payment, in shares
of Common Stock.&#xA0;&#xA0;If paid in shares of Common Stock, then
the price of the stock issued will be the lesser of $1.20 below or
95% of the five-day weighted average of the market price of the
Common Stock prior to the time of payment.&#xA0;&#xA0;Such
additional interest consideration is considered contingent and
therefore would only be recognized upon
occurrence.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The conversion price at June 30, 2011 was $6.29 per share which
represents an adjusted price from $8.70 at issuance due to certain
dilutive equity financings since the issuance of the notes. At June
30, 2011, the conversion price was above the current market price
of the Common Stock.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
Conversion of 2008 convertible notes during
2010</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
On January 26, 2010, the Company agreed to convert $397,988 of the
then outstanding 2008 Convertible Notes into Common Stock at a
price of $7.50 per share.&#xA0;&#xA0;As such, the Company issued
53,333 shares of Common Stock to the note holders in repayment of
such $397,988 principal amount plus interest.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The remaining balance outstanding on the remaining 2008 Convertible
Notes of $2,592,012 was repaid in full on March 15, 2010 with the
proceeds received from the 2010 Convertible
Notes.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company recognized a debt inducement charge in interest expense for
the differential between the original conversion rate of $30.00 per
share and the various adjusted conversion prices in 2009 and
2010.&#xA0;&#xA0;Non-cash interest expense recognized for these
conversions was $1,200,000 during the six months ended June 30,
2010.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19, 20, 22<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;RELATED
PARTY TRANSACTIONS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Approximately 63% of the Bio-Quant notes payable described in Note
8 were held by executives of the Company.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
FasTrack Pharmaceuticals, Inc. (&#x201C;FasTrack&#x201D;) and
Sorrento Pharmaceuticals, Inc. (&#x201C;Sorrento&#x201D;) were formed
by Bio-Quant in 2008 and in 2009 Bio-Quant spun-off its
pharmaceutical assets to the two companies to enable it to focus on
its core business of pre-clinical CRO testing
services.&#xA0;&#xA0;&#xA0;FasTrack subsequently acquired
Sorrento&#x2019;s assets and liabilities in March
2011.&#xA0;&#xA0;FasTrack is a privately-held, development stage
company of whom two executive officers and one director of the
Company are minority shareholders.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline">On April 4, 2011 the Company and
FasTrack entered&#xA0;&#xA0;into an Asset Purchase
Agreement</font>, <font style="DISPLAY: inline">pursuant to
which</font> <font style="DISPLAY: inline">FasTrack sold</font> to
the Company all <font style="DISPLAY: inline">the rights</font> it
had <font style="DISPLAY: inline">in</font> certain <font style="DISPLAY: inline">back-up compounds for
PrevOnco</font>&#x2122;.<font style="DISPLAY: inline">&#xA0;</font>PrevOnco&#x2122; for the treatment of
solid tumors, contains a marketed anti-ulcer compound, lansoprazole
that could be <font style="DISPLAY: inline">used alone or in
combination with other chemotherapeutic agents.&#xA0; The Company
believes</font> PrevOnco&#x2122; <font style="DISPLAY: inline">can
be optimized further to increase its efficacy in combination with
our NexAct&#xAE; technology.&#xA0;</font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
In exchange for the PrevOnco&#x2122; back up compound portfolio, the
Company loaned FasTrack $250,000 in the form of a secured
convertible note and restructured the existing outstanding demand
notes and interest payable due to the Company into a second secured
convertible note in the amount of $224,520. The notes are due on
April 4, 2013 and bear interest at the rate of prime plus 1%
(currently 4.25%).&#xA0;&#xA0;The notes automatically convert to
common stock of FasTrack if, prior to the maturity
date,&#xA0;&#xA0;FasTrack completes a material round of financing,
or closes a merger or acquisition transaction (&#x201C;M&amp;A
event&#x201D;), or completes a public offering at an offering price
equal to the financing or M&amp;A value at that time discounted by
10%.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
In addition and separately, the Company granted FasTrack an option
to enter into a license to the Company&#x2019;s NexACT&#xAE;
permeation enhancer for the combination of two to-be-determined
specific drugs chosen by FasTrack and agreed to by the Company. It
is understood that these to-be-determined products would be outside
of the Company&#x2019;s core focus and expertise and it is expected
that these drugs would not be candidates that the Company would
likely pursue on its own. Under the terms of the license, the
Company would receive $500,000 in cash, plus milestones of more
than $5,000,000 per compound, and product sales royalties following
the exercise of the license option by FasTrack.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Company considered whether FasTrack should be consolidated as a
Variable Interest Entity (VIE) under ASU No. 2009-17, <font style="FONT-STYLE: italic; DISPLAY: inline">Consolidations (Topic 810):
Improvements to Financial Reporting by Enterprises Involved with
Variable Interest Entities</font>. The Company determined that
FasTrack is a VIE because it lacks sufficient equity at risk to
fund its operational activities without additional subordinated
financial support. The Company has a variable interest in the VIE
related to the convertible notes due from FasTrack even though we
do not currently have a direct equity interest in
FasTrack.&#xA0;&#xA0;In the accompanying consolidated financial
statements the loans and Notes are valued at a zero book value at
June 30, 2011 and December 31, 2010 for accounting purposes for
lack of marketability of the FasTrack entity. As a result of the
notes being carried with no value, the net impact to the
consolidated financial statements in the case of a consolidation
for the periods ended June 30, 2011 and 2010 would be insignificant
and thus FasTrack has not been consolidated as its operations are
not material to the Company.</font></font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
In July 2011, FasTrack entered into a merger agreement with a
publicly-traded Company, North Horizon, Inc. Under the agreement,
FasTrack will become a subsidiary of North Horizon. The
shareholders, noteholder, and warrantholder of FasTrack will
receive in the transaction the number of shares comprising 92% of
the fully-diluted shares of North Horizon. The transaction is
subject to customary closing conditions. Apricus makes no
representation as to the likelihood of completion of the
transaction or of the value that may be associated with the
interests of Apricus following the merger.</font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 3A<br> -Section 04<br> -Paragraph b<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 57<br> -Paragraph 1-4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph k<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_NotesPayableDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;NOTES
PAYABLE</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
Former Bio-Quant Shareholders&#x2019; Notes</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
December 14, 2009, the Company issued $12,129,010 in promissory
notes (the &#x201C;Notes&#x201D;) in connection with the acquisition
of Bio-Quant as discussed in Note 2 above. The Notes bore interest
at a rate of 10% per annum, with all principal and interest accrued
thereunder becoming due and payable one year from the closing date
of the Merger, or December 14, 2010.&#xA0;&#xA0;The terms of the
Notes provided that the principal amounts and all interest
thereunder were payable by the Company in cash or, at the
Company&#x2019;s option, in shares of Company common stock, which
were valued at the fixed price of $2.52 per share.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
January and March 2010, the Company repaid $2,230,201 of
outstanding principal of the Notes through the issuance of Common
Stock at $2.52 per share, which is the fixed payment price pursuant
to the terms of the Notes.&#xA0;&#xA0;As such, the Company issued
1,003,210 shares of Common Stock to the note holders in repayment
of such $2,230,201 principal amount plus interest.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company recognized a beneficial conversion charge for the
differential between the original conversion rate of $2.52 per
share and the market price of the Company&#x2019;s Common Stock at
the time of the above payments.&#xA0;&#xA0;As such the beneficial
conversion charge non-cash interest expense recognized with respect
to the Notes for the&#xA0;&#xA0;three and six months ended June 30,
2010 was $1,627,101and $6,139,741, respectively.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
2010 Promissory Notes</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
January 2010, the Company raised gross proceeds of $2.3 million in
an offering of unsecured promissory notes (the &#x201C;2010
Notes&#x201D;).&#xA0;&#xA0;The 2010 Notes accrued interest at a rate
of 10% per annum and were due and payable in full six months from
the date of issuance. The principal and accrued interest due under
the Notes was payable, at the election of the Company, in either
cash or shares of Common Stock, par value $0.001 per
share.&#xA0;&#xA0;The weighted average conversion price of the 2010
Notes was $5.55 per share, with the conversion prices ranging from
$5.40 to $6.00 per share.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
On March 17, 2010, the 2010 Notes were repaid in full with the
issuance of 415,504 shares of common stock to repay such $2.3
million principal amount and interest.&#xA0;&#xA0;The Company
recognized a beneficial conversion charge on the differential
between the original conversion rates of $5.40 to $6.00 per share
and the market price of the Company&#x2019;s Common Stock at the
time of repayment.&#xA0;&#xA0;The Company has recorded a beneficial
conversion charge to interest expense of $0 and $660,819 during the
three and six months ended June 30, 2010, respectively, as a result
of the conversion.</font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_NotesPayableDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes Payable Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_NotesPayableDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;INTANGIBLE
ASSETS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline">The intangible assets of the Company
at December 31, 2010 and through June 30, 2011 consisted of
Know-How and Trade Name related to the Bio-Quant CRO segment. On
June 30, 2011, the Bio-Quant business was sold to BioTox and the
intangibles associated with the business were removed from the
consolidated accounts of the Company. During 2010 and for the first
half of 2011, the Company amortized Know-How over the expected
useful life of 10 years and the Trade Name over the expected useful
life of 20 years.</font> Amortization expense amounted to $59,509
and $179,924 for the six months ended June 30, 2011 and 2010,
respectively.&#xA0;&#xA0;During 2010, the Company took an
impairment charge of $1,083,646 to write down the fair value of
Know-How to $1,637,000.&#xA0;&#xA0;<font style="DISPLAY: inline">Such impairment was derived mainly from the fact
that Bio-Quant significantly changed its strategic focus in
2010.&#xA0;&#xA0;Rather than serve the greater CRO market,
Bio-Quant was primarily performing</font> internal <font style="DISPLAY: inline">CRO services for the Company&#x2019;s own
pharmaceutical product development segment</font> (NexMed
USA).<font style="DISPLAY: inline">&#xA0;&#xA0;As such, the ongoing
revenue, profits and cash flows for Bio-Quant were significantly
reduced from the initial projections for Bio-Quant when it was
acquired by the Company in December
2009.</font></font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 44, 45, 46<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EBEAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (11,205,098)<span></span></td>
        <td class="num">$ (13,516,103)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reserve for related party note receivable</a></td>
        <td class="nump">275,990<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">417,477<span></span></td>
        <td class="nump">471,398<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash interest, amortization of beneficial conversion feature and deferred financing costs</a></td>
        <td class="nump">18,571<span></span></td>
        <td class="nump">8,716,575<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_DeferredRevenueAmortization', window );">Non-cash write off of deferred revenue</a></td>
        <td class="nump">133,670<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
        <td class="nump">1,145,733<span></span></td>
        <td class="nump">1,194,927<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfProperty', window );">Loss on disposal of fixed assets</a></td>
        <td class="nump">920<span></span></td>
        <td class="nump">312<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Non-cash loss on sale of Bio-Quant subsidiary</a></td>
        <td class="nump">2,759,920<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
        <td class="nump">44,675<span></span></td>
        <td class="nump">67,182<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease (increase) in other receivable</a></td>
        <td class="num">(25,990)<span></span></td>
        <td class="nump">437,794<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Decrease in due from related party</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">204,896<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase (decrease) in prepaid expenses and other assets</a></td>
        <td class="nump">79,550<span></span></td>
        <td class="num">(117,061)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase (decrease) in accrued rental income and other assets</a></td>
        <td class="num">(17,984)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accrued expenses</a></td>
        <td class="nump">1,628,934<span></span></td>
        <td class="num">(120,122)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (decrease) in payroll related liabilities</a></td>
        <td class="num">(45,013)<span></span></td>
        <td class="nump">138,124<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Decrease in due to related party</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(99,682)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Decrease (increase) in deferred compensation</a></td>
        <td class="nump">286,975<span></span></td>
        <td class="num">(27,496)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenue</a></td>
        <td class="num">(5,100)<span></span></td>
        <td class="num">(16,107)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(4,506,770)<span></span></td>
        <td class="num">(2,665,363)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">1,142<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
        <td class="num">(176,710)<span></span></td>
        <td class="num">(296,856)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Release (deposit) of restricted cash</a></td>
        <td class="nump">534,343<span></span></td>
        <td class="num">(603,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="nump">357,633<span></span></td>
        <td class="num">(898,714)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of convertible notes payable</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">2,300,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
        <td class="nump">1,318,461<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of offering costs</a></td>
        <td class="nump">2,741,403<span></span></td>
        <td class="nump">3,306,296<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes payable, net of debt issue costs</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">3,896,310<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Repayment of short-term borrowing</a></td>
        <td class="num">(401,000)<span></span></td>
        <td class="nump">401,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes payable</a></td>
        <td class="text"> <span></span></td>
        <td class="num">(2,592,012)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayment of capital lease obligations</a></td>
        <td class="num">(15,204)<span></span></td>
        <td class="num">(12,310)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock', window );">Proceeds from sale of Bio-Quant subsidiary</a></td>
        <td class="nump">500,019<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">4,143,679<span></span></td>
        <td class="nump">7,299,284<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(5,458)<span></span></td>
        <td class="nump">3,735,207<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">9,145,683<span></span></td>
        <td class="nump">479,888<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">9,140,225<span></span></td>
        <td class="nump">4,215,095<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">174,422<span></span></td>
        <td class="nump">67,762<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Sales of investment in consolidated subsidiary:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts Receivable</a></td>
        <td class="nump">199,236<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">4,833<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet', window );">Equipment and leasehold improvements, net</a></td>
        <td class="nump">780,983<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet', window );">Intangible assets, net</a></td>
        <td class="nump">2,642,003<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses', window );">Accounts Payable</a></td>
        <td class="num">(207,923)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Payroll related liabilities</a></td>
        <td class="num">(40,923)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Capital lease payable</a></td>
        <td class="num">(118,270)<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Notes Payable</div>
        </td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Sales of investment in consolidated subsidiary:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of common stock in payment of debt</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">397,888<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Notes payable to former Bio-Quant shareholders</div>
        </td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Sales of investment in consolidated subsidiary:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of common stock in payment of debt</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">$ 12,129,010<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_DeferredRevenueAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred revenue recognized but not to be included in current operations cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_DeferredRevenueAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from (payments for) the sale of subsidiary stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_ProceedsFromPaymentsForSaleOfSubsidiaryStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 32<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), the aggregate of amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business and an amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection and net of any write-downs taken for collection uncertainty on the part of the holder, respectively.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), carrying value (net of any accumulated amortization and write-downs) of nonphysical assets (such as copyrights, customer lists, patents, trade names, core deposits, trade secrets, and contractual rights), not elsewhere itemized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), carrying amount of assets not otherwise specified in the taxonomy that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), obligations not otherwise itemized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), obligations not otherwise itemized that are due after one year or operating cycle, if longer, from the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), carrying value (net of accumulated depreciation and any write-downs) of tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 47<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfEquityInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15, 16, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfShortTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 16<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 20<br> -Subparagraph b<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26, 31<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SALE OF BIO-QUANT<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">SALE OF BIO-QUANT</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;SALE
OF BIO-QUANT</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Company sold all of the outstanding capital stock of Bio-Quant,
which was one of the Company&#x2019;s wholly owned subsidiaries, to
BioTox on June 30, 2011.&#xA0;&#xA0;&#xA0;The Company received
$500,019 at closing as an initial payment and will be entitled to
receive earn-out payments calculated as a percentage of the future
gross revenue of BioTox&#x2019;s CRO services
business.&#xA0;&#xA0;Over the ten-year term of the earn-out, the
Company will be entitled to receive a minimum of $4,500,000 with
the right to receive amounts in excess of this, depending on the
gross revenue of BioTox over this ten-year period.&#xA0;&#xA0;The
earn-out obligations are secured with a first priority lien on all
the assets of Bio-Quant as well as the assets of BioTox for a
certain period of time. After the sale, the Company does not
beneficially own any equity shares in Bio-Quant or
BioTox.&#xA0;&#xA0;The Company evaluated the sale of Bio-Quant in
accordance with ASC Topic 205-20, <font style="FONT-STYLE: italic; DISPLAY: inline">Discontinued
Operations</font>. The Company does not expect to recognize
continuing direct cash flows from Bio-Quant after the
sale.&#xA0;&#xA0;However, the transaction is structured with a low
down payment and a payment stream over 10 years that is contingent
on the operational success of BioTox. This payment structure was
negotiated as a means to improve the likely cash available for
investment in the growth of the business, which was expected to
have the effect of&#xA0;&#xA0;encouraging higher revenues for
BioTox and potentially greater earn-out payments to the Company
over the ten year earn-out period.&#xA0;&#xA0;The Company does not
have any vote or influence on the execution of the operations but
retains a significant amount of collection risk depending on the
operational success of the disposed CRO business.&#xA0;&#xA0;This
continued exposure to the operating risk of BioTox and the extended
post sale earn-out period indicates future continuing involvement
in the continuing operations of the CRO. As such, the Company
determined that it would not be appropriate to classify the sale of
Bio-Quant as a discontinued operation in the consolidated financial
statements.</font></font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company also considered whether BioTox should be consolidated as a
Variable Interest Entity (&#x201C;VIE&#x201D;) under ASU No. 2009-17,
<font style="FONT-STYLE: italic; DISPLAY: inline">Consolidations
(Topic 810): Improvements to Financial Reporting by Enterprises
Involved with Variable Interest Entities</font>. The Company
determined that BioTox is a VIE because it could potentially lack
sufficient equity at risk to fund its operational activities
without additional subordinated financial support. The Company
determined that it does not have the power to direct the activities
of BioTox, nor does it have the obligation to absorb additional
losses and it will not participate in any residual revenues thus it
is not the primary beneficiary of the VIE. As such, the Company
will not consolidate the financial information of the
Buyer.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The estimated fair value of the earn-out payments expected to be
received over the next ten years is approximately $2.3, million
which represents the minimum payments of $4,500,000 discounted at
13.0% over the ten-year period.&#xA0;&#xA0;&#xA0;This receivable is
carried on the Company&#x2019;s balance sheet as of June 30, 2011 at
$0 due to a reserve of $2.3 million established at June 30, 2011,
based on the length of time over which the payments will be
received and lack of measurable external inputs available to
determine the fair value of the minimum earn-out amounts due. This
reserve increases the loss on sale of the Bio-Quant subsidiary and
is not reflected as a bad debt expense. In the event that actual
future cash receipts from BioTox differ from our estimates or we
adjust our estimates in future periods, our financial position and
results of operations could be materially
impacted.</font></font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following represents proforma results for the six months ended June
30, 2011 and 2010, respectively, as if the transaction had occurred
on January 1, 2010.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2011</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pro
forma financial results</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
As Reported</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Bio-Quant</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Adjusted</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
revenue</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,182,217</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,094,041</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,088,176</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,205,098</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,946,748</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,258,350</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic
and diluted loss per share</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.58</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.15</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.42</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted
average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">used
for basic and diluted loss per share</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,475,598</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,475,598</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,475,598</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
</div>
<div align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
2010</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pro
forma financial results</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="10">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Unaudited)</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
As Reported</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Bio-Quant</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Adjusted</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total
revenue</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,916,679</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,560,266</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">356,413</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net
loss</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,516,103</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(52,499</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,463,604</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="#CCFFCC">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic
and diluted loss per share</font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.64</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1.63</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted
average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
used for basic and diluted loss per share</font></font></div>
</td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,264,515</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,264,515</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,264,515</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#xA0;</div>
</div>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
unaudited proforma condensed financial information may not
necessarily be indicative of the results of operations that would
have been achieved if the sale of the subsidiary had occurred at
that time. The proforma adjustments are based on certain
assumptions that the Company believes are reasonable under the
circumstances.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2443-110228<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 144<br> -Paragraph 43-48<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ACCOUNTING FOR STOCK-BASED COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">ACCOUNTING FOR STOCK-BASED COMPENSATION</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;ACCOUNTING
FOR STOCK-BASED COMPENSATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
value of restricted stock grants is calculated based upon the
closing stock price of the Company&#x2019;s Common Stock on the date
of the grant.&#xA0;&#xA0;For stock options granted to employees and
directors, we recognize compensation expense based on the
grant-date fair value estimated in accordance with the appropriate
accounting guidance, and recognized over the expected service
period. We estimate the fair value of each option award on the date
of grant using the Black-Scholes option pricing model. Stock
options and warrants issued to consultants are accounted for in
accordance with accounting guidance. Compensation expense is
calculated each quarter for consultants using the Black-Scholes
option pricing model until the option is fully vested and is
included in research and development or general and administrative
facility expenses, based upon the services performed by the
recipient.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
December 1996, the Company adopted the Stock Option and Long-Term
Incentive Compensation Plan (the &#x201C;Incentive Plan&#x201D;) and
the Recognition and Retention Stock Incentive Plan (the
&#x201C;Recognition Plan&#x201D;).&#xA0;&#xA0;A total of 133,333
shares were set aside for these two plans.&#xA0;&#xA0;In May 2000,
the Stockholders&#x2019; approved an increase in the number of
shares reserved for the Incentive Plan and Recognition Plan to a
total of 500,000.&#xA0;&#xA0;In June 2006, the Company adopted the
NexMed, Inc. 2006 Stock Incentive Plan (&#x201C;the 2006
Plan&#x201D;).&#xA0;&#xA0;A total of 200,000 shares were initially
reserved for the issuance under the 2006 Plan and an additional
133,333 shares were added to the 2006 Plan in June
2008.&#xA0;&#xA0;The Company received stockholder approval at its
May 24, 2010 meeting to add an additional 1,000,000 shares to the
2006 Plan. The Company received stockholder approval at its May 16,
2011 meeting to increase the number of shares reserved for the 2006
Plan by 2,500,000 to 3,833,333. Options granted under the
Company&#x2019;s plans generally vest over a period of one to five
years, with exercise prices of currently outstanding options
ranging from $1.69 to $48.75.&#xA0;&#xA0;The maximum term under
these plans is 10 years.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table summarizes information about options outstanding at
June 30, 2011:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="12%" colspan="2" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="45%" colspan="11"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Options Outstanding</font></font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="25%" colspan="8" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Options Exercisable</font></font></font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%" colspan="2" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="12%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Range of</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Exercise
Prices</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="12%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Number</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Outstanding</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="11%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Weighted</font></font></font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Average<br />

Remaining</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Contractual
Life</font></font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Weighted</font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Average</font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Exercise</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Price</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Aggregate</font></font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Intrinsic</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Value</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="9%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Number</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Exercisable</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="12%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Weighted</font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Average</font></font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">Exercise
Price</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="12%" colspan="2" align="right">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Aggregate</font></font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Intrinsic</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt; FONT-WEIGHT: bold">
Value</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">1.69
- 5.36</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">870,000</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">9.6
years</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">4.36</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">109,990</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">4.01</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">85,391</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">8.25
- 48.75</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">46,818</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">4.4
years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">14.61</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">46,818</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">14.61</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="8%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="11%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">916,818</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 4px" valign="bottom" width="11%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">9.3
years</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">4.88</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">-</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">156,808</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">7.18</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 9pt">85,391</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
<div align="left">&#xA0;</div>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
summary of stock option activity is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Average Remaining</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Total</font></font></font></div>
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aggregate</font></font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Number of</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exercise</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Contractual</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Intrinsic</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Shares</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Price</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Life</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Value</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2010</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">107,604</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.37</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
5.8</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 9%" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">842,500</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.44</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-LEFT: 9%" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 9%" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancelled</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(33,286</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11.50</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at June 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">916,818</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.88</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
9.3</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested
or expected to vest at</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;June
30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">892,431</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.88</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
9.3</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="38%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at June 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,808</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.18</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
7.5</font></font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="9%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">years</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Expected Volatility.</font> The Company uses analysis of historical
volatility to compute the expected volatility of its stock
options.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Expected Term.</font> The expected term is based on several factors
including historical observations of employee exercise patterns
during the Company&#x2019;s history and expectations of employee
exercise behavior in the future giving consideration to the
contractual terms of the stock-based awards.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Risk-Free Interest Rate</font>. The interest rate used in valuing
awards is based on the yield at the time of grant of a U.S.
Treasury security with an equivalent remaining term.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Dividend Yield</font>. The Company has never paid cash dividends,
and does not currently intend to pay cash dividends, and thus has
assumed a 0% dividend yield.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">
Pre-Vesting Forfeitures</font>. Estimates of pre-vesting option
forfeitures are based on Company experience. The Company will
adjust its estimate of forfeitures over the requisite service
period based on the extent to which actual forfeitures differ, or
are expected to differ, from such estimates. Changes in estimated
forfeitures will be recognized through a cumulative catch-up
adjustment in the period of change and will also impact the amount
of compensation expense to be recognized in future
periods.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Total
unrecognized compensation cost related to unvested stock options as
of June 30, 2011 was approximately $3.1 million.&#xA0;&#xA0;That
cost is expected to be recognized over 3 years.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">
Compensatory Share Issuances</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
value of restricted stock grants is calculated based upon the
closing stock price of the Company&#x2019;s Common Stock on the date
of the grant.&#xA0;&#xA0;The value of the grant is expensed over
the vesting period of the grant in accordance with FASB ASC
718.&#xA0;&#xA0;As of June 30, 2011, there was approximately
$839,000 of total unrecognized compensation cost related to
non-vested restricted stock.&#xA0;&#xA0;That cost is expected to be
recognized over 3 years.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
2011, the Board of Directors awarded Dr. Bassam Damaj, the
Company&#x2019;s current Chairman, President and Chief Executive
Officer an option (the &#x201C;Option&#x201D;)<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#xA0;</font>to
purchase up to 300,000 shares of common stock of the
Company.&#xA0;&#xA0;The exercise price of the Option is equal to
$3.89 per share, the fair market value of the Company&#x2019;s
common stock on the date of grant (January 31,
2011).&#xA0;&#xA0;The Options become exercisable over a period of
three years, with one-third of the Options vesting immediately upon
the date of grant and the remaining two-thirds vesting quarterly
over the two-year period beginning on the first anniversary of the
date of grant. The expense related to this Option grant will be
recorded in 2011, 2012 and 2013 based on the vesting
period.&#xA0;&#xA0;&#xA0;As a result of this Option grant, the
Company recognized approximately $429,000 as compensation expense
during the six months ended June 30, 2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
following table indicates where the total stock-based compensation
expense resulting from stock options and awards appears in the
Unaudited Consolidated Statements of Operations:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE THREE MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
FOR THE SIX&#xA0;MONTHS</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
ENDED JUNE 30,</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2011</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">
2010</font></font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research
and development</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">110,783</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,284</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">136,420</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,284</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General
and administrative</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">415,557</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,040,090</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,009,313</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,184,643</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="9%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="52%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based
compensation expense</font></div>
</td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">526,340</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,050,374</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,145,733</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,194,927</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
</table>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
stock-based compensation expense has not been tax-effected due to
the recording of a full valuation allowance against U.S. net
deferred tax assets.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Statement of Position (SOP)<br> -Number 93-6<br> -Paragraph 53<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64, 65, A240<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMON STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_CommonStockDisclosureTextBlock', window );">COMMON STOCK TRANSACTIONS</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;COMMON
STOCK TRANSACTIONS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
April 21, 2010, the Company entered into a Sales Agreement with
Brinson Patrick Securities Corporation (the &#x201C;Sales
Manager&#x201D;) to issue and sell through the Sales Manager, as
agent, up to $10,000,000 of common stock from time to time pursuant
to the Company&#x2019;s effective shelf registration statement on
Form S-3 (File No. 333-165960).&#xA0; During the six months ended
June 30, 2011, the Company had sold an aggregate of 674,466 shares
of common stock under the Sales Agreement at a weighted average
sales price of approximately $4.26 per share, resulting in offering
proceeds of approximately $2.7 million, net of sales
commissions.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During
2010, the Company had sold an aggregate of 518,264 shares of common
stock under the Sales Agreement at a weighted average sales price
of approximately $6.73 per share, resulting in offering proceeds of
approximately $3.3 million, net of sales commissions.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_CommonStockDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock disclosure</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_CommonStockDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>WARRANTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">WARRANTS</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;WARRANTS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
summary of warrant activity for the six month period ended June 30,
2011 is as follows:</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Weighted</font></div>
</td>
</tr>
<tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Common Shares</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Average</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Average</font></div>
</td>
</tr>
<tr>
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Issuable upon</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exercise</font></div>
</td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Contractual</font></div>
</td>
</tr>
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Exercise</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="16%" colspan="2">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Price</font></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Life</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="16%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at December 31, 2010</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,675,658</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.72</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.28
years</font></div>
</td>
</tr>
<tr bgcolor="white">
<td style="PADDING-LEFT: 4%" valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issued</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-LEFT: 4%" valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(581,332</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
$</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.27</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="white">
<td style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%" valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancelled</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,684</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17.25</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding
at June 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,077,642</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.29</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.54
years</font></div>
</td>
</tr>
<tr bgcolor="white">
<td valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
&#xA0;</font></td>
<td style="TEXT-ALIGN: right" valign="bottom" width="15%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
</tr>
<tr bgcolor="#C0FFC0">
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="49%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable
at June 30, 2011</font></div>
</td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">922,043</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%">
<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.63</font></td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td>
<td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.46
years</font></div>
</td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph d<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 1<br> -Section B<br> -Paragraph 7, 11A<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_SignificantAgreementsDisclosureTextBlock', window );">LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;LICENSING
AND RESEARCH AND DEVELOPMENT AGREEMENTS</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Vitaros&#xAE; - (2011 &#x2013; 2010)</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
On December 22, 2010, the Company entered into an exclusive license
agreement with Bracco SpA (&#x201C;the &#x201C;Bracco License
Agreement&#x201D;)&#xA0;&#xA0;for its <font style="DISPLAY: inline">Vitaros&#xAE; product</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#xA0;</font>for erectile
dysfunction. Under the terms of the Bracco License Agreement,
Bracco has been granted exclusive rights in Italy to commercialize
and market Vitaros<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#xAE;</font> under the Bracco
trademark, and the Company received <font style="DISPLAY: inline; FONT-SIZE: 10pt">&#x20AC;</font>750,000 as an
up-front payment and is entitled to receive up to <font style="DISPLAY: inline; FONT-SIZE: 10pt">&#x20AC;</font>4.75 million in
regulatory and sales milestone payments.&#xA0;&#xA0;Further, over
the life of the agreement, the Company will receive royalties based
on Bracco's sales of the product.&#xA0;&#xA0;The expected up-front
payment from Bracco was received in April 2011, in the amount of
USD $1,000,000, net of withholding taxes. Of this amount,
approximately $669,000 was recognized as license revenue in the
second quarter of 2011 in accordance with our revenue recognition
criteria and the remaining amount was deferred and will be
recognized at the time that the Company receives regulatory
marketing approval for the product in Europe in accordance with the
Bracco license agreement.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
January 3, 2011, the Company entered into a license agreement (the
&#x201C;Elis License Agreement&#x201D;) with Elis Pharmaceuticals
Ltd. (&#x201C;Elis&#x201D;), granting Elis the exclusive rights to
commercialize&#xA0;&#xA0;Vitaros&#xAE; for erectile dysfunction in
the United Arab Emirates, Oman, Bahrain, Qatar, Saudi Arabia,
Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen (the &#x201C;Elis
Territory&#x201D;). Under the Elis License Agreement, the Company is
entitled to receive upfront license fees and milestone payments of
up to $2.1 million over the term of the Elis License
Agreement.&#xA0;&#xA0;The future milestones are tied to regulatory
approval and the achievement of certain levels of aggregate net
sales of Vitaros<font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline">&#xAE;</font>.&#xA0;&#xA0;Additionally,
the Company is entitled to receive escalating tiered double-digit
royalties on Elis&#x2019;s sales of Vitaros<font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline">&#xAE;</font>
in the Elis Territory.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
February, 14,&#xA0;&#xA0;2011 the Company entered into a license
agreement (the &#x201C;Neopharm License Agreement&#x201D;) with the
Neopharm Group (&#x201C;Neopharm&#x201D;), granting Neopharm the
exclusive rights to commercialize&#xA0;&#xA0;Vitaros&#xAE; for
erectile dysfunction and when and if available, the Company&#x2019;s
product for premature ejaculation in&#xA0;&#xA0;Israel and the
Palestinian Territories (the &#x201C;Neopharm
Territory&#x201D;).&#xA0;&#xA0;Under the Neopharm License Agreement,
the Company is entitled to receive upfront license fees and
milestone payments of up to $4.35 million over the term of the
Neopharm License Agreement.&#xA0;&#xA0;The future milestones are
tied to regulatory approval and the achievement of certain levels
of aggregate net sales of Vitaros&#xAE;.&#xA0;&#xA0;Additionally,
the Company is entitled to receive escalating tiered double-digit
royalties on Neopharm&#x2019;s sales of Vitaros&#xAE; in the
Neopharm Territory.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company received $203,000 in up-front payments pursuant to the Elis
and Neopharm licensing agreements and has recorded the payments as
license fee revenue during the six months ended June 30,
2011.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
April 2011, the Company filed a marketing application in Europe for
Vitaros&#xAE; for erectile dysfunction.&#xA0;&#xA0;If it is
approved by the various European regulatory authorities, it would
give the Company the right to sell Vitaros<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xAE;</font>
in multiple chosen countries in the European Union. Under a
European system called the &#x201C;Decentralized Procedure&#x201D;
(DCP), a company files its application for marketing approval of a
drug in just one European country, which is designated the
Reference Member State (RMS). The Company has chosen The
Netherlands as its RMS. The RMS then evaluates the application and
prepares an assessment report that is submitted to other chosen
European Union countries for their consideration and
approval.&#xA0;The entire review process on average requires
approximately 240 days not including additional time associated
with responses to regulatory review questions. One of the major
advantages of the DCP is that a company may receive identical
marketing authorizations for its product in multiple chosen
European Member countries at the same time.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Vitaros&#xAE; &#x2013; (2009 &#x2013; 2007)</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">
On November 1, 2007, the Company signed an exclusive licensing
agreement with Warner Chilcott Company, Inc., (&#x201C;Warner
Chilcott&#x201D;) for Vitaros&#xAE; for erectile
dysfunction.&#xA0;&#xA0;Under the agreement, Warner Chilcott
acquired the exclusive rights in the United States to Vitaros&#xAE;
and would assume all further development, manufacturing, and
commercialization responsibilities as well as
costs.&#xA0;&#xA0;</font></div>
<div>&#xA0;</div>
<div>On February 3, 2009, the Company terminated the licensing
agreement and sold the U.S. rights for Vitaros&#xAE;&#xA0;to Warner
Chilcott.&#xA0;&#xA0;Under the terms of the Asset Purchase
Agreement, the Company received an up-front payment of $2.5 million
and is eligible to receive an additional payment of $2.5 million
upon Warner Chilcott&#x2019;s receipt of a New Drug Application
(NDA) approval for Vitaros&#xAE;from the FDA.</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_SignificantAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Significant Agreements Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_SignificantAgreementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EADBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2010</a></td>
        <td class="nump">$ 11,566,761<span></span></td>
        <td class="nump">$ 18,519<span></span></td>
        <td class="nump">$ 212,788,450<span></span></td>
        <td class="num">$ (201,240,208)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">18,521,951<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of stock and compensation expense for employees (in shares)</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">209,138<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of stock and compensation expense for employees</a></td>
        <td class="nump">1,037,295<span></span></td>
        <td class="nump">209<span></span></td>
        <td class="nump">1,037,086<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_StockIssuedDuringPeriodSharesDirectorStockAward', window );">Issuance of compensatory stock to the board of directors (in shares)</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">25,193<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_StockIssuedDuringPeriodValueDirectorStockAward', window );">Issuance of compensatory stock to the board of directors</a></td>
        <td class="nump">108,438<span></span></td>
        <td class="nump">26<span></span></td>
        <td class="nump">108,412<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">674,466<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
        <td class="nump">2,741,403<span></span></td>
        <td class="nump">676<span></span></td>
        <td class="nump">2,740,727<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">581,332<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
        <td class="nump">1,318,461<span></span></td>
        <td class="nump">582<span></span></td>
        <td class="nump">1,317,879<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(11,205,098)<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="num">(11,205,098)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2011</a></td>
        <td class="nump">$ 5,567,260<span></span></td>
        <td class="nump">$ 20,012<span></span></td>
        <td class="nump">$ 217,992,554<span></span></td>
        <td class="num">$ (212,445,306)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2011</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">20,012,080<span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_StockIssuedDuringPeriodSharesDirectorStockAward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of reissuance of treasury stock for Director stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_StockIssuedDuringPeriodSharesDirectorStockAward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_StockIssuedDuringPeriodSharesStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_StockIssuedDuringPeriodValueDirectorStockAward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of reissuance of treasury stock for Director stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_StockIssuedDuringPeriodValueDirectorStockAward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_StockIssuedDuringPeriodValueStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_StockIssuedDuringPeriodValueStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;COMMITMENTS
AND CONTINGENCIES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employment
Agreements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We
have an employment agreement with Dr. Damaj, our Chairman,
President and Chief Executive Officer. Pursuant to that agreement,
we may terminate Dr. Damaj&#x2019;s employment without cause on ten
days notice, in which event Dr. Damaj would be entitled to
severance pay equal to twelve months&#x2019; base salary which is
currently $450,000 per annum.&#xA0;&#xA0;&#xA0;The employment
agreement further provides that in the event that within one year
after a &#x201C;Change of Control&#x201D; (as defined therein) of the
Company occurs, and the President and Chief Executive
Officer&#x2019;s employment is terminated or resigns for cause, the
President and Chief Executive Officer will be paid a lump sum
amount equal to his base salary for a 12-month period following
termination or resignation.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Company is a party to other employment and compensatory
agreements in the normal course of business and the <font style="DISPLAY: inline">Company is a party to numerous short-term
consulting and research agreements that, generally, can be
cancelled pursuant to the terms of such
agreements.</font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
We are subject to certain legal proceedings in the ordinary course
of business.&#xA0;&#xA0;We do not expect any such items to have a
significant impact on our financial position.</font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Interpretation (FIN)<br> -Number 14<br> -Paragraph 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 9, 10, 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDER RIGHTS PLAN<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_StockholderRightsPlan', window );">STOCKHOLDER RIGHTS PLAN</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;STOCKHOLDER
RIGHTS PLAN</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
March 24, 2011, pursuant to the Company&#x2019;s shareholders rights
plan (the &#x201C;Plan&#x201D;) the Company declared a dividend
distribution of one preferred share purchase Right for each
outstanding share of the Company's<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font>Common
Stock to shareholders of record at the close of business on April
1, 2011.&#xA0; Initially, these rights will not be exercisable and
will trade with the shares of the Company's common
stock.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under
the Plan, the rights generally will become exercisable if a person
or group acquires beneficial ownership of 15% or more of the
Company's common stock in a transaction not approved by the
Company's Board. In that situation, each holder of a right (other
than the acquiring person) will be entitled to purchase, at the
then-current exercise price, additional shares of common stock
having a value of twice the exercise price of the right. In
addition, if the Company is acquired in a merger or other business
combination after an unapproved party acquires more than 15% of the
Company's common stock, each holder of the right would then be
entitled to purchase at the then-current exercise price, shares of
the acquiring company's stock, having a value of twice the exercise
price of the right.</font><br />
&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Board may redeem the rights for a nominal amount at any time before
an event that causes the rights to become exercisable. The rights
will expire on April 1, 2021.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_StockholderRightsPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stockholder Rights Plan Disclosure</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_StockholderRightsPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;BASIS
OF PRESENTATION</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
Apricus Biosciences, Inc. (formerly NexMed, Inc.) and subsidiaries
(the &#x201C;Company&#x201D; or &#x201C;our&#x201D; or
&#x201C;we&#x201D;) was incorporated in Nevada in 1987.&#xA0;&#xA0;On
September 10, 2010, the Company changed its name from
&#x201C;NexMed, Inc.&#x201D; to &#x201C;Apricus Biosciences,
Inc.&#x201D; The Company has historically focused its efforts on
drug development using its patented drug delivery technology known
as NexACT&#xAE;.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The consolidated financial statements have been prepared by the
Company pursuant to the rules and regulations of the U.S.
Securities and Exchange Commission.&#xA0;&#xA0;Certain information
and footnote disclosures normally included in financial statements
prepared in accordance with accounting principles generally
accepted in the United States have been condensed or omitted. In
the opinion of the Company&#x2019;s management, all adjustments that
are of a normal recurring nature, considered necessary for fair
presentation, have been included in the accompanying consolidated
financial statements. The unaudited consolidated financial
statements and statements of operations for the interim periods are
not necessarily indicative of results for the full year. For
further information, refer to the consolidated financial statements
and notes thereto included in the Company&#x2019;s annual report on
Form 10-K filed with the Securities Exchange Commission for the
year ended December 31, 2010. The preparation of these consolidated
financial statements requires the Company to make estimates and
judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, the Company evaluates its
estimates, including those related to bad debts, intangible assets,
income taxes, stock-based compensation and commitments and
contingencies.&#xA0;&#xA0;The Company&#x2019;s actual results may
differ from these estimates under different assumptions or
conditions.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
December 14, 2009, the Company acquired Bio-Quant, Inc.
(&#x201C;Bio-Quant&#x201D;), a <font style="DISPLAY: inline; FONT-SIZE: 10pt">specialty biotech contract
research organization (&#x201C;CRO&#x201D;) based in San
Diego.&#xA0;&#xA0;The acquisition was made pursuant to an</font>
Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;)
dated November 20, 2009 by and among the Company and BQ Acquisition
Corp., a wholly-owned subsidiary of the Company and
Bio-Quant.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline">Since that time, the Bio-Quant CRO
allowed the Company to increase its active pre-clinical and
clinical product pipeline from 4 drug candidates to 13 drug
candidates</font> utilizing <font style="DISPLAY: inline">the
internal</font> research <font style="DISPLAY: inline">capabilities
of the CRO.</font> The Company used the Bio-Quant resources to
advance its product candidates and expand the uses and routes of
its NexACT&#xAE; delivery technology. As <font style="DISPLAY: inline">a result of this internal</font> research
<font style="DISPLAY: inline">focus</font>, <font style="DISPLAY: inline">the cash flow generating capabilities of the CRO
diminished over time</font> since the Company was using the
capabilities and resources of Bio-Quant for internal development
activities rather than for external customer growth. In
<font style="DISPLAY: inline">connection with the</font> valuation
of the future expected cash flows and the goodwill related to
Bio-Quant at December 31, 2010, an impairment charge of $9,084,476
was taken in 2010 to write off the entire value of
goodwill<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font><font style="DISPLAY: inline">from
this acquisition</font>.<font style="DISPLAY: inline">&#xA0;During
2011, the Company considered the significance of its enhanced
product candidate pipeline, the resources needed to further develop
each of those product opportunities and the value being derived
from the CRO business with diminished cash flows towards
operations.</font> <font style="DISPLAY: inline">Based on the
change in strategic focus, on</font> June 30, 2011, the Company
entered into a stock purchase agreement with Samm Solutions, Inc.
doing business as BioTox Sciences (&#x201C;BioTox&#x201D;), a San
Diego-based CRO, to sell all of the outstanding capital stock of
Bio-Quant, Inc., which was one of the Company&#x2019;s wholly owned
subsidiaries (see Note 3).</font></font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through
June 30, 2011, the date of the sale of Bio-Quant, the Company
operated in two segments &#x2013; designing and developing
pharmaceutical products through its wholly-owned subsidiary NexMed
(USA), Inc. and providing pre-clinical CRO services through its
wholly-owned subsidiary, Bio-Quant.&#xA0;&#xA0;For periods
subsequent to June 30, 2011 the Company will operate in one segment
designing and developing pharmaceutical products through its
wholly-owned subsidiary NexMed (USA), Inc.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Company is focusing its efforts on new and patented
pharmaceutical products and product candidates based on our
patented drug delivery technology known as
NexACT&#xAE;.&#xA0;&#xA0;&#xA0;The Company continues with its
efforts to expand the uses of
the&#xA0;&#xA0;NexACT&#xAE;&#xA0;&#xA0;technology into the oral,
subcutaneous, ocular and rectal delivery of multi-classes of drugs
for these and other indications.&#xA0;&#xA0;The Company is also
seeking commercialization partnerships for its product,
Vitaros&#xAE;, which is approved in Canada for the treatment of
erectile dysfunction (&#x201C;ED&#x201D;) and its additional existing
clinical and pre-clinical pipeline of product candidates such
as&#xA0;&#xA0;Femprox&#xAE; for female sexual arousal disorder,
MycoVa&#x2122; for onychomycosis excluding tinea pedis (nail fungal
infection), RayVa&#x2122; for Raynaud&#x2019;s Syndrome and
PrevOnco&#x2122; for liver cancer and is enhancing its business
development efforts by offering potential partners clearly defined
regulatory paths for our products and product candidates under
development.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
June&#xA0;21, 2010, the Company completed a reverse stock split
pursuant to which each fifteen shares of Company's common stock
then issued and outstanding were automatically converted into one
share of the Company's common stock; no change was made to the
per-share par value of the common stock. The authorized common
stock was also proportionately reverse split by a factor of
fifteen-for-one. All share and per share amounts in the
accompanying consolidated financial statements have been adjusted
to reflect the reverse stock split as if it had occurred at the
beginning of the earliest period presented.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Liquidity</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
accompanying consolidated financial statements have been prepared
on a basis which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course of
business.&#xA0;&#xA0;The Company has an accumulated deficit of
approximately $212.4 million at June 30, 2011 and recorded a net
loss of approximately $11.2&#xA0;&#xA0;million for the six months
ended June 30, 2011 and has principally been financed through
private placements of equity securities,&#xA0;&#xA0;debt financing
and up-front payments received from commercial partners for its
products under development.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company&#x2019;s cash reserves of approximately $9.1 million at June
30, 2011, are expected to provide us with sufficient cash to fund
our operations into the second half of 2012.&#xA0;&#xA0;This
projection is based on the monthly operating expenses of
maintaining our public listing, continuing essential business
development and research and development efforts for our current
pipeline together with the receipt of multiple licensing payments
from commercial partners and from possible future cash earn-out
revenues resulting from the sale of
Bio-Quant.&#xA0;&#xA0;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To
the extent we sign additional licensing agreements in 2011 or 2012
and receive up-front and milestone payments for</font> one or more
of our product pipeline candidates and/or the NexACT<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xAE;</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#xA0;</font>technology
itself, we expect that our cash reserves plus those payments should
provide us with sufficient cash to fund our operations well into
2013. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A
change in any of these assumptions or any unexpected expenses, may
change these projected cash reserve amounts and/or
timelines.</font></font></font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#xA0;</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
The Company currently expects that it will be cash flow positive
from operations, which includes cash expected to be received from
up-front and milestone payments from the licensing of its products
and NexACT&#xAE;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#xA0;</font>technology, during
2011 as the Company plans to enter into out-licensing agreements
for its NexACT&#xAE; technology with pharmaceutical and
biotechnology companies worldwide. The Company&#x2019;s cash flow
positive guidance assumes the Company does not commence any
clinical trials, which would be expected to increase our expenses
significantly.&#xA0;&#xA0;At the same time, the Company is actively
pursuing partnering opportunities for its approved and clinical
stage NexACT&#xAE; based candidates in the areas of sexual
dysfunction, oncology, inflammation, dermatology, pain and
autoimmune diseases.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#xA0;</font>The successful
licensing of one or more of these candidates and/or the
NexACT&#xAE; technology itself would be expected to generate
additional revenues for funding the Company&#x2019;s long-term
growth strategy.&#xA0;&#xA0;To that end, as discussed in Note 15,
the Company, in December 2010, entered into a licensing agreement
with Bracco SpA (&#x201C;Bracco&#x201D;) for its topical
alprostadil-based cream treatment for erectile dysfunction
(&#x201C;Vitaros&#xAE;&#x201D;) for sale in Italy and in January
2011, and the Company entered into exclusive license agreement with
Elis Pharmaceuticals Ltd. (&#x201C;Elis&#x201D;) and Neopharm Group
(&#x201C;Neopharm&#x201D;) for Vitaros&#xAE;.&#xA0;&#xA0;Under the
terms of the Elis License Agreement, Elis has been granted
exclusive rights in United Arab Emirates, Oman, Bahrain, Qatar,
Saudi Arabia, Kuwait, Lebanon, Syria, Jordan, Iraq and Yemen and
under the terms of the Neopharm License Agreement, Neopharm has
been granted exclusive rights in Israel and the Palestinian
Territories of the Gaza Strip and the West Bank to commercialize
and market Vitaros&#xAE;. The Company continues to be active in
discussions with other potential commercial partners for other
territories. In April 2011, we filed a marketing application in
Europe for approval of Vitaros&#xAE; as a treatment for patients
with ED. In addition, the Company expects revenues from the sale of
Vitaros&#xAE; in the approved territory(ies) which would also
increase its cash position.</font></font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#xA0;</div>
</div>
</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
Recent accounting pronouncements</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective
January 1, 2010, the Company adopted ASU No. 2009-17, <font style="FONT-STYLE: italic; DISPLAY: inline">Consolidations (Topic 810):
Improvements to Financial Reporting by Enterprises Involved with
Variable Interest Entities</font>. The amendments in this update
replace the<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>quantitative-based
risks and rewards calculation for determining which reporting
entity, if any, has a controlling financial interest in
a</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">variable
interest entity with an approach focused on identifying which
reporting entity has the power to direct the activities of a
variable interest entity that most significantly impact the
entity&#x2019;s economic performance and (1) the obligation to
absorb losses of the entity or (2) the right to receive benefits
from the entity. An approach that is expected to be primarily
qualitative will be more effective for identifying which reporting
entity has a controlling financial interest in a variable interest
entity. The amendments in this update also require additional
disclosures about a reporting entity&#x2019;s involvement in
variable interest entities, which will enhance the information
provided to users of financial statements. The Company evaluated
their business relationships to identify potential variable
interest entities and have concluded that consolidation of such
entities is not required for the periods presented. On a quarterly
basis, the Company will continue to reassess our involvement with
variable interest entities.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
April 2010, the FASB issued ASU No. 2010-17, Topic 605 - Revenue
Recognition - Milestone Method (&#x201C;USA 2010-17&#x201D;), which
provides guidance on defining a milestone and determining when it
may be appropriate to apply the milestone method of revenue
recognition for research or development transactions. The
amendments in ASU 2010-17 are effective on a prospective basis for
milestones achieved in fiscal years beginning on or after June 15,
2010, and interim periods within those years. The Company has
adopted ASU 2010-17 effective as of the first quarter of fiscal
2011. This ASU did not have any impact on the Company&#x2019;s
consolidated financial statements upon adoption.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
December 2010, the FASB issued ASU No. 2010-28, <font style="FONT-STYLE: italic; DISPLAY: inline">Intangibles &#x2014; Goodwill
and Other (Topic 350): &#x201C;When to Perform Step 2 of the
Goodwill Impairment Test for Reporting Units with Zero or Negative
Carrying Amounts</font>. ASU 2010-28 is effective for fiscal
years<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>beginning after
December 15, 2010 and amends the criteria for performing Step 2 of
the goodwill impairment test for reporting units<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>with zero or
negative carrying amounts and requires performing Step 2 if
qualitative factors indicate that it is more likely than not
that<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>a goodwill
impairment exists. The Company has adopted ASU 2010-28 effective as
of the first quarter of fiscal 2011. This ASU did not have any
impact on the Company&#x2019;s consolidated financial statements
upon adoption.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In
December 2010, the FASB issued ASU No. 2010-27, <font style="FONT-STYLE: italic; DISPLAY: inline">Fees Paid to the Federal
Government by Pharmaceutical Manufacturers</font> ( &#x201C;ASU
2010-27&#x201D;) which provides guidance on how to recognize and
classify the fees mandated by the Patient<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>Protection and
Affordable Care Act as amended by the Health Care and Education
Reconciliation Act (together, the &#x201C;Acts&#x201D;). The
Acts<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>impose an annual
fee for each calendar year beginning on or after January 1, 2011
payable by branded prescription drug<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>manufacturers
and importers on branded prescription drugs. The liability for the
fee should be estimated and recorded in full upon the<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>first qualifying
sale with a corresponding deferred cost that is amortized to
expense using a straight-line method of allocation over
the<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>calendar year
that it is payable. ASU 2010-27 is effective for calendar years
beginning on or after December 31, 2010, when the fee<font style="FONT-STYLE: italic; DISPLAY: inline">&#xA0;</font>initially
becomes effective. As the Company does not currently have a
commercial product, the effect of this guidance will be limited to
future transactions.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LINES OF CREDIT<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apri_LineOfCreditFacilitiesTextBlock', window );">LINES OF CREDIT</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;LINES
OF CREDIT</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On
March 8, 2010, Bio-Quant entered into a Loan and Security Agreement
with Square 1 Bank for a revolving line of credit (&#x201C;Credit
Line&#x201D;) in the amount of $250,000.&#xA0;&#xA0;The Credit Line
was secured by a $255,000 cash deposit from the Company which was
classified as restricted cash on the accompanying consolidated
balance sheet at December 31, 2010.&#xA0;&#xA0;The Credit Line bore
interest at the rate of 4.25% per annum or 1% above the Prime Rate
and expired on March 7, 2011 and was repaid in full at that
time.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
On April 12, 2010, Bio-Quant entered into a Loan and Security
Agreement with Torrey Pines Bank for a revolving line of credit
(&#x201C;TP Credit Line&#x201D;) in the amount of
$250,000.&#xA0;&#xA0;The TP Credit Line was secured by a $278,824
cash deposit from the Company which is included in restricted cash
on the accompanying consolidated balance sheet at December 31,
2010.&#xA0;&#xA0;The TP Credit Line bore interest at the rate of
2.6% per annum and expired on April 12, 2011 and was repaid in full
at that time.</font></font></div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apri_LineOfCreditFacilitiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Line of Credit Facilities [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>apri_LineOfCreditFacilitiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>apri</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ELG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;INCOME
TAXES</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company has incurred losses since inception, which have generated
net operating loss carryforwards of approximately $36 million for
federal and state income tax purposes through December 31,
2010.&#xA0;&#xA0;These carryforwards are available to offset future
taxable income and expire beginning in 2014 through 2029 for
federal income tax purposes.&#xA0;&#xA0;Internal Revenue Code
Section 382 places a limitation on the utilization of federal net
operating loss carryforwards when an ownership change, as defined
by tax law, occurs.&#xA0;&#xA0;Generally, an ownership change, as
defined, occurs when a greater than 50 percent change in ownership
takes place during any three-year period. The Company performed a
review of stock transactions for the years beginning January 1,
2008 and ending December 31, 2010 as the Company feels that was the
likely period that such an ownership change likely
occurred.&#xA0;&#xA0;Based on this limited review, the Company
determined that an ownership change took place in June 2010 when
the Bio-Quant notes were converted to common stock as discussed in
Note 8.&#xA0;&#xA0;As a result of this ownership change, the
ability to utilize the current net operating loss carryforwards
generated prior to this change in ownership is limited to
approximately $1.2 million per year based on our calculations at
the time of the ownership change.&#xA0;&#xA0;The Company has
recorded a full valuation allowance against the deferred tax assets
arising from the net operating loss carryforwards.</font></div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The
Company follows the provisions of ASC 740-10-25. ASC 740-10-25
provides recognition criteria and a related measurement model for
uncertain tax positions taken or expected to be taken in income tax
returns. ASC 740-10-25 requires that a position taken or expected
to be taken in a tax return be recognized in the financial
statements when it is more likely than not that the position would
be sustained upon examination by tax authorities. Tax positions
that meet the more likely than not threshold are then measured
using a probability weighted approach recognizing the largest
amount of tax benefit that is greater than 50% likely of being
realized upon ultimate settlement. The Company&#x2019;s Federal
income tax returns for 2007 to 2009 are still open and subject to
audit.&#xA0;&#xA0;In addition, net operating losses arising from
prior years are also subject to examination at the time they are
utilized in future years.&#xA0;&#xA0;The Company had no tax
positions relating to open income tax returns that were considered
to be uncertain. Accordingly, we have not recorded a liability for
unrecognized tax benefits upon adoption of ASC 740-10-25. There
continues to be no liability related to unrecognized tax benefits
at June 30, 2011.</font></div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 109<br> -Paragraph 136, 172<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 109<br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E5SAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 9,140,225<span></span></td>
        <td class="nump">$ 9,145,683<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">44,867<span></span></td>
        <td class="nump">288,778<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">70,000<span></span></td>
        <td class="nump">604,343<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">106,693<span></span></td>
        <td class="nump">188,504<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">9,361,785<span></span></td>
        <td class="nump">10,477,308<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
        <td class="nump">4,457,778<span></span></td>
        <td class="nump">5,420,939<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">2,701,512<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Accrued rental income and other assets</a></td>
        <td class="nump">204,890<span></span></td>
        <td class="nump">189,478<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance cost, net of accumulated amortization of $47,860 and $29,289</a></td>
        <td class="nump">55,830<span></span></td>
        <td class="nump">74,401<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">14,080,283<span></span></td>
        <td class="nump">18,863,638<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term borrowing from banks</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">401,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">2,210,555<span></span></td>
        <td class="nump">789,544<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll related liabilities</a></td>
        <td class="nump">730,584<span></span></td>
        <td class="nump">816,520<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">343,375<span></span></td>
        <td class="nump">209,705<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease payable - current portion</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">31,263<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Deferred compensation - current portion</a></td>
        <td class="nump">392,477<span></span></td>
        <td class="nump">68,596<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">3,676,991<span></span></td>
        <td class="nump">2,316,628<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="nump">4,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
        <td class="nump">67,150<span></span></td>
        <td class="nump">72,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease payable</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">102,211<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation</a></td>
        <td class="nump">768,882<span></span></td>
        <td class="nump">805,788<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">8,513,023<span></span></td>
        <td class="nump">7,296,877<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;<span></span></td>
        <td class="text">&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, 75,000,000 shares authorized, 20,012,080 and 18,521,951 issued and outstanding at June 30, 2011 and December 31, 2010, respectively</a></td>
        <td class="nump">20,012<span></span></td>
        <td class="nump">18,519<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
        <td class="nump">217,992,554<span></span></td>
        <td class="nump">212,788,450<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(212,445,306)<span></span></td>
        <td class="num">(201,240,208)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">5,567,260<span></span></td>
        <td class="nump">11,566,761<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 14,080,283<span></span></td>
        <td class="nump">$ 18,863,638<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 13<br> -Paragraph 7, 10, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 13<br> -Paragraph 7, 10, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 17<br> -Article 9<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 19<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 25<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 22<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationLiabilityCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 21<br> -Paragraph 16<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 17<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNoncurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 48<br> -Paragraph 6<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 42, 45<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 17<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Section A<br> -Paragraph 4<br> -Chapter 3<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 8<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 12<br> -Paragraph 5<br> -Subparagraph b, c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Audit and Accounting Guide (AAG)<br> -Number AAG-BRD<br> -Chapter 4<br> -Paragraph 80<br> -Subparagraph Exhibit 4-8, 3<br> -IssueDate 2006-05-01<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),16(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 13<br> -Article 9<br> -Subparagraph 2, 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 16<br> -Subparagraph a(1)<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermBorrowings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>20</ContextCount>
  <ElementCount>129</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - ACQUISITION OF BIO-QUANT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock</Role>
      <ShortName>ACQUISITION OF BIO-QUANT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - SALE OF BIO-QUANT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</Role>
      <ShortName>SALE OF BIO-QUANT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - ACCOUNTING FOR STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>ACCOUNTING FOR STOCK-BASED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>WARRANTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>LOSS PER SHARE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - CONVERTIBLE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsNotesPayableDisclosureTextBlock</Role>
      <ShortName>NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - LINES OF CREDIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsLineOfCreditFacilitiesTextBlock</Role>
      <ShortName>LINES OF CREDIT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - DEFERRED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsDeferredCompensationPlansDisclosureTextBlock</Role>
      <ShortName>DEFERRED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - COMMON STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock</Role>
      <ShortName>COMMON STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSignificantAgreementsDisclosureTextBlock</Role>
      <ShortName>LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - STOCKHOLDER RIGHTS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apricusbio.com/taxonomy/role/NotesToFinancialStatementsStockholderRightsPlan</Role>
      <ShortName>STOCKHOLDER RIGHTS PLAN</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>apri-20110630.xml</File>
    <File>apri-20110630.xsd</File>
    <File>apri-20110630_cal.xml</File>
    <File>apri-20110630_def.xml</File>
    <File>apri-20110630_lab.xml</File>
    <File>apri-20110630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T
M-C%D.#(U.34B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T
M-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S=F
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N=%]O9E]#:&%N/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0D%325-?3T9?4%)%4T5.5$%424]./"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^04-154E3251)3TY?3T9?
M0DE/455!3E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y304Q%7T]&7T))3U%504Y4/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^04-#3U5.5$E.1U]&3U)?4U1/0TM"05-%1%]#3TU0/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5T%24D%.5%,\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,3U-37U!%
M4E]32$%213PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DE.5$%.1TE"3$5?05-31513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].5D525$E"3$5?3D]415-?4$%904),13PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DY/5$537U!!64%"3$4\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,24Y%4U]/
M1E]#4D5$250\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y$149%4E)%1%]#3TU014Y3051)3TX\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#3TU-3TY?4U1/0TM?5%)!3E-!0U1)3TY3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4D5,051%1%]0
M05)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y)3D-/345?5$%815,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y,24-%3E-)3D=?04Y$7U)%4T5!4D-(7T%.1%]$
M158\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44U]!3D1?0T].5$E.1T5.0TE%4SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-%1TU%3E1?24Y&3U)-051)3TX\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E]2
M24=(5%-?4$Q!3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T
M>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@
M/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C
M=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0
M<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z
M17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*
M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I
M=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?
M-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O
M5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-$=!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T
M:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`P.2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$;V-U;65N="!);F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M43QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE
M;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A
M;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DIU;B`S,"P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES
M8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E$R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^05!223QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES
M=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^05!2
M24-54R!"24]30TE%3D-%4RP@24Y#+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@
M2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`Q,#$W-#DQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O
M<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-M86QL97(@4F5P
M;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L
M,#(R+#`X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<W9C,T8F1F7V4P9C!?-#-A-U]A
M864P7S0W,#0V,60X,C4Y-2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4U4T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E
M9"!"86QA;F-E(%-H965T<R`H55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M=7)R96YT(&%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#DL,30P+#(R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@.2PQ-#4L-C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-"PX-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#@L-S<X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!R96-E
M:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8P-"PS-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R
M(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#8L-CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@X+#4P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,V,2PW.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT-S<L,S`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&:7AE9"!A<W-E=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PT-3<L-S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PT,C`L.3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<RP@
M;F5T(&]F(&%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPW,#$L-3$R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(')E;G1A;"!I
M;F-O;64@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C`T+#@Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X.2PT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@:7-S=6%N8V4@8V]S="P@
M;F5T(&]F(&%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;B!O9B`F;F)S<#LD-#<L
M.#8P(&%N9"`F;F)S<#LD,CDL,C@Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU-2PX,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-"PT,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`X,"PR.#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PX-C,L-C,X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!B;W)R;W=I;F<@
M9G)O;2!B86YK<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`Q
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,3`L-34U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@Y+#4T
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&%Y<F]L;"!R96QA=&5D(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW,S`L-3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$V+#4R,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V
M96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0S+#,W-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M.2PW,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<&ET86P@;&5A<V4@<&%Y86)L92`M(&-U<G)E;G0@<&]R=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,C8S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!C;VUP96YS871I;VX@+2!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,BPT-S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PU.38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C
M=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#8W-BPY.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#,Q-BPV,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9R!T97)M(&QI
M86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<L
M,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S(L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87!I=&%L(&QE87-E('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,BPR,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8X+#@X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P
M-2PW.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PU,3,L,#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR.38L.#<W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A
M;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL("9N8G-P.R0N,#`Q('!A<B!V86QU92P@-S4L,#`P+#`P
M,"!S:&%R97,@875T:&]R:7IE9"P@,C`L,#$R+#`X,"!A;F0@,3@L-3(Q+#DU
M,2!I<W-U960@86YD(&]U='-T86YD:6YG(&%T($IU;F4@,S`L(#(P,3$@86YD
M($1E8V5M8F5R(#,Q+"`R,#$P+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+#`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#4Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P
M86ED+6EN+6-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q-RPY.3(L-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$R+#<X."PT-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q,BPT-#4L,S`V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P
M,2PR-#`L,C`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#4V-RPR-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PU-C8L-S8Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#$T+#`X
M,"PR.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XF;F)S<#LD(#$X+#@V,RPV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W
M,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S
M-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%04Q!0SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC
M86PI("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(&ES<W5A;F-E(&-O<W0L(&%C
M8W5M=6QA=&5D(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`T-RPX-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(Y+#(X.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`Q,BPP.#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PU,C$L.34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL(&]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,3(L,#@P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-3(Q+#DU,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S=F,S1B
M9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V
M,60X,C4Y-2]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$593T%'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE
M;G1S(&]F($]P97)A=&EO;G,@*%531"`F;F)S<#LD*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI
M8V5N<V4@9F5E(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B9N8G-P.R0@-C8X+#@Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,S(L-34P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`X-S$L
M-#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)FYB<W`[)"`S-2PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R86-T('-E<G9I8V4@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(V+#(U,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#,X+#,W
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,S$P+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L.#@Q+#4W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3DU+#$U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<P+#DR-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3@R
M+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L.3$V+#8W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]S="!O9B!S97)V:6-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP,#8L,C(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,C$L.34Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,3$L,C,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPP-3DL,3@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)O<W,@<')O9FET/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU.#@L.3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#0X+#DW-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3<P+#DX-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U-RPT.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V]S=',@86YD(&5X<&5N<V5S/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-S$L.#,R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<W
M+#4V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#<R+#,W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDP,RPY-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T
M:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8X-RPP-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#8T,"PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+#4Y,RPR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#@W.2PY,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@<V%L92!O9B!"
M:6\M475A;G0@<W5B<VED:6%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPW-3DL.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPW-3DL.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]S=',@86YD(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#0Q."PW
M.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$Q-RPY-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,BPT,C4L-3DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW.#,L.#DU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P
M97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L.#(Y
M+#@V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R+#8V."PY.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3$L,C4T+#8P."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#DR-BPS.3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]T:&5R(&EN8V]M92`H97AP96YS92D\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS92P@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-2PW,#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,#DL-C4W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$W,RPT-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH."PU.#DL-S`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5N=&%L(&EN8V]M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$Q+#0X,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R,BPY-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O
M=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-2PW-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#8P.2PV-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DL-3$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PU.#DL-S`T*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#<L-SDT+#`Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B9N8G-P.R0@*#0L,C<X+#8T-RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#$Q+#(P-2PP
M.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XF;F)S<#LD("@Q,RPU,38L,3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;&]S
M<R!P97(@8V]M;6]N('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B9N8G-P.R0@*#`N,SDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C0W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XU."D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N
M8G-P.R0@*#$N-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<@=7-E9"!F;W(@8F%S:6,@86YD(&1I;'5T960@;&]S<R!P
M97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#@Q
M-RPP,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#$T,"PT-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.2PT-S4L-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR-C0L-3$U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S
M83=?86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU+U=O
M<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$0D<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N="!O9B!#:&%N
M9V5S(&EN(%-T;V-K:&]L9&5R<R<@17%U:71Y("A54T0@)FYB<W`[)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@
M4&%I9"U);B!#87!I=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D%C8W5M=6QA=&5D($1E9FEC:70\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E(&%T($1E8RX@,S$L
M(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M,3$L-38V+#<V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@,3@L-3$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`R,3(L-S@X+#0U,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB
M<W`[)"`H,C`Q+#(T,"PR,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92`H:6X@<VAA
M<F5S*2!A="!$96,N(#,Q+"`R,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ."PU,C$L.34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!S=&]C:R!A;F0@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&5M<&QO>65E<R`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`Y+#$S.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@<W1O8VL@86YD(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&9O<B!E;7!L
M;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#,W+#(Y
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,#,W+#`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M<&5N<V%T;W)Y('-T;V-K
M('1O('1H92!B;V%R9"!O9B!D:7)E8W1O<G,@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#$Y,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M<&5N<V%T;W)Y('-T;V-K('1O('1H92!B;V%R9"!O9B!D:7)E8W1O<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PT,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PT
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG
M(&-O<W1S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-S0L-#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O
M9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPW-#$L-#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPW-#`L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<R`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@Q+#,S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S$X+#0V,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S$W+#@W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$Q+#(P-2PP.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3$L,C`U+#`Y."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T
M($IU;BX@,S`L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B9N8G-P.R0@-2PU-C<L,C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`R,"PP,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(Q-RPY
M.3(L-34T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@R,3(L-#0U+#,P-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E("AI
M;B!S:&%R97,I(&%T($IU;BX@,S`L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#`Q,BPP.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W
M,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S
M-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3
M:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%0D5!23X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A5
M4T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!O<&5R871I;F<@86-T
M:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF
M;F)S<#LD("@Q,2PR,#4L,#DX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,3,L-3$V+#$P,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C
M87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S97)V92!F;W(@<F5L
M871E9"!P87)T>2!N;W1E(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(W-2PY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I
M>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3<L-#<W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<Q+#,Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N+6-A<V@@:6YT97)E<W0L(&%M;W)T:7IA=&EO;B!O9B!B
M96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A='5R92!A;F0@9&5F97)R960@9FEN
M86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PU-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX+#<Q-BPU-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H('=R:71E(&]F9B!O9B!D969E<G)E
M9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S,L
M-C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;VXM8V%S:"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-#4L-S,S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.30L.3(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S
M(&]N(&1I<W!O<V%L(&]F(&9I>&5D(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8V%S:"!L;W-S(&]N('-A;&4@
M;V8@0FEO+5%U86YT('-U8G-I9&EA<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-S4Y+#DR,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A
M=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@
M:6X@86-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C<L,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92`H:6YC<F5A<V4I(&EN
M(&]T:&5R(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(U+#DY,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,S<L-SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92!I;B!D=64@9G)O;2!R96QA
M=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#0L
M.#DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN('!R97!A:60@97AP96YS97,@
M86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-SDL-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3$W+#`V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@86-C
M<G5E9"!R96YT86P@:6YC;VUE(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#DX-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R
M96%S92D@:6X@86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,C@L.3,T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(P
M+#$R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@<&%Y<F]L;"!R96QA=&5D
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M-2PP,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,X+#$R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@:6X@9'5E('1O(')E;&%T960@<&%R
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DY+#8X,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M8W)E87-E("AI;F-R96%S92D@:6X@9&5F97)R960@8V]M<&5N<V%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#8L.3<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L-#DV*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC<F5A<V4@*&1E8W)E87-E*2!I;B!D969E<G)E9"!R979E;G5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#$P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPQ,#<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-"PU,#8L-S<P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-C8U+#,V,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%S:"!F;&]W<R!F<F]M(&EN=F5S=&EN9R!A8W1I=FET:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@<V%L92!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&5X<&5N9&ET=7)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<V+#<Q,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.38L.#4V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5L96%S92`H9&5P;W-I="D@;V8@<F5S=')I8W1E9"!C87-H/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,S0L,S0S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C`S+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U-RPV,S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M.3@L-S$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C
M=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VYV97)T:6)L92!N
M;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S$X+#0V,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@;V9F97)I;F<@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S0Q+#0P,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S`V
M+#(Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VYV97)T:6)L92!N
M;W1E<R!P87EA8FQE+"!N970@;V8@9&5B="!I<W-U92!C;W-T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX.38L,S$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE;G0@
M;V8@<VAO<G0M=&5R;2!B;W)R;W=I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0P,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#`Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F(&-O;G9E
M<G1I8FQE(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L-3DR+#`Q,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N="!O9B!C87!I=&%L(&QE87-E
M(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-2PR,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3(L,S$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F($)I;RU1=6%N
M="!S=6)S:61I87)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,#`L,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,30S+#8W
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,CDY+#(X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S92`H9&5C<F5A<V4I(&EN(&-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4L-#4X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-S,U+#(P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<RP@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PQ-#4L-C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#<Y+#@X.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<RP@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PQ-#`L,C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR,34L,#DU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R
M(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S0L
M-#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C<L-S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-A;&5S(&]F(&EN=F5S=&UE;G0@:6X@8V]N
M<V]L:61A=&5D('-U8G-I9&EA<GDZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(%)E8V5I=F%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y.2PR,S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#@S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:7!M96YT(&%N9"!L96%S96AO
M;&0@:6UP<F]V96UE;G1S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<X,"PY.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C0R+#`P,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M4&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`W+#DR
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>7)O;&P@<F5L871E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#`L.3(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!L96%S92!P87EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,3@L,C<P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=F5R=&EB;&4@3F]T97,@4&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-A;&5S(&]F(&EN=F5S=&UE;G0@:6X@
M8V]N<V]L:61A=&5D('-U8G-I9&EA<GDZ/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!I;B!P87EM96YT(&]F(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Y-RPX.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO=&5S('!A>6%B;&4@=&\@9F]R;65R($)I;RU1
M=6%N="!S:&%R96AO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY386QE<R!O9B!I;G9E<W1M96YT(&EN(&-O;G-O;&ED
M871E9"!S=6)S:61I87)Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@:6X@<&%Y
M;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#$R+#$R.2PP,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X
M,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E
M,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#`W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0D%3
M25,@3T8@4%)%4T5.5$%424]./&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)!4TE3($]&(%!215-%3E1!5$E/3CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$N)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[0D%325,-"D]&(%!215-%3E1!5$E/3CPO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU
M<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*07!R:6-U<R!":6]S8VEE;F-E<RP@26YC+B`H
M9F]R;65R;'D@3F5X365D+"!);F,N*2!A;F0@<W5B<VED:6%R:65S#0HH=&AE
M("8C>#(P,4,[0V]M<&%N>28C>#(P,40[(&]R("8C>#(P,4,[;W5R)B-X,C`Q
M1#L@;W(-"B8C>#(P,4,[=V4F(W@R,#%$.RD@=V%S(&EN8V]R<&]R871E9"!I
M;B!.979A9&$@:6X@,3DX-RXF(WA!,#LF(WA!,#M/;@T*4V5P=&5M8F5R(#$P
M+"`R,#$P+"!T:&4@0V]M<&%N>2!C:&%N9V5D(&ET<R!N86UE(&9R;VT-"B8C
M>#(P,4,[3F5X365D+"!);F,N)B-X,C`Q1#L@=&\@)B-X,C`Q0SM!<')I8W5S
M($)I;W-C:65N8V5S+`T*26YC+B8C>#(P,40[(%1H92!#;VUP86YY(&AA<R!H
M:7-T;W)I8V%L;'D@9F]C=7-E9"!I=',@969F;W)T<R!O;@T*9')U9R!D979E
M;&]P;65N="!U<VEN9R!I=',@<&%T96YT960@9')U9R!D96QI=F5R>2!T96-H
M;F]L;V=Y(&MN;W=N#0IA<R!.97A!0U0F(WA!13LN/"]F;VYT/CPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"E1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
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M92!O<&EN:6]N(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&UA;F%G96UE;G0L
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M;VUP86YY)B-X,C`Q.3MS(&%N;G5A;"!R97!O<G0@;VX-"D9O<FT@,3`M2R!F
M:6QE9"!W:71H('1H92!396-U<FET:65S($5X8VAA;F=E($-O;6UI<W-I;VX@
M9F]R('1H90T*>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,"X@5&AE('!R
M97!A<F%T:6]N(&]F('1H97-E(&-O;G-O;&ED871E9`T*9FEN86YC:6%L('-T
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M87-S971S+`T*:6YC;VUE('1A>&5S+"!S=&]C:RUB87-E9"!C;VUP96YS871I
M;VX@86YD(&-O;6UI=&UE;G1S(&%N9`T*8V]N=&EN9V5N8VEE<RXF(WA!,#LF
M(WA!,#M4:&4@0V]M<&%N>28C>#(P,3D[<R!A8W1U86P@<F5S=6QT<R!M87D-
M"F1I9F9E<B!F<F]M('1H97-E(&5S=&EM871E<R!U;F1E<B!D:69F97)E;G0@
M87-S=6UP=&EO;G,@;W(-"F-O;F1I=&EO;G,N/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"D1E8V5M8F5R(#$T+"`R
M,#`Y+"!T:&4@0V]M<&%N>2!A8W%U:7)E9"!":6\M475A;G0L($EN8RX-"B@F
M(W@R,#%#.T)I;RU1=6%N="8C>#(P,40[*2P@82`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^<W!E8VEA;'1Y(&)I
M;W1E8V@@8V]N=')A8W0-"G)E<V5A<F-H(&]R9V%N:7IA=&EO;B`H)B-X,C`Q
M0SM#4D\F(W@R,#%$.RD@8F%S960@:6X@4V%N#0I$:65G;RXF(WA!,#LF(WA!
M,#M4:&4@86-Q=6ES:71I;VX@=V%S(&UA9&4@<'5R<W5A;G0@=&\@86X\+V9O
M;G0^#0I!9W)E96UE;G0@86YD(%!L86X@;V8@365R9V5R("AT:&4@)B-X,C`Q
M0SM-97)G97(@06=R965M96YT)B-X,C`Q1#LI#0ID871E9"!.;W9E;6)E<B`R
M,"P@,C`P.2!B>2!A;F0@86UO;F<@=&AE($-O;7!A;GD@86YD($)1($%C<75I
M<VET:6]N#0I#;W)P+BP@82!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!O9B!T
M:&4@0V]M<&%N>2!A;F0-"D)I;RU1=6%N="X\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\
M8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^9F]C=7,\+V9O;G0^+"`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/G1H92!C87-H(&9L;W<@
M9V5N97)A=&EN9R!C87!A8FEL:71I97,@;V8@=&AE($-23PT*9&EM:6YI<VAE
M9"!O=F5R('1I;64\+V9O;G0^('-I;F-E('1H92!#;VUP86YY('=A<R!U<VEN
M9R!T:&4-"F-A<&%B:6QI=&EE<R!A;F0@<F5S;W5R8V5S(&]F($)I;RU1=6%N
M="!F;W(@:6YT97)N86P@9&5V96QO<&UE;G0-"F%C=&EV:71I97,@<F%T:&5R
M('1H86X@9F]R(&5X=&5R;F%L(&-U<W1O;65R(&=R;W=T:"X@26X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^8V]N;F5C=&EO;B!W:71H('1H
M93PO9F]N=#X@=F%L=6%T:6]N#0IO9B!T:&4@9G5T=7)E(&5X<&5C=&5D(&-A
M<V@@9FQO=W,@86YD('1H92!G;V]D=VEL;"!R96QA=&5D('1O#0I":6\M475A
M;G0@870@1&5C96UB97(@,S$L(#(P,3`L(&%N(&EM<&%I<FUE;G0@8VAA<F=E
M(&]F("9N8G-P.R0Y+#`X-"PT-S8-"G=A<R!T86ME;B!I;B`R,#$P('1O('=R
M:71E(&]F9B!T:&4@96YT:7)E('9A;'5E(&]F#0IG;V]D=VEL;#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SYF<F]M#0IT:&ES(&%C<75I<VET
M:6]N/"]F;VYT/BX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/B8C
M>$$P.T1U<FEN9PT*,C`Q,2P@=&AE($-O;7!A;GD@8V]N<VED97)E9"!T:&4@
M<VEG;FEF:6-A;F-E(&]F(&ET<R!E;FAA;F-E9`T*<')O9'5C="!C86YD:61A
M=&4@<&EP96QI;F4L('1H92!R97-O=7)C97,@;F5E9&5D('1O(&9U<G1H97(@
M9&5V96QO<`T*96%C:"!O9B!T:&]S92!P<F]D=6-T(&]P<&]R='5N:71I97,@
M86YD('1H92!V86QU92!B96EN9R!D97)I=F5D#0IF<F]M('1H92!#4D\@8G5S
M:6YE<W,@=VET:"!D:6UI;FES:&5D(&-A<V@@9FQO=W,@=&]W87)D<PT*;W!E
M<F%T:6]N<RX\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M92<^0F%S960@;VX@=&AE#0IC:&%N9V4@:6X@<W1R871E9VEC(&9O8W5S+"!O
M;CPO9F]N=#X@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A;GD-"F5N=&5R960@
M:6YT;R!A('-T;V-K('!U<F-H87-E(&%G<F5E;65N="!W:71H(%-A;6T@4V]L
M=71I;VYS+"!);F,N#0ID;VEN9R!B=7-I;F5S<R!A<R!":6]4;W@@4V-I96YC
M97,@*"8C>#(P,4,[0FEO5&]X)B-X,C`Q1#LI+"!A(%-A;@T*1&EE9V\M8F%S
M960@0U)/+"!T;R!S96QL(&%L;"!O9B!T:&4@;W5T<W1A;F1I;F<@8V%P:71A
M;"!S=&]C:R!O9@T*0FEO+5%U86YT+"!);F,N+"!W:&EC:"!W87,@;VYE(&]F
M('1H92!#;VUP86YY)B-X,C`Q.3MS('=H;VQL>2!O=VYE9`T*<W5B<VED:6%R
M:65S("AS964@3F]T92`S*2X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E1H<F]U9V@-"DIU;F4@,S`L(#(P,3$L('1H92!D
M871E(&]F('1H92!S86QE(&]F($)I;RU1=6%N="P@=&AE($-O;7!A;GD-"F]P
M97)A=&5D(&EN('1W;R!S96=M96YT<R`F(W@R,#$S.R!D97-I9VYI;F<@86YD
M(&1E=F5L;W!I;F<-"G!H87)M86-E=71I8V%L('!R;V1U8W1S('1H<F]U9V@@
M:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y($YE>$UE9`T**%5302DL($EN
M8RX@86YD('!R;W9I9&EN9R!P<F4M8VQI;FEC86P@0U)/('-E<G9I8V5S('1H
M<F]U9V@@:71S#0IW:&]L;'DM;W=N960@<W5B<VED:6%R>2P@0FEO+5%U86YT
M+B8C>$$P.R8C>$$P.T9O<B!P97)I;V1S#0IS=6)S97%U96YT('1O($IU;F4@
M,S`L(#(P,3$@=&AE($-O;7!A;GD@=VEL;"!O<&5R871E(&EN(&]N92!S96=M
M96YT#0ID97-I9VYI;F<@86YD(&1E=F5L;W!I;F<@<&AA<FUA8V5U=&EC86P@
M<')O9'5C=',@=&AR;W5G:"!I=',-"G=H;VQL>2UO=VYE9"!S=6)S:61I87)Y
M($YE>$UE9"`H55-!*2P@26YC+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"E1H92!#;VUP86YY(&ES(&9O8W5S:6YG(&ET<R!E9F9O<G1S
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M:&5S92!A;F0@;W1H97(@:6YD:6-A=&EO;G,N)B-X03`[)B-X03`[5&AE($-O
M;7!A;GD@:7,@86QS;PT*<V5E:VEN9R!C;VUM97)C:6%L:7IA=&EO;B!P87)T
M;F5R<VAI<',@9F]R(&ET<R!P<F]D=6-T+`T*5FET87)O<R8C>$%%.RP@=VAI
M8V@@:7,@87!P<F]V960@:6X@0V%N861A(&9O<B!T:&4@=')E871M96YT(&]F
M#0IE<F5C=&EL92!D>7-F=6YC=&EO;B`H)B-X,C`Q0SM%1"8C>#(P,40[*2!A
M;F0@:71S(&%D9&ET:6]N86P@97AI<W1I;F<-"F-L:6YI8V%L(&%N9"!P<F4M
M8VQI;FEC86P@<&EP96QI;F4@;V8@<')O9'5C="!C86YD:61A=&5S('-U8V@-
M"F%S)B-X03`[)B-X03`[1F5M<')O>"8C>$%%.R!F;W(@9F5M86QE('-E>'5A
M;"!A<F]U<V%L(&1I<V]R9&5R+`T*37EC;U9A)B-X,C$R,CL@9F]R(&]N>6-H
M;VUY8V]S:7,@97AC;'5D:6YG('1I;F5A('!E9&ES("AN86EL(&9U;F=A;`T*
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M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^169F96-T:79E#0I*=6YE)B-X03`[,C$L(#(P,3`L('1H92!#;VUP86YY
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M9"X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*3&EQ=6ED:71Y/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S
M=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E1H90T*86-C;VUP86YY:6YG(&-O;G-O;&ED871E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@<')E<&%R960-"F]N
M(&$@8F%S:7,@=VAI8V@@8V]N=&5M<&QA=&5S('1H92!R96%L:7IA=&EO;B!O
M9B!A<W-E=',@86YD('1H90T*<V%T:7-F86-T:6]N(&]F(&QI86)I;&ET:65S
M(&%N9"!C;VUM:71M96YT<R!I;B!T:&4@;F]R;6%L(&-O=7)S92!O9@T*8G5S
M:6YE<W,N)B-X03`[)B-X03`[5&AE($-O;7!A;GD@:&%S(&%N(&%C8W5M=6QA
M=&5D(&1E9FEC:70@;V8-"F%P<')O>&EM871E;'D@)FYB<W`[)#(Q,BXT(&UI
M;&QI;VX@870@2G5N92`S,"P@,C`Q,2!A;F0@<F5C;W)D960@82!N970-"FQO
M<W,@;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD,3$N,B8C>$$P.R8C>$$P.VUI
M;&QI;VX@9F]R('1H92!S:7@@;6]N=&AS#0IE;F1E9"!*=6YE(#,P+"`R,#$Q
M(&%N9"!H87,@<')I;F-I<&%L;'D@8F5E;B!F:6YA;F-E9"!T:')O=6=H#0IP
M<FEV871E('!L86-E;65N=',@;V8@97%U:71Y('-E8W5R:71I97,L)B-X03`[
M)B-X03`[9&5B="!F:6YA;F-I;F<-"F%N9"!U<"UF<F]N="!P87EM96YT<R!R
M96-E:79E9"!F<F]M(&-O;6UE<F-I86P@<&%R=&YE<G,@9F]R(&ET<PT*<')O
M9'5C=',@=6YD97(@9&5V96QO<&UE;G0N/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S
M=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H90T*0V]M<&%N
M>28C>#(P,3D[<R!C87-H(')E<V5R=F5S(&]F(&%P<')O>&EM871E;'D@)FYB
M<W`[)#DN,2!M:6QL:6]N(&%T($IU;F4-"C,P+"`R,#$Q+"!A<F4@97AP96-T
M960@=&\@<')O=FED92!U<R!W:71H('-U9F9I8VEE;G0@8V%S:"!T;R!F=6YD
M#0IO=7(@;W!E<F%T:6]N<R!I;G1O('1H92!S96-O;F0@:&%L9B!O9B`R,#$R
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M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;PT*=&AE(&5X=&5N="!W92!S
M:6=N(&%D9&ET:6]N86P@;&EC96YS:6YG(&%G<F5E;65N=',@:6X@,C`Q,2!O
M<B`R,#$R#0IA;F0@<F5C96EV92!U<"UF<F]N="!A;F0@;6EL97-T;VYE('!A
M>6UE;G1S(&9O<CPO9F]N=#X@;VYE(&]R(&UO<F4-"F]F(&]U<B!P<F]D=6-T
M('!I<&5L:6YE(&-A;F1I9&%T97,@86YD+V]R('1H92!.97A!0U0\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X044[/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`W,"4[(%9%
M4E1)0T%,+4%,24=..B!T97AT+71O<"<^)B-X03`[/"]F;VYT/G1E8VAN;VQO
M9WD-"FET<V5L9BP@=V4@97AP96-T('1H870@;W5R(&-A<V@@<F5S97)V97,@
M<&QU<R!T:&]S92!P87EM96YT<R!S:&]U;&0-"G!R;W9I9&4@=7,@=VET:"!S
M=69F:6-I96YT(&-A<V@@=&\@9G5N9"!O=7(@;W!E<F%T:6]N<R!W96QL(&EN
M=&\-"C(P,3,N(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!
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M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M)B-X03`[/"]F;VYT/G1E8VAN;VQO9WDL(&1U<FEN9PT*,C`Q,2!A<R!T:&4@
M0V]M<&%N>2!P;&%N<R!T;R!E;G1E<B!I;G1O(&]U="UL:6-E;G-I;F<@86=R
M965M96YT<PT*9F]R(&ET<R!.97A!0U0F(WA!13L@=&5C:&YO;&]G>2!W:71H
M('!H87)M86-E=71I8V%L(&%N9`T*8FEO=&5C:&YO;&]G>2!C;VUP86YI97,@
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M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SXF
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M=&4@,34L#0IT:&4@0V]M<&%N>2P@:6X@1&5C96UB97(@,C`Q,"P@96YT97)E
M9"!I;G1O(&$@;&EC96YS:6YG(&%G<F5E;65N=`T*=VET:"!"<F%C8V\@4W!!
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M,4,[16QI<R8C>#(P,40[*2!A;F0@3F5O<&AA<FT@1W)O=7`-"B@F(W@R,#%#
M.TYE;W!H87)M)B-X,C`Q1#LI(&9O<B!6:71A<F]S)B-X044[+B8C>$$P.R8C
M>$$P.U5N9&5R('1H90T*=&5R;7,@;V8@=&AE($5L:7,@3&EC96YS92!!9W)E
M96UE;G0L($5L:7,@:&%S(&)E96X@9W)A;G1E9`T*97AC;'5S:79E(')I9VAT
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M26X@07!R:6P@,C`Q,2P@=V4@9FEL960@82!M87)K971I;F<@87!P;&EC871I
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/B8C>$$P.SPO
M9&EV/@T*/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY%9F9E8W1I=F4-"DIA;G5A<GD@,2P@,C`Q,"P@=&AE($-O
M;7!A;GD@861O<'1E9"!!4U4@3F\N(#(P,#DM,3<L(#QF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY#;VYS;VQI
M9&%T:6]N<R`H5&]P:6,@.#$P*3H-"DEM<')O=F5M96YT<R!T;R!&:6YA;F-I
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SYV87)I86)L90T*:6YT97)E<W0@96YT
M:71Y('=I=&@@86X@87!P<F]A8V@@9F]C=7-E9"!O;B!I9&5N=&EF>6EN9R!W
M:&EC:`T*<F5P;W)T:6YG(&5N=&ET>2!H87,@=&AE('!O=V5R('1O(&1I<F5C
M="!T:&4@86-T:79I=&EE<R!O9B!A#0IV87)I86)L92!I;G1E<F5S="!E;G1I
M='D@=&AA="!M;W-T('-I9VYI9FEC86YT;'D@:6UP86-T('1H90T*96YT:71Y
M)B-X,C`Q.3MS(&5C;VYO;6EC('!E<F9O<FUA;F-E(&%N9"`H,2D@=&AE(&]B
M;&EG871I;VX@=&\-"F%B<V]R8B!L;W-S97,@;V8@=&AE(&5N=&ET>2!O<B`H
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN#0I!
M<')I;"`R,#$P+"!T:&4@1D%30B!I<W-U960@05-5($YO+B`R,#$P+3$W+"!4
M;W!I8R`V,#4@+2!2979E;G5E#0I296-O9VYI=&EO;B`M($UI;&5S=&]N92!-
M971H;V0@*"8C>#(P,4,[55-!(#(P,3`M,3<F(W@R,#%$.RDL('=H:6-H#0IP
M<F]V:61E<R!G=6ED86YC92!O;B!D969I;FEN9R!A(&UI;&5S=&]N92!A;F0@
M9&5T97)M:6YI;F<@=VAE;B!I=`T*;6%Y(&)E(&%P<')O<')I871E('1O(&%P
M<&QY('1H92!M:6QE<W1O;F4@;65T:&]D(&]F(')E=F5N=64-"G)E8V]G;FET
M:6]N(&9O<B!R97-E87)C:"!O<B!D979E;&]P;65N="!T<F%N<V%C=&EO;G,N
M(%1H90T*86UE;F1M96YT<R!I;B!!4U4@,C`Q,"TQ-R!A<F4@969F96-T:79E
M(&]N(&$@<')O<W!E8W1I=F4@8F%S:7,@9F]R#0IM:6QE<W1O;F5S(&%C:&EE
M=F5D(&EN(&9I<V-A;"!Y96%R<R!B96=I;FYI;F<@;VX@;W(@869T97(@2G5N
M92`Q-2P-"C(P,3`L(&%N9"!I;G1E<FEM('!E<FEO9',@=VET:&EN('1H;W-E
M('EE87)S+B!4:&4@0V]M<&%N>2!H87,-"F%D;W!T960@05-5(#(P,3`M,3<@
M969F96-T:79E(&%S(&]F('1H92!F:7)S="!Q=6%R=&5R(&]F(&9I<V-A;`T*
M,C`Q,2X@5&AI<R!!4U4@9&ED(&YO="!H879E(&%N>2!I;7!A8W0@;VX@=&AE
M($-O;7!A;GDF(W@R,#$Y.W,-"F-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!U<&]N(&%D;W!T:6]N+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^26X-"D1E8V5M8F5R(#(P,3`L('1H92!&05-"(&ES<W5E9"!!4U4@
M3F\N(#(P,3`M,C@L(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI
M8SL@1$E34$Q!63H@:6YL:6YE)SY);G1A;F=I8FQE<R`F(W@R,#$T.R!';V]D
M=VEL;`T*86YD($]T:&5R("A4;W!I8R`S-3`I.B`F(W@R,#%#.U=H96X@=&\@
M4&5R9F]R;2!3=&5P(#(@;V8@=&AE#0I';V]D=VEL;"!);7!A:7)M96YT(%1E
M<W0@9F]R(%)E<&]R=&EN9R!5;FET<R!W:71H(%IE<F\@;W(@3F5G871I=F4-
M"D-A<G)Y:6YG($%M;W5N=',\+V9O;G0^+B!!4U4@,C`Q,"TR."!I<R!E9F9E
M8W1I=F4@9F]R(&9I<V-A;`T*>65A<G,\9F]N="!S='EL93TS1"=&3TY4+5-4
M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^)B-X03`[/"]F;VYT/F)E
M9VEN;FEN9R!A9G1E<@T*1&5C96UB97(@,34L(#(P,3`@86YD(&%M96YD<R!T
M:&4@8W)I=&5R:6$@9F]R('!E<F9O<FUI;F<@4W1E<"`R(&]F#0IT:&4@9V]O
M9'=I;&P@:6UP86ER;65N="!T97-T(&9O<B!R97!O<G1I;F<@=6YI=',\9F]N
M="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN
M92<^)B-X03`[/"]F;VYT/G=I=&@@>F5R;R!O<@T*;F5G871I=F4@8V%R<GEI
M;F<@86UO=6YT<R!A;F0@<F5Q=6ER97,@<&5R9F]R;6EN9R!3=&5P(#(@:68-
M"G%U86QI=&%T:79E(&9A8W1O<G,@:6YD:6-A=&4@=&AA="!I="!I<R!M;W)E
M(&QI:V5L>2!T:&%N(&YO=`T*=&AA=#QF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SXF(WA!,#L\+V9O;G0^82!G
M;V]D=VEL;`T*:6UP86ER;65N="!E>&ES=',N(%1H92!#;VUP86YY(&AA<R!A
M9&]P=&5D($%352`R,#$P+3(X(&5F9F5C=&EV92!A<PT*;V8@=&AE(&9I<G-T
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M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*1&5C96UB97(@,C`Q,"P@
M=&AE($9!4T(@:7-S=65D($%352!.;RX@,C`Q,"TR-RP@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D9E97,@
M4&%I9"!T;R!T:&4@1F5D97)A;`T*1V]V97)N;65N="!B>2!0:&%R;6%C975T
M:6-A;"!-86YU9F%C='5R97)S/"]F;VYT/B`H("8C>#(P,4,[05-5#0HR,#$P
M+3(W)B-X,C`Q1#LI('=H:6-H('!R;W9I9&5S(&=U:61A;F-E(&]N(&AO=R!T
M;R!R96-O9VYI>F4@86YD#0IC;&%S<VEF>2!T:&4@9F5E<R!M86YD871E9"!B
M>2!T:&4@4&%T:65N=#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI
M8SL@1$E34$Q!63H@:6YL:6YE)SXF(WA!,#L\+V9O;G0^4')O=&5C=&EO;B!A
M;F0-"D%F9F]R9&%B;&4@0V%R92!!8W0@87,@86UE;F1E9"!B>2!T:&4@2&5A
M;'1H($-A<F4@86YD($5D=6-A=&EO;@T*4F5C;VYC:6QI871I;VX@06-T("AT
M;V=E=&AE<BP@=&AE("8C>#(P,4,[06-T<R8C>#(P,40[*2X@5&AE#0I!8W1S
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4G/B8C>$$P.SPO9F]N=#YI;7!O<V4@86X@86YN=6%L#0IF964@9F]R
M(&5A8V@@8V%L96YD87(@>65A<B!B96=I;FYI;F<@;VX@;W(@869T97(@2F%N
M=6%R>2`Q+"`R,#$Q#0IP87EA8FQE(&)Y(&)R86YD960@<')E<V-R:7!T:6]N
M(&1R=6<\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,
M05DZ(&EN;&EN92<^)B-X03`[/"]F;VYT/FUA;G5F86-T=7)E<G,-"F%N9"!I
M;7!O<G1E<G,@;VX@8G)A;F1E9"!P<F5S8W)I<'1I;VX@9')U9W,N(%1H92!L
M:6%B:6QI='D@9F]R('1H90T*9F5E('-H;W5L9"!B92!E<W1I;6%T960@86YD
M(')E8V]R9&5D(&EN(&9U;&P@=7!O;B!T:&4\9F]N="!S='EL93TS1"=&3TY4
M+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^)B-X03`[/"]F;VYT
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M(&ET(&ES('!A>6%B;&4N($%352`R,#$P+3(W(&ES(&5F9F5C=&EV92!F;W(@
M8V%L96YD87(@>65A<G,-"F)E9VEN;FEN9R!O;B!O<B!A9G1E<B!$96-E;6)E
M<B`S,2P@,C`Q,"P@=VAE;B!T:&4@9F5E/&9O;G0@<W1Y;&4],T0G1D].5"U3
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S
M-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P
M-#8Q9#@R-3DU+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%#455)4TE424].($]&($))3RU1
M54%.5#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M0U%525-)5$E/3B!/1B!"24\M455!3E0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR+B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.T%#455)4TE4
M24].#0I/1B!"24\M455!3E0\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C
M>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"DEN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!A8W%U:7-I=&EO;B!O9B!":6\M475A;G0L#0IW:&EC:"!W87,@8V]N
M<W5M;6%T960@;VX@1&5C96UB97(@,30L(#(P,#D@*'1H92`F(W@R,#%#.T5F
M9F5C=&EV90T*5&EM928C>#(P,40[*2P@96%C:"!O=71S=&%N9&EN9R!S:&%R
M92!O9B!C;VUM;VX@<W1O8VL@;V8@0FEO+5%U86YT#0IW87,@8V%N8V5L960@
M86YD(&-O;G9E<G1E9"!I;G1O('1H92!R:6=H="!T;R!R96-E:79E(#8P+CDS
M('-H87)E<PT*;V8@8V]M;6]N('-T;V-K+"!P87(@=F%L=64@)FYB<W`[)#`N
M,#`Q('!E<B!S:&%R92P@;V8@=&AE($-O;7!A;GD@*'1H90T*)B-X,C`Q0SM!
M<')I8W5S(%-H87)E<R8C>#(P,40[*2P@87,@=V5L;"!A<R!A('!R;VUI<W-O
M<GD@;F]T92`H96%C:"P-"F$@)B-X,C`Q0SM.;W1E)B-X,C`Q1#LI(&EN('1H
M92!O<FEG:6YA;"!P<FEN8VEP86P@86UO=6YT(&]F#0HF;F)S<#LD,BPW-S$N
M,S<N)B-X03`[)B-X03`[)B-X03`[26X@8V]N;F5C=&EO;B!W:71H('1H92!C
M;&]S:6YG(&]F('1H90T*365R9V5R+"!T:&4@0V]M<&%N>2!I<W-U960@86X@
M86=G<F5G871E(&]F(#(V-BPV-C<@07!R:6-U<R!3:&%R97,-"F%N9"!.;W1E
M<R!I;B!T:&4@86=G<F5G871E(&]R:6=I;F%L('!R:6YC:7!A;"!A;6]U;G0@
M;V8@)FYB<W`[)#$R+#$R.2PP,3`-"G1O('1H92!S:&%R96AO;&1E<G,@;V8@
M0FEO+5%U86YT+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I4:&4@
M3F]T97,@86-C<G5E9"!I;G1E<F5S="!A="!A(')A=&4@;V8@,3`E('!E<B!A
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M,#M4:&4@365R9V5R($%G<F5E;65N=`T*<')O=FED97,@=&AA="!I9B!T:&4@
M0V]M<&%N>2!R97!A:60@=&AE($YO=&5S(&EN($%P<FEC=7,@4VAA<F5S+`T*
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M970N)B-X03`[)B-X03`[5&AE($-O;7!A;GD@<F5C96EV960@<W1O8VMH;VQD
M97(-"F%P<')O=F%L(&%T(&ET<R!-87D@,C0L(#(P,3`@;65E=&EN9R!F;W(@
M=&AE('!O=&5N=&EA;"!I<W-U86YC92!O9@T*<VAA<F5S(&EN(&9U;&P@<F5P
M87EM96YT(&]F('1H92!R96UA:6YI;F<@86UO=6YT<R!O=V5D('5N9&5R('1H
M90T*3F]T97,L(&%N9"P@;VX@2G5N92`R,2P@,C`Q,"P@=&AE($-O;7!A;GD@
M<F5P86ED('1H92!R96UA:6YI;F<-"F]U='-T86YD:6YG('!R:6YC:7!A;"!A
M;F0@:6YT97)E<W0@86-C<G5E9"!U;F1E<B!T:&4@3F]T97,@:6X-"D%P<FEC
M=7,@4VAA<F5S+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/DEN=&%N9VEB;&4-"F%S<V5T<R!A8W%U:7)E9"!F<F]M
M($)I;RU1=6%N="!O9B`F;F)S<#LD-"PQ-C`L,#`P(&-O;G-I<W1E9"!P<FEM
M87)I;'D@;V8-"F1E=F5L;W!E9"!+;F]W+4AO=R!A;F0@=&AE($)I;RU1=6%N
M="!4<F%D92!.86UE+B!$979E;&]P960@2VYO=RU(;W<-"G)E;&%T960@=&\@
M0FEO+5%U86YT)B-X,C`Q.3MS('!R92UC;&EN:6-A;"!S97)V:6-E(&5X<&5R
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D%T('1H92!T:6UE(&]F(&%C
M<75I<VET:6]N+"!":6\M475A;G0@=V%S(&$@<F5V96YU92!G96YE<F%T:6YG
M+`T*8V%S:"!F;&]W('!O<VET:79E($-23RXF(WA!,#LF(WA!,#M":6\M475A
M;G0@=V%S(&5X<&5C=&5D('1O#0IC;VYT:6YU92!I=',@<F5V96YU92!G<F]W
M=&@@86YD(&-A<V@@9V5N97)A=&EN9R!#4D\-"F)U<VEN97-S+B8C>$$P.R8C
M>$$P.U1H92`F;F)S<#LD.2PP.#0L-#<V(&]F(&=O;V1W:6QL(&=E;F5R871E
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M960@:6X@3F]T92`Q+"!T:&4@0V]M<&%N>2!S:&EF=&5D('1H92!F;V-U<R!O
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M8W0@<&EP96QI;F4@9G)O;2`T(&1R=6<@8V%N9&ED871E<PT*=&\@,3,@9')U
M9R!C86YD:61A=&5S/"]F;VYT/B!U=&EL:7II;F<@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE)SYT:&4@:6YT97)N86P@8V%P86)I;&ET:65S(&]F
M('1H92!#4D\N($AO=V5V97(L(&%S#0IA(')E<W5L="!O9B!T:&ES(&EN=&5R
M;F%L/"]F;VYT/B!R97-E87)C:"`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4G/F9O8W5S('1H92!C87-H(&9L;W<@9V5N97)A=&EN9R!C87!A8FEL
M:71I97,@;V8-"G1H92!#4D\@9&EM:6YI<VAE9"!O=F5R('1I;64@86YD(&EN
M(&-O;FYE8W1I;VX@=VET:"!T:&4\+V9O;G0^#0IV86QU871I;VX@;V8@=&AE
M(&9U='5R92!E>'!E8W1E9"!C87-H(&9L;W=S(&%N9"!T:&4@9V]O9'=I;&P-
M"G)E;&%T960@=&\@0FEO+5%U86YT(&%T($1E8V5M8F5R(#,Q+"`R,#$P+"!A
M;B!I;7!A:7)M96YT(&-H87)G92!O9@T*)FYB<W`[)#DL,#@T+#0W-B!W87,@
M=&%K96X@:6X@,C`Q,"!T;R!W<FET92!O9F8@=&AE(&5N=&ER92!V86QU92!O
M9@T*9V]O9'=I;&P\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M9G)O;0T*=&AI<R!A8W%U:7-I=&EO;CPO9F]N=#XN(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN92<^1'5R:6YG(#(P,3$L#0IT:&4@0V]M<&%N>2P@
M8V]N<VED97)E9"!T:&4@<VEG;FEF:6-A;F-E(&]F(&ET<R!E;FAA;F-E9`T*
M<')O9'5C=#PO9F]N=#X@8V%N9&ED871E(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN92<^<&EP96QI;F4L#0IT:&4@<F5S;W5R8V5S(&YE961E9"!T
M;R!F=7)T:&5R(&1E=F5L;W`@96%C:"!O9B!T:&]S92!P<F]D=6-T#0IO<'!O
M<G1U;FET:65S(&%N9"!T:&4@=F%L=64@8F5I;F<@9&5R:79E9"!F<F]M('1H
M92!#4D\@8G5S:6YE<W,-"G=I=&@@9&EM:6YI<VAE9"!C87-H(&9L;W=S('1O
M=V%R9',@;W!E<F%T:6]N<RX@0F%S960@;VX\+V9O;G0^('1H:7,-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^8VAA;F=E(&EN('-T<F%T96=I
M8R!F;V-U<RP@;VX\+V9O;G0^#0I*=6YE(#,P+"`R,#$Q+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!S=&]C:R!P=7)C:&%S92!A9W)E96UE;G0-"G=I
M=&@@0FEO5&]X('1O('-E;&P@86QL(&]F('1H92!O=71S=&%N9&EN9R!C87!I
M=&%L('-T;V-K(&]F#0I":6\M475A;G0N("A3964@3F]T92`S*2X\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A
M864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H
M965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4T%,12!/1B!"24\M455!3E0\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4T%,12!/1B!"24\M455!3E0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+B8C>$$P.R8C>$$P.R8C
M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.U-!3$4-"D]&($))3RU154%.5#PO9F]N=#X\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB
M<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"E1H92!#;VUP86YY('-O;&0@86QL(&]F('1H92!O=71S=&%N
M9&EN9R!C87!I=&%L('-T;V-K(&]F($)I;RU1=6%N="P-"G=H:6-H('=A<R!O
M;F4@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@=VAO;&QY(&]W;F5D('-U8G-I
M9&EA<FEE<RP@=&\-"D)I;U1O>"!O;B!*=6YE(#,P+"`R,#$Q+B8C>$$P.R8C
M>$$P.R8C>$$P.U1H92!#;VUP86YY(')E8V5I=F5D#0HF;F)S<#LD-3`P+#`Q
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M96-E:79E(&$@;6EN:6UU;2!O9B`F;F)S<#LD-"PU,#`L,#`P('=I=&@-"G1H
M92!R:6=H="!T;R!R96-E:79E(&%M;W5N=',@:6X@97AC97-S(&]F('1H:7,L
M(&1E<&5N9&EN9R!O;B!T:&4-"F=R;W-S(')E=F5N=64@;V8@0FEO5&]X(&]V
M97(@=&AI<R!T96XM>65A<B!P97)I;V0N)B-X03`[)B-X03`[5&AE#0IE87)N
M+6]U="!O8FQI9V%T:6]N<R!A<F4@<V5C=7)E9"!W:71H(&$@9FER<W0@<')I
M;W)I='D@;&EE;B!O;B!A;&P-"G1H92!A<W-E=',@;V8@0FEO+5%U86YT(&%S
M('=E;&P@87,@=&AE(&%S<V5T<R!O9B!":6]4;W@@9F]R(&$-"F-E<G1A:6X@
M<&5R:6]D(&]F('1I;64N($%F=&5R('1H92!S86QE+"!T:&4@0V]M<&%N>2!D
M;V5S(&YO=`T*8F5N969I8VEA;&QY(&]W;B!A;GD@97%U:71Y('-H87)E<R!I
M;B!":6\M475A;G0@;W(-"D)I;U1O>"XF(WA!,#LF(WA!,#M4:&4@0V]M<&%N
M>2!E=F%L=6%T960@=&AE('-A;&4@;V8@0FEO+5%U86YT(&EN#0IA8V-O<F1A
M;F-E('=I=&@@05-#(%1O<&EC(#(P-2TR,"P@/&9O;G0@<W1Y;&4],T0G1D].
M5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D1I<V-O;G1I;G5E
M9`T*3W!E<F%T:6]N<SPO9F]N=#XN(%1H92!#;VUP86YY(&1O97,@;F]T(&5X
M<&5C="!T;R!R96-O9VYI>F4-"F-O;G1I;G5I;F<@9&ER96-T(&-A<V@@9FQO
M=W,@9G)O;2!":6\M475A;G0@869T97(@=&AE#0IS86QE+B8C>$$P.R8C>$$P
M.TAO=V5V97(L('1H92!T<F%N<V%C=&EO;B!I<R!S=')U8W1U<F5D('=I=&@@
M82!L;W<-"F1O=VX@<&%Y;65N="!A;F0@82!P87EM96YT('-T<F5A;2!O=F5R
M(#$P('EE87)S('1H870@:7,@8V]N=&EN9V5N=`T*;VX@=&AE(&]P97)A=&EO
M;F%L('-U8V-E<W,@;V8@0FEO5&]X+B!4:&ES('!A>6UE;G0@<W1R=6-T=7)E
M('=A<PT*;F5G;W1I871E9"!A<R!A(&UE86YS('1O(&EM<')O=F4@=&AE(&QI
M:V5L>2!C87-H(&%V86EL86)L92!F;W(-"FEN=F5S=&UE;G0@:6X@=&AE(&=R
M;W=T:"!O9B!T:&4@8G5S:6YE<W,L('=H:6-H('=A<R!E>'!E8W1E9"!T;PT*
M:&%V92!T:&4@969F96-T(&]F)B-X03`[)B-X03`[96YC;W5R86=I;F<@:&EG
M:&5R(')E=F5N=65S(&9O<@T*0FEO5&]X(&%N9"!P;W1E;G1I86QL>2!G<F5A
M=&5R(&5A<FXM;W5T('!A>6UE;G1S('1O('1H92!#;VUP86YY#0IO=F5R('1H
M92!T96X@>65A<B!E87)N+6]U="!P97)I;V0N)B-X03`[)B-X03`[5&AE($-O
M;7!A;GD@9&]E<R!N;W0-"FAA=F4@86YY('9O=&4@;W(@:6YF;'5E;F-E(&]N
M('1H92!E>&5C=71I;VX@;V8@=&AE(&]P97)A=&EO;G,@8G5T#0IR971A:6YS
M(&$@<VEG;FEF:6-A;G0@86UO=6YT(&]F(&-O;&QE8W1I;VX@<FES:R!D97!E
M;F1I;F<@;VX@=&AE#0IO<&5R871I;VYA;"!S=6-C97-S(&]F('1H92!D:7-P
M;W-E9"!#4D\@8G5S:6YE<W,N)B-X03`[)B-X03`[5&AI<PT*8V]N=&EN=65D
M(&5X<&]S=7)E('1O('1H92!O<&5R871I;F<@<FES:R!O9B!":6]4;W@@86YD
M('1H92!E>'1E;F1E9`T*<&]S="!S86QE(&5A<FXM;W5T('!E<FEO9"!I;F1I
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP86YY(&%L<V\@8V]N
M<VED97)E9"!W:&5T:&5R($)I;U1O>"!S:&]U;&0@8F4@8V]N<V]L:61A=&5D
M(&%S(&$-"E9A<FEA8FQE($EN=&5R97-T($5N=&ET>2`H)B-X,C`Q0SM6244F
M(W@R,#%$.RD@=6YD97(@05-5($YO+B`R,#`Y+3$W+`T*/&9O;G0@<W1Y;&4]
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M<F(@861D:71I;VYA;`T*;&]S<V5S(&%N9"!I="!W:6QL(&YO="!P87)T:6-I
M<&%T92!I;B!A;GD@<F5S:61U86P@<F5V96YU97,@=&AU<R!I=`T*:7,@;F]T
M('1H92!P<FEM87)Y(&)E;F5F:6-I87)Y(&]F('1H92!6244N($%S('-U8V@L
M('1H92!#;VUP86YY#0IW:6QL(&YO="!C;VYS;VQI9&%T92!T:&4@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N(&]F('1H90T*0G5Y97(N/"]F;VYT/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:R<^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL
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M;W9E<B!T:&4@;F5X="!T96X@>65A<G,@:7,@87!P<F]X:6UA=&5L>2`F;F)S
M<#LD,BXS+"!M:6QL:6]N#0IW:&EC:"!R97!R97-E;G1S('1H92!M:6YI;75M
M('!A>6UE;G1S(&]F("9N8G-P.R0T+#4P,"PP,#`@9&ES8V]U;G1E9"!A=`T*
M,3,N,"4@;W9E<B!T:&4@=&5N+7EE87(@<&5R:6]D+B8C>$$P.R8C>$$P.R8C
M>$$P.U1H:7,@<F5C96EV86)L92!I<PT*8V%R<FEE9"!O;B!T:&4@0V]M<&%N
M>28C>#(P,3D[<R!B86QA;F-E('-H965T(&%S(&]F($IU;F4@,S`L(#(P,3$@
M870-"B9N8G-P.R0P(&1U92!T;R!A(')E<V5R=F4@;V8@)FYB<W`[)#(N,R!M
M:6QL:6]N(&5S=&%B;&ES:&5D(&%T($IU;F4@,S`L(#(P,3$L#0IB87-E9"!O
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M($)I;RU1=6%N="!S=6)S:61I87)Y(&%N9`T*:7,@;F]T(')E9FQE8W1E9"!A
M<R!A(&)A9"!D96)T(&5X<&5N<V4N($EN('1H92!E=F5N="!T:&%T(&%C='5A
M;`T*9G5T=7)E(&-A<V@@<F5C96EP=',@9G)O;2!":6]4;W@@9&EF9F5R(&9R
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4:&4-"F9O;&QO=VEN9R!R97!R97-E;G1S('!R;V9O<FUA(')E
M<W5L=',@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4-"C,P+"`R,#$Q
M(&%N9"`R,#$P+"!R97-P96-T:79E;'DL(&%S(&EF('1H92!T<F%N<V%C=&EO
M;B!H860@;V-C=7)R960-"F]N($IA;G5A<GD@,2P@,C`Q,"X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SXF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV/@T*/&1I=B!A
M;&EG;CTS1&QE9G0^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$P/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I&3U(@5$A%(%-)6"!-3TY42%,\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#$P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I%3D1%1"!*54Y%(#,P+#PO9F]N
M=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,3`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"C(P,3$\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY0<F\-"F9O<FUA(&9I;F%N8VEA;"!R97-U
M;'1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I"
M:6\M475A;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E(&%L:6=N/3-$;&5F=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+#$X,BPR,3<\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M+#`T,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H
M:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3F5T#0IL;W-S/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*#$Q+#(P-2PP.3@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXH,BPY-#8L-S0X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXH,"XU.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M25I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P
M.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*#`N-#(\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A
M;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY796EG:'1E9`T*879E<F%G92!C;VUM;VX@<VAA<F5S(&]U
M='-T86YD:6YG/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M3$5&5#H@,'!T.R!-05)'24XM3$5&5#H@.7!T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@86QI9VX],T1L969T/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^=7-E
M9`T*9F]R(&)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E/"]F;VYT
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ.2PT-S4L-3DX/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF(WA!,#L\+V1I=CX-
M"CPO9&EV/@T*/&1I=B!A;&EG;CTS1&QE9G0^#0H\9&EV(&%L:6=N/3-$;&5F
M=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I&3U(@5$A%(%-)6"!-3TY4
M2%,\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#$P/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I%3D1%
M1"!*54Y%(#,P+#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,3`^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"C(P,3`\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY0<F\-"F9O<FUA
M(&9I;F%N8VEA;"!R97-U;'1S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,3`^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BA5;F%U9&ET960I/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"D%S(%)E<&]R=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I":6\M475A;G0\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO
M<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
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M3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M+#DQ-BPV-SD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M(&)G8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0V-"4@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXH,3,L-#8S+#8P-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
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M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXH,2XV-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M3TY4+5-)6D4Z(#$P<'0G/B@P+C`Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1'=H:71E/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)2!A;&EG
M;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY796EG:'1E9`T*879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"G5S960@9F]R(&)A<VEC(&%N9"!D:6QU=&5D(&QO
M<W,@<&5R('-H87)E/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX+#(V-"PU,34\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:R<^)B-X03`[/"]D:78^#0H\+V1I=CX-"CPO9&EV/@T*/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4
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M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E
M,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R
M-3DU+U=O<FMS:&5E=',O4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D%#0T]53E1)3D<@1D]2(%-43T-++4)!4T5$
M($-/35!%3E-!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!0T-/54Y424Y'($9/4B!35$]#2RU"05-%1"!#3TU014Y3051)
M3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+B8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C
M>$$P.R8C>$$P.R8C>$$P.T%#0T]53E1)3D<-"D9/4B!35$]#2RU"05-%1"!#
M3TU014Y3051)3TX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^5&AE#0IV86QU92!O9B!R97-T<FEC=&5D('-T;V-K(&=R86YT<R!I<R!C
M86QC=6QA=&5D(&)A<V5D('5P;VX@=&AE#0IC;&]S:6YG('-T;V-K('!R:6-E
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS($-O;6UO;B!3=&]C:R!O;B!T:&4@
M9&%T90T*;V8@=&AE(&=R86YT+B8C>$$P.R8C>$$P.T9O<B!S=&]C:R!O<'1I
M;VYS(&=R86YT960@=&\@96UP;&]Y965S(&%N9`T*9&ER96-T;W)S+"!W92!R
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M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY);@T*1&5C96UB97(@,3DY-BP@=&AE($-O;7!A;GD@861O<'1E
M9"!T:&4@4W1O8VL@3W!T:6]N(&%N9"!,;VYG+51E<FT-"DEN8V5N=&EV92!#
M;VUP96YS871I;VX@4&QA;B`H=&AE("8C>#(P,4,[26YC96YT:79E(%!L86XF
M(W@R,#%$.RD@86YD#0IT:&4@4F5C;V=N:71I;VX@86YD(%)E=&5N=&EO;B!3
M=&]C:R!);F-E;G1I=F4@4&QA;B`H=&AE#0HF(W@R,#%#.U)E8V]G;FET:6]N
M(%!L86XF(W@R,#%$.RDN)B-X03`[)B-X03`[02!T;W1A;"!O9B`Q,S,L,S,S
M#0IS:&%R97,@=V5R92!S970@87-I9&4@9F]R('1H97-E('1W;R!P;&%N<RXF
M(WA!,#LF(WA!,#M);B!-87D@,C`P,"P-"G1H92!3=&]C:VAO;&1E<G,F(W@R
M,#$Y.R!A<'!R;W9E9"!A;B!I;F-R96%S92!I;B!T:&4@;G5M8F5R(&]F#0IS
M:&%R97,@<F5S97)V960@9F]R('1H92!);F-E;G1I=F4@4&QA;B!A;F0@4F5C
M;V=N:71I;VX@4&QA;B!T;R!A#0IT;W1A;"!O9B`U,#`L,#`P+B8C>$$P.R8C
M>$$P.TEN($IU;F4@,C`P-BP@=&AE($-O;7!A;GD@861O<'1E9"!T:&4-"DYE
M>$UE9"P@26YC+B`R,#`V(%-T;V-K($EN8V5N=&EV92!0;&%N("@F(W@R,#%#
M.W1H92`R,#`V#0I0;&%N)B-X,C`Q1#LI+B8C>$$P.R8C>$$P.T$@=&]T86P@
M;V8@,C`P+#`P,"!S:&%R97,@=V5R92!I;FET:6%L;'D-"G)E<V5R=F5D(&9O
M<B!T:&4@:7-S=6%N8V4@=6YD97(@=&AE(#(P,#8@4&QA;B!A;F0@86X@861D
M:71I;VYA;`T*,3,S+#,S,R!S:&%R97,@=V5R92!A9&1E9"!T;R!T:&4@,C`P
M-B!0;&%N(&EN($IU;F4-"C(P,#@N)B-X03`[)B-X03`[5&AE($-O;7!A;GD@
M<F5C96EV960@<W1O8VMH;VQD97(@87!P<F]V86P@870@:71S#0I-87D@,C0L
M(#(P,3`@;65E=&EN9R!T;R!A9&0@86X@861D:71I;VYA;"`Q+#`P,"PP,#`@
M<VAA<F5S('1O('1H90T*,C`P-B!0;&%N+B!4:&4@0V]M<&%N>2!R96-E:79E
M9"!S=&]C:VAO;&1E<B!A<'!R;W9A;"!A="!I=',@36%Y(#$V+`T*,C`Q,2!M
M965T:6YG('1O(&EN8W)E87-E('1H92!N=6UB97(@;V8@<VAA<F5S(')E<V5R
M=F5D(&9O<B!T:&4@,C`P-@T*4&QA;B!B>2`R+#4P,"PP,#`@=&\@,RPX,S,L
M,S,S+B!/<'1I;VYS(&=R86YT960@=6YD97(@=&AE#0I#;VUP86YY)B-X,C`Q
M.3MS('!L86YS(&=E;F5R86QL>2!V97-T(&]V97(@82!P97)I;V0@;V8@;VYE
M('1O(&9I=F4-"GEE87)S+"!W:71H(&5X97)C:7-E('!R:6-E<R!O9B!C=7)R
M96YT;'D@;W5T<W1A;F1I;F<@;W!T:6]N<PT*<F%N9VEN9R!F<F]M("9N8G-P
M.R0Q+C8Y('1O("9N8G-P.R0T."XW-2XF(WA!,#LF(WA!,#M4:&4@;6%X:6UU
M;2!T97)M('5N9&5R#0IT:&5S92!P;&%N<R!I<R`Q,"!Y96%R<RX\+V9O;G0^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M=71S=&%N9&EN9R!A=`T*2G5N92`S,"P@,C`Q,3H\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"CQD:78^#0H\
M9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#4E(&-O;'-P86X],T0Q,3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT
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M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/@T*/&9O;G0@<W1Y
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
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M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT
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M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"DYU;6)E<CPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3W5T
M<W1A;F1I;F<\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3$E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I796EG:'1E9#PO9F]N=#X\+V9O;G0^/"]F;VYT/CPO
M9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y
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M5"U325I%.B`Y<'0[($9/3E0M5T5)1TA4.B!B;VQD)SY#;VYT<F%C='5A;`T*
M3&EF93PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@8V]L<W!A;CTS1#(@86QI9VX]
M,T1R:6=H=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX-"E=E:6=H=&5D/"]F;VYT/CPO9F]N=#X\+V9O;G0^
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP=#L@
M1D].5"U714E'2%0Z(&)O;&0G/@T*079E<F%G93PO9F]N=#X\+V9O;G0^/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
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M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Y<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0I);G1R:6YS:6,\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
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M1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG
M:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I.=6UB97(\+V9O;G0^/"]F;VYT/CPO
M9F]N=#X\+V9O;G0^/"]D:78^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP=#L@1D].
M5"U714E'2%0Z(&)O;&0G/D5X97)C:7-A8FQE/"]F;VYT/CPO9F]N=#X\+V1I
M=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O
M;'-P86X],T0R(&%L:6=N/3-$<FEG:'0^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Y<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I7
M96EG:'1E9#PO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0[($9/3E0M5T5)1TA4.B!B;VQD
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M;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
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M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0S!&1D,P
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/C$N-CD-"BT@-2XS
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P
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M.#<P+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/@T*)FYB<W`[)#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Y<'0G/C0N,S8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/@T*)FYB<W`[
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Y<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#EP="<^,3`Y+#DY,#PO9F]N=#X\+W1D/@T*/'1D('-T
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M;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
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M=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/C0N,#$\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G
M/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXX-2PS.3$\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXX+C(U#0HM(#0X+C<U/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Y<'0G/C0N-`T*>65A<G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXQ-"XV,3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$."4^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#EP="<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
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M5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F
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M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#EP="<^,30N-C$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$(T,P1D9#,#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y
M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
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M6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M1D].5"U325I%.B`Y<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(]
M,T1W:&ET93X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Y<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/CDQ-BPX
M,3@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,24^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/CDN,PT*>65A<G,\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)FYB
M<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
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M;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
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M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#@E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Y<'0G/C$U-BPX,#@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@.7!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=.
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Y<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#EP
M="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\9&EV(&%L:6=N/3-$;&5F
M=#XF(WA!,#L\+V1I=CX-"CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,C=P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^00T*<W5M;6%R>2!O9B!S
M=&]C:R!O<'1I;VX@86-T:79I='D@:7,@87,@9F]L;&]W<SH\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS
M1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0I796EG:'1E9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*
M)B-X03`[/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I7
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
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M(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C
M96YT97(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*5&]T86P\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SY!9V=R96=A=&4\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
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M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0I%>&5R8VES93PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#
M;VYT<F%C='5A;#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*26YT<FEN<VEC/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$P)2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*4')I
M8V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@
M8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
M;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3W5T<W1A;F1I;F<-"F%T($1E
M8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3`W+#8P-#PO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0HF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ,"XS-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!A;&EG;CTS
M1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SYY96%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI
M=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`Y)2<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,S@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C@T,BPU,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0S!&1D,P/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M3$5&5#H@.24G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,X
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^/"]D:78^#0H\+W1D/@T*
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M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$=VAI=&4^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@
M4$%$1$E.1RU,1494.B`Y)2<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S@E
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/D-A;F-E;&QE9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#,$9&0S`^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,S@E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]U='-T86YD:6YG#0IA="!*=6YE(#,P+"`R,#$Q
M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^.3$V+#@Q.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+C@X/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R
M/3-$=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S@E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C
M0S!&1D,P/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,X)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY697-T960-
M"F]R(&5X<&5C=&5D('1O('9E<W0@870\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S."4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[2G5N
M90T*,S`L(#(P,3$\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX.3(L-#,Q/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4G/@T*.2XS/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@86QI9VX],T1L969T/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^>65A<G,\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
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M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R(&)G8V]L;W(],T0C0S!&1D,P/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,X)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
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M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
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M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D5X97)C:7-A8FQE#0IA="!*=6YE(#,P+"`R,#$Q/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,34V+#@P.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+C$X/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
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M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
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M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-4
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I
M9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
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M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
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M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M<V5D(&]N($-O;7!A;GD@97AP97)I96YC92X@5&AE($-O;7!A;GD@=VEL;`T*
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M960@=&AR;W5G:"!A(&-U;75L871I=F4@8V%T8V@M=7`-"F%D:G5S=&UE;G0@
M:6X@=&AE('!E<FEO9"!O9B!C:&%N9V4@86YD('=I;&P@86QS;R!I;7!A8W0@
M=&AE(&%M;W5N=`T*;V8@8V]M<&5N<V%T:6]N(&5X<&5N<V4@=&\@8F4@<F5C
M;V=N:7IE9"!I;B!F=71U<F4-"G!E<FEO9',N/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E1O=&%L#0IU;G)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N(&-O<W0@<F5L871E9"!T;R!U;G9E<W1E9"!S=&]C:R!O<'1I;VYS
M(&%S#0IO9B!*=6YE(#,P+"`R,#$Q('=A<R!A<'!R;WAI;6%T96QY("9N8G-P
M.R0S+C$@;6EL;&EO;BXF(WA!,#LF(WA!,#M4:&%T#0IC;W-T(&ES(&5X<&5C
M=&5D('1O(&)E(')E8V]G;FEZ960@;W9E<B`S('EE87)S+CPO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SX-"D-O
M;7!E;G-A=&]R>2!3:&%R92!)<W-U86YC97,\+V9O;G0^/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
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M86YC92!W:71H($9!4T(@05-##0HW,3@N)B-X03`[)B-X03`[07,@;V8@2G5N
M92`S,"P@,C`Q,2P@=&AE<F4@=V%S(&%P<')O>&EM871E;'D-"B9N8G-P.R0X
M,SDL,#`P(&]F('1O=&%L('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S
M="!R96QA=&5D('1O#0IN;VXM=F5S=&5D(')E<W1R:6-T960@<W1O8VLN)B-X
M03`[)B-X03`[5&AA="!C;W-T(&ES(&5X<&5C=&5D('1O(&)E#0IR96-O9VYI
M>F5D(&]V97(@,R!Y96%R<RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C
M>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^1'5R:6YG#0HR,#$Q+"!T:&4@0F]A<F0@;V8@1&ER96-T;W)S
M(&%W87)D960@1'(N($)A<W-A;2!$86UA:BP@=&AE#0I#;VUP86YY)B-X,C`Q
M.3MS(&-U<G)E;G0@0VAA:7)M86XL(%!R97-I9&5N="!A;F0@0VAI968@17AE
M8W5T:79E#0I/9F9I8V5R(&%N(&]P=&EO;B`H=&AE("8C>#(P,4,[3W!T:6]N
M)B-X,C`Q1#LI/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$
M25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+V9O
M;G0^=&\-"G!U<F-H87-E('5P('1O(#,P,"PP,#`@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!O9B!T:&4-"D-O;7!A;GDN)B-X03`[)B-X03`[5&AE(&5X97)C
M:7-E('!R:6-E(&]F('1H92!/<'1I;VX@:7,@97%U86P@=&\-"B9N8G-P.R0S
M+C@Y('!E<B!S:&%R92P@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!#
M;VUP86YY)B-X,C`Q.3MS#0IC;VUM;VX@<W1O8VL@;VX@=&AE(&1A=&4@;V8@
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M<F]X:6UA=&5L>2`F;F)S<#LD-#(Y+#`P,"!A<R!C;VUP96YS871I;VX@97AP
M96YS90T*9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P
M,3$N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
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M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0I&3U(@5$A%(%-)6"8C>$$P.TU/3E1(4SPO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
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M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/@T*14Y$140@2E5.12`S,"P\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<CX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE)SX-"C(P,3`\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,C`Q
M,3PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
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M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0S!&1D,P/@T*/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-E87)C:`T*86YD(&1E
M=F5L;W!M96YT/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,3`L,C@T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M<'0G/C$S-BPT,C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M,3`L,C@T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY'96YE<F%L#0IA;F0@861M:6YI
M<W1R871I=F4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT,34L-34W/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^,2PP-#`L,#DP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#,$9&0S`^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3=&]C:RUB87-E9`T*8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W
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M25I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU,C8L,S0P/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PP
M-3`L,S<T/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D
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M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4
M:&4-"G-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&AA<R!N;W0@
M8F5E;B!T87@M969F96-T960@9'5E('1O#0IT:&4@<F5C;W)D:6YG(&]F(&$@
M9G5L;"!V86QU871I;VX@86QL;W=A;F-E(&%G86EN<W0@52Y3+B!N970-"F1E
M9F5R<F5D('1A>"!A<W-E=',N/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E
M,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R
M-3DU+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E=!4E)!3E13/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=!4E)!3E13/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^-2XF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#M7
M05)204Y44SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!
M#0IS=6UM87)Y(&]F('=A<G)A;G0@86-T:79I='D@9F]R('1H92!S:7@@;6]N
M=&@@<&5R:6]D(&5N9&5D($IU;F4@,S`L#0HR,#$Q(&ES(&%S(&9O;&QO=W,Z
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^#0H\9&EV(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*
M/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Y)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I796EG:'1E9#PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"E=E
M:6=H=&5D/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#DE/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P
M86X],T0R/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I#;VUM;VX@4VAA<F5S/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS
M1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,34E/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I!=F5R86=E/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-#DE/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0I)<W-U86)L92!U<&]N/"]F;VYT/CPO9&EV/@T*
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-
M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS
M1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^#0I0<FEC93PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)3X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V
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M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^3W5T<W1A;F1I;F<-"F%T($1E8V5M8F5R
M(#,Q+"`R,#$P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+C<R/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
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M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY)<W-U960\+V9O;G0^/"]D:78^#0H\
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#,$9&0S`^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU,1494.B`T)2<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#DE
M(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/D5X97)C:7-E9#PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO
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M<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,BXR-SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^
M#0H\='(@8F=C;VQO<CTS1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%!!1$1)3D<M3$5&5#H@-"4G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0Y)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#86YC96QL960\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
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M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
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M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
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M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T0C0S!&1D,P/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0Y
M)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9PT*870@2G5N92`S,"P@,C`Q,3PO
M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ+#`W-RPV-#(\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#,$9&0S`^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-#DE(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-A8FQE#0IA="!*=6YE(#,P+"`R
M,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CDR,BPP-#,\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,34E/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXS+C0V#0IY96%R<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?
M-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3$]34R!015(@4TA!4D4\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3$]34R!015(@4TA!4D4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV+B8C>$$P.R8C>$$P.R8C
M>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.TQ/4U,-"E!%4B!32$%213PO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O
M/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^070-"DIU;F4@,S`L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L
M>2P@;W!T:6]N<R!T;R!A8W%U:7)E(#DQ-BPX,3@-"F%N9"`Q-38L-S<Q('-H
M87)E<R!O9B!#;VUM;VX@4W1O8VLL('=A<G)A;G1S('1O(&%C<75I<F4@,2PP
M-S<L-C0R#0IA;F0@,C4P+#@Y-2!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%N
M9"!C;VYV97)T:6)L92!S96-U<FET:65S#0IC;VYV97)T:6)L92!I;G1O(#8S
M-BPR-3<@86YD(#0V-BPR,#`@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!W97)E
M#0IE>&-L=61E9"!F<F]M('1H92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&QO
M<W,@<&5R('-H87)E+"!A<R!T:&5I<@T*969F96-T('=O=6QD(&)E(&%N=&DM
M9&EL=71I=F4N)B-X03`[)B-X03`[3&]S<R!P97(@<VAA<F4@9F]R('1H90T*
M=&AR964@86YD('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2!A;F0@
M,C`Q,"!W87,@8V%L8W5L871E9"!A<PT*9F]L;&]W<R`H;F5T(&QO<W,@+R!W
M96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,-"F]U='-T86YD:6YG*3H\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV
M(&%L:6=N/3-$;&5F=#X-"CQT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R/@T*/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#8^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
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M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^#0I&3U(@5$A%(%-)6"!-3TY42%,\+V9O;G0^/"]D:78^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*14Y$140@2E5.12`S
M,"P\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#8^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX-"D5.
M1$5$($I53D4@,S`L/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
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M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,C`Q,3PO9F]N=#X\+V9O;G0^
M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4G/@T*,C`Q,#PO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
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M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O
M;&]R/3-$(T,P1D9#,#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@86QI9VX],T1L969T
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
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M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@W+#<Y-"PP.3(\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S
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M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\
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M.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXH,3,L-3$V+#$P,SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
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M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
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M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$
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M5"U325I%.B`Q,'!T)SXY+#$T,"PT-3$\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG
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M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ
M.2PT-S4L-3DX/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^."PR-C0L-3$U/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS1"-#
M,$9&0S`^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO<CTS
M1'=H:71E/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"87-I8PT*
M86YD(&1I;'5T960@;&]S<R!P97(@8V]M;6]N('-H87)E/"]F;VYT/CPO9&EV
M/@T*/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD
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M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,"XT-SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
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M:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^*#`N-3@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W
M9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T
M-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y404Y'24),12!!4U-%5%,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y404Y'
M24),12!!4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXW+B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.TE.5$%.1TE"3$4-"D%34T544SPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN92<^5&AE(&EN=&%N9VEB;&4@87-S971S(&]F('1H92!#
M;VUP86YY#0IA="!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@=&AR;W5G:"!*=6YE
M(#,P+"`R,#$Q(&-O;G-I<W1E9"!O9@T*2VYO=RU(;W<@86YD(%1R861E($YA
M;64@<F5L871E9"!T;R!T:&4@0FEO+5%U86YT($-23R!S96=M96YT+B!/;@T*
M2G5N92`S,"P@,C`Q,2P@=&AE($)I;RU1=6%N="!B=7-I;F5S<R!W87,@<V]L
M9"!T;R!":6]4;W@@86YD('1H90T*:6YT86YG:6)L97,@87-S;V-I871E9"!W
M:71H('1H92!B=7-I;F5S<R!W97)E(')E;6]V960@9G)O;2!T:&4-"F-O;G-O
M;&ED871E9"!A8V-O=6YT<R!O9B!T:&4@0V]M<&%N>2X@1'5R:6YG(#(P,3`@
M86YD(&9O<B!T:&4@9FER<W0-"FAA;&8@;V8@,C`Q,2P@=&AE($-O;7!A;GD@
M86UO<G1I>F5D($MN;W<M2&]W(&]V97(@=&AE(&5X<&5C=&5D#0IU<V5F=6P@
M;&EF92!O9B`Q,"!Y96%R<R!A;F0@=&AE(%1R861E($YA;64@;W9E<B!T:&4@
M97AP96-T960@=7-E9G5L#0IL:69E(&]F(#(P('EE87)S+CPO9F]N=#X@06UO
M<G1I>F%T:6]N(&5X<&5N<V4@86UO=6YT960@=&\@)FYB<W`[)#4Y+#4P.0T*
M86YD("9N8G-P.R0Q-SDL.3(T(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*
M=6YE(#,P+"`R,#$Q(&%N9"`R,#$P+`T*<F5S<&5C=&EV96QY+B8C>$$P.R8C
M>$$P.T1U<FEN9R`R,#$P+"!T:&4@0V]M<&%N>2!T;V]K(&%N#0II;7!A:7)M
M96YT(&-H87)G92!O9B`F;F)S<#LD,2PP.#,L-C0V('1O('=R:71E(&1O=VX@
M=&AE(&9A:7(@=F%L=64@;V8-"DMN;W<M2&]W('1O("9N8G-P.R0Q+#8S-RPP
M,#`N)B-X03`[)B-X03`[/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M)SY3=6-H(&EM<&%I<FUE;G0@=V%S(&1E<FEV960@;6%I;FQY(&9R;VT@=&AE
M(&9A8W0-"G1H870@0FEO+5%U86YT('-I9VYI9FEC86YT;'D@8VAA;F=E9"!I
M=',@<W1R871E9VEC(&9O8W5S(&EN#0HR,#$P+B8C>$$P.R8C>$$P.U)A=&AE
M<B!T:&%N('-E<G9E('1H92!G<F5A=&5R($-23R!M87)K970L#0I":6\M475A
M;G0@=V%S('!R:6UA<FEL>2!P97)F;W)M:6YG/"]F;VYT/B!I;G1E<FYA;"`\
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M($1E8V5M8F5R#0HR,#`Y+CPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*
M/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y
M-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E,&8P
M7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#$T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].5D52
M5$E"3$4@3D]415,@4$%904),13QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#3TY615)424),12!.3U1%4R!005E!0DQ%/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^."XF(WA!,#LF(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#M#3TY615)424),10T*3D]415,@4$%904),13PO9F]N=#X\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
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M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^
M)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*3VX@36%R8V@@,34L(#(P,3`L('1H92!#;VUP86YY(&ES
M<W5E9"!C;VYV97)T:6)L92!N;W1E<R`H=&AE#0HF(W@R,#%#.S(P,3`@0V]N
M=F5R=&EB;&4@3F]T97,F(W@R,#%$.RD@:6X@86X@86=G<F5G871E('!R:6YC
M:7!A;`T*86UO=6YT(&]F("9N8G-P.R0T(&UI;&QI;VXN(%1H92`R,#$P($-O
M;G9E<G1I8FQE($YO=&5S(&%R92!S96-U<F5D(&)Y(&$-"F9I<G-T('!R:6]R
M:71Y(&UO<G1G86=E(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&9A8VEL:71Y
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M=6-H+"!T:&4@0V]M<&%N>2!R96-E:79E9`T*87!P<F]X:6UA=&5L>2`F;F)S
M<#LD,2XT(&UI;&QI;VX@:6X@;F5T('!R;V-E961S(&9R;VT@=&AE(&ES<W5A
M;F-E(&]F('1H90T*,C`Q,"!#;VYV97)T:6)L92!.;W1E<RX\+V9O;G0^/"]F
M;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"E1H
M92`R,#$P($-O;G9E<G1I8FQE($YO=&5S(&%R92P@870@=&AE(&AO;&1E<G,F
M(W@R,#$Y.PT*;W!T:6]N+"8C>$$P.R8C>$$P.W!A>6%B;&4@:6X@8V%S:"!A
M="!M871U<FET>2!O;B!$96-E;6)E<B`S,2P@,C`Q,@T*;W(@8V]N=F5R=&EB
M;&4@870@86YY('1I;64@:6YT;R!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&%T
M(&$@8W5R<F5N=`T*8V]N=F5R<VEO;B!P<FEC92!O9B`F;F)S<#LD-BXR.2!P
M97(@<VAA<F4@*'=I=&@@86X@:6YI=&EA;"!C;VYV97)S:6]N#0IP<FEC92!O
M9B`F;F)S<#LD."XW,"!P97(@<VAA<F4I("AT:&4@)B-X,C`Q0SMC;VYV97)S
M:6]N('!R:6-E)B-X,C`Q1#LI+`T*=VAI8V@@<')I8V4@:7,@<W5B:F5C="!T
M;R!A9&IU<W1M96YT('5P;VX@8V5R=&%I;B!D:6QU=&EV90T*:7-S=6%N8V5S
M(&]F(&-O;6UO;B!S=&]C:RXF(WA!,#LF(WA!,#M4:&4@,C`Q,"!#;VYV97)T
M:6)L92!.;W1E<PT*:&%V92!A(&-O=7!O;B!R871E(&]F(#<E('!E<B!A;FYU
M;2P@=VAI8V@@:7,@<&%Y86)L92!A="!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@
M;W!T:6]N(&EN(&-A<V@@;W(L(&EF('1H92!#;VUP86YY)B-X,C`Q.3MS(&YE
M="!C87-H#0IB86QA;F-E(&ES(&QE<W,@=&AA;B`F;F)S<#LD,R!M:6QL:6]N
M(&%T('1H92!T:6UE(&]F('!A>6UE;G0L(&EN('-H87)E<PT*;V8@0V]M;6]N
M(%-T;V-K+B8C>$$P.R8C>$$P.TEF('!A:60@:6X@<VAA<F5S(&]F($-O;6UO
M;B!3=&]C:RP@=&AE;@T*=&AE('!R:6-E(&]F('1H92!S=&]C:R!I<W-U960@
M=VEL;"!B92!T:&4@;&5S<V5R(&]F("9N8G-P.R0Q+C(P(&)E;&]W(&]R#0HY
M-24@;V8@=&AE(&9I=F4M9&%Y('=E:6=H=&5D(&%V97)A9V4@;V8@=&AE(&UA
M<FME="!P<FEC92!O9B!T:&4-"D-O;6UO;B!3=&]C:R!P<FEO<B!T;R!T:&4@
M=&EM92!O9B!P87EM96YT+B8C>$$P.R8C>$$P.U-U8V@-"F%D9&ET:6]N86P@
M:6YT97)E<W0@8V]N<VED97)A=&EO;B!I<R!C;VYS:61E<F5D(&-O;G1I;F=E
M;G0@86YD#0IT:&5R969O<F4@=V]U;&0@;VYL>2!B92!R96-O9VYI>F5D('5P
M;VX-"F]C8W5R<F5N8V4N/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I
M9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+V1I=CX-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"E1H92!C;VYV97)S:6]N('!R:6-E(&%T($IU
M;F4@,S`L(#(P,3$@=V%S("9N8G-P.R0V+C(Y('!E<B!S:&%R92!W:&EC:`T*
M<F5P<F5S96YT<R!A;B!A9&IU<W1E9"!P<FEC92!F<F]M("9N8G-P.R0X+C<P
M(&%T(&ES<W5A;F-E(&1U92!T;R!C97)T86EN#0ID:6QU=&EV92!E<75I='D@
M9FEN86YC:6YG<R!S:6YC92!T:&4@:7-S=6%N8V4@;V8@=&AE(&YO=&5S+B!!
M="!*=6YE#0HS,"P@,C`Q,2P@=&AE(&-O;G9E<G-I;VX@<')I8V4@=V%S(&%B
M;W9E('1H92!C=7)R96YT(&UA<FME="!P<FEC90T*;V8@=&AE($-O;6UO;B!3
M=&]C:RX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV
M/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M
M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SX-"D-O;G9E<G-I;VX@;V8@,C`P."!C
M;VYV97)T:6)L92!N;W1E<R!D=7)I;F<-"C(P,3`\+V9O;G0^/"]F;VYT/CPO
M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I/;B!*86YU87)Y(#(V+"`R
M,#$P+"!T:&4@0V]M<&%N>2!A9W)E960@=&\@8V]N=F5R="`F;F)S<#LD,SDW
M+#DX."!O9B!T:&4-"G1H96X@;W5T<W1A;F1I;F<@,C`P."!#;VYV97)T:6)L
M92!.;W1E<R!I;G1O($-O;6UO;B!3=&]C:R!A="!A#0IP<FEC92!O9B`F;F)S
M<#LD-RXU,"!P97(@<VAA<F4N)B-X03`[)B-X03`[07,@<W5C:"P@=&AE($-O
M;7!A;GD@:7-S=65D#0HU,RPS,S,@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!T
M;R!T:&4@;F]T92!H;VQD97)S(&EN(')E<&%Y;65N="!O9@T*<W5C:"`F;F)S
M<#LD,SDW+#DX."!P<FEN8VEP86P@86UO=6YT('!L=7,@:6YT97)E<W0N/"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"E1H92!R96UA:6YI;F<@8F%L86YC92!O=71S=&%N9&EN9R!O;B!T:&4@<F5M
M86EN:6YG(#(P,#@@0V]N=F5R=&EB;&4-"DYO=&5S(&]F("9N8G-P.R0R+#4Y
M,BPP,3(@=V%S(')E<&%I9"!I;B!F=6QL(&]N($UA<F-H(#$U+"`R,#$P('=I
M=&@@=&AE#0IP<F]C965D<R!R96-E:79E9"!F<F]M('1H92`R,#$P($-O;G9E
M<G1I8FQE#0I.;W1E<RX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO9&EV/@T*/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@<F5C;V=N:7IE9"!A(&1E
M8G0@:6YD=6-E;65N="!C:&%R9V4@:6X@:6YT97)E<W0@97AP96YS92!F;W(-
M"G1H92!D:69F97)E;G1I86P@8F5T=V5E;B!T:&4@;W)I9VEN86P@8V]N=F5R
M<VEO;B!R871E(&]F("9N8G-P.R0S,"XP,"!P97(-"G-H87)E(&%N9"!T:&4@
M=F%R:6]U<R!A9&IU<W1E9"!C;VYV97)S:6]N('!R:6-E<R!I;B`R,#`Y(&%N
M9`T*,C`Q,"XF(WA!,#LF(WA!,#M.;VXM8V%S:"!I;G1E<F5S="!E>'!E;G-E
M(')E8V]G;FEZ960@9F]R('1H97-E#0IC;VYV97)S:6]N<R!W87,@)FYB<W`[
M)#$L,C`P+#`P,"!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S
M,"P-"C(P,3`N/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?
M86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU+U=O<FMS
M:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/DY/5$53(%!!64%"3$4\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3D]415,@4$%904),13PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDN)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[3D]415,-"E!!64%"3$4\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
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M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*1&5C
M96UB97(@,30L(#(P,#DL('1H92!#;VUP86YY(&ES<W5E9"`F;F)S<#LD,3(L
M,3(Y+#`Q,"!I;B!P<F]M:7-S;W)Y#0IN;W1E<R`H=&AE("8C>#(P,4,[3F]T
M97,F(W@R,#%$.RD@:6X@8V]N;F5C=&EO;B!W:71H('1H92!A8W%U:7-I=&EO
M;@T*;V8@0FEO+5%U86YT(&%S(&1I<V-U<W-E9"!I;B!.;W1E(#(@86)O=F4N
M(%1H92!.;W1E<R!B;W)E(&EN=&5R97-T#0IA="!A(')A=&4@;V8@,3`E('!E
M<B!A;FYU;2P@=VET:"!A;&P@<')I;F-I<&%L(&%N9"!I;G1E<F5S="!A8V-R
M=65D#0IT:&5R975N9&5R(&)E8V]M:6YG(&1U92!A;F0@<&%Y86)L92!O;F4@
M>65A<B!F<F]M('1H92!C;&]S:6YG(&1A=&4-"F]F('1H92!-97)G97(L(&]R
M($1E8V5M8F5R(#$T+"`R,#$P+B8C>$$P.R8C>$$P.U1H92!T97)M<R!O9B!T
M:&4-"DYO=&5S('!R;W9I9&5D('1H870@=&AE('!R:6YC:7!A;"!A;6]U;G1S
M(&%N9"!A;&P@:6YT97)E<W0-"G1H97)E=6YD97(@=V5R92!P87EA8FQE(&)Y
M('1H92!#;VUP86YY(&EN(&-A<V@@;W(L(&%T('1H90T*0V]M<&%N>28C>#(P
M,3D[<R!O<'1I;VXL(&EN('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C
M:RP@=VAI8V@-"G=E<F4@=F%L=65D(&%T('1H92!F:7AE9"!P<FEC92!O9B`F
M;F)S<#LD,BXU,B!P97(@<VAA<F4N/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY);@T*2F%N=6%R>2!A;F0@36%R8V@@,C`Q,"P@=&AE($-O;7!A;GD@
M<F5P86ED("9N8G-P.R0R+#(S,"PR,#$@;V8-"F]U='-T86YD:6YG('!R:6YC
M:7!A;"!O9B!T:&4@3F]T97,@=&AR;W5G:"!T:&4@:7-S=6%N8V4@;V8@0V]M
M;6]N#0I3=&]C:R!A="`F;F)S<#LD,BXU,B!P97(@<VAA<F4L('=H:6-H(&ES
M('1H92!F:7AE9"!P87EM96YT('!R:6-E('!U<G-U86YT#0IT;R!T:&4@=&5R
M;7,@;V8@=&AE($YO=&5S+B8C>$$P.R8C>$$P.T%S('-U8V@L('1H92!#;VUP
M86YY(&ES<W5E9`T*,2PP,#,L,C$P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@
M=&\@=&AE(&YO=&4@:&]L9&5R<R!I;B!R97!A>6UE;G0-"F]F('-U8V@@)FYB
M<W`[)#(L,C,P+#(P,2!P<FEN8VEP86P@86UO=6YT('!L=7,@:6YT97)E<W0N
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M)B-X03`[)B-X03`[07,@<W5C:"!T:&4@8F5N969I8VEA;`T*8V]N=F5R<VEO
M;B!C:&%R9V4@;F]N+6-A<V@@:6YT97)E<W0@97AP96YS92!R96-O9VYI>F5D
M('=I=&@@<F5S<&5C=`T*=&\@=&AE($YO=&5S(&9O<B!T:&4F(WA!,#LF(WA!
M,#MT:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+`T*,C`Q,"!W
M87,@)FYB<W`[)#$L-C(W+#$P,6%N9"`F;F)S<#LD-BPQ,SDL-S0Q+"!R97-P
M96-T:79E;'DN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@5$585"U$14-/4D%4
M24]..B!U;F1E<FQI;F4G/@T*,C`Q,"!0<F]M:7-S;W)Y($YO=&5S/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*2F%N
M=6%R>2`R,#$P+"!T:&4@0V]M<&%N>2!R86ES960@9W)O<W,@<')O8V5E9',@
M;V8@)FYB<W`[)#(N,R!M:6QL:6]N(&EN#0IA;B!O9F9E<FEN9R!O9B!U;G-E
M8W5R960@<')O;6ES<V]R>2!N;W1E<R`H=&AE("8C>#(P,4,[,C`Q,`T*3F]T
M97,F(W@R,#%$.RDN)B-X03`[)B-X03`[5&AE(#(P,3`@3F]T97,@86-C<G5E
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M.R0P+C`P,2!P97(-"G-H87)E+B8C>$$P.R8C>$$P.U1H92!W96EG:'1E9"!A
M=F5R86=E(&-O;G9E<G-I;VX@<')I8V4@;V8@=&AE(#(P,3`-"DYO=&5S('=A
M<R`F;F)S<#LD-2XU-2!P97(@<VAA<F4L('=I=&@@=&AE(&-O;G9E<G-I;VX@
M<')I8V5S(')A;F=I;F<@9G)O;0T*)FYB<W`[)#4N-#`@=&\@)FYB<W`[)#8N
M,#`@<&5R('-H87)E+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[
M/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*3VX@36%R8V@@,3<L(#(P,3`L('1H92`R,#$P($YO=&5S('=E<F4@
M<F5P86ED(&EN(&9U;&P@=VET:"!T:&4-"FES<W5A;F-E(&]F(#0Q-2PU,#0@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!R97!A>2!S=6-H("9N8G-P.R0R
M+C,-"FUI;&QI;VX@<')I;F-I<&%L(&%M;W5N="!A;F0@:6YT97)E<W0N)B-X
M03`[)B-X03`[5&AE($-O;7!A;GD-"G)E8V]G;FEZ960@82!B96YE9FEC:6%L
M(&-O;G9E<G-I;VX@8VAA<F=E(&]N('1H92!D:69F97)E;G1I86P-"F)E='=E
M96X@=&AE(&]R:6=I;F%L(&-O;G9E<G-I;VX@<F%T97,@;V8@)FYB<W`[)#4N
M-#`@=&\@)FYB<W`[)#8N,#`@<&5R('-H87)E#0IA;F0@=&AE(&UA<FME="!P
M<FEC92!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!#;VUM;VX@4W1O8VL@870@
M=&AE#0IT:6UE(&]F(')E<&%Y;65N="XF(WA!,#LF(WA!,#M4:&4@0V]M<&%N
M>2!H87,@<F5C;W)D960@82!B96YE9FEC:6%L#0IC;VYV97)S:6]N(&-H87)G
M92!T;R!I;G1E<F5S="!E>'!E;G-E(&]F("9N8G-P.R0P(&%N9"`F;F)S<#LD
M-C8P+#@Q.2!D=7)I;F<@=&AE#0IT:')E92!A;F0@<VEX(&UO;G1H<R!E;F1E
M9"!*=6YE(#,P+"`R,#$P+"!R97-P96-T:79E;'DL(&%S(&$@<F5S=6QT#0IO
M9B!T:&4@8V]N=F5R<VEO;BX\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]D:78^
M#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?
M86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3$E.15,@3T8@0U)%
M1$E4/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQ)
M3D53($]&($-2141)5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C$P+B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C
M>$$P.R8C>$$P.TQ)3D53#0I/1B!#4D5$250\+V9O;G0^/"]D:78^#0H\9&EV
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J
M=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^3VX-"DUA<F-H(#@L(#(P,3`L($)I;RU1=6%N
M="!E;G1E<F5D(&EN=&\@82!,;V%N(&%N9"!396-U<FET>2!!9W)E96UE;G0-
M"G=I=&@@4W%U87)E(#$@0F%N:R!F;W(@82!R979O;'9I;F<@;&EN92!O9B!C
M<F5D:70@*"8C>#(P,4,[0W)E9&ET#0I,:6YE)B-X,C`Q1#LI(&EN('1H92!A
M;6]U;G0@;V8@)FYB<W`[)#(U,"PP,#`N)B-X03`[)B-X03`[5&AE($-R961I
M="!,:6YE#0IW87,@<V5C=7)E9"!B>2!A("9N8G-P.R0R-34L,#`P(&-A<V@@
M9&5P;W-I="!F<F]M('1H92!#;VUP86YY('=H:6-H('=A<PT*8VQA<W-I9FEE
M9"!A<R!R97-T<FEC=&5D(&-A<V@@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS
M;VQI9&%T960-"F)A;&%N8V4@<VAE970@870@1&5C96UB97(@,S$L(#(P,3`N
M)B-X03`[)B-X03`[5&AE($-R961I="!,:6YE(&)O<F4-"FEN=&5R97-T(&%T
M('1H92!R871E(&]F(#0N,C4E('!E<B!A;FYU;2!O<B`Q)2!A8F]V92!T:&4@
M4')I;64@4F%T90T*86YD(&5X<&ER960@;VX@36%R8V@@-RP@,C`Q,2!A;F0@
M=V%S(')E<&%I9"!I;B!F=6QL(&%T('1H870-"G1I;64N/"]F;VYT/CPO9&EV
M/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0I/;B!!<')I;"`Q,BP@,C`Q,"P@
M0FEO+5%U86YT(&5N=&5R960@:6YT;R!A($QO86X@86YD(%-E8W5R:71Y#0I!
M9W)E96UE;G0@=VET:"!4;W)R97D@4&EN97,@0F%N:R!F;W(@82!R979O;'9I
M;F<@;&EN92!O9B!C<F5D:70-"B@F(W@R,#%#.U10($-R961I="!,:6YE)B-X
M,C`Q1#LI(&EN('1H92!A;6]U;G0@;V8-"B9N8G-P.R0R-3`L,#`P+B8C>$$P
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M;2!A;F0@97AP:7)E9"!O;B!!<')I;"`Q,BP@,C`Q,2!A;F0@=V%S(')E<&%I
M9"!I;B!F=6QL#0IA="!T:&%T('1I;64N/"]F;VYT/CPO9F]N=#X\+V1I=CX-
M"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U
M.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-S=F,S1B9&9?93!F
M,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU+U=O<FMS:&5E=',O4VAE970Q-RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1%1D52
M4D5$($-/35!%3E-!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$149%4E)%1"!#3TU014Y3051)3TX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,2XF(WA!,#LF(WA!,#LF(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#M$149%4E)%1`T*0T]-4$5.4T%424]./"]F;VYT/CPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S
M=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]N#0I&96)R=6%R>2`R-RP@,C`P,BP@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O(&%N(&5M<&QO>6UE;G0@86=R965M96YT#0IW
M:71H(%DN($IO<V5P:"!-;RP@4&@N1"XL('1H870@:&%D(&$@8V]N<W1A;G0@
M=&5R;2!O9B!F:79E('EE87)S+`T*86YD('!U<G-U86YT('1O('=H:6-H($1R
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M<F]U9V@@2F%N=6%R>2`Q+"`R,#`W+"!A<PT*<V5T(&9O<G1H(&EN('1H92!E
M;7!L;WEM96YT(&%G<F5E;65N="XF(WA!,#LF(WA!,#M4:&4@9&5F97)R960-
M"F-O;7!E;G-A=&EO;B!I<R!P87EA8FQE(&UO;G1H;'D@9F]R(#$X,"!M;VYT
M:',@8V]M;65N8VEN9R!O;@T*=&5R;6EN871I;VX@;V8@96UP;&]Y;65N="XF
M(WA!,#LF(WA!,#M$<BX@36\F(W@R,#$Y.W,@96UP;&]Y;65N="!W87,-"G1E
M<FUI;F%T960@87,@;V8@1&5C96UB97(@,34L(#(P,#4N)B-X03`[)B-X03`[
M070@<W5C:"!D871E+"!T:&4-"D-O;7!A;GD@86-C<G5E9"!D969E<G)E9"!C
M;VUP96YS871I;VX@;V8@)FYB<W`[)#$L,3<X+#$Y-R!B87-E9"!U<&]N('1H
M90T*97-T:6UA=&5D('!R97-E;G0@=F%L=64@;V8@=&AE(&]B;&EG871I;VXN
M)B-X03`[)B-X03`[5&AE(&UO;G1H;'D-"F1E9F5R<F5D(&-O;7!E;G-A=&EO
M;B!P87EM96YT('1H<F]U9V@@36%Y(#$U+"`R,#(Q(&ES#0HF;F)S<#LD.2PQ
M-3@N)B-X03`[)B-X03`[07,@;V8@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A
M;GD@:&%S(&$-"F1I<V-O=6YT960@86-C<G5E9"!B86QA;F-E(&]F(&%P<')O
M>&EM871E;'D@)FYB<W`[)#@S.2PU,#`@:6YC;'5D960@:6X-"F1E9F5R<F5D
M(&-O;7!E;G-A=&EO;BX@5&AE(')E;6%I;FEN9R!A;6]U;G1S(&%C8W)U960@
M:6X@1&5F97)R960-"D-O;7!E;G-A=&EO;B!A;'-O(')E;&%T92!T;R!S979E
M<F%N8V4@86UO=6YT<R!D=64@=&\@9F]R;65R#0IE;7!L;WEE97,@;V8@=&AE
M($-O;7!A;GDN/"]F;VYT/CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?
M86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU+U=O<FMS
M:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-/34U/3B!35$]#2R!44D%.4T%#5$E/3E,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34].(%-43T-+(%12
M04Y304-424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
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M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/;@T*07!R:6P@
M,C$L(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(%-A;&5S($%G
M<F5E;65N="!W:71H#0I"<FEN<V]N(%!A=')I8VL@4V5C=7)I=&EE<R!#;W)P
M;W)A=&EO;B`H=&AE("8C>#(P,4,[4V%L97,-"DUA;F%G97(F(W@R,#%$.RD@
M=&\@:7-S=64@86YD('-E;&P@=&AR;W5G:"!T:&4@4V%L97,@36%N86=E<BP@
M87,-"F%G96YT+"!U<"!T;R`F;F)S<#LD,3`L,#`P+#`P,"!O9B!C;VUM;VX@
M<W1O8VL@9G)O;2!T:6UE('1O('1I;64@<'5R<W5A;G0-"G1O('1H92!#;VUP
M86YY)B-X,C`Q.3MS(&5F9F5C=&EV92!S:&5L9B!R96=I<W1R871I;VX@<W1A
M=&5M96YT(&]N#0I&;W)M(%,M,R`H1FEL92!.;RX@,S,S+3$V-3DV,"DN)B-X
M03`[($1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9`T*2G5N92`S,"P@,C`Q
M,2P@=&AE($-O;7!A;GD@:&%D('-O;&0@86X@86=G<F5G871E(&]F(#8W-"PT
M-C8@<VAA<F5S#0IO9B!C;VUM;VX@<W1O8VL@=6YD97(@=&AE(%-A;&5S($%G
M<F5E;65N="!A="!A('=E:6=H=&5D(&%V97)A9V4-"G-A;&5S('!R:6-E(&]F
M(&%P<')O>&EM871E;'D@)FYB<W`[)#0N,C8@<&5R('-H87)E+"!R97-U;'1I
M;F<@:6X@;V9F97)I;F<-"G!R;V-E961S(&]F(&%P<')O>&EM871E;'D@)FYB
M<W`[)#(N-R!M:6QL:6]N+"!N970@;V8@<V%L97,-"F-O;6UI<W-I;VYS+CPO
M9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I;F<-"C(P,3`L
M('1H92!#;VUP86YY(&AA9"!S;VQD(&%N(&%G9W)E9V%T92!O9B`U,3@L,C8T
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M=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R
M-3DU#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S<W9C,T8F1F7V4P
M9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y-2]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5,1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY214Q!
M5$5$(%!!4E19(%1204Y304-424].4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y214Q!5$5$(%!!4E19(%1204Y304-424].4SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
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M4$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D%P<')O>&EM871E;'D@-C,E(&]F
M('1H92!":6\M475A;G0@;F]T97,@<&%Y86)L92!D97-C<FEB960@:6X@3F]T
M90T*."!W97)E(&AE;&0@8GD@97AE8W5T:79E<R!O9B!T:&4@0V]M<&%N>2X\
M+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*1F%S5')A8VL@4&AA<FUA
M8V5U=&EC86QS+"!);F,N("@F(W@R,#%#.T9A<U1R86-K)B-X,C`Q1#LI(&%N
M9`T*4V]R<F5N=&\@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(W@R,#%#.U-O
M<G)E;G1O)B-X,C`Q1#LI('=E<F4@9F]R;65D#0IB>2!":6\M475A;G0@:6X@
M,C`P."!A;F0@:6X@,C`P.2!":6\M475A;G0@<W!U;BUO9F8@:71S#0IP:&%R
M;6%C975T:6-A;"!A<W-E=',@=&\@=&AE('1W;R!C;VUP86YI97,@=&\@96YA
M8FQE(&ET('1O(&9O8W5S(&]N#0II=',@8V]R92!B=7-I;F5S<R!O9B!P<F4M
M8VQI;FEC86P@0U)/('1E<W1I;F<-"G-E<G9I8V5S+B8C>$$P.R8C>$$P.R8C
M>$$P.T9A<U1R86-K('-U8G-E<75E;G1L>2!A8W%U:7)E9`T*4V]R<F5N=&\F
M(W@R,#$Y.W,@87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!-87)C:`T*,C`Q
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M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SY/
M;B!!<')I;"`T+"`R,#$Q('1H92!#;VUP86YY(&%N9`T*1F%S5')A8VL@96YT
M97)E9"8C>$$P.R8C>$$P.VEN=&\@86X@07-S970@4'5R8VAA<V4-"D%G<F5E
M;65N=#PO9F]N=#XL(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^
M<'5R<W5A;G0@=&\-"G=H:6-H/"]F;VYT/B`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4G/D9A<U1R86-K('-O;&0\+V9O;G0^('1O#0IT:&4@0V]M
M<&%N>2!A;&P@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE)SYT:&4@
M<FEG:'1S/"]F;VYT/B!I=`T*:&%D(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN92<^:6X\+V9O;G0^(&-E<G1A:6X@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE)SYB86-K+75P(&-O;7!O=6YD<R!F;W(-"E!R979/;F-O
M/"]F;VYT/B8C>#(Q,C([+CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M92<^)B-X03`[/"]F;VYT/E!R979/;F-O)B-X,C$R,CL@9F]R('1H92!T<F5A
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M044[('1E8VAN;VQO9WDN)B-X03`[/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D
M:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0I);B!E>&-H86YG92!F;W(@=&AE(%!R979/;F-O)B-X
M,C$R,CL@8F%C:R!U<"!C;VUP;W5N9"!P;W)T9F]L:6\L('1H90T*0V]M<&%N
M>2!L;V%N960@1F%S5')A8VL@)FYB<W`[)#(U,"PP,#`@:6X@=&AE(&9O<FT@
M;V8@82!S96-U<F5D#0IC;VYV97)T:6)L92!N;W1E(&%N9"!R97-T<G5C='5R
M960@=&AE(&5X:7-T:6YG(&]U='-T86YD:6YG(&1E;6%N9`T*;F]T97,@86YD
M(&EN=&5R97-T('!A>6%B;&4@9'5E('1O('1H92!#;VUP86YY(&EN=&\@82!S
M96-O;F0@<V5C=7)E9`T*8V]N=F5R=&EB;&4@;F]T92!I;B!T:&4@86UO=6YT
M(&]F("9N8G-P.R0R,C0L-3(P+B!4:&4@;F]T97,@87)E(&1U92!O;@T*07!R
M:6P@-"P@,C`Q,R!A;F0@8F5A<B!I;G1E<F5S="!A="!T:&4@<F%T92!O9B!P
M<FEM92!P;'5S(#$E#0HH8W5R<F5N=&QY(#0N,C4E*2XF(WA!,#LF(WA!,#M4
M:&4@;F]T97,@875T;VUA=&EC86QL>2!C;VYV97)T('1O#0IC;VUM;VX@<W1O
M8VL@;V8@1F%S5')A8VL@:68L('!R:6]R('1O('1H92!M871U<FET>0T*9&%T
M92PF(WA!,#LF(WA!,#M&87-4<F%C:R!C;VUP;&5T97,@82!M871E<FEA;"!R
M;W5N9"!O9B!F:6YA;F-I;F<L#0IO<B!C;&]S97,@82!M97)G97(@;W(@86-Q
M=6ES:71I;VX@=')A;G-A8W1I;VX@*"8C>#(P,4,[329A;7`[00T*979E;G0F
M(W@R,#%$.RDL(&]R(&-O;7!L971E<R!A('!U8FQI8R!O9F9E<FEN9R!A="!A
M;B!O9F9E<FEN9R!P<FEC90T*97%U86P@=&\@=&AE(&9I;F%N8VEN9R!O<B!-
M)F%M<#M!('9A;'5E(&%T('1H870@=&EM92!D:7-C;W5N=&5D(&)Y#0HQ,"4N
M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"DEN(&%D9&ET:6]N(&%N
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M('1O(&)Y('1H92!#;VUP86YY+B!)=`T*:7,@=6YD97)S=&]O9"!T:&%T('1H
M97-E('1O+6)E+61E=&5R;6EN960@<')O9'5C=',@=V]U;&0@8F4@;W5T<VED
M90T*;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]R92!F;V-U<R!A;F0@97AP
M97)T:7-E(&%N9"!I="!I<R!E>'!E8W1E9`T*=&AA="!T:&5S92!D<G5G<R!W
M;W5L9"!N;W0@8F4@8V%N9&ED871E<R!T:&%T('1H92!#;VUP86YY('=O=6QD
M#0IL:6ME;'D@<'5R<W5E(&]N(&ET<R!O=VXN(%5N9&5R('1H92!T97)M<R!O
M9B!T:&4@;&EC96YS92P@=&AE#0I#;VUP86YY('=O=6QD(')E8V5I=F4@)FYB
M<W`[)#4P,"PP,#`@:6X@8V%S:"P@<&QU<R!M:6QE<W1O;F5S(&]F(&UO<F4-
M"G1H86X@)FYB<W`[)#4L,#`P+#`P,"!P97(@8V]M<&]U;F0L(&%N9"!P<F]D
M=6-T('-A;&5S(')O>6%L=&EE<R!F;VQL;W=I;F<-"G1H92!E>&5R8VES92!O
M9B!T:&4@;&EC96YS92!O<'1I;VX@8GD@1F%S5')A8VLN/"]F;VYT/CPO9F]N
M=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"E1H92!#;VUP86YY(&-O;G-I9&5R960@=VAE
M=&AE<B!&87-4<F%C:R!S:&]U;&0@8F4@8V]N<V]L:61A=&5D(&%S(&$-"E9A
M<FEA8FQE($EN=&5R97-T($5N=&ET>2`H5DE%*2!U;F1E<B!!4U4@3F\N(#(P
M,#DM,3<L(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E3
M4$Q!63H@:6YL:6YE)SY#;VYS;VQI9&%T:6]N<R`H5&]P:6,@.#$P*3H-"DEM
M<')O=F5M96YT<R!T;R!&:6YA;F-I86P@4F5P;W)T:6YG(&)Y($5N=&5R<')I
M<V5S($EN=F]L=F5D('=I=&@-"E9A<FEA8FQE($EN=&5R97-T($5N=&ET:65S
M/"]F;VYT/BX@5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T#0I&87-4<F%C
M:R!I<R!A(%9)12!B96-A=7-E(&ET(&QA8VMS('-U9F9I8VEE;G0@97%U:71Y
M(&%T(')I<VL@=&\-"F9U;F0@:71S(&]P97)A=&EO;F%L(&%C=&EV:71I97,@
M=VET:&]U="!A9&1I=&EO;F%L('-U8F]R9&EN871E9`T*9FEN86YC:6%L('-U
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M<F4@=F%L=65D(&%T(&$@>F5R;R!B;V]K('9A;'5E(&%T#0I*=6YE(#,P+"`R
M,#$Q(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"!F;W(@86-C;W5N=&EN9R!P=7)P
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M92`S,"P@,C`Q,2!A;F0@,C`Q,"!W;W5L9"!B92!I;G-I9VYI9FEC86YT#0IA
M;F0@=&AU<R!&87-4<F%C:R!H87,@;F]T(&)E96X@8V]N<V]L:61A=&5D(&%S
M(&ET<R!O<&5R871I;VYS(&%R90T*;F]T(&UA=&5R:6%L('1O('1H92!#;VUP
M86YY+CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^
M)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*26X@2G5L>2`R,#$Q+"!&87-4<F%C:R!E;G1E<F5D(&EN
M=&\@82!M97)G97(@86=R965M96YT('=I=&@@80T*<'5B;&EC;'DM=')A9&5D
M($-O;7!A;GDL($YO<G1H($AO<FEZ;VXL($EN8RX@56YD97(@=&AE(&%G<F5E
M;65N="P-"D9A<U1R86-K('=I;&P@8F5C;VUE(&$@<W5B<VED:6%R>2!O9B!.
M;W)T:"!(;W)I>F]N+B!4:&4-"G-H87)E:&]L9&5R<RP@;F]T96AO;&1E<BP@
M86YD('=A<G)A;G1H;VQD97(@;V8@1F%S5')A8VL@=VEL;`T*<F5C96EV92!I
M;B!T:&4@=')A;G-A8W1I;VX@=&AE(&YU;6)E<B!O9B!S:&%R97,@8V]M<')I
M<VEN9R`Y,B4@;V8-"G1H92!F=6QL>2UD:6QU=&5D('-H87)E<R!O9B!.;W)T
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M/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X
M,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E
M,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#(P
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y#
M3TU%(%1!6$53/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DE.0T]-12!405A%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C$T+B8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P
M.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.R8C>$$P.TE.0T]-10T*5$%815,\
M+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S
M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5&AE#0I#;VUP
M86YY(&AA<R!I;F-U<G)E9"!L;W-S97,@<VEN8V4@:6YC97!T:6]N+"!W:&EC
M:"!H879E(&=E;F5R871E9`T*;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R
M=V%R9',@;V8@87!P<F]X:6UA=&5L>2`F;F)S<#LD,S8@;6EL;&EO;B!F;W(-
M"F9E9&5R86P@86YD('-T871E(&EN8V]M92!T87@@<'5R<&]S97,@=&AR;W5G
M:"!$96-E;6)E<B`S,2P-"C(P,3`N)B-X03`[)B-X03`[5&AE<V4@8V%R<GEF
M;W)W87)D<R!A<F4@879A:6QA8FQE('1O(&]F9G-E="!F=71U<F4-"G1A>&%B
M;&4@:6YC;VUE(&%N9"!E>'!I<F4@8F5G:6YN:6YG(&EN(#(P,30@=&AR;W5G
M:"`R,#(Y(&9O<@T*9F5D97)A;"!I;F-O;64@=&%X('!U<G!O<V5S+B8C>$$P
M.R8C>$$P.TEN=&5R;F%L(%)E=F5N=64@0V]D90T*4V5C=&EO;B`S.#(@<&QA
M8V5S(&$@;&EM:71A=&EO;B!O;B!T:&4@=71I;&EZ871I;VX@;V8@9F5D97)A
M;"!N970-"F]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@=VAE;B!A;B!O
M=VYE<G-H:7`@8VAA;F=E+"!A<R!D969I;F5D#0IB>2!T87@@;&%W+"!O8V-U
M<G,N)B-X03`[)B-X03`[1V5N97)A;&QY+"!A;B!O=VYE<G-H:7`@8VAA;F=E
M+"!A<PT*9&5F:6YE9"P@;V-C=7)S('=H96X@82!G<F5A=&5R('1H86X@-3`@
M<&5R8V5N="!C:&%N9V4@:6X@;W=N97)S:&EP#0IT86ME<R!P;&%C92!D=7)I
M;F<@86YY('1H<F5E+7EE87(@<&5R:6]D+B!4:&4@0V]M<&%N>2!P97)F;W)M
M960@80T*<F5V:65W(&]F('-T;V-K('1R86YS86-T:6]N<R!F;W(@=&AE('EE
M87)S(&)E9VEN;FEN9R!*86YU87)Y(#$L#0HR,#`X(&%N9"!E;F1I;F<@1&5C
M96UB97(@,S$L(#(P,3`@87,@=&AE($-O;7!A;GD@9F5E;',@=&AA="!W87,@
M=&AE#0IL:6ME;'D@<&5R:6]D('1H870@<W5C:"!A;B!O=VYE<G-H:7`@8VAA
M;F=E(&QI:V5L>0T*;V-C=7)R960N)B-X03`[)B-X03`[0F%S960@;VX@=&AI
M<R!L:6UI=&5D(')E=FEE=RP@=&AE($-O;7!A;GD-"F1E=&5R;6EN960@=&AA
M="!A;B!O=VYE<G-H:7`@8VAA;F=E('1O;VL@<&QA8V4@:6X@2G5N92`R,#$P
M('=H96X-"G1H92!":6\M475A;G0@;F]T97,@=V5R92!C;VYV97)T960@=&\@
M8V]M;6]N('-T;V-K(&%S(&1I<V-U<W-E9"!I;@T*3F]T92`X+B8C>$$P.R8C
M>$$P.T%S(&$@<F5S=6QT(&]F('1H:7,@;W=N97)S:&EP(&-H86YG92P@=&AE
M#0IA8FEL:71Y('1O('5T:6QI>F4@=&AE(&-U<G)E;G0@;F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y9F]R=V%R9',-"F=E;F5R871E9"!P<FEO<B!T;R!T:&ES
M(&-H86YG92!I;B!O=VYE<G-H:7`@:7,@;&EM:71E9"!T;PT*87!P<F]X:6UA
M=&5L>2`F;F)S<#LD,2XR(&UI;&QI;VX@<&5R('EE87(@8F%S960@;VX@;W5R
M(&-A;&-U;&%T:6]N<R!A=`T*=&AE('1I;64@;V8@=&AE(&]W;F5R<VAI<"!C
M:&%N9V4N)B-X03`[)B-X03`[5&AE($-O;7!A;GD@:&%S#0IR96-O<F1E9"!A
M(&9U;&P@=F%L=6%T:6]N(&%L;&]W86YC92!A9V%I;G-T('1H92!D969E<G)E
M9"!T87@@87-S971S#0IA<FES:6YG(&9R;VT@=&AE(&YE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F1S+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^
M)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4-"D-O;7!A;GD@9F]L;&]W<R!T:&4@<')O=FES:6]N
M<R!O9B!!4T,@-S0P+3$P+3(U+B!!4T,@-S0P+3$P+3(U#0IP<F]V:61E<R!R
M96-O9VYI=&EO;B!C<FET97)I82!A;F0@82!R96QA=&5D(&UE87-U<F5M96YT
M(&UO9&5L(&9O<@T*=6YC97)T86EN('1A>"!P;W-I=&EO;G,@=&%K96X@;W(@
M97AP96-T960@=&\@8F4@=&%K96X@:6X@:6YC;VUE('1A>`T*<F5T=7)N<RX@
M05-#(#<T,"TQ,"TR-2!R97%U:7)E<R!T:&%T(&$@<&]S:71I;VX@=&%K96X@
M;W(@97AP96-T960-"G1O(&)E('1A:V5N(&EN(&$@=&%X(')E='5R;B!B92!R
M96-O9VYI>F5D(&EN('1H92!F:6YA;F-I86P-"G-T871E;65N=',@=VAE;B!I
M="!I<R!M;W)E(&QI:V5L>2!T:&%N(&YO="!T:&%T('1H92!P;W-I=&EO;B!W
M;W5L9`T*8F4@<W5S=&%I;F5D('5P;VX@97AA;6EN871I;VX@8GD@=&%X(&%U
M=&AO<FET:65S+B!487@@<&]S:71I;VYS#0IT:&%T(&UE970@=&AE(&UO<F4@
M;&EK96QY('1H86X@;F]T('1H<F5S:&]L9"!A<F4@=&AE;B!M96%S=7)E9`T*
M=7-I;F<@82!P<F]B86)I;&ET>2!W96EG:'1E9"!A<'!R;V%C:"!R96-O9VYI
M>FEN9R!T:&4@;&%R9V5S=`T*86UO=6YT(&]F('1A>"!B96YE9FET('1H870@
M:7,@9W)E871E<B!T:&%N(#4P)2!L:6ME;'D@;V8@8F5I;F<-"G)E86QI>F5D
M('5P;VX@=6QT:6UA=&4@<V5T=&QE;65N="X@5&AE($-O;7!A;GDF(W@R,#$Y
M.W,@1F5D97)A;`T*:6YC;VUE('1A>"!R971U<FYS(&9O<B`R,#`W('1O(#(P
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M($%30R`W-#`M,3`M,C4N(%1H97)E#0IC;VYT:6YU97,@=&\@8F4@;F\@;&EA
M8FEL:71Y(')E;&%T960@=&\@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<PT*
M870@2G5N92`S,"P@,C`Q,2X\+V9O;G0^/"]D:78^#0H\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P
M9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U
M.34O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^3$E#14Y324Y'($%.1"!215-%05)#2"!!3D0@
M1$5614Q/4$U%3E0@04=2145-14Y44SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,24-%3E-)3D<@04Y$(%)%4T5!4D-(($%.1"!$
M159%3$]0345.5"!!1U)%14U%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,34N)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[3$E#14Y324Y'
M#0I!3D0@4D5314%20T@@04Y$($1%5D5,3U!-14Y4($%'4D5%345.5%,\+V9O
M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/@T*5FET87)O<R8C>$%%.R`M("@R,#$Q("8C>#(P,3,[(#(P,3`I
M/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"D]N($1E8V5M8F5R
M(#(R+"`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@97AC;'5S
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M,#`@87,@86X-"G5P+69R;VYT('!A>6UE;G0@86YD(&ES(&5N=&ET;&5D('1O
M(')E8V5I=F4@=7`@=&\@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
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M.R8C>$$P.U1H92!E>'!E8W1E9"!U<"UF<F]N=`T*<&%Y;65N="!F<F]M($)R
M86-C;R!W87,@<F5C96EV960@:6X@07!R:6P@,C`Q,2P@:6X@=&AE(&%M;W5N
M="!O9@T*55-$("9N8G-P.R0Q+#`P,"PP,#`L(&YE="!O9B!W:71H:&]L9&EN
M9R!T87AE<RX@3V8@=&AI<R!A;6]U;G0L#0IA<'!R;WAI;6%T96QY("9N8G-P
M.R0V-CDL,#`P('=A<R!R96-O9VYI>F5D(&%S(&QI8V5N<V4@<F5V96YU92!I
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M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J
M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]D:78^#0H\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M+`T*2W5W86ET+"!,96)A;F]N+"!3>7)I82P@2F]R9&%N+"!)<F%Q(&%N9"!9
M96UE;B`H=&AE("8C>#(P,4,[16QI<PT*5&5R<FET;W)Y)B-X,C`Q1#LI+B!5
M;F1E<B!T:&4@16QI<R!,:6-E;G-E($%G<F5E;65N="P@=&AE($-O;7!A;GD@
M:7,-"F5N=&ET;&5D('1O(')E8V5I=F4@=7!F<F]N="!L:6-E;G-E(&9E97,@
M86YD(&UI;&5S=&]N92!P87EM96YT<R!O9@T*=7`@=&\@)FYB<W`[)#(N,2!M
M:6QL:6]N(&]V97(@=&AE('1E<FT@;V8@=&AE($5L:7,@3&EC96YS90T*06=R
M965M96YT+B8C>$$P.R8C>$$P.U1H92!F=71U<F4@;6EL97-T;VYE<R!A<F4@
M=&EE9"!T;R!R96=U;&%T;W)Y#0IA<'!R;W9A;"!A;F0@=&AE(&%C:&EE=F5M
M96YT(&]F(&-E<G1A:6X@;&5V96QS(&]F(&%G9W)E9V%T92!N970-"G-A;&5S
M(&]F(%9I=&%R;W,\9F]N="!S='EL93TS1"="3U)$15(M0D]45$]-.B`Q<'0@
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/CPO9&EV/@T*
M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^3VX-
M"D9E8G)U87)Y+"`Q-"PF(WA!,#LF(WA!,#LR,#$Q('1H92!#;VUP86YY(&5N
M=&5R960@:6YT;R!A(&QI8V5N<V4-"F%G<F5E;65N="`H=&AE("8C>#(P,4,[
M3F5O<&AA<FT@3&EC96YS92!!9W)E96UE;G0F(W@R,#%$.RD@=VET:"!T:&4-
M"DYE;W!H87)M($=R;W5P("@F(W@R,#%#.TYE;W!H87)M)B-X,C`Q1#LI+"!G
M<F%N=&EN9R!.96]P:&%R;2!T:&4-"F5X8VQU<VEV92!R:6=H=',@=&\@8V]M
M;65R8VEA;&EZ928C>$$P.R8C>$$P.U9I=&%R;W,F(WA!13L@9F]R#0IE<F5C
M=&EL92!D>7-F=6YC=&EO;B!A;F0@=VAE;B!A;F0@:68@879A:6QA8FQE+"!T
M:&4@0V]M<&%N>28C>#(P,3D[<PT*<')O9'5C="!F;W(@<')E;6%T=7)E(&5J
M86-U;&%T:6]N(&EN)B-X03`[)B-X03`[27-R865L(&%N9"!T:&4-"E!A;&5S
M=&EN:6%N(%1E<G)I=&]R:65S("AT:&4@)B-X,C`Q0SM.96]P:&%R;0T*5&5R
M<FET;W)Y)B-X,C`Q1#LI+B8C>$$P.R8C>$$P.U5N9&5R('1H92!.96]P:&%R
M;2!,:6-E;G-E($%G<F5E;65N="P-"G1H92!#;VUP86YY(&ES(&5N=&ET;&5D
M('1O(')E8V5I=F4@=7!F<F]N="!L:6-E;G-E(&9E97,@86YD#0IM:6QE<W1O
M;F4@<&%Y;65N=',@;V8@=7`@=&\@)FYB<W`[)#0N,S4@;6EL;&EO;B!O=F5R
M('1H92!T97)M(&]F('1H90T*3F5O<&AA<FT@3&EC96YS92!!9W)E96UE;G0N
M)B-X03`[)B-X03`[5&AE(&9U='5R92!M:6QE<W1O;F5S(&%R90T*=&EE9"!T
M;R!R96=U;&%T;W)Y(&%P<')O=F%L(&%N9"!T:&4@86-H:65V96UE;G0@;V8@
M8V5R=&%I;B!L979E;',-"F]F(&%G9W)E9V%T92!N970@<V%L97,@;V8@5FET
M87)O<R8C>$%%.RXF(WA!,#LF(WA!,#M!9&1I=&EO;F%L;'DL#0IT:&4@0V]M
M<&%N>2!I<R!E;G1I=&QE9"!T;R!R96-E:79E(&5S8V%L871I;F<@=&EE<F5D
M(&1O=6)L92UD:6=I=`T*<F]Y86QT:65S(&]N($YE;W!H87)M)B-X,C`Q.3MS
M('-A;&5S(&]F(%9I=&%R;W,F(WA!13L@:6X@=&AE#0I.96]P:&%R;2!497)R
M:71O<GDN/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-
M"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H
M90T*0V]M<&%N>2!R96-E:79E9"`F;F)S<#LD,C`S+#`P,"!I;B!U<"UF<F]N
M="!P87EM96YT<R!P=7)S=6%N="!T;R!T:&4@16QI<PT*86YD($YE;W!H87)M
M(&QI8V5N<VEN9R!A9W)E96UE;G1S(&%N9"!H87,@<F5C;W)D960@=&AE('!A
M>6UE;G1S(&%S#0IL:6-E;G-E(&9E92!R979E;G5E(&1U<FEN9R!T:&4@<VEX
M(&UO;G1H<R!E;F1E9"!*=6YE(#,P+`T*,C`Q,2X\+V9O;G0^/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
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M=7)O<&5A;B!R96=U;&%T;W)Y(&%U=&AO<FET:65S+"!I="!W;W5L9`T*9VEV
M92!T:&4@0V]M<&%N>2!T:&4@<FEG:'0@=&\@<V5L;"!6:71A<F]S/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$%%.SPO9F]N=#X-"FEN
M(&UU;'1I<&QE(&-H;W-E;B!C;W5N=')I97,@:6X@=&AE($5U<F]P96%N(%5N
M:6]N+B!5;F1E<B!A#0I%=7)O<&5A;B!S>7-T96T@8V%L;&5D('1H92`F(W@R
M,#%#.T1E8V5N=')A;&EZ960@4')O8V5D=7)E)B-X,C`Q1#L-"BA$0U`I+"!A
M(&-O;7!A;GD@9FEL97,@:71S(&%P<&QI8V%T:6]N(&9O<B!M87)K971I;F<@
M87!P<F]V86P@;V8@80T*9')U9R!I;B!J=7-T(&]N92!%=7)O<&5A;B!C;W5N
M=')Y+"!W:&EC:"!I<R!D97-I9VYA=&5D('1H90T*4F5F97)E;F-E($UE;6)E
M<B!3=&%T92`H4DU3*2X@5&AE($-O;7!A;GD@:&%S(&-H;W-E;B!4:&4-"DYE
M=&AE<FQA;F1S(&%S(&ET<R!235,N(%1H92!235,@=&AE;B!E=F%L=6%T97,@
M=&AE(&%P<&QI8V%T:6]N(&%N9`T*<')E<&%R97,@86X@87-S97-S;65N="!R
M97!O<G0@=&AA="!I<R!S=6)M:71T960@=&\@;W1H97(@8VAO<V5N#0I%=7)O
M<&5A;B!5;FEO;B!C;W5N=')I97,@9F]R('1H96ER(&-O;G-I9&5R871I;VX@
M86YD#0IA<'!R;W9A;"XF(WA!,#M4:&4@96YT:7)E(')E=FEE=R!P<F]C97-S
M(&]N(&%V97)A9V4@<F5Q=6ER97,-"F%P<')O>&EM871E;'D@,C0P(&1A>7,@
M;F]T(&EN8VQU9&EN9R!A9&1I=&EO;F%L('1I;64@87-S;V-I871E9`T*=VET
M:"!R97-P;VYS97,@=&\@<F5G=6QA=&]R>2!R979I97<@<75E<W1I;VYS+B!/
M;F4@;V8@=&AE(&UA:F]R#0IA9'9A;G1A9V5S(&]F('1H92!$0U`@:7,@=&AA
M="!A(&-O;7!A;GD@;6%Y(')E8V5I=F4@:61E;G1I8V%L#0IM87)K971I;F<@
M875T:&]R:7IA=&EO;G,@9F]R(&ET<R!P<F]D=6-T(&EN(&UU;'1I<&QE(&-H
M;W-E;@T*175R;W!E86X@365M8F5R(&-O=6YT<FEE<R!A="!T:&4@<V%M92!T
M:6UE+CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VLG/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*5FET87)O<R8C>$%%.R`F
M(W@R,#$S.R`H,C`P.2`F(W@R,#$S.R`R,#`W*3PO9F]N=#X\+V1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4U193$4Z(&YO<FUA;#L@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*3VX@3F]V
M96UB97(@,2P@,C`P-RP@=&AE($-O;7!A;GD@<VEG;F5D(&%N(&5X8VQU<VEV
M92!L:6-E;G-I;F<-"F%G<F5E;65N="!W:71H(%=A<FYE<B!#:&EL8V]T="!#
M;VUP86YY+"!);F,N+"`H)B-X,C`Q0SM787)N97(-"D-H:6QC;W1T)B-X,C`Q
M1#LI(&9O<B!6:71A<F]S)B-X044[(&9O<B!E<F5C=&EL90T*9'ES9G5N8W1I
M;VXN)B-X03`[)B-X03`[56YD97(@=&AE(&%G<F5E;65N="P@5V%R;F5R($-H
M:6QC;W1T#0IA8W%U:7)E9"!T:&4@97AC;'5S:79E(')I9VAT<R!I;B!T:&4@
M56YI=&5D(%-T871E<R!T;R!6:71A<F]S)B-X044[#0IA;F0@=V]U;&0@87-S
M=6UE(&%L;"!F=7)T:&5R(&1E=F5L;W!M96YT+"!M86YU9F%C='5R:6YG+"!A
M;F0-"F-O;6UE<F-I86QI>F%T:6]N(')E<W!O;G-I8FEL:71I97,@87,@=V5L
M;"!A<PT*8V]S=',N)B-X03`[)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=CXF
M(WA!,#L\+V1I=CX-"CQD:78^3VX@1F5B<G5A<GD@,RP@,C`P.2P@=&AE($-O
M;7!A;GD@=&5R;6EN871E9"!T:&4@;&EC96YS:6YG#0IA9W)E96UE;G0@86YD
M('-O;&0@=&AE(%4N4RX@<FEG:'1S(&9O<B!6:71A<F]S)B-X044[)B-X03`[
M=&\@5V%R;F5R#0I#:&EL8V]T="XF(WA!,#LF(WA!,#M5;F1E<B!T:&4@=&5R
M;7,@;V8@=&AE($%S<V5T(%!U<F-H87-E#0I!9W)E96UE;G0L('1H92!#;VUP
M86YY(')E8V5I=F5D(&%N('5P+69R;VYT('!A>6UE;G0@;V8@)FYB<W`[)#(N
M-2!M:6QL:6]N#0IA;F0@:7,@96QI9VEB;&4@=&\@<F5C96EV92!A;B!A9&1I
M=&EO;F%L('!A>6UE;G0@;V8@)FYB<W`[)#(N-2!M:6QL:6]N#0IU<&]N(%=A
M<FYE<B!#:&EL8V]T="8C>#(P,3D[<R!R96-E:7!T(&]F(&$@3F5W($1R=6<@
M07!P;&EC871I;VX-"BA.1$$I(&%P<')O=F%L(&9O<B!6:71A<F]S)B-X044[
M9G)O;2!T:&4@1D1!+CPO9&EV/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?
M-#-A-U]A864P7S0W,#0V,60X,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O
M5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4
M345.5%,@04Y$($-/3E1)3D=%3D-)15,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXQ-BXF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#M#3TU-251-
M14Y44PT*04Y$($-/3E1)3D=%3D-)15,\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T
M:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^16UP;&]Y;65N=`T*06=R965M96YT<SPO9F]N=#X\
M+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY790T*:&%V92!A;B!E;7!L
M;WEM96YT(&%G<F5E;65N="!W:71H($1R+B!$86UA:BP@;W5R($-H86ER;6%N
M+`T*4')E<VED96YT(&%N9"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<BX@4'5R
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M<F5N=&QY("9N8G-P.R0T-3`L,#`P('!E<B!A;FYU;2XF(WA!,#LF(WA!,#LF
M(WA!,#M4:&4@96UP;&]Y;65N=`T*86=R965M96YT(&9U<G1H97(@<')O=FED
M97,@=&AA="!I;B!T:&4@979E;G0@=&AA="!W:71H:6X@;VYE('EE87(-"F%F
M=&5R(&$@)B-X,C`Q0SM#:&%N9V4@;V8@0V]N=')O;"8C>#(P,40[("AA<R!D
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M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B-X03`[/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"E1H92!#;VUP86YY(&ES(&$@<&%R='D@
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M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P
M7S0S83=?86%E,%\T-S`T-C%D.#(U.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO-S=F,S1B9&9?93!F,%\T,V$W7V%A93!?-#<P-#8Q9#@R-3DU
M+U=O<FMS:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-%1TU%3E0@24Y&3U)-051)3TX\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4T5'345.5"!)3D9/4DU!
M5$E/3CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$:G5S=&EF>3XF(WA!,#L\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1H<F]U9V@-"DIU;F4@
M,S`L(#(P,3$L('1H92!#;VUP86YY(&AA9"!T=V\@86-T:79E(&)U<VEN97-S
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M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY396=M
M96YT#0II;F9O<FUA=&EO;B!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N
M92`S,"P@,C`Q,2!A;F0@,C`Q,"P-"G)E<W!E8W1I=F5L>2!I<R!A<R!F;VQL
M;W=S.CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU<W1I9GD^)B-X03`[/"]D:78^#0H\
M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/@T*/&1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/&1I=B!A;&EG
M;CTS1&QE9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<CX-"CQT9"!V86QI
M9VX],T1B;W1T;VT^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
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M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I%3D1%1"!*54Y%
M(#,P+"`R,#$Q/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&QE9G0^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/@T*/&1I=B!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
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M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`W,"4[(%9%4E1)0T%,+4%,
M24=..B!T97AT+71O<#L@1D].5"U714E'2%0Z(&)O;&0G/B8C>$%%.SPO9F]N
M=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@
M-S`E.R!615)424-!3"U!3$E'3CH@=&5X="UT;W`G/B8C>$$P.SPO9F]N=#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B
M;VQD)SY$<G5G/"]F;VYT/CPO9F]N=#X\+V9O;G0^/"]D:78^#0H\9&EV('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
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M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
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M<FEG:'0G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*0FEO+5%U86YT($-23SPO9F]N=#X\
M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)R!V86QI9VX],T1B;W1T
M;VT^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I/=&AE
M<CPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
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M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I!;&QO
M8V%T960@=&\\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I3
M96=M96YT<SPO9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,G!X)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
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M3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^#0H\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/@T*0V]N<V]L:61A=&5D/"]F;VYT
M/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0H\9F]N="!S='EL93TS
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2979E;G5E<SPO9F]N=#X\+V1I
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M<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX-S$L-#0Y/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M<'0G/C(L,#DT+#`T,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,38L-S(W/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L
M;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
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M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO
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M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
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M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M86X[($9/3E0M4TE:13H@,3!P="<^*#(L,C`P+#DR.3PO9F]N=#X\+W1D/@T*
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
M,3<T+#`Y.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH."PX-SDL-3@P/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q
M,2PR-30L-C`X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4Q%1E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#EP="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`Y<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYE=`T*
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M6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R+#(P,"PY
M,CD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^
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M13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
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M,T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXH,3$L,C`U+#`Y.#PO9F]N=#X\+W1D/@T*/'1D('-T
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M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$=VAI=&4^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@
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M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
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M:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BT\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$T+#`X,"PR.#,\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$T+#`X,"PR.#,\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX-
M"CPO9&EV/@T*/"]D:78^#0H\9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]D:78^#0H\9&EV(&%L:6=N/3-$
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M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^#0I&3U(@5$A%(%-)6"!-3TY42%,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G('9A;&EG;CTS1&)O='1O;3X-"CQD:78@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*14Y$140@2E5.12`S,"P@,C`Q,#PO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\9&EV(&%L:6=N
M/3-$;&5F=#X-"CQD:78@86QI9VX],T1L969T/@T*/&1I=B!A;&EG;CTS1&QE
M9G0^#0H\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<CX-"CQT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$;&5F=#X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO9F]N
M=#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U714E'2%0Z
M(&)O;&0G/DYE>$%#5#PO9F]N=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M4TE:13H@-S`E.R!615)424-!3"U!3$E'3CH@=&5X="UT
M;W`[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!13L\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#<P)3L@5D525$E#
M04PM04Q)1TXZ('1E>'0M=&]P)SXF(WA!,#L\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^1')U9SPO
M9F]N=#X\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&YO=W)A
M<#TS1&YO=W)A<#X-"CQD:78@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I":6\M475A;G0@0U)//"]F
M;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X-
M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97(G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I/
M=&AE<CPO9F]N=#X\+V9O;G0^/"]F;VYT/@T*/&1I=B!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
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M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I!;&QO8V%T
M960@=&\\+V9O;G0^/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CQD:78@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0I396=M
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M24=..B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
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M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$
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M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@8F=C;VQO<CTS1"-#0T9&0T,^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3(E(&%L:6=N/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M+#4V,"PR-C8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)FYB<W`[)#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXR+#DQ-BPV-SD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!B9V-O;&]R/3-$
M=VAI=&4^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E(&%L:6=N
M/3-$;&5F=#X-"CQD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
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M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXY,38L-S0S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C0L,#DX+#8V-#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#
M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE
M9G0^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY,;W-S#0IF<F]M(&]P97)A=&EO;G,\+V9O;G0^/"]D:78^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXH.#@Q+#8T,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-C,L,C0R/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
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M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
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M1RU,1494.B`P<'0[($U!4D=)3BU,1494.B`Y<'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4R)2!A;&EG;CTS1&QE9G0^#0H\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M.7!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.970-"FQO<W,\+V9O;G0^/"]D
M:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C
M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X-"CQF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH.#@Q+#8T,SPO9F]N=#X\+W1D/@T*
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH
M-3(L-#DY/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT
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M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[
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M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q
M,RPU,38L,3`S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)3X\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE/@T*/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
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M/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@
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M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^
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M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M<'0G/@T*)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
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M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@
M86QI9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5&]T86P-"F%S<V5T<SPO9F]N=#X\+V1I=CX-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]4
M5$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO
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M9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,34L,#0U+#0R,SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.2PT,S4L,C0P/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
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M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXR-"PT.#`L-C8S/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^#0H\+V1I=CX-"CPO9&EV
M/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X
M,C4Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W-V8S-&)D9E]E
M,&8P7S0S83=?86%E,%\T-S`T-C%D.#(U.34O5V]R:W-H965T<R]3:&5E=#(T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/
M0TM(3TQ$15(@4DE'2%13(%!,04X\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4U1/0TM(3TQ$15(@4DE'2%13(%!,04X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\9&EV('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ."XF(WA!,#LF(WA!,#LF
M(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!
M,#LF(WA!,#M35$]#2TA/3$1%4@T*4DE'2%13(%!,04X\+V9O;G0^/"]D:78^
M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^3VX-"DUA<F-H(#(T+"`R,#$Q+"!P=7)S
M=6%N="!T;R!T:&4@0V]M<&%N>28C>#(P,3D[<R!S:&%R96AO;&1E<G,@<FEG
M:'1S#0IP;&%N("AT:&4@)B-X,C`Q0SM0;&%N)B-X,C`Q1#LI('1H92!#;VUP
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M<VEN97-S(&]N($%P<FEL#0HQ+"`R,#$Q+B8C>$$P.R!);FET:6%L;'DL('1H
M97-E(')I9VAT<R!W:6QL(&YO="!B92!E>&5R8VES86)L92!A;F0-"G=I;&P@
M=')A9&4@=VET:"!T:&4@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@8V]M;6]N
M#0IS=&]C:RX\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
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M<')O=F5D('!A<G1Y(&%C<75I<F5S(&UO<F4@=&AA;B`Q-24@;V8@=&AE#0I#
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M/CQB<B`O/@T*)B-X03`[/"]D:78^#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"D)O87)D(&UA>2!R961E96T@=&AE
M(')I9VAT<R!F;W(@82!N;VUI;F%L(&%M;W5N="!A="!A;GD@=&EM92!B969O
M<F4-"F%N(&5V96YT('1H870@8V%U<V5S('1H92!R:6=H=',@=&\@8F5C;VUE
M(&5X97)C:7-A8FQE+B!4:&4@<FEG:'1S#0IW:6QL(&5X<&ER92!O;B!!<')I
M;"`Q+"`R,#(Q+CPO9F]N=#X\+V1I=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-S=F,S1B9&9?93!F,%\T,V$W
M7V%A93!?-#<P-#8Q9#@R-3DU#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S<W9C,T8F1F7V4P9C!?-#-A-U]A864P7S0W,#0V,60X,C4Y-2]7;W)K
M<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C
M:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN
M1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"CPO>&UL
M/@T*+2TM+2TM/5].97AT4&%R=%\W-V8S-&)D9E]E,&8P7S0S83=?86%E,%\T
/-S`T-C%D.#(U.34M+0T*
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
